Protease inhibitors

ABSTRACT

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget&#39;s disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.

FIELD OF THE INVENTION

[0001] This invention relates in general to 4-amino-azepan-3-oneprotease inhibitors, particularly such inhibitors of cysteine and serineproteases, more particularly compounds which inhibit cysteine proteases,even more particularly compounds which inhibit cysteine proteases of thepapain superfamily, yet more particularly compounds which inhibitcysteine proteases of the cathepsin family, most particularly compoundswhich inhibit cathepsin K. Such compounds are particularly useful fortreating diseases in which cysteine proteases are implicated, especiallydiseases of excessive bone or cartilage loss, e.g., osteoporosis,periodontitis, and arthritis.

BACKGROUND OF THE INVENTION

[0002] Cathepsins are a family of enzymes which are part of the papainsuperfamily of cysteine proteases. Cathepsins B, H, L, N and S have beendescribed in the literature. Recently, cathepsin K polypeptide and thecDNA encoding such polypeptide were disclosed in U.S. Pat. No. 5,501,969(called cathepsin O therein). Cathepsin K has been recently expressed,purified, and characterized. Bossard, M. J., et al., (1996) J. Biol.Chem. 271, 12517-12524; Drake, F. H., et al., (1996) J. Biol. Chem. 271,12511-12516; Bromme, D., et al., (1996) J. Biol. Chem. 271, 2126-2132.

[0003] Cathepsin K has been variously denoted as cathepsin O orcathepsin O2 in the literature. The designation cathepsin K isconsidered to be the more appropriate one.

[0004] Cathepsins function in the normal physiological process ofprotein degradation in animals, including humans, e.g., in thedegradation of connective tissue. However, elevated levels of theseenzymes in the body can result in pathological conditions leading todisease. Thus, cathepsins have been implicated as causative agents invarious disease states, including but not limited to, infections bypneumocystis carinii, trypsanoma cruzi, trypsanoma brucei brucei, andCrithidia fusiculata; as well as in schistosomiasis, malaria, tumormetastasis, metachromatic leukodystrophy, muscular dystrophy, amytrophy,and the like. See International Publication Number WO 94/04172,published on Mar. 3, 1994, and references cited therein. See alsoEuropean Patent Application EP 0 603 873 A1, and references citedtherein. Two bacterial cysteine proteases from P. gingivallis, calledgingipains, have been implicated in the pathogenesis of gingivitis.Potempa, J., et al. (1994) Perspectives in Drug Discovery and Design, 2,445-458.

[0005] Cathepsin K is believed to play a causative role in diseases ofexcessive bone or cartilage loss. Bone is composed of a protein matrixin which spindle-or plate-shaped crystals of hydroxyapatite areincorporated. Type I collagen represents the major structural protein ofbone comprising approximately 90% of the protein matrix. The remaining10% of matrix is composed of a number of non-collagenous proteins,including osteocalcin, proteoglycans, osteopontin, osteonectin,thrombospondin, fibronectin, and bone sialoprotein. Skeletal boneundergoes remodelling at discrete foci throughout life. These foci, orremodelling units, undergo a cycle consisting of a bone resorption phasefollowed by a phase of bone replacement.

[0006] Bone resorption is carried out by osteoclasts, which aremultinuclear cells of hematopoietic lineage. The osteoclasts adhere tothe bone surface and form a tight sealing zone, followed by extensivemembrane ruffling on their apical (i.e., resorbing) surface. Thiscreates an enclosed extracellular compartment on the bone surface thatis acidified by proton pumps in the ruffled membrane, and into which theosteoclast secretes proteolytic enzymes. The low pH of the compartmentdissolves hydroxyapatite crystals at the bone surface, while theproteolytic enzymes digest the protein matrix. In this way, a resorptionlacuna, or pit, is formed. At the end of this phase of the cycle,osteoblasts lay down a new protein matrix that is subsequentlymineralized. In several disease states, such as osteoporosis and Paget'sdisease, the normal balance between bone resorption and formation isdisrupted, and there is a net loss of bone at each cycle. Ultimately,this leads to weakening of the bone and may result in increased fracturerisk with minimal trauma.

[0007] Several published studies have demonstrated that inhibitors ofcysteine proteases are effective at inhibiting osteoclast-mediated boneresorption, and indicate an essential role for a cysteine proteases inbone resorption. For example, Delaisse, et al., Biochem. J., 1980, 192,365, disclose a series of protease inhibitors in a mouse bone organculture system and suggest that inhibitors of cysteine proteases (e.g.,leupeptin, Z-Phe-Ala-CHN₂) prevent bone resorption, while serineprotease inhibitors were ineffective. Delaisse, et al., Biochem.Biophys. Res. Commun., 1984, 125, 441, disclose that E-64 and leupeptinare also effective at preventing bone resorption in vivo, as measured byacute changes in serum calcium in rats on calcium deficient diets.Lerner, et al., J. Bone Min. Res., 1992, 7, 433, disclose that cystatin,an endogenous cysteine protease inhibitor, inhibits PTH stimulated boneresorption in mouse calvariae. Other studies, such as by Delaisse, etal., Bone, 1987, 8, 305, Hill, et al., J. Cell. Biochem., 1994, 56, 118,and Everts, et al., J. Cell. Physiol., 1992, 150, 221, also report acorrelation between inhibition of cysteine protease activity and boneresorption. Tezuka, et al., J. Biol. Chem., 1994, 269, 1106, Inaoka, etal., Biochem. Biophys. Res. Commun., 1995, 206, 89 and Shi, et al., FEBSLett., 1995, 357, 129 disclose that under normal conditions cathepsin K,a cysteine protease, is abundantly expressed in osteoclasts and may bethe major cysteine protease present in these cells.

[0008] The abundant selective expression of cathepsin K in osteoclastsstrongly suggests that this enzyme is essential for bone resorption.Thus, selective inhibition of cathepsin K may provide an effectivetreatment for diseases of excessive bone loss, including, but notlimited to, osteoporosis, gingival diseases such as gingivitis andperiodontitis, Paget's disease, hypercalcemia of malignancy, andmetabolic bone disease. Cathepsin K levels have also been demonstratedto be elevated in chondroclasts of osteoarthritic synovium. Thus,selective inhibition of cathepsin K may also be useful for treatingdiseases of excessive cartilage or matrix degradation, including, butnot limited to, osteoarthritis and rheumatoid arthritis. Metastaticneoplastic cells also typically express high levels of proteolyticenzymes that degrade the surrounding matrix. Thus, selective inhibitionof cathepsin K may also be useful for treating certain neoplasticdiseases.

[0009] Several cysteine protease inhibitors are known. Palmer, (1995) J.Med. Chem., 38, 3193, disclose certain vinyl sulfones which irreversiblyinhibit cysteine proteases, such as the cathepsins B, L, S, O2 andcruzain. Other classes of compounds, such as aldehydes, nitrites,α-ketocarbonyl compounds, halomethyl ketones, diazomethyl ketones,(acyloxy)methyl ketones, ketomethylsulfonium salts and epoxy succinylcompounds have also been reported to inhibit cysteine proteases. SeePalmer, id, and references cited therein.

[0010] U.S. Pat. No. 4,518,528 discloses peptidyl fluoromethyl ketonesas irreversible inhibitors of cysteine protease. Published InternationalPatent Application No. WO 94/04172, and European Patent Application Nos.EP 0 525 420 A1, EP 0 603 873 A1, and EP 0 611 756 A2 describealkoxymethyl and mercaptomethyl ketones which inhibit the cysteineproteases cathepsins B, H and L. International Patent Application No.PCT/US94/08868 and and European Patent Application No. EP 0 623 592 A1describe alkoxymethyl and mercaptomethyl ketones which inhibit thecysteine protease IL-1β convertase. Alkoxymethyl and mercaptomethylketones have also been described as inhibitors of the serine proteasekininogenase (International Patent Application No. PCT/GB91/01479).

[0011] Azapeptides which are designed to deliver the azamino acid to theactive site of serine proteases, and which possess a good leaving group,are disclosed by Elmore et al., Biochem. J., 1968, 107, 103, Garker etal., Biochem. J., 1974, 139, 555, Gray et al., Tetrahedron, 1977, 33,837, Gupton et al., J. Biol. Chem., 1984, 259, 4279, Powers et al., J.Biol. Chem., 1984, 259, 4288, and are known to inhibit serine proteases.In addition, J. Med. Chem., 1992, 35, 4279, discloses certain azapeptideesters as cysteine protease inhibitors.

[0012] Antipain and leupeptin are described as reversible inhibitors ofcysteine protease in McConnell et al., J. Med. Chem., 33, 86; and alsohave been disclosed as inhibitors of serine protease in Umezawa et al.,45 Meth. Enzymol. 678. E64 and its synthetic analogs are also well-knowncysteine protease inhibitors (Barrett, Biochem. J., 201, 189, andGrinde, Biochem. Biophys. Acta, 701, 328).

[0013] 1,3-diamido-propanones have been described as analgesic agents inU.S. Pat. Nos. 4,749,792 and 4,638,010.

[0014] Thus, a structurally diverse variety of protease inhibitors havebeen identified. However, these known inhibitors are not consideredsuitable for use as therapeutic agents in animals, especially humans,because they suffer from various shortcomings. These shortcomingsinclude lack of selectivity, cytotoxicity, poor solubility, and overlyrapid plasma clearance. A need therefore exists for methods of treatingdiseases caused by pathological levels of proteases, particularlycysteine proteases, more particularly cathepsins, most particularlycathepsin K, and for novel inhibitor compounds useful in such methods.

[0015] We have now discovered a novel class of 4-amino-azepan-3-onecompounds which are protease inhibitors, most particularly of cathepsinK.

SUMMARY OF THE INVENTION

[0016] An object of the present invention is to provide4-amino-azepan-3-one carbonyl protease inhibitors, particularly suchinhibitors of cysteine and serine proteases, more particularly suchcompounds which inhibit cysteine proteases, even more particularly suchcompounds which inhibit cysteine proteases of the papain superfamily,yet more particularly such compounds which inhibit cysteine proteases ofthe cathepsin family, most particularly such compounds which inhibitcathepsin K, and which are useful for treating diseases which may betherapeutically modified by altering the activity of such proteases.

[0017] Accordingly, in the first aspect, this invention provides acompound according to Formula I.

[0018] In another aspect, this invention provides a pharmaceuticalcomposition comprising a compound according to Formula I and apharmaceutically acceptable carrier, diluent or excipient.

[0019] In yet another aspect, this invention provides intermediatesuseful in the preparation of the compounds of Formula I.

[0020] In still another aspect, this invention provides a method oftreating diseases in which the disease pathology may be therapeuticallymodified by inhibiting proteases, particularly cysteine and serineproteases, more particularly cysteine proteases, even more particularlycysteine proteases of the papain superfamily, yet more particularlycysteine proteases of the cathepsin family, most particularly cathepsinK.

[0021] In a particular aspect, the compounds of this invention areespecially useful for treating diseases characterized by bone loss, suchas osteoporosis and gingival diseases, such as gingivitis andperiodontitis, or by excessive cartilage or matrix degradation, such asosteoarthritis and rheumatoid arthritis.

DETAILED DESCRIPTION OF THE INVENTION

[0022] The present invention provides compounds of Formula I:

[0023] wherein:

[0024] R¹ is selected from the group consisting of:

[0025] R² is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹C(S)—,R⁹SO₂—, R⁹OC(O)—, R⁹R¹¹NC(O)—, R⁹R¹¹NC(S)—, R⁹ (R¹¹)NSO₂—

[0026] and R⁹SO₂R¹¹NC(O)—;

[0027] R³ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl;

[0028] R³ and R′ may be connected to form a pyrrolidine, piperidine ormorpholine ring;

[0029] R⁴ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)—, R⁵C(S)—,R⁵SO₂—, R⁵OC(O)—, R⁵R¹²NC(O)—, and R⁵R¹²NC(S)—;

[0030] R⁵ is selected from the group consisting of: H, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl andHet-C₀₋₆alkyl;

[0031] R⁶ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0032] R⁷ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R¹⁰C(O)—,R¹⁰C(S)—, R¹⁰SO₂—, R¹⁰OC(O)—, R¹⁰R¹³NC(O)—, and R¹⁰R¹³NC(S)—;

[0033] R⁸ is selected from the group consisting of: H, C₁₋₁₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl and ArC₀₋₆alkyl;

[0034] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl;

[0035] Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0036] R¹⁰ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0037] R¹¹ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0038] R¹² is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0039] R¹³ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0040] R′ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0041] R″ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl;

[0042] R′″ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-CO₀₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0043] R″″ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl;

[0044] X is selected from the group consisting of: CH₂, S, and O;

[0045] Z is selected from the group consisting of: C(O) and CH₂;

[0046] n is an integer from 1 to 5;

[0047] and pharmaceutically acceptable salts, hydrates and solvatesthereof.

[0048] In compounds of Formula I, when R¹ is

[0049] R³ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl;

[0050] R³ is preferably selected from the group consisting of: H,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, Ar—C₀₋₆alkyl, and C₁₋₆alkyl;

[0051] R³ is more preferably selected from the group consisting of:

[0052] H, methyl, ethyl, n-propyl, prop-2-yl, n-butyl, isobutyl,but-2-yl, cyclopropylmethyl, cyclohexylmethyl, 2-methanesulfinyl-ethyl,1-hydroxyethyl, toluyl, naphthalen-2-ylmethyl, benzyloxymethyl, andhydroxymethyl.

[0053] R³ is even more preferably selected from the group consisting of:toluyl, isobutyl and cyclohexylmethyl.

[0054] R³ is most preferably isobutyl.

[0055] R⁴ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)—, R⁵C(S)—,R⁵SO₂—, R⁵OC(O)—, R⁵R¹³NC(O)—, and R⁵R¹³NC(S)—.

[0056] R⁴ is preferably selected from the group consisting of: R⁵OC(O)—,R⁵C(O)— and R⁵SO₂—.

[0057] R⁴ is most preferably R⁵C(O)—.

[0058] In some embodiments, R⁴ is preferably methanesulfonyl.

[0059] R⁵ is selected from the group consisting of: H, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl orHet-C₀₋₆alkyl.

[0060] Preferably R⁵ is selected from the group consisting of:C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl.

[0061] More preferably, and especially when R⁴ is R⁵C(O)—, R⁵ isselected from the group consisting of:

[0062] methyl, especially halogenated methyl, more especiallytrifluoromethyl, especially C₁₋₆alkoxy substituted methyl, moreespecially phenoxy-methyl, 4-fluoro-phenoxy-methyl, especiallyheterocycle substituted methyl, more especially 2-thiophenyl-methylethyl, especially piperidin-1-yl-ethyl;

[0063] butyl, especially aryl substituted butyl, more especially4-(4-methoxy)phenyl-butyl;

[0064] isopentyl;

[0065] cyclohexyl;

[0066] pentanonyl, especially 4-pentanonyl;

[0067] butenyl, especially aryl substituted butenyl, more especially4,4-bis(4-methoxyphenyl)-but-3-enyl;

[0068] acetyl;

[0069] phenyl, especially phenyl substituted with one or more halogens,more especially 3,4-dichlorophenyl and 4-fluorophenyl, especially phenylsubstituted with one or more aryloxy or C₁₋₆alkoxy groups, moreespecially 3,4-dimethoxy-phenyl, 3-benzyloxy-4-methoxy-phenyl,especially phenyl substituted with one or more C₁₋₆alkyl sulfonylgroups, more especially 4-methanesulfonyl-phenyl;

[0070] benzyl;

[0071] naphthalenyl, especially naphthylen-2-yl;

[0072] benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;

[0073] furanyl, especially furan-2-yl, especially substituted furanyl,such as 5-nitro-furan-2-yl, 5-(4-nitrophenyl)-furan-2-yl,5-(3-trifluoromethyl-phenyl)-furan-2-yl, more especially halogensubstituted furanyl, even more especially 5-bromo-furan-2-yl, moreespecially aryl substituted furanyl, even more especially5-(4-chloro-phenyl)-furan-2-yl, more especially C₁₋₆alkyl substitutedfuranyl, even more especially 3-methyl-furan-2-yl, 4-methyl-furan-2-yl,2,5-dimethyl-furan-2-yl, and 2,4-dimethyl-furan-3-yl;

[0074] tetrahydrofuranyl, tetrahydrofuran-2-yl;

[0075] benzofuranyl, especially benzofuran-2-yl, and substitutedbenzofuranyl, more especially 5-(2-piperazin-4-carboxylic acidtert-butyl ester-ethoxy) benzofuran-2-yl,5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-yl,5-(2-piperazin-1-yl-ethoxy)benzofuran-2-yl,5-(2-cyclohexyl-ethoxy)-benzofuran-2-yl; especially C₁₋₆alkoxysubstituted benzofuranyl, more especially 7-methoxy-benzofuran-2-yl,5-methoxy-benzofuran-2-yl, 5,6-dimethoxy-benzofuran-2-yl, especiallyhalogen substituted benzofuranyl, more especially5-fluoro-benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl, especiallyC₁₋₆alkyl substituted benzofuranyl, most especially3-methyl-benzofuran-2-yl, 3,5-dimethyl-benzofuran-2-yl, and3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl,6-fluoro-3-methyl-benzofuran-2-yl, 5-methoxy-3-methyl-benzofuran-2-yl,4-methoxy-3-methyl-benzofuran-2-yl, and6-methoxy-3-methyl-benzofuran-2-yl;

[0076] naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl,alkyl substituted naphtho[2,1-b]-furanyl, especially1-methyl-naphtho[2,1-b]-furan-2-yl;

[0077] benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; especiallyC₁₋₆alkoxy substituted benzo[b]thiophenyl, more especially5,6-dimethoxy-benzo[b]thiophen-2-yl;

[0078] quinolinyl, especially quinolin-2-yl, quinolin-3-yl,quinolin-4-yl, quinolin-6-yl, and quinolin-8-yl;

[0079] quinoxalinyl, especially quinoxalin-2-yl;

[0080] 1,8 naphthyridinyl, especially 1,8 naphthyridin-2-yl;

[0081] indolyl, especially indol-2-yl, especially indol-6-yl,indol-5-yl, especially C₁₋₆alkyl substituted indolyl, more especiallyN-methyl-indol-2-yl;

[0082] pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl,especially C₁₋₆alkyl substituted pyridinyl, more especially2-methyl-pyridin-5-yl, and oxy-pyridinyl, especially1-oxy-pyridin-2-yland 1-oxy-pyridin-3-yl;

[0083] furo[3,2-b]-pyridinyl, especially furo[3,2-b]-pyridin-2-yl,C₁₋₆alkyl substituted furo[3,2-b]-pyridinyl, especially3-methyl-furo[3,2-b]-pyridin-2-yl;

[0084] thiophenyl, especially thiophen-3-yl, also thiophen-2-yl,especially C₁₋₆alkyl substituted thiophenyl, more especially5-methyl-thiophen-2-yland 5-methyl-thiophen-3-yl, especially halogensubstituted thiophenyl, more especially 4,5-dibromo-thiophen-2-yl;

[0085] thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl,more especially C₁₋₆alkyl substituted thieno[3,2-b]thiophene-2-yl, moreespecially 5-tert-butyl-3-methyl-thieno[3,2-b]thiophene-2-yl;

[0086] isoxazolyl, especially isoxazol-4-yl, especially C₁₋₆alkylsubstituted isoxazolyl, more especially 3,5-dimethyl-isoxazol-4-yl;

[0087] oxazolyl, especially oxazol-4-yl, more especially5-methyl-2-phenyl oxazol-4-yl, 2-phenyl-5-trifluoromethyl-oxazol-4-yl;and

[0088] 1H-benzoimidazolyl, especially 1H-benzoimidazol-5-yl.

[0089] When R⁴ is R⁵SO₂, R⁵ is preferably pyridin-2-yl or1-oxo-pyridin-2-yl.

[0090] R′ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0091] Preferably R′ is selected from the group consisting of: H andnaphthalen-2-yl-methyl.

[0092] Most preferably R′ is H.

[0093] R″ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0094] Most preferably R″ is H.

[0095] R′″ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0096] R′″ is preferably selected from the group consisting of: H andC₁₋₆alkyl.

[0097] R′″ is more preferably selected from the group consisting of: H,methyl and 6,6-dimethyl.

[0098] R′″ is still more preferably selected from the group consistingof: H and 6,6-dimethyl.

[0099] Most preferably R′″ is H.

[0100] In compounds of Formula I, when R¹ is

[0101] R³ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl.

[0102] R³ is preferably C₁₋₆alkyl.

[0103] R³ is more preferably selected from the group consisting ofmethyl, ethyl, n-propyl, n-butyl, isobutyl, t-butyl, cyclohexylmethyl,and toluyl.

[0104] R″″ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl;

[0105] R″″ is preferably C₁₋₆alkyl;

[0106] R″″ is more preferably selected from the group consisting ofmethyl, ethyl, n-propyl, n-butyl, isobutyl and t-butyl.

[0107] R″″ is most preferably methyl.

[0108] In such compounds, R′, R″, R′″, R⁴, and R⁵ are as described abovewherein

[0109] In compounds of Formula I, when R¹ is

[0110] n is preferably an integer of from 1 to 5; and

[0111] R′, R″, R′″, R⁴, and R⁵ are as described above wherein

[0112] R¹ is

[0113] n is most preferably 3.

[0114] The ring may be unsubstituted or substituted with one or more ofC₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,HetCO₆alkyl, ArCO₆alkyl, or halogen.

[0115] The ring is preferably unsubstituted.

[0116] In compounds of Formula I, R² is selected from the groupconsisting of:

[0117] H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl,Het-C₀₋₆alkyl, R⁹C(O)—, R⁹C(S)—, R⁹SO₂—, R⁹OC(O)—, R⁹R¹¹NC(O)—,R⁹R¹¹NC(S)—, R⁹R¹¹NSO₂—,

[0118] and R⁹SO₂R¹¹NC(O)—.

[0119] More preferably R² is selected from the group consisting of:Ar—C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂, R⁹R¹ INC(O)—, and

[0120] Even more preferably, R² is selected from the group consistingof: Ar—C₀₋₆alkyl, R⁹C(O)—, and R⁹SO₂.

[0121] Most preferably R² is R⁹SO₂.

[0122] In such embodiments:

[0123] R⁶ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl, preferably H.

[0124] R⁷ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R¹⁰C(O)—,R¹⁰C(S)—, R¹⁰SO₂—, R¹⁰OC(O)—, R¹⁰R¹⁴NC(O)—, R¹⁰R¹⁴NC(S)—, R⁷ ispreferably R¹⁰OC(O).

[0125] R⁸ is selected from the group consisting of: H, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl and ArCO₆alkyl; preferablyC₁₋₆alkyl, more preferably isobutyl.

[0126] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0127] R⁹ is preferably selected from the group consisting of:C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0128] More preferably, R⁹ is selected from the group consisting of:

[0129] methyl;

[0130] ethyl, especially C₁₋₆alkyl-substituted ethyl, more especially2-cyclohexyl-ethyl;

[0131] propyl;

[0132] butyl, especially C₁₋₆butyl, more especially 3-methylbutyl;

[0133] tert-butyl, particularly when R² is R⁹OC(O);

[0134] isopentyl;

[0135] phenyl, especially halogen substituted phenyl, more especially3,4-dichlorophenyl, 4-bromophenyl, 2-fluorophenyl, 3-fluorophenyl,4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,especially C₁ 1₆alkoxy phenyl, more especially 3-methoxyphenyl,4-methoxyphenyl, 3,4-dimethoxyphenyl, especially cyanophenyl, moreespecially 2-cyanophenyl; especially C₁₋₆alkyl substituted phenyl, moreespecially 4-ethyl-phenyl, 2-methyl phenyl, 4-methyl phenyl, especiallyC₁₋₆alkyl sulfonyl substituted phenyl, more especially 4-methanesulfonylphenyl, and 2-methanesulfonyl phenyl;

[0136] toluyl, especially Het-substituted toluyl, more especially3-(pyridin-2-yl)toluyl;

[0137] naphthylene, especially naphthyl-2-ene;

[0138] benzoic acid, especially 2-benzoic acid;

[0139] benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;

[0140] benzo[1,2,5]oxadiazolyl, especially benzo[1,2,5]oxadiazol-4-yl;

[0141] pyridinyl, especially pyridin-2-yl, pyridin-3-yl, especially1-oxy-pyridinyl, more especially 1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl;especially C₁₋₆alkylpyridinyl, more especially 3-methyl-pyridin-2-yl,6-methyl-pyridin-2-yl;

[0142] thiophenyl, especially thiophenyl-2-yl;

[0143] thiazolyl, especially thiazol-2-yl;

[0144] 1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl,more especially C₁₋₆alkyl substituted imidazolyl, even more especially1-methyl-1H-imidazol-2-yl, 1-methyl-1H-imidazol-4-yl, and1,2-dimethyl-1H-imidazol-4-yl;

[0145] triazolyl, especially 1H-[1,2,4]triazolyl, more especially1H-[1,2,4]triazol-3-yl, especially C₁₋₆alkyl substituted1H-[1,2,4]triazolyl, more especially 5-methyl-1H-[1,2,4]triazol-3-yl;and

[0146] isoxazolyl, especially isoxazol-4-yl, especially C₁₋₆alkylsubstituted isoxazolyl, more especially 3,5-dimethyl-isoxazol-4-yl.

[0147] When R² is R⁹SO₂, R⁹ is most preferably selected from the groupconsisting of: pyridin-2-yl and 1-oxy-pyridin-2-yl.

[0148] When R² is R⁹SO₂R¹¹NC(O)—, R⁹ is preferably Ar—C₀₋₆alkyl, morepreferably Ar, most preferably substituted phenyl such as 2-methylphenyl, 4-methyl phenyl, 2-chloro phenyl, and 4-fluoro phenyl.

[0149] When R² is R⁹C(O)—, R⁹ is preferably selected from the groupconsisting of C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, and Het-C₀₋₆alkyl,more preferably 1-oxy-pyridin-2-yl, cyclohexyl ethyl, and 3-methylbutyl.

[0150] R¹¹ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0151] When R² is R⁹SO₂R¹¹NC(O)—, R¹¹ is preferably H.

[0152] When R² is Ar—C₀₋₆alkyl, R² is preferably phenyl, especiallysubstituted phenyl, more especially halogen substituted phenyl, evenmore especially 2-fluorobenzyl.

[0153] When R² is C₁₋₆alkyl, R² is preferably selected from l-propyl,1-butyl, and 1-pentyl.

[0154] When R² is Het-C₀₋₆alkyl, Het-C₀₋₆alkyl is preferably Het-methyl,and Het in Het-methyl is preferably selected from the group consistingof:

[0155] pyridinyl, especially pyridin-2-yl, especiallyC₁₋₆alkylpyridinyl, more especially 6-methyl-pyridin-2-yl;

[0156] thiophenyl, especially thiophene-2-yl, more especiallythiophen-2-yl or benzo[b]thiophen-2-yl;

[0157] thiazolyl, especially thiazol-4-yl such as1-(2-morpholin-4-yl-thiazol-4-yl), and 1-(isothiazol-3-yl);

[0158] 1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl,especially C₁₋₆alkyl substituted imidazolyl, more especially1-methyl-1H-imidazol-2yl;

[0159] triazolyl, especially 3H-[1,2,3]triazolyl, more especially3H-[1,2,3]triazol-4-yl, especially C₁₋₆alkyl substituted3H-[1,2,3]triazolyl, more especially 3-phenyl-3H-[1,2,3]triazolyl-4-yl;

[0160] quinolinyl, especially quinolin-2-yl, quinolin-2-yl;

[0161] furanyl, especially furan-2-yl, especially substituted furanyl,such as 5-ethyl-furan-2-yl;

[0162] thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl,especially C₁₋₆alkyl substituted thieno[3,2-b]thiophenyl, especially3,4-dimethyl-thieno[3,2-b]thiophene-2-yl.

[0163] R² is also preferably:

[0164] H;

[0165] toluyl;

[0166] aryl substituted ethyl, especially 2-phenyl ethyl,2-[3-(pyridin-2-yl) phenyl]ethyl.

[0167] Compounds of Formula I where R″ and R′″ are both H are preferred.

[0168] More preferred are compounds of Formula I wherein:

[0169] R¹ is

[0170] R² is selected from the group consisting of: Ar—C₀₋₆alkyl,R⁹C(O)—, R⁹SO₂, R⁹R¹¹NC(O)—, and

[0171] R³ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl and Ar—C₀₋₆alkyl;

[0172] R⁴ is selected from the group consisting of: R⁵OC(O)—, R⁵C(O)—and R⁵SO₂—;

[0173] R⁵ is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0174] R⁶ is H;

[0175] R⁷ is R¹⁰OC(O);

[0176] R⁸ is C₁₋₆alkyl;

[0177] R⁹ is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0178] R¹⁰ is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0179] R′ is H;

[0180] R″ is H;

[0181] R′″ is H; and

[0182] Z is selected from the group consisting of: C(O) and CH₂.

[0183] Even more preferred are such compounds of Formula I wherein R² isselected from the group consisting of: Ar—C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂.

[0184] Yet more preferred are compounds of Formula I wherein:

[0185] R¹ is

[0186] R² is selected from the group consisting of: Ar—C₀₋₆alkyl,R⁹C(O)— and R⁹SO₂;

[0187] R³ is selected from the group consisting of: H, methyl, ethyl,n-propyl, prop-2-yl, n-butyl, isobutyl, but-2-yl, cyclopropylmethyl,cyclohexylmethyl, 2-methanesulfinyl-ethyl, 1-hydroxyethyl, toluyl,naphthalen-2-ylmethyl, benzyloxymethyl, and hydroxymethyl;

[0188] R⁴ is R⁵C(O)—;

[0189] R⁵ is selected from the group consisting of:

[0190] methyl, especially halogenated methyl, more especiallytrifluoromethyl, especially C₁₋₆alkoxy substituted methyl, moreespecially phenoxy-methyl, 4-fluoro-phenoxy-methyl, especiallyheterocycle substituted methyl, more especially 2-thiophenyl-methyl;

[0191] ethyl, especially piperidin-1-yl-ethyl;

[0192] butyl, especially aryl substituted butyl, more especially4-(4-methoxy)phenyl-butyl;

[0193] isopentyl;

[0194] cyclohexyl;

[0195] pentanonyl, especially 4-pentanonyl;

[0196] butenyl, especially aryl substituted butenyl, more especially4,4-bis(4-methoxyphenyl)-but-3-enyl;

[0197] acetyl;

[0198] phenyl, especially phenyl substituted with one or more halogens,more especially 3,4-dichlorophenyl and 4-fluorophenyl, especially phenylsubstituted with one or more aryloxy or C₁₋₆alkoxy groups, moreespecially 3,4-dimethoxy-phenyl, 3-benzyloxy-4-methoxy-phenyl,especially phenyl substituted with one or more C₁₋₆alkyl sulfonylgroups, more especially 4-methanesulfonyl-phenyl;

[0199] benzyl;

[0200] naphthalenyl, especially naphthylen-2-yl;

[0201] benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;

[0202] furanyl, especially furan-2-yl, especially substituted furanyl,such as 5-nitro-furan-2-yl, 5-(4-nitrophenyl)-furan-2-yl,5-(3-trifluoromethyl-phenyl)-furan-2-yl, more especially halogensubstituted furanyl, even more especially 5-bromo-furan-2-yl, moreespecially aryl substituted furanyl, even more especially5-(4-chloro-phenyl)-furan-2-yl, more especially C₁₋₆alkyl substitutedfuranyl, even more especially 3-methyl-furan-2-yl, 4-methyl-furan-2-yl,2,5-dimethyl-furan-2-yl, and 2,4-dimethyl-furan-3-yl;

[0203] tetrahydrofuranyl, especially tetrahydrofuran-2-yl;

[0204] benzofuranyl, especially benzofuran-2-yl, and substitutedbenzofuranyl, more especially 5-(2-piperazin-4-carboxylic acidtert-butyl ester-ethoxy) benzofuran-2-yl,5-(2morpholino-4-yl-ethoxy)-benzofuran-2-yl,5-(2-piperazin-1-yl-ethoxy)benzofuran-2-yl,5-(2-cyclohexyl-ethoxy)-benzofuran-2-yl; especially C₁₋₆alkoxysubstituted benzofuranyl, more especially 7-methoxy-benzofuran-2-yl,5-methoxy-benzofuran-2-yl, 5,6-dimethoxy-benzofuran-2-yl, especiallyhalogen substituted benzofuranyl, more especially5-fluoro-benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl, especiallyC₁₋₆alkyl substituted benzofuranyl, most especially3-methyl-benzofuran-2-yl, 3,5-dimethyl-benzofuran-2-yl, and3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl,6-fluoro-3-methyl-benzofuran-2-yl, 5-methoxy-3-methyl-benzofuran-2-yl,4-methoxy-3-methyl-benzofuran-2-yl, and6-methoxy-3-methyl-benzofuran-2-yl;

[0205] naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl,alkyl substituted naphtho[2,1-b]-furanyl, especially1-methyl-naphtho[2,1-b]-furan-2-yl;

[0206] benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl; especiallyC₁₋₆alkoxy substituted benzo[b]thiophenyl, more especially5,6-dimethoxy-benzo[b]thiophen-2-yl;

[0207] quinolinyl, especially quinolin-2-yl, quinolin-3-yl,quinolin-4-yl, quinolin-6-yl, and quinolin-8-yl;

[0208] quinoxalinyl, especially quinoxalin-2-yl;

[0209] 1,8 naphthyridinyl, especially 1,8 naphthyridin-2-yl;

[0210] indolyl, especially indol-2-yl, especially indol-6-yl,indol-5-yl, especially C₁₋₆alkyl substituted indolyl, more especiallyN-methyl-indol-2-yl;

[0211] pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl,especially C₁₋₆alkyl substituted pyridinyl, more especially2-methyl-pyridin-5-yl, and oxy-pyridinyl, especially1-oxy-pyridin-2-yland 1-oxy-pyridin-3-yl;

[0212] furo[3,2-b]-pyridinyl, especially furo[3,2-b]-pyridin-2-yl,C₁₋₆alkyl substituted furo[3,2-b]-pyridinyl, especially3-methyl-furo[3,2-b]-pyridin-2-yl;

[0213] thiophenyl, especially thiophen-3-yl, also thiophen-2-yl,especially C₁₋₆alkyl substituted thiophenyl, more especially5-methyl-thiophen-2-yland 5-methyl-thiophen-3-yl, especially halogensubstituted thiophenyl, more especially 4,5-dibromo-thiophen-2-yl;

[0214] thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl,more especially C₁₋₆alkyl substituted thieno[3,2-b]thiophene-2-yl, moreespecially 5-tert-butyl-3-methyl-thieno[3,2-b]thiophene-2-yl;

[0215] isoxazolyl, especially isoxazol-4-yl, especially C₁₋₆alkylsubstituted isoxazolyl, more especially 3,5-dimethyl-isoxazol-4-yl;

[0216] oxazolyl, especially oxazol-4-yl, more especially5-methyl-2-phenyl oxazol-4-yl, 2-phenyl-5-trifluoromethyl-oxazol-4-yl;and

[0217] 1H-benzoimidazolyl, especially 1H-benzoimidazol-5-yl.

[0218] R⁹ is selected from the group consisting of:

[0219] methyl;

[0220] ethyl, especially C₁₋₆alkyl-substituted ethyl, more especially2-cyclohexyl-ethyl;

[0221] propyl;

[0222] butyl, especially C₁₋₆butyl, more especially 3-methylbutyl;

[0223] tert-butyl, particularly when R² is R⁹OC(O);

[0224] isopentyl;

[0225] phenyl, especially halogen substituted phenyl, more especially3,4-dichlorophenyl, 4-bromophenyl, 2-fluorophenyl, 3-fluorophenyl,4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,especially C₁₋₆alkoxy phenyl, more especially 3-methoxyphenyl,4-methoxyphenyl, 3,4-dimethoxyphenyl, especially cyanophenyl, moreespecially 2-cyanophenyl; especially C₁₋₆alkyl substituted phenyl, moreespecially 4-ethyl-phenyl, 2-methyl phenyl, 4-methyl phenyl, especiallyC₁₋₆alkyl sulfonyl substituted phenyl, more especially 4-methanesulfonylphenyl, and 2-methanesulfonyl phenyl;

[0226] toluyl, especially Het-substituted toluyl, more especially3-(pyridin-2-yl)toluyl;

[0227] naphthylene, especially naphthyl-2-ene;

[0228] benzoic acid, especially 2-benzoic acid;

[0229] benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;

[0230] benzo[1,2,5]oxadiazolyl, especially benzo[1,2,5]oxadiazol-4-yl;

[0231] pyridinyl, especially pyridin-2-yl, pyridin-3-yl, especially1-oxy-pyridinyl, more especially 1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl;especially C₁₋₆alkylpyridinyl, more especially 3-methyl-pyridin-2-yl,6-methyl-pyridin-2-yl;

[0232] thiophenyl, especially thiophenyl-2-yl;

[0233] thiazolyl, especially thiazol-2-yl;

[0234] 1H-imidazolyl, especially 1H-imidazol-2-yl, 1H-imidazol-4-yl,more especially C₁₋₆alkyl substituted imidazolyl, even more especially1-methyl-1H-imidazol-2-yl, 1-methyl-1H-imidazol-4-yl, and1,2-dimethyl-H-imidazol-4-yl;

[0235] triazolyl, especially 1H-[1,2,4]triazolyl, more especially1H-[1,2,4]triazol-3-yl, especially C₁₋₆alkyl substituted1H-[1,2,4]triazolyl, more especially 5-methyl-1H-[1,2,4]triazol-3-yl;and

[0236] isoxazolyl, especially isoxazol-4-yl, especially C₁₋₆alkylsubstituted isoxazolyl, more especially 3,5-dimethyl-isoxazol-4-yl.

[0237] R′ is H;

[0238] R″ is H; and

[0239] R′″ is H.

[0240] More preferred are compounds of Formula I wherein:

[0241] R¹ is

[0242] R² is R⁹SO₂;

[0243] R³ is isobutyl;

[0244] R⁴ is R⁵C(O);

[0245] R⁵ is selected from the group consisting of:3-methyl-benzofuran-2-yl, thieno[3,2-b]thiophen-2-yl,5-methoxybenzofuran-2-yl, quinoxalin-2-yl, and quinolin-2-yl, preferably3-methyl-benzofuran-2-yl;

[0246] R⁹ is selected from the group consisting of: pyridin-2-yl andl-oxy-pyridin-2-yl, preferably 1-oxy-pyridin-2-yl.

[0247] R′ is H; and

[0248] R′″ is H;

[0249] Most preferred is such compound wherein:

[0250] R⁵ is 3-methyl-benzofuran-2-yl; and

[0251] R⁹ is 1-oxy-pyridin-2-yl.

[0252] An embodiment (IA) of the present invention provides compounds ofFormula IA:

[0253] wherein:

[0254] R¹ is selected from the group consisting of:

[0255] R² is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂—, R⁹R¹¹NC(O)—, andR⁹SO₂R¹¹NC(O)—;

[0256] R³ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl, preferably C₁₋₆alkyl;

[0257] R³ and R′ may be connected to form a pyrrolidine, piperidine ormorpholine ring;

[0258] R⁴ is R⁵C(O)—;

[0259] R⁵ is selected from the group consisting of: C₁₋₆alkyl andHet-C₀₋₆alkyl, preferably Het-C₀₋₆alkyl;

[0260] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0261] R¹¹ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl, preferably H;

[0262] R′ is H;

[0263] R″ is H;

[0264] R′″ is selected from the group consisting of: H and C₁₋₆alkyl,preferably H;

[0265] R″″ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl; and

[0266] n is an integer from 1 to 5, preferably n is 3;

[0267] and pharmaceutically acceptable salts, hydrates and solvatesthereof.

[0268] In embodiment IA, when R¹ is

[0269] R³ is preferably C₁₋₆alkyl;

[0270] R³ is more preferably selected from the group consisting of:but-2-yl and isobutyl.

[0271] R³ is most preferably isobutyl.

[0272] R⁴ is R⁵C(O)—.

[0273] R⁵ is selected from the group consisting of: C₁₋₆alkyl andHet-C₀₋₆alkyl, preferably Het-C₁₋₆alkyl;

[0274] More preferably, R⁵ is selected from the group consisting of:

[0275] piperidin-ethyl, especially piperidin-1-yl-ethyl;

[0276] benzo[1,3]dioxolyl, especially benzo[1,3]dioxol-5-yl;

[0277] furanyl, especially furan-2-yl, especially aryl substitutedfuranyl, such as 5-(3-trifluoromethyl-phenyl)-furan-2-yl, moreespecially C₁₋₆alkyl substituted furanyl, even more especially3-methyl-furan-2-yl, 4-methyl-furan-2-yl, 2,5-dimethyl-furan-2-yl, and2,4-dimethyl-furan-3-yl;

[0278] benzofuranyl, especially benzofuran-2-yl, especially C₁₋₆alkoxysubstituted benzofuranyl, more especially 5-methoxy-benzofuran-2-yl,especially halogen substituted benzofuranyl, more especially5-fluoro-benzofuran-2-yl, especially C₁₋₆alkyl substituted benzofuranyl,most especially 3-methyl-benzofuran-2-yl, 3,5-dimethyl-benzofuran-2-yl,and 3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl,5-methoxy-3-methyl-benzofuran-2-yl, 4-methoxy-3-methyl-benzofuran-2-yl,and 6-methoxy-3-methyl-benzofuran-2-yl;

[0279] naphtho[2,1-b]-furanyl, especially naphtho[2,1-b]-furan-2-yl,C₁₋₆alkyl substituted naphtho[2,1-b]-furanyl, especially1-methyl-naphtho[2,1-b]-furan-2-yl;

[0280] benzo[b]thiophenyl, especially benzo[b]thiophen-2-yl;

[0281] quinolinyl, especially quinolin-2-yl;

[0282] quinoxalinyl, especially quinoxalin-2-yl;

[0283] pyridinyl, especially pyridin-2-yl, pyridin-3-yl, pyridin-5-yl,and oxy-pyridinyl, especially 1-oxy-pyridin-2-yl and 1-oxy-pyridin-3-yl;

[0284] furo[3,2-b]-pyridinyl, especially furo[3,2-b]-pyridin-2-yl,C₁₋₆alkyl substituted furo[3,2-b]-pyridin-2-yl, especially3-methyl-furo[3,2-b]-pyridin-2-yl;

[0285] thiophenyl, especially thiophen-3-yl, and thiophen-2-yl, C₁₋₆ylsubstituted thiophenyl, especially 5-methyl-thiophen-2-yland5-methyl-thiophen-3-yl; and

[0286] thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl;and

[0287] 1H-benzoimidazolyl, especially 1H-benzoimidazol-5-yl.

[0288] R⁵ is more preferably selected from the group consisting of:

[0289] 3-methyl-benzofuran-2-yl, thieno[3,2-b]thiophen-2-yl,5-methoxybenzofuran-2-yl, quinoxalin-2-yl, and quinolin-2-yl.

[0290] In embodiment IA, when R¹ is

[0291] R³ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl.

[0292] R³ is preferably C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, andAr—C₀₋₆alkyl.

[0293] R³ is more preferably selected from the group consisting ofmethyl, ethyl, n-propyl, n-butyl, isobutyl, t-butyl, cyclohexylmethyl,and toluyl.

[0294] R″″ is selected from the group consisting of: C₁₋₁₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl;

[0295] R″″ is preferably C₁₋₆alkyl;

[0296] R″″ is more preferably selected from the group consisting ofmethyl, ethyl, n-propyl, n-butyl, isobutyl and t-butyl.

[0297] Most preferably R″″ is methyl.

[0298] In such compounds, R′ and R⁴ are as described above wherein

[0299] In embodiment IA, when R¹ is

[0300] n is an integer of from 1 to 5; preferably 3; and

[0301] R′ and R⁴ are as described above wherein

[0302] The cyclic ring may be unsubstituted or substituted with one ormore of C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,HetC₀₋₆alkyl, ArC₀₋₆alkyl, or halogen.

[0303] The cyclic ring is preferably unsubstituted.

[0304] In embodiment IA, R² is selected from the group consisting of:

[0305] C₁₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂—,R⁹R¹¹NC(O)—, and R⁹SO₂R¹¹NC(O)—.

[0306] More preferably R² is selected from the group consisting of:Ar—C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂, and R⁹R¹¹NC(O)—.

[0307] Even more preferably, R² is selected from the group consistingof: Ar—C₀₋₆alkyl, R⁹C(O)—, and R⁹SO₂.

[0308] Most preferably R² is R⁹SO₂.

[0309] In such embodiment:

[0310] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0311] R⁹ is preferably selected from the group consisting of:C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl.

[0312] More preferably, R⁹ is selected from the group consisting of:

[0313] ethyl, especially C₁₋₆alkyl-substituted ethyl, more especially2-cyclohexyl-ethyl;

[0314] propyl, especially prop-1-yl;

[0315] isopentyl;

[0316] butyl, especially but-1-yl;

[0317] phenyl, especially halogen substituted phenyl, more especially3-fluorophenyl, 4-fluorophenyl, 2-chlorophenyl; especially C₁₋₆alkylsubstituted phenyl, more especially 4-ethyl-phenyl, 2-methyl phenyl,4-methyl phenyl, especially C₁₋₆alkyl sulfonyl substituted phenyl, moreespecially 4-methanesulfonyl phenyl, and 2-methanesulfonyl phenyl;

[0318] pyridinyl, especially pyridin-2-yl, 1-oxy-pyridinyl, moreespecially l-oxy-pyridin-2-yl;

[0319] 1H-imidazolyl, especially 1H-imidazol-2-yl C₁₋₆alkyl substitutedimidazolyl, especially 1-methyl-1H-imidazol-2-yl; and

[0320] isoxazolyl, especially isoxazol-4-yl, C₁₋₆alkyl substitutedisoxazolyl, especially 3,5-dimethyl-isoxazol-4-yl.

[0321] When R² is R⁹SO₂, R⁹ is most preferably selected from the groupconsisting of: pyridin-2-yl and 1-oxy-pyridin-2-yl.

[0322] When R² is R⁹SO₂R¹¹NC(O)—, R⁹ is preferably Ar—C₀₋₆alkyl, morepreferably Ar, most preferably substituted phenyl such as 2-methylphenyl, 4-methyl phenyl, 2-chloro phenyl, 4-fluoro phenyl.

[0323] When R² is R⁹C(O)—, R⁹ is preferably selected from the groupconsisting of C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, and Het-C₀₋₆alkyl,more preferably 1-oxy-pyridin-2-yl, 2-cyclohexyl ethyl, and isopentyl.

[0324] When R² is R⁹SO₂R¹¹NC(O)—, R¹¹ is selected from the groupconsisting of:

[0325] H, C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl. Preferably in suchembodiment, R¹¹ is H.

[0326] R² may suitably be selected from the group consisting of:

[0327] C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl, preferably C₁₋₆alkyland Het-C₀₋₆alkyl,

[0328] When R² is Ar—C₀₋₆alkyl, R² is preferably phenyl, especiallysubstituted phenyl, more especially halogen substituted phenyl, evenmore especially 2-fluorobenzyl.

[0329] When R² is C₁₋₆alkyl, R² is preferably selected from 1-propyl,1-butyl, and 1-pentyl.

[0330] When R² is Het-C₀₋₆alkyl, Het-C₀₋₆alkyl is preferably Het-methyl,and Het in Het-methyl is preferably selected from the group consistingof:

[0331] pyridinyl, especially pyridin-2-yl, C₁₋₆alkylpyridinyl,especially 6-methyl-pyridin-2-yl;

[0332] thiophenyl, especially thiophene-2-yl;

[0333] benzo[b]thiophen-2-yl;

[0334] thiazolyl, especially thiazol-4-yl such as isothiazol-3-yl;

[0335] 1H-imidazolyl, especially 1H-imidazol-2-yl, C₁₋₆alkyl substitutedimidazolyl, especially 1-methyl-1H-imidazol-2yl;

[0336] triazolyl, especially 3H-[1,2,3]triazolyl, more especially3H-[1,2,3]triazol-4-yl, especially C₁₋₆alkyl substituted3H-[1,2,3]triazolyl, more especially 3-phenyl-3H-1,2,3]triazolyl-4-yl;

[0337] quinolinyl, especially quinolin-2-yl, quinolin-2-yl;

[0338] furanyl, especially furan-2-yl, especially substituted furanyl,such as 5-ethyl-furan-2-yl;

[0339] thieno[3,2-b]thiophene, especially thieno[3,2-b]thiophene-2-yl,C₁ 1₆alkyl substituted thieno[3,2-b]thiophene-2-yl, especially3,4-dimethyl-thieno[3,2-b]thiophene-2-yl.

[0340] The compounds of embodiment IA have the same uses describedthroughout this specification for compounds of Formula I. The compoundsof embodiment IA may be formulated into pharmaceutical compositions andused in methods of treatment as described for compounds of Formula Ithroughout this specification.

[0341] Compounds of Formula I selected from the following group areparticularly preferred embodiments of the present invention: Ex- am- pleNo. Chemical Name  1{(S)-1-[1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamic acid benzyl ester;  2Naphthylene-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  3 Benzo[1,3]dioxole-5-carboxylicacid [(S)-1-(1-benzyl-3-oxo- azepan-4-ylcarbamoyl)-3-methyl-butyl]amide; 4 Benzofuran-2-carboxylic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  5 Benzo[b]thiophene-2-carboxylicacid [(S)-1-(1-benzyl-3-oxo- azepan-4-ylcarbamoyl)-3-methyl-butyl]amide; 6 Naphthylene-2-sulphonyl [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;  7 Quinoline-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4- ylcarbamoyl)-3-methyl-butyl]amide;  83,4-dichlorobenzoic acid [(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  94-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]azepanium;  101-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino-3-oxo-azepanium;  111-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium;  121-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium;  133-Oxo-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-etloxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium;  145-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl- butyl]amide; 15 4-((S)-4-Methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-3-oxo-azepane-1-carboxylic acidphenylamide;  16 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylicacid ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide;  175-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  185-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl- butyl]amide; 19 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl- butyl]amide; 20 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  21 Naphthlene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  221H_Indole-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  231H-Indole-2-carboxylic acid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  24 Benzofuran-2-carboxylicacid [(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;  25 Benzofuran-2-carboxylicacid [(S)-3-methyl-l-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  265-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbamoyl]- butyl}amide;  27Naphthylene-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbamoyl]-butyl}amide;  28 Benzofuran-2-carboxylicacid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;  29Naphthylene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;  305-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;  314-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-amino}-pentanoylamino)-3-oxo-azepane-1-carboxylic acidtert-butyl ester;  324-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;  33 4-Methyl-pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl- acetyl]-azepan-4-yl}-amide;  34((S)-3-Methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamic acidtert-butyl ester;  35(S)-4-Methyl-2-[(naphthylen-2-ylmethyl)-amino]-pentenoic acid[3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide;  364-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester;  375-(2-Piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-3-methyl-l-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-butyl}-amide;  38 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3- methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  39 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid((S)-3- methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  404-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl[azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acid tert-butyl ester;  415-(2-piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;  42(S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid[3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide;  43(S)-4-Methy1-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}- amide;  445-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid methyl((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide;  45Benzofuran-2-carboxylic acid methyl {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]- amide;  462,2,2-Trifluoro-N-((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-N-naphthylen-2-ylmethyl-acetamide;  474-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-oxo-azepane-1-carboxylic acid benzyl ester;  48Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  49Quinoline-8-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  50Quinoline-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  51Quinoline-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  52Quinoline-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  53Isoquinoline-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  54Isoquinoline-1-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  55Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  56Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  571,8-Naphthyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  581H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  595-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  605-Bromo-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  61Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  625-Nitro-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  635-(4-Nitro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  645-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  65 Tetrahydro-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  66(S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid [3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;  67(S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic acid[3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;  68Benzofuran-2-carboxylic acid }(S)-3-methyl-1-[3-oxo-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide;  69Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  704-((S)-2-tert-Butylcarbonylamino-4-methyl-pentanoylamino)-3-oxo-azepane-1-carboxylic acid benzyl ester;  715,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  72 Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(5-methyl-1H-[1,2,4]triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide; 73 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;  74Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;  75Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  76Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;  775-(4-Oxy-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  78 Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  79Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  80Quinoline-3-carboxylic acid {(S)-1-(3,4-dichloro-benzene-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl)]-3-methyl-butyl}-amide;  815-Hydroxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;  82 Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl}- amide;  832-(4-{(S)-2-{(Benzofuran-2-carbonyl)-amino}-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoic acid;  843-(4-{(S)-2-{(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoic acid;  85Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  865-Bromo-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  875,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide; 88 1-Oxy-pyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  89(S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;  90(S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;  91(S)-4-Methyl-2-(3-phenyl-uriedo)-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;  92 Benzofuran-2-carboxylicacid {(S)-1-[6,6-dimethyl-3-oxo-1(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;  935-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide;  94Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide;  95Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  96Quinoline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  97Thiophene-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  981H-Indole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;  99Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 100Furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 101(S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid [3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide; 1021H-Indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1034-Fluoro-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide; 1045-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-(1-oxy-pyridine2-sulphonyl)-azepan-4- ylcarbamoyl]--buty}-amide; 105 Thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1063-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1076-Methyl-N-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamide; 108(S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoic acid-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide; 1091H-Indole-6-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 110Benzo[1,3]dioxole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1113,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]butyl}amide; 112 5-Methyl-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1134,5-Dibromo-thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide; 1143,5-Dimethyl-isoxazole-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide; 115(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-y1]-amide; 1165-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 117 5-Methyl-2-phenyl-oxazole-4-carboxylicacid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide;118 Benzofuran-2-carboxylic acid {(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide; 119Benzofuran-2-carboxylic acid {(S)-1-[1-(4-bromo-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 120Benzofuran-2-carboxylic acid {(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 121Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 1223-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 123Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1245-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 125 5-Methyl-2-phenyl-oxazole-4-carboxylicacid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 1262-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 127 Quinoline-2-carboxylic acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 1281-Methyl-1H-indole-2-carboxylic acid [(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 129Furan-2-carboxylic acid {[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-amide; 1305-Methoxy-benzofuran-2-carboxylic acid [(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]- amide; 131Quinoxaline-2-carboxylic acid [(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 1325-(4-Chloro-phenyl)-furan-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 133(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid(1-methanesulfonyl-3-oxo-azepan-4-yl)-amide; 134 Quinoline-2-carboxylicacid {[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 1351-Methyl-1H-indole-2-carboxylic acid {[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methylbutyl}- amide; 136Furan-2-carboxylic acid ({(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoy1]-3-methyl-butylcarbamoyl}-methyl)- amide; 1375-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 138Quinoxaline-2-carboxylic acid {(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methylbutyl}- amide; 139(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide; 140Quinoline-2-carboxylic acid {[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-buty}- amide; 1411-Methyl-1H-indole-2-carboxylic acid {[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 142Furan-2-carboxylic acid ({(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)- amide; 1435-Methoxy-benzofuran-2-carboxylic acid {[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 144Quinoxaline-2-carboxylic acid {[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 145(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide; 1461-Methyl-1H-indole-2-carboxylic acid {[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 147Furan-2-carboxylic acid ({(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)- amide; 1485-Methoxy-benzofuran-2-carboxylic acid {[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 149Quinoxaline-2-carboxylic acid {[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 150(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide; 151Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;152 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;153 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;154 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;155 3-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;156 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;157 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;158 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;159 Benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;160 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;161 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;162 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;163 5-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;164 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;165 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;166 (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 167Quinoxaline-2-carboxylic acid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;168 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 1697-Methoxy-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 1705,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}- amide; 1713-Methyl-benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 172Benzo[b]thiophene-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 1731-Methyl-1-H-indole-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 174Quinoxaline-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 175Benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;176 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;177 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl- butyl}-amide;178 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;179 3-Methyl-benzofuran-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;180 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;181 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;182 Quinoxaline-2-carboxylic acid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;183 Benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;184 5-Methoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;185 7-Methoxy-benzofuran-2-carboxylic acid-{(S)-1[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;186 5,6-Dimethoxy-benzofuran-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 187 3-Methyl-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;188 Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;189 1-Methyl-1H-indole-2-carboxylic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;190 Quinoxaline-2-carboxyiic acid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;191 Benzofuran-2-carboxylic acid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 192Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[(2,2′,4-tridueterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 193 Benzofuran-2-carboxylic acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl]-amide; 194Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide; 195Benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 196Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 197Benzofuran-2-carboxylic acid {(S)-3-methanesulfinyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide; 198Benzofuran-2-carboxylic acid {[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-methyl}-amide; 199 Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide; 200Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 201Benzofuran-2-carboxylic acid {(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide; 202Benzofuran-2-carboxylic acid {(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide; 203Benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide; 2041-(Benzofuran-2-carbonyl)-pyrrolidine-2-carboxylic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 2053,4-Dimethoxy-N-{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-benzamide; 206Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(4-imethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 207Benzo[1,3]dioxole-5-carboxylic acid {(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3methyl-butyl}- amide; 208(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide; 209Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl]-3-methyl-butyl}- amide;210 Benzofuran-2-carboxylic acid {(S)-1-[1-benzoyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 211(S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 212(S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 213Benzofuran-2-carboxylic acid-{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl]-3-methyl-butyl}- amide;214 N-{(S)-1-[1-(4-Fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-3,4-dimethoxy-benzamide; 215Cyclohexanecarboxylic acid {(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-amide; 216(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(methanesulfonyl)-3-oxo-azepan-4-yl]-amide; 217Benzo[b]thiophene-2-carboxylic acid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-amide; 218Benzo[1,3]dioxole-5-carboxylic acid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-amide; 219Benzofuran-2-carboxylic acid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]-amide; 220N-[(S)-1-(1-Methanesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-3,4-dimethoxy-benzamide; 221(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(2-cyano-benzensulfonyl)-3-oxo-azepan-4-yl]-amide; 222N-{(S)-1-[1-(2-Cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-4-methanesulfonyl-1-benzamide; 223Benzo[b]thiophene-2-carboxylic acid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-yl carbamoyl)-3-methyl-butyl]- amide;224 Benzo[1,3]dioxole-5-carboxylic acid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]- amide; 225(S)-4-Methyl-2-[4-oxo-4-((4-phenoxy-phenyl)-butyrylamino}- pentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 226N-{(S)-1-[(1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-3,4-dimethoxy-benzamide; 227Cyclohexanecarboxylic acid {(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}- amide; 2284-Methansulfonyl-N-{(S)-1-[4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide; 2294-Methansulfonyl-N-{(S)-1-[4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide; 230({(S)-3-Methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-carbamic acid benzyl ester; 231(S)-2-[5-(4-Methoxy-phenyl)-pentanoylamnio]-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 232(S)-2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamino]-4- methylpentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]- amide; 2335,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide; 234(S)-4-Methyl-2-(5-oxo-hexanoylamino)-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 235 Benzofuran-2-carboxylicacid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide; 2365-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;237 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;238 7-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide; 2395,6-Dimethoxy-benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide; 240 (R)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic acid{(S)-3-methyl- 1-{3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 241 (S)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic acid{(S)-3-methyl- 1-{3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 242 Benzofuran-2-carboxylic acid{(S)-2-cyclopropyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide; 243Benzofuran-2-carboxylic acid {(S)-3-methylsulfanyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-propyl]-amide; 244Benzofuran-2-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide; 245Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;246 Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;247 3-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;248 5-Methoxy-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]- butyl}amide;249 5,6-Difluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]- butyl}amide;250 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 251 5-(4-Chloro-phenyl)-furan-2-carboxylicacid {(S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}- amide; 252Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[6-methyl-3-oxo-1-(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 2535-(4-Chloro-phenyl)-furan-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 254 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2- cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 255 5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 2565,6-Dimethoxy-benzofuran-2-carboxylic acid {(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide; 257 5,5-Bis-(4-methoxy-phenyl)-pent-4-enoic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]}-butyl}- amide; 258Quinoline-8-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide; 259Naphthylene-1-carboxylic acid {(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonly)-azepan-4-ylcarbamoyl)-ethyl]-amide; 260Quinoline-8-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide; 261Naphthyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 262Naphthylene-1-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide; 2633-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 2643-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl}- amide; 2653-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 266(S)-Acetylamino-4-methyl-pentanoic acid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 267 Quinoline-2-carboxylic acid{1-[3-oxo-1-(pyridine-2-sulfonyl)- azepan-4-ylcarbamoyl]-pentyl}-amide;268 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 269Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 270Quinoline-2-carboxylic acid {(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide; 271Benzofuran-2-carboxylic acid {(S)-2-benzyloxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide; 272Benzofuran-2-carboxylic acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide; 2735-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 2747-Methoxybenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 2753-Methylbenzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 276Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 2771-Methyl-1H-indole-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide; 278Quinoxaline-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]butyl}amide; 279 Quinoline-2-carboxylicacid {[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; The followingcompounds are also particularly preferred embodiments of the presentinvention: 280 Benzofuran-2-carboxylic acid{(S)-1-[-(3-fluoro-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 281(S)-4-methyl-2-(3-piperidin-1-yl-propanoylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; 282Benzofuran-2-carboxylic acid {(S)-1-[-(4-ethyl-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 2835-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 284 Benzo[1,3]-dioxole-5-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)- amide; 2855-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 286 Benzo[1,3]-dioxole-5-carboxylic acid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 2875-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid {(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide;288 Benzo[1,3]-dioxole-5-carboxylic acid {(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 289Benzofuran-2-carboxylic acid {(S)1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide 290Benzofuran-2-carboxylic acid [(S)-1-[3-oxo-1-(ethanesulfonyl-azepan-4-ylcarbamoyl)-3-methyl-1-butyl]-amide; 2915-Fluoro-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 2925-Fluoro-3-methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 293 6-Fluoro-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 294 3-Methyl-benzofuran-2-carboxylic acid{(R)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 2953-Methyl-furo[3,2-b]-pyridine-2-carboxylic acid {(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 296 5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 2973-Methyl-benzofuran-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 298Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 2993-methyl-furan-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 300Quinoline-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 301Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 302Quinoxaline-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 303Thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 3045-Methyl-thiophene-2-carboxylic acid {(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3055-Methoxy-benzofuran-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 3063-Methyl-benzofuran-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 307Benzo[b]thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 3083-Methyl-furan-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 309 Quinoline-2-carboxylicacid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 310Thieno[3,2-b]thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]- amide; 311Quinoxaline-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 312 Thiophene-2-carboxylicacid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 3135-Methyl-thiophene-2-carboxylic acid [(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 3145-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}- amide; 3153-Methyl-benzofuran-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 316Benzo[b]thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 3173-Methyl-furan-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 3182,5-Dimethyl-furan-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 319Quinoline-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 320Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}- amide; 321Quinoxaline-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 322Thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 3235-Methyl-thiophene-2-carboxylic acid {(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide; 3245-Methoxy-3-methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 325 3,5-Dimethyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}- amide;326 3-Ethyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}- amide; 3274-Methoxy-3-methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 328 1-methyl-naphtho[2,1-b]-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 329 6-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonly)-azepan-4-ylcarbamoyl]-butyl}-amide; 330 3-Methyl-benzofuran-2-carboxylic acid{1,3-dimethyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 331Benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide; 3323-Methyl-benzofuran-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide; 333Benzo[b]thiophene-2-carboxylic acid [(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide; 334Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}- butyl)-amide;335 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 336 Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}- butyl)-amide;337 Benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)- amide;338 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 339 Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 340 Benzofuran-2-carboxylic acid((S)-3-methyl-1-[3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)- amide;341 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 342 Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 343 Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-to1uene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}- butyl)-amide;344 3-Methyl-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide; 345 Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}- butyl)-amide;346 Benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide; 3473-Methyl-benzofuran-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}- amide;348 Benzo[b]thiophene-2-carboxylic acid {(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}- amide;349 Benzo[b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3503-Methyl-benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3512,4-Dimethylfuran-3-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 352Quinoxaline-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 353Thieno[3,2-b]thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 354Quinoline-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3554-Methyl-thiophene-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3565-Methoxy-benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 3574-Methyl-furan-2-carboxylic acid {(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 358Benzofuran-2-carboxylic acid [(S)-1-(1-butyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; 359 Benzofuran-2-carboxylic acid[(S)-1-(1-propyl-3-oxo-azepan-4- ylcarbamoyl)-3-methyl-butyl]-amide; 360Benzofuran-2-carboxylic acid {(S)-1-[1-(2-fluoro-benzyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 361 Benzofuran-2-carboxylicacid {(S)-3-methyl-1-[1-(2-morpholin-4-yl-thiazol-4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}- amide; 362Benzofuran-2-carboxylic acid {(S)-1-[1-(5-ethyl-furan-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 363Benzofuran-2-carboxylic acid {(S)-1-[1-(3,4-dimethyl-thieno[3,2-b]thiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 364 Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(3-phenyl-3H-[1,2,3]triazol-4-ylmethyl)-azepan-4-ylcarbamoyl]-butyl}- amide; 365Benzofuran-2-carboxylic acid [(S)-1-[1-(isothiazol-3-ylmethyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl}-amide; 366Benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-thiophen-2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide; 367Benzofuran-2-carboxylic acid [(S)-1-(1-benzo[b]thiophen-2-ylmethyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl]-amide; 368Benzofuran-2-carboxylic acid [(S)-3-methyl-1-(3-oxo-1-pentyl-azepan-4-ylcarbamoyl)-butyl]-amide; 369 Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazol-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide; 3701-Oxy-pyridine-2-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 3712-Oxy-pyridine-3-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 3721H-Benzoimidazole-5-carboxylic acid {(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 3734-{(S)-2-[(1-Benzofuran-2-yl-methanoyl)-amino]-4-methyl-pentanoylamino}-1-methyl-3-oxo-1-pentyl-azepanium; 374Benzofuran-2-carboxylic acid {(S)-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 375 Benzofuran-2-carboxylic acid {(S)-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 376 Benzofuran-2-carboxylic acid{(S)-1-[1-(4-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 377Benzofuran-2-carboxylic acid {(S)-1-[1-(2-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}- amide; 378Benzofuran-2-carboxylic acid {(S)-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide; 3793-Methyl-benzofuran-2-carboxylic acid {(1S,2R)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide; 3803-Methyl-benzofuran-2-carboxylic acid {1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-cyclopentyl}-amide; and 381Furo[3,2-b]-pyridine-2-carboxylic acid {(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide.

[0342] Particularly preferred compounds of embodiment IA are ExampleNos. 280 to 381 in the list herein above.

[0343] Specific representative compounds of the present invention areset forth in Examples 1-381.

[0344] Compared to the corresponding 5 and 6 membered ring compounds,the 7 membered ring compounds of the present invention areconfigurationally more stable at the carbon center alpha to the ketone.

[0345] The present invention includes deuterated analogs of theinventive compounds. A representative example of such a deuteratedcompound is set forth in Example 192. A representative synthetic routefor the deuterated compounds of the present invention is set forth inScheme 4, below. The deuterated compounds of the present inventionexhibit superior chiral stability compared to the protonated isomer.

[0346] Where possible the present invention includes quaternary salts ofthe inventive compounds. A representative example of such a quaternarysalt is set forth in Example 373. A representative synthetic route forthe quaternary salts of the present invention is set forth in Scheme 6,below.

Definitions

[0347] The present invention includes all hydrates, solvates, complexesand prodrugs of the compounds of this invention. Prodrugs are anycovalently bonded compounds which release the active parent drugaccording to Formula I in vivo. If a chiral center or another form of anisomeric center is present in a compound of the present invention, allforms of such isomer or isomers, including enantiomers anddiastereomers, are intended to be covered herein. Inventive compoundscontaining a chiral center may be used as a racemic mixture, anenantiomerically enriched mixture, or the racemic mixture may beseparated using well-known techniques and an individual enantiomer maybe used alone. In cases in which compounds have unsaturatedcarbon-carbon double bonds, both the cis (Z) and trans (E) isomers arewithin the scope of this invention. In cases wherein compounds may existin tautomeric forms, such as keto-enol tautomers, each tautomeric formis contemplated as being included within this invention whether existingin equilibrium or predominantly in one form.

[0348] The meaning of any substituent at any one occurrence in Formula Ior any subformula thereof is independent of its meaning, or any othersubstituent's meaning, at any other occurrence, unless specifiedotherwise.

[0349] Abbreviations and symbols commonly used in the peptide andchemical arts are used herein to describe the compounds of the presentinvention. In general, the amino acid abbreviations follow the IUPAC-IUBJoint Commission on Biochemical Nomenclature as described in Eur. J.Biochem., 158, 9 (1984).

[0350] “Proteases” are enzymes that catalyze the cleavage of amide bondsof peptides and proteins by nucleophilic substitution at the amide bond,ultimately resulting in hydrolysis. Such proteases include: cysteineproteases, serine proteases, aspartic proteases, and metalloproteases.The compounds of the present invention are capable of binding morestrongly to the enzyme than the substrate and in general are not subjectto cleavage after enzyme catalyzed attack by the nucleophile. Theytherefore competitively prevent proteases from recognizing andhydrolyzing natural substrates and thereby act as inhibitors.

[0351] The term “amino acid” as used herein refers to the D-or L-isomersof alanine, arginine, asparagine, aspartic acid, cysteine, glutamine,glutamic acid, glycine, histidine, isoleucine, leucine, lysine,methionine, phenylalanine, proline, serine, threonine, tryptophan,tyrosine and valine.

[0352] “C₁₋₆alkyl” as applied herein is meant to include substituted andunsubstituted methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl andt-butyl, pentyl, n-pentyl, isopentyl, neopentyl and hexyl and the simplealiphatic isomers thereof. C₁₋₆alkyl may be optionally substituted by amoiety selected from the group consisting of: OR¹⁴, C(O)R¹⁴, SR¹⁴,S(O)R¹⁴, NR¹⁴ ₂, R¹⁴NC(O)OR⁵, CO₂R¹⁴, CO₂NR¹⁴ ₂, N(C═NH)NH₂, Het,C₃₋₆cycloalkyl, and Ar; where R⁵ is selected from the group consistingof: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; and R¹⁴ is selected from the groupconsisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0353] “C₃₋₆cycloalkyl” as applied herein is meant to includesubstituted and unsubstituted cyclopropane, cyclobutane, cyclopentaneand cyclohexane.

[0354] “C₂₋₆ alkenyl” as applied herein means an alkyl group of 2 to 6carbons wherein a carbon-carbon single bond is replaced by acarbon-carbon double bond. C₂₋₆alkenyl includes ethylene, 1-propene,2-propene, 1-butene, 2-butene, isobutene and the several isomericpentenes and hexenes. Both cis and trans isomers are included.

[0355] “C₂₋₆alkynyl” means an alkyl group of 2 to 6 carbons wherein onecarbon-carbon single bond is replaced by a carbon-carbon triple bond.C₂₋₆ alkynyl includes acetylene, 1-propyne, 2-propyne, 1-butyne,2-butyne, 3-butyne and the simple isomers of pentyne and hexyne.

[0356] “Halogen” means F, Cl, Br, and I.

[0357] “Ar” or “aryl” means phenyl or naphthyl, optionally substitutedby one or more of Ph-C₀₋₆alkyl; Het-C₀₋₆alkyl; C₁₋₆alkoxy;Ph-C₀₋₆alkoxy; Het-C₀₋₆alkoxy; OH, (CH₂)₁₋₆NR¹⁵R¹⁶; O(CH₂)₁₋₆NR¹⁵R¹⁶;C₁₋₆alkyl, OR¹⁷, N(R¹⁷)₂, SR¹⁷, CF₃, NO₂, CN, CO₂R¹⁷, CON(R¹⁷), F, Cl,Br or I; where R¹⁵ and R¹⁶ are H, C₁₋₆alkyl, Ph-C₀₋₆alkyl,naphthyl-C₀₋₆alkyl or Het-C₀₋₆alkyl; and R¹⁷ is phenyl, naphthyl, orC₁₋₆alkyl.

[0358] As used herein “Het” or “heterocyclic” represents a stable 5-to7-membered monocyclic, a stable 7-to 10-membered bicyclic, or a stable11-to 18-membered tricyclic heterocyclic ring which is either saturatedor unsaturated, and which consists of carbon atoms and from one to threeheteroatoms selected from the group consisting of N, O and S, andwherein the nitrogen and sulfur heteroatoms may optionally be oxidized,and the nitrogen heteroatom may optionally be quaternized, and includingany bicyclic group in which any of the above-defined heterocyclic ringsis fused to a benzene ring. The heterocyclic ring may be attached at anyheteroatom or carbon atom which results in the creation of a stablestructure, and may optionally be substituted with one or two moietiesselected from CO₆Ar, C₁₋₆alkyl, OR¹⁷, N(R¹⁷)₂, SR¹⁷, CF₃, NO₂, CN,CO₂R¹⁷, CON(R¹⁷), F, Cl, Br and I, where R¹⁷ is phenyl, naphthyl, orC₁₋₆alkyl. Examples of such heterocycles include piperidinyl,piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl,2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl,pyrazolyl, pyrazolidinyl, imidazolyl, pyridinyl, 1-oxo-pyridinyl,pyrazinyl, oxazolidinyl, oxazolinyl, oxazolyl, isoxazolyl, morpholinyl,thiazolidinyl, thiazolinyl, thiazolyl, quinuclidinyl, indolyl,quinolinyl, quinoxalinyl, isoquinolinyl, benzimidazolyl, benzopyranyl,benzoxazolyl, furanyl, benzofuranyl, thiophenyl, benzo[b]thiophenyl,thieno[3,2-b]thiophenyl, benzo[1,3]dioxolyl, 1,8 naphthyridinyl,pyranyl, tetrahydrofuranyl, tetrahydropyranyl, thienyl, benzoxazolyl,thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl, aswell as triazolyl, thiadiazolyl, oxadiazolyl, isothiazolyl, imidazolyl,pyridazinyl, pyrimidinyl, triazinyl and tetrazinyl which are availableby routine chemical synthesis and are stable. The term heteroatom asapplied herein refers to oxygen, nitrogen and sulfur.

[0359] Here and throughout this application the term Co denotes theabsence of the substituent group immediately following; for instance, inthe moiety ArCO₆alkyl, when C is 0, the substituent is Ar, e.g., phenyl.Conversely, when the moiety ArCO₆alkyl is identified as a specificaromatic group, e.g., phenyl, it is understood that the value of C is 0.

[0360] Certain radical groups are abbreviated herein. t-Bu refers to thetertiary butyl radical, Boc refers to the t-butyloxycarbonyl radical,Fmoc refers to the fluorenylmethoxycarbonyl radical, Ph refers to thephenyl radical, Cbz refers to the benzyloxycarbonyl radical.

[0361] Certain reagents are abbreviated herein. m-CPBA refers to3-chloroperoxybenzoic acid, EDC refers toN-ethyl-N′(dimethylaminopropyl)-carbodiimide, DMF refers to dimethylformamide, DMSO refers to dimethyl sulfoxide, TEA refers totriethylamine, TFA refers to trifluoroacetic acid, and THF refers totetrahydrofuran.

[0362] Methods of Preparation

[0363] Compounds of the general formula I may be prepared in a fashionanalogous to that outlined in Schemes 1, 2 and 3. Alkylation oftert-butyl N-allylcarbamate (1) with a base such as sodium hydride and5-bromo-1-pentene provides the diene 2. Treatment of 2 with either2,6-diisopropylphenylimido neophylidene molybenum bis(tert-butoxide) orbis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride olefinmetathesis catalysts developed by Grubbs provides the azepine 3.Epoxidation of 3 with standard oxidizing agents common to the art suchas m-CPBA provide the epoxide 4. Nucleophilic epoxide ring opening maybe effected with a reagent such as sodium azide to provide the azidoalcohol (not shown) which may be reduced to the amino alcohol 5 underconditions common to the art such as 1,3-propanedithiol andtriethylamine in methanol or with hydrogen gas in the presence of acatalyst such as palladium on carbon. Acylation of 5 with an acid suchas Cbz-leucine in the presence of a coupling agent such as EDC followedby removal of the BOC protecting group under acidic conditions providesthe amine salt 6. Coupling of 6 with Cbz-leucine may be effected with acoupling agent such as EDC to provide the intermediate alcohol (notshown) which was oxidized with an oxidant such as pyridine sulfurtrioxide complex in DMSO and triethylamine to provide the ketone 7.

[0364] Reagents and conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.)2,6-diisopropylphenylimido neophylidene molybenum bis(tert-butoxide) orbis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloridecatalyst, toluene c.) m-CPBA, CH₂Cl₂; d.) NaN₃, CH₃OH, H₂O, NH₄Cl; e.)10% Pd/C, H₂, f.) Cbz-leucine, EDC, CH₂Cl₂; g.) HCl, EtOAc; h.)Cbz-leucine, EDC, CH₂Cl₂; i.) pyridine sulfur trioxide complex, DMSO,TEA.

[0365] Compounds of the general formula I wherein R¹ and R² are amidesmay be prepared in the general fashion outlined in Scheme 2. Alkylationof N-Cbz allyl amine (8) with a base such as sodium hydride and5-bromo-1-pentene provides the diene 9. Treatment of 9 withbis(tricyclohexylphosphine)benzylidine ruthenium(IV)dichloride olefinmetathesis catalyst developed by Grubbs provides the azepine 10.Epoxidation of 10 with standard oxidizing agents common to the art suchas m-CPBA provide the epoxide 11. Nucleophilic epoxide ring opening maybe effected with a reagent such as sodium azide to provide the azidoalcohol (not shown) which may be reduced to the amino alcohol 12 with areducing agent such as propanedithiol in the presence of triethylamine.Acylation of 12 with N-Boc-leucine and a coupling agent such as EDCfollowed by removal of the Cbz protecting group under hydrogenolysisconditions provides the amine 13. Coupling of 13 with a carboxylic acidwas effected with a coupling agent such as EDC followed by removal ofthe acid labile N-Boc protecting group with an acid such as HCl or TFAprovides intermediate 14. Acylation of 14 may be effected with acarboxylic acid in the presence of a coupling agent common to the artsuch as EDC to give the intermediate alcohol (not shown) which isoxidized with an oxidant such as pyridine sulfur trioxide complex inDMSO and triethylamine to provide the ketone 15.

[0366] Reagents and conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.)bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloridecatalyst, CH₂Cl₂; c.) m-CPBA, CH₂Cl₂; d.) NaN₃, CH₃OH, H₂O, NH₄Cl; e.)propanedithiol, CH₃OH, TEA; f.) Boc-leucine, EDC, CH₂Cl₂; g.) 10% Pd/C,H₂; h.) R₁CO₂H, EDC, CH₂Cl₂ or R₁COCl, CH₂Cl₂; i.) HCl/EtOAc; j.) R₂CO2H, EDC, CH₂Cl₂; k.) pyridine sulfur trioxide complex, DMSO, TEA.

[0367] Compounds of the general formula I wherein R² is an alkyl, ureaor sulphonamide group and R¹ is an amide may be prepared in the generalfashion outlined in Scheme 3. Reductive amination of 13 may be effectedby treatment with an aldehyde followed by a reducing agent such assodium triacetoxyborohydride. Subsequent deprotection of the N-Boc groupunder acidic conditions provides the amine salt 16. Coupling of 16 withan acid chloride or with a carboxylic acid in the presence of a couplingagent common to the art such as EDC followed by oxidation of theintermediate alcohol (not shown) with an oxidant such as pyridine sulfurtrioxide complex provides the ketone 17. Alternatively, treatment ofamine 13 with an isocyanate followed by deprotection of the N-Boc groupprovides the amine salt 18. Acylation and oxidation provides the ketone19. Further derivatization of amine 13 may be effected by treatment witha sulphonyl chloride followed by deprotection of the N-Boc group toprovide the amine salt 20. Acylation and oxidation provides the ketone21.

[0368] Reagents and conditions: a.) R₁CHO, NaBH(OAc)₃; b.) HCl; c.)R₂CO₂H, EDC, CH₂Cl₂; d.) pyridine sulfur trioxide complex, DMSO, TEA;e.) R,NCO, base; f.) R₁SO₂Cl, TEA, CH₂Cl₂.

[0369] The deuterated compound of the Example 192 may be convenientlyprepared according to Scheme 4. The skilled artisan will understand fromExample 192 and Scheme 4 how to make any of the the deuterated compoundsof the present invention.

[0370] The individual diastereomers of benzofuran-2-carboxylic acid{(S)-3-methyl-1-[(2,2′,4-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide31 and 32 may be prepared as outlined in Scheme 4. Alkylation ofallyl-carbamic acid benzyl ester 22 with 5-bromo-1-pentene in thepresence of a base such as sodium hydride provides the diene 23.Treatment of diene 23 with bis(tricyclohexylphosphine)benzylidineruthenium (IV) dichloride developed by Grubbs provides the2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester 24.Epoxidation of azepine 24 may be effected with standard oxidizing agentscommon to the art such as m-CPBA to provide epoxide 25. Nucleophilicepoxide ring opening of 25 may be effected with a reagent such as sodiumazide to provide the azido alcohol (not shown).

[0371] Reagents and Conditions: a.) NaH, 5-bromo-1-pentene, DMF; b.)bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride,CH₂Cl₂; c.) m-CPBA, CH₂Cl₂; d.) NaN₃, CH₃OH, H₂O, NH₄Cl; e.)1,3-propanedithiol, TEA, methanol; f.) N-Boc-leucine, EDC, CH₂Cl₂; g.)10% Pd/C, H₂; h.) 2-pyridinesulphonyl chloride, TEA, CH₂Cl₂; i.) 4 NHCl/dioxane, methanol; j.) benzofuran-2-carboxylic acid, EDC, CH₂Cl₂;k.) pyridine sulfur trioxide complex, DMSO, TEA; 1.) CD₃OD;D₂O (10:1),TEA; m.) HPLC separation. The intermediate azido alcohol may be reducedto the amino alcohol 26 under conditions common to the art such as1,3-propanedithiol and triethylamine in methanol or withtriphenylphosphine in tetrahydrofuran and water. Acylation of 26 may beeffected with an acid such as N-Boc-leucine in the presence of acoupling agent such as EDC. Removal of the benzyloxycarbonyl protectinggroup with hydrogen gas in the presence of 10% Pd/C provides the amine27. Treatment of the amine 27 with 2-pyridinesulphonyl chloride in thepresence of triethylamine or saturated sodium bicarbonate and CH₂Cl₂followed by removal of the tert-butoxycarbonyl protecting group underacidic conditions provides 28. Coupling of 28 withbenzofuran-2-carboxylic acid may be effected with a coupling agent suchas EDC to provide intermediate alcohol 29. Alcohol 29 may be oxidizedwith an oxidant such as sulfur trioxide pyridine complex in DMSO andtriethylamine to provide the ketone 30 as a mixture of diastereomers.Treatment of ketone 30 with triethylamine in CD₃OD:D₂O at refluxprovides the deuterated analog as a mixture of diastereomers which areseparated by HPLC to provide the deuterated compounds 31 and 32.Compounds of the general formula I may also be prepared as outlined inScheme 5. The amine of compound 12 may be protected with withdi-tert-butyldicarbonate to provide the N-Boc derivative 33 (Scheme 2).Removal of the benzyloxycarbonyl protecting group may be effected bytreatment of 33 with hydrogen gas in the presence of a catalyst such as10% Pd/C to provide the amine 34. Treatment of amine 34 with a sulfonylchloride such as 2-pyridinesulfonyl chloride in the presence of a basesuch as N-methylmorpholine or triethylamine provides the sulfonamidederivative 35. Removal of the tert-butoxycarbonyl protecting group maybe effected with an acid such as hydrochloric acid to provideintermediate 36. Coupling of 36 with an acid such asN-Boc-cyclohexylalanine in the presence of a coupling agent common tothe art such as HBTU or polymer supported EDC provides the alcoholintermediate 37. Removal of the tert-butoxycarbonyl protecting groupunder acidic conditions provides amine 38. Coupling of 38 with an acidsuch as benzofuran-2-carboxylic acid in the presence of a coupling agentsuch as HBTU or polymer supported EDC provides alcohol 39. Alcohol 39may be oxidized with an oxidant common to the art such as pyridinesulfur trioxide complex in DMSO and triethylamine or the Dess-Martinperiodinane to provide the ketone 40.

[0372] Reagents and Conditions: (a) Di-tert-butyldicarbonate, THF; (b)H₂, 10% Pd/C, EtOAc; (c) 2-pyridylsulfonyl chloride, TEA; (d) HCl,EtOAc; (e) N-Boc-cylohexylalanine, P-EDC, CH₂Cl₂; (f) HCl, CH₂Cl₂; (g)benzofuran-2-carboxylic acid, P-EDC, CH₂Cl₂; (h) Dess-Martinperiodinane, methylene chloride.

[0373] The quaternized, 4-amino-azepan-3-one compounds of the presentinvention may be conveniently prepared according to Scheme 6. Theskilled artisan will understand from Scheme 6 how to make any of thequaternized, 4-amino-azepan-3-one compounds of the present invention.Reductive amination of 13 may be effected by treatment with an aldehydefollowed by a reducing agent such as sodium triacetoxyborohydride.Subsequent deprotection of the N-Boc group under acidic conditionsprovides the amine salt 16. Treatment of 16 with an acid chloride orwith a carboxylic acid in the presence of a coupling agent common to theart such as EDC followed by oxidation of the intermediate alcohol (notshown) with an oxidant such as pyridine sulfur trioxide complex providesthe ketone 17. Quaternization of the amine of 17 may be effected bytreatment with an alkylating agent such as iodomethane to provide thequaternary amine salt 41.

[0374] Reagents and conditions: a.) R₁CHO, NaBH(OAc),; b.) HCl; c.)R₂CO₂H, EDC, CH₂Cl₂; d.) pyridine sulfur trioxide complex, DMSO, TEA;e.) iodomethane

[0375] The starting materials used herein are commercially availableamino acids or are prepared by routine methods well known to those ofordinary skill in the art and can be found in standard reference books,such as the COMPENDIUM OF ORGANIC SYNTHETIC METHODS, Vol. I-VI(published by Wiley-Interscience).

[0376] Coupling methods to form amide bonds herein are generally wellknown to the art. The methods of peptide synthesis generally set forthby Bodansky et al., THE PRACTICE OF PEPTIDE SYNTHESIS, Springer-Verlag,Berlin, 1984; E. Gross and J. Meienhofer, THE PEPTIDES, Vol. 1, 1-284(1979); and J. M. Stewart and J. D. Young, SOLID PHASE PEPTIDESYNTHESIS, 2d Ed., Pierce Chemical Co., Rockford, Ill., 1984, aregenerally illustrative of the technique and are incorporated herein byreference.

[0377] Synthetic methods to prepare the compounds of this inventionfrequently employ protective groups to mask a reactive functionality orminimize unwanted side reactions. Such protective groups are describedgenerally in Green, T. W, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS, JohnWiley & Sons, New York (1981). The term “amino protecting groups”generally refers to the Boc, acetyl, benzoyl, Fmoc and Cbz groups andderivatives thereof as known to the art. Methods for protection anddeprotection, and replacement of an amino protecting group with anothermoiety are well known.

[0378] Acid addition salts of the compounds of Formula I are prepared ina standard manner in a suitable solvent from the parent compound and anexcess of an acid, such as hydrochloric, hydrobromic, hydrofluoric,sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic ormethanesulfonic. Certain of the compounds form inner salts orzwitterions which may be acceptable. Cationic salts are prepared bytreating the parent compound with an excess of an alkaline reagent, suchas a hydroxide, carbonate or alkoxide, containing the appropriatecation; or with an appropriate organic amine. Cations such as Li⁺, Na⁺,K⁺, Ca⁺⁺, Mg₄ ⁺⁺ and NH₄+are specific examples of cations present inpharmaceutically acceptable salts. Halides, sulfate, phosphate,alkanoates (such as acetate and trifluoroacetate), benzoates, andsulfonates (such as mesylate) are examples of anions present inpharmaceutically acceptable salts. Quaternary ammonium salts areprepared by treating a parent amine compound with an excess of alkylhalide, such as methyl iodide.

[0379] This invention also provides a pharmaceutical composition whichcomprises a compound according to Formula I and a pharmaceuticallyacceptable carrier, diluent or excipient. Accordingly, the compounds ofFormula I may be used in the manufacture of a medicament. Pharmaceuticalcompositions of the compounds of Formula I prepared as hereinbeforedescribed may be formulated as solutions or lyophilized powders forparenteral administration. Powders may be reconstituted by addition of asuitable diluent or other pharmaceutically acceptable carrier prior touse. The liquid formulation may be a buffered, isotonic, aqueoussolution. Examples of suitable diluents are normal isotonic salinesolution, standard 5% dextrose in water or buffered sodium or ammoniumacetate solution. Such formulation is especially suitable for parenteraladministration, but may also be used for oral administration orcontained in a metered dose inhaler or nebulizer for insufflation. Itmay be desirable to add excipients such as polyvinylpyrrolidone,gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol,sodium chloride or sodium citrate.

[0380] Alternately, these compounds may be encapsulated, tableted orprepared in an emulsion or syrup for oral administration.Pharmaceutically acceptable solid or liquid carriers may be added toenhance or stabilize the composition, or to facilitate preparation ofthe composition. Solid carriers include starch, lactose, calcium sulfatedihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin,acacia, agar or gelatin. Liquid carriers include syrup, peanut oil,olive oil, saline and water. The carrier may also include a sustainedrelease material such as glyceryl monostearate or glyceryl distearate,alone or with a wax. The amount of solid carrier varies but, preferably,will be between about 20 mg to about 1 g per dosage unit. Thepharmaceutical preparations are made following the conventionaltechniques of pharmacy involving milling, mixing, granulating, andcompressing, when necessary, for tablet forms; or milling, mixing andfilling for hard gelatin capsule forms. When a liquid carrier is used,the preparation will be in the form of a syrup, elixir, emulsion or anaqueous or non-aqueous suspension. Such a liquid formulation may beadministered directly p.o. or filled into a soft gelatin capsule.

[0381] For rectal administration, the compounds of this invention mayalso be combined with excipients such as cocoa butter, glycerin, gelatinor polyethylene glycols and molded into a suppository.

Novel Intermediates

[0382] Referring to the methods of preparing the compounds of Formula Iset forth in Schemes 1-4 above, the skilled artisan will appreciate thatthe present invention includes all novel intermediates required to makethe compounds of Formula I. In particular, the present inventionprovides the compounds of Formula II:

[0383] wherein:

[0384] R¹ is selected from the group consisting of:

[0385] R² is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹C(S)—,R⁹SO₂—, R⁹OC(O)—,

[0386] R⁹R¹¹NC(O)—, R⁹R¹¹NC(S)—, R⁹ (R¹¹)NSO₂—

[0387] and R⁹SO₂R¹¹NC(O)—;

[0388] R³ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl andArC₀₋₆alkyl;

[0389] R³ and R′ may be connected to form a pyrrolidine, piperidine ormorpholine ring;

[0390] R⁴ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)—, R⁵C(S)—,R⁵SO₂—, R⁵OC(O)—, R⁵R¹²NC(O)—, and R⁵R¹²NC(S)—;

[0391] R⁵ is selected from the group consisting of: H, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl andHet-C₀₋₆alkyl;

[0392] R⁶ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl;

[0393] R⁷ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R¹⁰C(O)—,R₁₀C(S)—, R¹OSO₂—, R¹⁰OC(O)—, R¹⁰R¹³NC(O)—, and R¹⁰R¹³NC(S)—;

[0394] R⁸ is selected from the group consisting of: H, C₁₋₆alkyl,C₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl and ArC₀₋₆alkyl;

[0395] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0396] R¹⁰ is independently selected from the group consisting of:C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0397] R¹¹ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0398] R¹² is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0399] R¹³ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0400] R′ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0401] R″ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl;

[0402] R′″ is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl;

[0403] R″″ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl;

[0404] n is an integer of from 1 to 5;

[0405] and salts, hydrates and solvates thereof.

[0406] With reference to embodiment IA, the present invention includesthe novel intermediates of Formula IIA:

[0407] wherein:

[0408] R¹ is selected from the group consisting of:

[0409] R² is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂—, R⁹R¹¹NC(O)—, andR⁹SO₂R¹¹NC(O)—;

[0410] R³ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl, preferably C₁₋₆alkyl;

[0411] R³ and R′ may be connected to form a pyrrolidine, piperidine ormorpholine ring;

[0412] R⁴ is R⁵C(O)—;

[0413] R⁵ is selected from the group consisting of: C₁₋₆alkyl andHet-C₀₋₆alkyl, preferably Het-C₀₋₆alkyl;

[0414] R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl;

[0415] R¹¹ is selected from the group consisting of: H, C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl, preferably H;

[0416] R′ is H;

[0417] R″ is H;

[0418] R′″ is selected from the group consisting of: H and C₁₋₆alkyl,preferably H;

[0419] R″″ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetCO₆alkyl andArCO₆alkyl, preferably C₁₋₆alkyl; and

[0420] n is an integer from 1 to 5, preferably n is 3;

[0421] and pharmaceutically acceptable salts, hydrates and solvatesthereof.

[0422] The following compounds are preferred novel intermediates:

[0423] [(S)-1 (3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamicacid benzyl ester;

[0424] (S)-2-Amino-4-methyl-pentanoic acid(1-benzyl-3-hydroxy-azepan-4-yl)-amide;

[0425] (S)-2-Amino-4-methyl-pentanoicacid{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide;

[0426]{(S)-1-[4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-ylmethyl]-3-methyl-butyl}-carbamicacid benzyl ester;

[0427] (S)-2-Amino-4-methyl-pentanoicacid-(1-benzoyl-3-hydroxy-azepan-4-yl)-amide;

[0428] (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-]-(4-methyl-pentanoyl)-azepan-4-yl]-amide;

[0429] (S)-2-Amino-4-methyl-pentanoic acid(1-benzenesulfonyl-3-hydroxy-azepan-4-yl)-amide;

[0430] thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;

[0431] 5-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;

[0432] thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;

[0433] 3-methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;

[0434] quinoline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;and

[0435] quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide.

Process for Synthesis of Inventive Compounds

[0436] Referring to Schemes 1-6 herein above, the present inventionprovides a process for the synthesis of compounds of Formula (I)comprising the step of oxidizing the appropriate compound of Formula(II) with an oxidant to provide the compound of Formula (I) as a mixtureof diastereomers. Preferably the oxidant is sulfur trioxide pyridinecomplex in DMSO and triethylamine.

[0437] Referring to Scheme 4, the present invention also provides aprocess for the synthesis of deuterated compounds of Formula (I).Specifically, when a deuterated isomer is desired, an additional step,following the oxidation step, of deuterating the protonated isomer witha deuterating agent to provide the deuterated compound of Formula (I) asa mixture of diastereomers is added to the synthesis. Preferably, thedeuterating agent is CD₃OD:D₂O (10:1) in triethylamine.

[0438] The process further comprises the step of separating thediasteromers of Formula (I) by separating means, preferably by highpresssure liquid chromatography (HPLC).

[0439] Referring to Scheme 6, the present invention also provides aprocess for the synthesis of quaternary salts of the4-amino-azepan-3-one compounds of Formula (I).

Utility of the Present Invention

[0440] The compounds of Formula I are useful as protease inhibitors,particularly as inhibitors of cysteine and serine proteases, moreparticularly as inhibitors of cysteine proteases, even more particularlyas inhibitors of cysteine proteases of the papain superfamily, yet moreparticularly as inhibitors of cysteine proteases of the cathepsinfamily, most particularly as inhibitors of cathepsin K. The presentinvention also provides useful compositions and formulations of saidcompounds, including pharmaceutical compositions and formulations ofsaid compounds.

[0441] The present compounds are useful for treating diseases in whichcysteine proteases are implicated, including infections by pneumocystiscarinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata;as well as in schistosomiasis, malaria, tumor metastasis, metachromaticleukodystrophy, muscular dystrophy, amytrophy; and especially diseasesin which cathepsin K is implicated, most particularly diseases ofexcessive bone or cartilage loss, including osteoporosis, gingivaldisease including gingivitis and periodontitis, arthritis, morespecifically, osteoarthritis and rheumatoid arthritis, Paget's disease;hypercalcemia of malignancy, and metabolic bone disease.

[0442] Metastatic neoplastic cells also typically express high levels ofproteolytic enzymes that degrade the surrounding matrix, and certaintumors and metastatic neoplasias may be effectively treated with, thecompounds of this invention.

[0443] The present invention also provides methods of treatment ofdiseases caused by pathological levels of proteases, particularlycysteine and serine proteases, more particularly cysteine proteases,even more particularly cysteine proteases of the papain superfamily, yetmore particularly cysteine proteases of the cathepsin family, whichmethods comprise administering to an animal, particularly a mammal, mostparticularly a human in need thereof a compound of the presentinvention. The present invention especially provides methods oftreatment of diseases caused by pathological levels of cathepsin K,which methods comprise administering to an animal, particularly amammal, most particularly a human in need thereof an inhibitor ofcathepsin K, including a compound of the present invention. The presentinvention particularly provides methods for treating diseases in whichcysteine proteases are implicated, including infections by pneumocystiscarinii, trypsanoma cruzi, trypsanoma brucei, and Crithidia fusiculata;as well as in schistosomiasis, malaria, tumor metastasis, metachromaticleukodystrophy, muscular dystrophy, amytrophy, and especially diseasesin which cathepsin K is implicated, most particularly diseases ofexcessive bone or cartilage loss, including osteoporosis, gingivaldisease including gingivitis and periodontitis, arthritis, morespecifically, osteoarthritis and rheumatoid arthritis, Paget's disease,hypercalcemia of malignancy, and metabolic bone disease.

[0444] This invention further provides a method for treatingosteoporosis or inhibiting bone loss which comprises internaladministration to a patient of an effective amount of a compound ofFormula I, alone or in combination with other inhibitors of boneresorption, such as bisphosphonates (i.e., allendronate), hormonereplacement therapy, anti-estrogens, or calcitonin. In addition,treatment with a compound of this invention and an anabolic agent, suchas bone morphogenic protein, iproflavone, may be used to prevent boneloss or to increase bone mass.

[0445] For acute therapy, parenteral administration of a compound ofFormula I is preferred. An intravenous infusion of the compound in 5%dextrose in water or normal saline, or a similar formulation withsuitable excipients, is most effective, although an intramuscular bolusinjection is also useful. Typically, the parenteral dose will be about0.01 to about 100 mg/kg; preferably between 0.1 and 20 mg/kg, in amanner to maintain the concentration of drug in the plasma at aconcentration effective to inhibit cathepsin K. The compounds areadministered one to four times daily at a level to achieve a total dailydose of about 0.4 to about 400 mg/kg/day. The precise amount of aninventive compound which is therapeutically effective, and the route bywhich such compound is best administered, is readily determined by oneof ordinary skill in the art by comparing the blood level of the agentto the concentration required to have a therapeutic effect.

[0446] The compounds of this invention may also be administered orallyto the patient, in a manner such that the concentration of drug issufficient to inhibit bone resorption or to achieve any othertherapeutic indication as disclosed herein. Typically, a pharmaceuticalcomposition containing the compound is administered at an oral dose ofbetween about 0. I to about 50 mg/kg in a manner consistent with thecondition of the patient. Preferably the oral dose would be about 0.5 toabout 20 mg/kg. No unacceptable toxicological effects are expected whencompounds of the present invention are administered in accordance withthe present invention.

Biological Assays

[0447] The compounds of this invention may be tested in one of severalbiological assays to determine the concentration of compound which isrequired to have a given pharmacological effect.

[0448] Determination of Cathepsin K Proteolytic Catalytic Activity

[0449] All assays for cathepsin K were carried out with humanrecombinant enzyme. Standard assay conditions for the determination ofkinetic constants used a fluorogenic peptide substrate, typicallyCbz-Phe-Arg-AMC, and were determined in 100 mM Na acetate at pH 5.5containing 20 mM cysteine and 5 mM EDTA. Stock substrate solutions wereprepared at concentrations of 10 or 20 mM in DMSO with 20 uM finalsubstrate concentration in the assays. All assays contained 10% DMSO.Independent experiments found that this level of DMSO had no effect onenzyme activity or kinetic constants. All assays were conducted atambient temperature. Product fluorescence (excitation at 360 nM;emission at 460 nM) was monitored with a Perceptive Biosystems CytofluorII fluorescent plate reader. Product progress curves were generated over20 to 30 minutes following formation of AMC product.

[0450] Inhibition Studies

[0451] Potential inhibitors were evaluated using the progress curvemethod. Assays were carried out in the presence of variableconcentrations of test compound. Reactions were initiated by addition ofenzyme to buffered solutions of inhibitor and substrate. Data analysiswas conducted according to one of two procedures depending on theappearance of the progress curves in the presence of inhibitors. Forthose compounds whose progress curves were linear, apparent inhibitionconstants (K_(i,app)) were calculated according to equation I (Brandt etal., Biochemitsry, 1989, 28, 140):

v=V _(m) A/[K _(a)(1+l/K _(i, app))+A]  (1)

[0452] where v is the velocity of the reaction with maximal velocityV_(m), A is the concentration of substrate with Michaelis constant ofK_(a), and l is the concentration of inhibitor.

[0453] For those compounds whose progress curves showed downwardcurvature characteristic of time-dependent inhibition, the data fromindividual sets was analyzed to give k_(obs) according to equation 2:

[AMC]=v _(ss) t+(v ₀ −v _(ss))[1−exp (−k _(obs) t)]/k _(obs)  (2)

[0454] where [AMC] is the concentration of product formed over time t,v₀ is the initial reaction velocity and v_(ss) is the final steady staterate. Values for k_(obs) were then analyzed as a linear function ofinhibitor concentration to generate an apparent second order rateconstant (k_(obs)/inhibitor concentration or k_(obs)/[I]) describing thetime-dependent inhibition. A complete discussion of this kinetictreatment has been fully described (Morrison et al., Adv. Enzymol.Relat. Areas Mol. Biol., 1988, 61, 201).

[0455] Human Osteoclast Resorption Assay

[0456] Aliquots of osteoclastoma-derived cell suspensions were removedfrom liquid nitrogen storage, warmed rapidly at 37° C. and washed ×1 inRPMI-1640 medium by centrifugation (1000 rpm, 5 min at 4° C.). Themedium was aspirated and replaced with murine anti-HLA-DR antibody,diluted 1:3 in RPMI-1640 medium, and incubated for 30 min on ice Thecell suspension was mixed frequently.

[0457] The cells were washed ×2 with cold RPMI-1640 by centrifugation(1000 rpm, 5 min at 4° C.) and then transferred to a sterile 15 mLcentrifuge tube. The number of mononuclear cells were enumerated in animproved Neubauer counting chamber.

[0458] Sufficient magnetic beads (5/mononuclear cell), coated with goatanti-mouse IgG, were removed from their stock bottle and placed into 5mL of fresh medium (this washes away the toxic azide preservative). Themedium was removed by immobilizing the beads on a magnet and is replacedwith fresh medium.

[0459] The beads were mixed with the cells and the suspension wasincubated for 30 min on ice. The suspension was mixed frequently. Thebead-coated cells were immobilized on a magnet and the remaining cells(osteoclast-rich fraction) were decanted into a sterile 50 mL centrifugetube. Fresh medium was added to the bead-coated cells to dislodge anytrapped osteoclasts. This wash process was repeated ×10. The bead-coatedcells were discarded.

[0460] The osteoclasts were enumerated in a counting chamber, using alarge-bore disposable plastic pasteur pipette to charge the chamber withthe sample. The cells were pelleted by centrifugation and the density ofosteoclasts adjusted to 1.5×10⁴/mL in EMEM medium, supplemented with 10%fetal calf serum and 1.7 g/litre of sodium bicarbonate. 3 mL aliquots ofthe cell suspension (per treatment) were decanted into 15 mL centrifugetubes. These cells were pelleted by centrifugation. To each tube 3 mL ofthe appropriate treatment was added (diluted to 50 uM in the EMEMmedium). Also included were appropriate vehicle controls, a positivecontrol (87MEM 1 diluted to 100 ug/mL) and an isotype control (IgG2adiluted to 100 ug/mL). The tubes were incubate at 37° C. for 30 min. 0.5mL aliquots of the cells were seeded onto sterile dentine slices in a48-well plate and incubated at 37° C. for 2 h. Each treatment wasscreened in quadruplicate. The slices were washed in six changes of warmPBS (10 mL/well in a 6-well plate) and then placed into fresh treatmentor control and incubated at 37° C. for 48 h. The slices were then washedin phosphate buffered saline and fixed in 2% glutaraldehyde (in 0.2Msodium cacodylate) for 5 min., following which they were washed in waterand incubated in buffer for 5 min at 37° C. The slices were then washedin cold water and incubated in cold acetate buffer/fast red garnet for 5min at 4° C. Excess buffer was aspirated, and the slices were air driedfollowing a wash in water.

[0461] The TRAP positive osteoclasts were enumerated by bright-fieldmicroscopy and were then removed from the surface of the dentine bysonication. Pit volumes were determined using the Nikon/Lasertec ILM2 IWconfocal microscope.

General

[0462] Nuclear magnetic resonance spectra were recorded at either 250 or400 MHz using, respectively, a Bruker AM 250 or Bruker AC 400spectrometer. CDCl₃ is deuteriochloroform, DMSO-d₆ ishexadeuteriodimethylsulfoxide, and CD₃OD is tetradeuteriomethanol.Chemical shifts are reported in parts per million (d) downfield from theinternal standard tetramethylsilane. Abbreviations for NMR data are asfollows: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet,dd=doublet of doublets, dt=doublet of triplets, app=apparent, br=broad.J indicates the NMR coupling constant measured in Hertz. Continuous waveinfrared (1R) spectra were recorded on a Perkin-Elmer 683 infraredspectrometer, and Fourier transform infrared (FTIR) spectra wererecorded on a Nicolet Impact 400 D infrared spectrometer. IR and FTIRspectra were recorded in transmission mode, and band positions arereported in inverse wavenumbers (cm⁻¹). Mass spectra were taken oneither VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fastatom bombardment (FAB) or electrospray (ES) ionization techniques.Elemental analyses were obtained using a Perkin-Elmer 240C elementalanalyzer. Melting points were taken on a Thomas-Hoover melting pointapparatus and are uncorrected. All temperatures are reported in degreesCelsius.

[0463] Analtech Silica Gel GF and E. Merck Silica Gel 60 F-254 thinlayer plates were used for thin layer chromatography. Both flash andgravity chromatography were carried out on E. Merck Kieselgel 60(230-400 mesh) silica gel.

[0464] Where indicated, certain of the materials were purchased from theAldrich Chemical Co., Milwaukee, Wis., Chemical Dynamics Corp., SouthPlainfield, New Jersey, and Advanced Chemtech, Louisville, Ky.

EXAMPLES

[0465] In the following synthetic examples, temperature is in degreesCentigrade (° C.). Unless otherwise indicated, all of the startingmaterials were obtained from commercial sources. Without furtherelaboration, it is believed that one skilled in the art can, using thepreceding description, utilize the present invention to its fullestextent. These Examples are given to illustrate the invention, not tolimit its scope. Reference is made to the claims for what is reserved tothe inventors hereunder.

Example I

[0466] Preparation of{(S)-1-[1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamicAcid Benzyl Ester

[0467] a.) Allyl-pent-4-enyl-carbamic Acid Tert-Butyl Ester

[0468] To a suspension of NaH (3.05 g, 76.33 mmol of 60% NaH in oil;washed with hexanes) in DMF (30 mL) was added tert-butylN-allylcarbamate (6.0 g, 38.2 mmol) in a dropwise fashion. The mixturewas stirred at room temperature for approximately 10 minutes whereupon5-bromo-1-pentene (6.78 mL, 57.24 mmol) was added in a dropwise fashion.The reaction was heated to 40° C. for approximately 2 hours whereuponthe reaction was partitioned between ethyl acetate and water. Theorganic layer was washed with water (2×'s), brine, dried (MgSO₄),filtered and concentrated to give 10 grams of the title compound as anoil: MS(EI) 226 (M+H⁺).

[0469] b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic Acid Tert-Butyl Ester

[0470] To a solution of compound of Example 1a (4.5 g) in benzene wasadded the 2,6-diisopropylphenylimidoneophylidene molybdenumbis(t-butoxide) (600 mg). The reaction was heated to reflux for 1.5hours whereupon the reaction was concentrated in vacuo. Chromatography(50% CH₂Cl₂:hexanes) of the residue gave 3.92 g of the product:

[0471] c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic Acid Tert-ButylEster

[0472] To a solution of the compound of Example 1b (3.0 g, 15.2 mmol) inCH₂Cl₂ was added m-CPBA (7.8 g, 45.6 mmol). The mixture was stirredovernight at room temperature whereupon it was partitioned betweenCH₂Cl₂ and staurated K₂CO₃. The organic layer was washed with sat.NaHCO₃, water, brine, dried (MgSO₄), filtered and concentrated to give3.11 g of the title compound as an oil: MS(EI) 214 (M+H⁺).

[0473] d.) 4-Azido-3-hydroxy-azepane-1-carboxylic Acid Tert-Butyl Ester

[0474] To a solution of the epoxide from Example 1c (3.92 g, 20 mmol) inmethanol:water (180 mL of an 8:1 solution) was added NH₄Cl (3.18 g, 60mmol) and sodium azide (3.9 g, 60 mmol). The reaction was heated to 40°C. until complete consumption of the starting epoxide was observed byTLC analysis. The majority of the solvent was removed in vacuo and theremaining solution was diluted with ethyl acetate and washed with water,brine dried (Na₂SO₄), filtered and concentrated. Column chromatography(40% ethyl acetate:hexanes) of the residue provided 3.43 g of the titlecompound.

[0475] e.) 4-Amino-3-hydroxy-azepane-1-carboxylic Acid Tert-Butyl Ester

[0476] To a solution of the azido alcohol of Example 1d (3.4 g) and 10%Pd/C (catalytic) in ethyl acetate:methanol (2:1 solution) was affixed aballoon of hydrogen. The reaction was stirred until complete consumptionof the starting material was observed by TLC analysis. The reaction wasfiltered to remove the catalyst and the filtrate was concentrated invacuo. Column chromatography of the residue (25%methanol:dichloromethane) provided 2.57 g of the title compound: MS(EI)231 (M+H⁺).

[0477] f.)4-((S)-2-benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Tert Butyl Ester

[0478] To a solution of the amino alcohol of Example I e (160 mg, 0.70mmol) in CH₂Cl₂ was added EDC (134 mg), HOBt (94 mg) and Cbz-leucine(185 mg). The reaction was maintained at room temperature until completeconsumption of the starting material was observed by TLC analysis. Thereaction was diluted with ethyl acetate and washed with 1N HCl, sat.K₂CO₃, water, brine, dried (MgSO₄), filtered and concentrated. Columnchromatography of the residue (3% methanol:dichloromethane) gave 200 mgof the title compound: MS(EI) 478 (M+H⁺), 500 (M+Na⁺).

[0479] g.)[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-Carbamic AcidBenzyl Ester

[0480] A solution of the compound of Example 1f (200 mg, 0.42 mmol) inmethanol (5 mL) was added 4M HCl in dioxane (5 mL). The reaction wasstirred at room temperature for approximately 2 hours whereupon thesolvent was removed in vacuo to provide 168 mg of the title compound:MS(EI) 378 (M+H⁺).

[0481] h.){(S)-1-[4-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carbonyl]-3-methyl-butyl}carbamicAcid Benzyl Ester

[0482] To a solution of the amine salt of Example 1g (168 mg, 0.42 mmol)in CH₂Cl₂ was added EDC (81 mg), HOBt (57 mg), triethylamine (0.09 mL)and Cbz-leucine (111 mg). The reaction was stirred until complete by TLCanalaysis. Workup followed by column chromatography (5% CH₃OH:CH₂Cl₂)provided 159 mg of the title compound: MS(EI) 625 (M+H⁺).

[0483] i.){(S)-1-[4-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-oxo-azepane-1-carbonyl]-3-methyl-butyl}carbamicAcid Benzyl Ester

[0484] To a solution of the alcohol of Example 1h (130 mg, 0.21 mmol) inDMSO was added TEA (0.17 mL) and pyridine sulfur trioxide complex (97mg, 0.62 mmol). The reaction was stirred at room temperature forapproximately 2 hours whereupon it was partitioned between ethyl acetateand water. The organic layer was washed with brine, dried (MgSO₄),filtered and concentrated. Column chromatography of the residue (5%CH₃OH:CH₂Cl₂) provided 100 mg of the title compound as a mixture ofdiastereomers: ¹H NMR (CDCl₃): δ 1.0 (m, 12H), 1.5-2.1 (m, 8H), 2.2 (m,4H), 3.0 (m, 1H), 3.5 (d, 1H). 3.6 (d, 1H), 4.01 (m, 1H), 4.5 (m, 2H),4.7 (m, 1H), 5.0 (m, 5H), 7.3 (m, 10H): MS (EI) 623 (M+H⁺), 645 (M+Na⁺).Separation of the diastereomers by HPLC provided diastereomer I MS (EI)623 (M+H⁺), 645 (M+Na⁺) and diastereomer 2: MS (ES) 623 (M+H⁺), 645(M+Na⁺).

Example 2

[0485] Preparation of Naphthylene-2-carboxylicacid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0486] a.) Allyl-pent-4-enyl-carbamic Acid Benzyl Ester

[0487] To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF wasadded benzyl allyl-carbamic acid benzyl ester (7.3 g, 38.2 mmol) in adropwise fashion. The mixture was stirred at room temperature forapproximately 10 minutes whereupon 5-bromo-1-pentene (6.78 mL, 57.24mmol) was added in a dropwise fashion. The reaction was heated to 40° C.for approximately 4 hours whereupon the reaction was partitioned betweendichloromethane and water. The organic layer was washed with water(2×'s), brine, dried (MgSO₄), filtered and concentrated. Columnchromatography of the residue (10% ethyl acetate:hexanes) provided 10.3grams of the title compound as an oil: MS(EI) 260 (M+H⁺).

[0488] b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic Acid Benzyl Ester

[0489] To a solution of compound of Example 2a (50 g) in dichloromethanewas added bis(tricyclohexylphosphine)benzylidine ruthenium (IV)dichloride (5.0 g). The reaction was heated to reflux until complete asdetermined by TLC analysis. The reaction was concentrated in vacuo.Column chromatography of the residue (50% dichloromethane:hexanes) gave35 g of the title compound: MS(EI) 232 (M+H⁺).

[0490] c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic Acid BenzylEster

[0491] Following the general procedure of Example 1c except substitutingthe compound of Example 2b the title compound was prepared: MS(EI) 248(M+H⁺), 270 (M+Na⁺).

[0492] d.) 4-azido-3-hydroxy-azepane-1-carboxylic Acid Benzyl Ester

[0493] To a solution of the epoxide from Example 2c (2.0 g, 8.1 mmol) inmethanol:water (8:1 solution) was added NH₄Cl (1.29 g, 24.3 mmol) andsodium azide (1.58 g, 24.30 mmol). The reaction was heated to 40° C.until complete consumption of the starting epoxide was observed by TLCanalysis. The majority of the solvent was removed in vacuio and theremaining solution was partitioned between ethyl acetate and pH 4buffer. The organic layer was washed with sat. NaHCO₃, water, brinedried (MgSO₄), filtered and concentrated. Column chromatography (20%ethyl acetate:hexanes) of the residue provided 1.3 g of the titlecompound: MS(EI) 291 (M+H⁺) plus 0.14 g oftrans-4-hydroxy-3-azido-hexahydro-1H-azepine

[0494] e.) 4-amino-3-hydroxy-azepane-1-carboxylic Acid Benzyl Ester

[0495] To a solution of the azido alcohol of Example 2d (1.1 g, 3.79mmol) in methanol was added triethylamine (1.5 mL, 11.37 mmol) and1,3-propanedithiol (1.1 mL, 11.37 mL). The reaction was stirred untilcomplete consumption of the starting material was observed by TLCanalysis whereupon the reaction was concentrated in vacuo. Columnchromatography of the residue (20% methanol:dichloromethane) provided0.72 g of the title compound: MS(EI) 265 (M+H⁺).

[0496] f.)4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylicAcid Benzyl Ester

[0497] To a solution of the amino alcohol of Example 2e (720 mg, 2.72mmol) in CH₂Cl₂ was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucine(630 mg). The reaction was maintained at room temperature until completeconsumption of the starting material was observed by TLC analysis. Thereaction was diluted with ethyl acetate and washed with 1N HCl, sat.K₂CO₃, water, brine, dried (MgSO₄), filtered and concentrated. Columnchromatography of the residue (3% methanol:dichloromethane) gave 1.0 gof the title compound: MS(EI) 478 (M+H⁺).

[0498] g.)[(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic AcidTert Butyl Ester

[0499] To a solution of the compound of Example 2f (1.0 g) and 10% Pd/C(catalytic) in ethyl acetate:methanol (2:1 solution) was affixed aballoon of hydrogen. The reaction was stirred until complete consumptionof the starting material was observed by TLC analysis. The reaction wasfiltered to remove the catalyst and the filtrate was concentrated invacuo to provide 0.82 g of the title compound: MS(EI) 344 (M+H⁺).

[0500] h.)[(S)-1-(1-Benzyl-3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamicAcid Tert Butyl Ester

[0501] To a solution of the compound of Example 2g (0.69 g, 2.01 mmol)in CH₂Cl₂ was added benzaldehyde (0.32 mL, 3.01 mmol) followed by sodiumtriacetoxyborohydride (0.85 g, 4.02 mmol). The reaction was stirreduntil complete as determined by TLC analysis whereupon several drops ofwater were added to the reaction to destroy the excess sodiumtriacetoxyborohydride. The mixture was diluted with ethyl acetate washedwith sat. NaHCO₃, water, brine, dried (Na₂SO₄), filtered andconcentrated. Column chromatography of the residue (5%methanol:dichloromethane) gave 800 mg of the title compound: MS(ES) 434(M+H⁺).

[0502] i.) (S)-2-Amino-4-methyl-pentanoic acid(1-benzyl-3-hydroxy-azepan-4-yl)-amide

[0503] To a solution of the compound of Example 2h (800 mg) in methanol(15 mL) was added 4M HCl in dioxane (15 mL). The reaction was stirred atroom temperature overnight whereupon it was concentrated in vacuo togive 800 mg of the title compound: MS(ES) 334 (M+H⁺).

[0504] j.) Naphthylene-2-carboxylic acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0505] To a solution of the amine salt of Example 2i (200 mg, 0.49 mmol)in CH₂Cl₂ was added triethylamine (0.17 mL, 1.22 mmol), EDC (103.5 mg,0.54 mmol), HOBt (73 mg, 0.54 mmol) and 2-naphthoic acid (93 mg, 0.54mmol). The reaction was stirred until complete by TLC analysis. Thereaction was diluted with ethyl acetate and washed with sat. NaHCO₃,water, brine, dried (Na₂SO₄), filtered and concentrated. Columnchromatography of the residue (5% methanol:dichloromethane) gave 0.14 gof the title compound: MS(EI) 488 (M+H⁺).

[0506] k.) Naphthylene-2-carboxylicacid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0507] Following the general procedure of Example 1i except substitutingthe compound of Example 2j for the compound of Example 1i the titlecompound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H),2.2 (m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7(m, 1H), 5.2 (m, 1H), 7.2-8.4 (m, 12H); MS(EI): 486 (M+H⁺, 100%).Separation of the diastereomers by HPLC provided diastereomer 1: MS (EI)486.3 (M+H⁺), and diastereomer 2: MS (ES) 486.3 (M+H⁺).

Example 3

[0508] Preparation of Benzo[1,3]dioxole-5-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0509] a.) Benzo[1,3]dioxole-5-carboxylic acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0510] Following the general procedure of Example 2j except substitutingpiperonylic acid for 2-naphthoic acid the title compound was prepared:MS(ES) 482 (M+H⁺).

[0511] b.) Benzo[1,3]dioxole-5-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0512] Following the general procedure of Example 1i except substitutingthe compound of Example 3a the title compound was prepared: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.0(m, 1H). 3.2 (d, 1H), 3.5 (q, 1H), 3.7 (m, 2H), 4.7 (m, 1H), 5.2 (m,1H), 6.0 (s, 2H), 6.8 (m, 2H).7.2 (m, 6H); MS(EI): 480 (M+H⁺, 100%). Thediastereomers were separated by preparative scale HPLC. Lyophilisationof the eluents provided diastereomer 1: MS (EI) 480.3 (M+H⁺), 959.62M+H⁺) and diastereomer 2: MS (EI) 480.3 (M+H⁺), 959.6 2M+H⁺).

Example 4

[0513] Preparation of Benzofuran-2-carboxylic Acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0514] a.) Benzofuran-2-carboxylic acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0515] Following the general procedure of Example 2j except substitutingbenzofuran-2-carboxylic acid for 2-naphthoic acid the title compound wasprepared: MS(ES) 478 (M+H⁺).

[0516] b.) Benzofuran-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0517] Following the general procedure of Example 1i except substitutingthe compound of Example 4a the title compound was prepared: 476 MS(EI):492 (M+H⁺, 100%). The diastereomers were separated by preparative scaleHPLC. Lyophilisation of the eluents provided diastereomer 1: MS (EI)476.4 (M+H⁺), 951.6 (M+H⁺) and diastereomer 2: MS (EI) 476.4 (M+H⁺),951.6 2M+H⁺).

Example 5

[0518] Preparation of Benzo[b]thiophene-2-carboxylic Acidf(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0519] a.) Benzo[b]thiophene-2-carboxylic acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0520] Following the general procedure of Example 2j except substitutingbenzothiophene-2-carboxylic acid for 2-naphthoic acid the title compoundwas prepared: MS(ES) 494 (M+H⁺).

[0521] b.) Benzo[b]thiophene-2-carboxylic acid[(S)-1-(-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0522] Following the general procedure of Example 1i except substitutingthe compound of Example 5a the title compound was prepared: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.2(dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-8.4(m, 10H): MS(EI): 492 (M+H⁺, 100%)

[0523] The diastereomers were separated by preparative scale HPLC.Lyophilisation of the eluents provided diastereomer 1: MS (EI) 492.4(M+H⁺), 983.7 2M+H⁺) and diastereomer 2: MS (EI) 492.4 (M+H⁺), 983.72M+H⁺).

Example 6

[0524] Preparation of Naphthylene-2-sulphonyl[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0525] a.) Naphthylene-2-sulphonyl[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0526] To a solution of the amine salt of Example 2i (200 mg, 0.49 mmol)in CH₂Cl₂ was added triethylamine (0.24 mL, 1.72 mmol) and2-naphthalenesulphonyl chloride (122 mg, 0.54 mmol). The reaction wasstirred at room temperature until complete as determined by TLCanalysis. The reaction was worked-up, dried (Na₂SO₄), filtered andconcentrated. Column chromatography of the residue (10%methanol:dichloromethane) provided 52 mg of the title compound: MS(EI)524 (M+H⁺).

[0527] b.) Naphthylene-2-sulphonyl[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0528] Following the general procedure of Example 1i except substitutingthe compound of Example 6a the title compound was prepared: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0(dd, 1H). 3.3 (m, 1H), 3.6 (m, 2H), 3.7 (m, 1H), 4.7 (m, 1H), 5.3 (m,1H), 7.2-8.4 (m, 12H): MS(EI): 522 (M+H⁺, 100%)

Example 7

[0529] Preparation of Quinoline-2-carboxylic Acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0530] a.) Quinoline-2-carboxylic Acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0531] Following the general procedure of Example 2j except substituting2-quinolinecarboxylic acid for 2-naphthoic acid, the title compound wasprepared: MS(ES) 489 (M+H⁺).

[0532] b.) Quinoline-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0533] Following the general procedure of Example 1i except substitutingthe compound of Example 7a the title compound was prepared: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.2(dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-8.4(m, 11H); MS(ET): 487 (M+H⁺, 100%). The diastereomers were separated bypreparative scale HPLC. Lyophilisation of the eluents provideddiastereomer 1: MS (EI) 492.4 (M+H⁺), 983.7 2M+H⁺) and diastereomer 2:MS (EI) 492.4 (M+H⁺), 983.7 2M+H⁺).

Example 8

[0534] Preparation of 3,4-dichlorobenzoic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0535] a.) 3,4-dichlorobenzoic acid[(S)-1-(1-benzyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0536] Following the general procedure of Example 2j except substituting3,4-dichlorbenzoic acid for 2-naphthoic acid the title compound wasprepared: MS(ES) 506 (M+H⁺).

[0537] b.) 3,4-dichlorobenzoic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0538] Following the general procedure of Example 1i except substitutingthe compound of Example 8a the title compound was prepared: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.2(dd, 1H). 3.4 (m, 1H), 3.7 (m, 2H), 4.7 (m, 2H), 5.2 (m, 1H), 7.2-8.4(m, 8H); MS(EI): 504 (M⁺, 100%).

Example 9

[0539] Preparation of4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino1-3-oxo-1-12-(3-pyridin-2-yl-phenyl)-acetyl]azepanium

[0540] a.)4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepanium

[0541] To a solution of the compound of Example 2g (0.5 g, 1.46 mmol) inCH₂Cl₂ was added EDC (307 mg, 1.60 mmol), HOBt (216 mg, 1.60 mmol) and3-(2-pyridyl)phenyl acetic acid (341 mg, 1.60 mmol). The reaction wasstirred at room temperature until complete as determined by TLCanalysis. Workup and column chromatography (2% methanol:dichloromethane)provided the title compound: MS(ES) 539 (M+H⁺).

[0542] b.)4-((S)-Amino-4-methyl-pentanoylamino)-3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepanium

[0543] To a solution of the compound of Example 9a (1.3 g) dissolved inmethanol (20 mL was added 4M HCl in dixoane (20 mL). The reaction wasstirred until complete by TLC analysis whereupon it was concentrated invacuo to give 1.1 g of the title compound: MS(EI) 439 (M+H⁺).

[0544] c.)4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]azepanium

[0545] Following the procedure of Example 7a except substituting thecompound of Example 9b the title compound was prepared: MS(EI) 594(M+H⁺).

[0546] d.)4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]azepanium

[0547] Following the procedure of Example 1i except substituting thecompound of Example 9c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.4 (dd, 1H).3.8 (m, 3H), 4.1 (m, 2H), 4.7 (m, 3H), 5.4 (m, 1H), 7.2-8.4 (m, 14H);MS(EI): 592 (M+H⁺, 100%).

Example 10 Preparation of1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-oxo-azepanium

[0548] a.)I-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepanium

[0549] Following the procedure of Example 2h except substitutingCbz-leucinal for benzaldehyde the title compound was prepared: MS(EI)577 (M+H⁺).

[0550] b.)4-((S)-2-Amino-4-methy-pentanoylamino)-1-((S)-2-tert-benzylxycarbonylamino-4-methyl-pentyl)-3-hydroxy-azepanium

[0551] Following the procedure of Example 2i except substituting thecompound of Example 1 Oa the title compound was prepared: MS(EI) 477(M+H⁺).

[0552] c.) 1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-1(S)-4-methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-hydroxy-azepanium

[0553] Following the procedure of Example 7a except substituting thecompound of Example 10b the title compound was prepared: MS(EI) 632(M+H⁺).

[0554] d.)1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-oxo-azepanium

[0555] Following the procedure of Example 1i except substituting thecompound of Example 10c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 12H), 1.5-2.1 (m, 10H), 2.2 (m, 4H), 2.9 (m, 1H), 3.4 (M, 2H).3.7 (m, 1H), 4.7 (m, 2H), 5.2 (m, 3H), 7.2 (m, 4H), 7.5 (m, 1H), 7.6 (m,1H), 7.7 (m, 1H), 8.1 (m, 1H), 8.2 (m, 2H), 8.5 (m, 1H); MS(EI): 630(M+H⁺, 100%).

Example 11

[0556] Preparation of1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium

[0557] a.)I-Benzoyl-4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepanium

[0558] Following the procedure of Example 9a except substituting benzoicacid for 3-(2-pyridyl)phenyl acetic acid the title compound wasprepared: MS(EI) 448 (M+H⁺).

[0559] b.)4-((S)-2-Amino-4-methyl-pentanoylamino)-1-benzoyl-3-hydroxy-azepanium

[0560] Following the procedure of Example 2i except substituting thecompound of Example 11a the title compound was prepared: MS(EI) 348(M+H⁺).

[0561] c.)1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-pentanoylamino)-3-hydroxy-azepanium

[0562] Following the procedure of Example 2j except substituting thecompound of Example 11b for the compound of Example 2j and piperonylicacid for 2-naphthoic acid the title compound was prepared: MS(EI) 496(M+H⁺).

[0563] d.)I-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium

[0564] Following the procedure of Example 1i except substituting thecompound of Example 11c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 1H), 3.2 (dd, 1H).3.4 (m, 1H), 3.7 (m, 2H), 4.7 (m, 1H), 5.2 (m, 1H), 6.0 (s, 2H), 7.2-8.4(m, 8H); MS(ET): 494 (M+H⁺, 70%).

Example 12 Preparation of1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium

[0565] a.)I-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-hydroxy-azepanium

[0566] Following the procedure of Example 11c except substituting4-fluorobenzoic acid for piperonylic acid the title compound wasprepared: MS(EI) 470 (M+H⁺).

[0567] b.)I-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium

[0568] Following the procedure of Example 1i except substituting thecompound of Example 12a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 11H), 3.0 (dd, 1H).3.6 (m, 1H), 4.0 (m, 2H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-8.4 (m, 9H);MS(EI): 468 (M+H⁺, 10%).

Example 13

[0569] Preparation of3-Oxo-4-((S)-4-methyl-2-15-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium

[0570] a.)4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-1-(4-methyl-pentanoyl)-azepanium

[0571] Following the procedure of Example 9a except substitutingiso-caproic acid for 3-(2-pyridyl)phenyl acetic acid the title compoundwas prepared: MS(EI) 442 (M+H⁺).

[0572] b.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-1-(4-methyl-pentanoyl)-azepanium

[0573] Following the procedure of Example 2i except substituting thecompound of

[0574] Example 13a the title compound was prepared: MS(EI) 342 (M+H⁺).

[0575] c.)3-Hydroxy-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium

[0576] To a solution of the compound of Example 13b (200 mg, 0.53 mmol)in dichloromethane was added EDC (111 mg, 0.58 mmol), HOBt (78 mg, 0.58mmol), TEA (0.11 mL, 0.79 mmol) and5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid. The reactionwas stirred at room temperature until complete as indicated by TLCanalysis. Workup and column chromatography (5% methanol:dichloromethane)provided 160 mg of the title compound: MS(EI) 615 (M+H⁺).

[0577] d.)3-Oxo-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium

[0578] Following the procedure of Example 1i except substituting thecompound of Example 13d the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 12H), 1.5-2.1 (m, 8H), 2.2 (m, 2H), 2.3 (m, 1H), 2.4-2.5 (m,2H), 2.6 (m 5H), 2.7 (m, 2H), 2.9 (m, 1H), 3.4 (m, 1H), 3.7 (m, 4H), 4.1(m, 2H), 4.5-4.6 (m, 2H), 5.2 (m, 1H), 7.2-8.4 (m, 4H): MS(EI): 613(M+H⁺, 100%). The diastereomers were separated by preparative scaleHPLC. Lyophilisation of the eluents provided diastereomer 1 anddiastereomer 2.

Example 14

[0579] Preparation of3-Oxo-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-benzenesulphonyl-azepanium

[0580] a.)1-Benzenesulphonyl-4-((S)-2-tert-butoxycarbonylamino-methyl-pentanoylamino)-3-hydroxy-azepanium

[0581] To a solution of the amine of Example 2g (0.5 g, 1.46 mmol) indichloromethane was added triethylamine (0.4 mL, 2.92 mmol) followed bybenzenesulphonyl chloride (0.28 mL, 2.18 mmol). The reaction was stirredat room temperature until complete as determined by TLC analysis. Workupand column chromatography (10% methanol:dichloromethane) provided 450 mgof the title compound: MS(EI) 484 (M+H⁺).

[0582] b.) 4-((S)-2-Amino-methyl-pentanoylamino)1-benzenesulphonyl-3-hydroxy-azepanium

[0583] Following the procedure of Example 2i except substituting thecompound of Example 14a the title compound was prepared: MS(EI) 384(M+H⁺).

[0584] c.)3-Hydroxy-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-benzenesulphonyl-azepanium

[0585] Following the procedure of Example]3c except substituting thecompound of Example 14b the title compound was prepared: MS(EI) 657(M+H⁺).

[0586] d.)3-Oxo-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-benzenesulphonyl-azepanium

[0587] Following the procedure of Example 1i except substituting thecompound of Example 14c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.4 (m, 1H), 2.7 (m, 4H),2.8 (m, 2H), 3.5 (m, 1H), 3.8 (m, 4H), 4.0 (m, 11H), 4.1 (m, 2H), 4.4(m, 1H), 4.5 (m, 1H), 4.7 (m, 1H), 5.1 (m, 1H), 7.0 (m, 3H), 7.3 (m,2H), 7.5 (m, 3H), 7.7 (m, 2H): MS(EI): 655 (M+H⁺, 100%).

[0588] Analysis of the diastereomeric mixture by analytical HPLC (40:60to 45:55 CH₃CN:20 mm KHPO₄ (pH 7 buffer) 60 min. gradient 1 mL/min.;inertsil ODS-3 column 4.6×250 mm; UV detection at 215 nM) showed twopeaks (R_(t)=44.6 mins. and 45.9 mins). The diastereomers were separatedby preparative scale HPLC (40:60 to 50:50 CH₃CN: mm KHPO₄ (pH 7buffer)gradient, 12 mL/min., 60 mins; inertsil ODS-3 column 250×20 mm;UV detection at 215 nM). Lyophilisation of the eluents provideddiastereomer 1 (anal. R_(t) 44.6 mins.) and diastereomer 2 (anal.Rt=45.9 mins).

Example 15

[0589] Preparation of4-((S)-4-Methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicAcid Phenylamide

[0590] a.)[(S)-1-(3-Hydroxy-1-phenylcarbamoyl-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamicAcid Tert-Butyl Ester

[0591] To a solution of the amine of Example 2g (0.5 g, 1.46 mmol) indichloromethane (20 mL) was added phenyl isocyanate (0.24 mL, 2.18mmol). The reaction was stirred at room temperature until complete asdetermined by TLC analysis. Workup and column chromatography (5%methanol:dichloromethane) provided 578 mg of the title compound: MS(EI)463 (M+H⁺).

[0592] b.)4-((S)-2-Amino-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Phenyl Amide

[0593] Following the procedure of Example 2i except substituting thecompound of Example 15a the title compound was prepared: MS(EI) 363(M+H⁺).

[0594] c.)3-Hydroxy-4-((S)-4-Methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-azepane-1-carboxylicAcid Phenylamide

[0595] Following the procedure of Example 13c except substituting thecompound of Example 15b the title compound was prepared: MS(EI) 636(M+H⁺).

[0596] d.)4-((S)-4-Methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicAcid Phenylamide

[0597] Following the procedure of Example 1i except substituting thecompound of Example 15c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 4H), 3.0 (m, 2H),3.1 (m, 1H), 3.8 (m, 1H), 3.9 (m, 4H), 4.2 (m, 1H), 4.3 (m, 2H), 4.9 (m,2H), 5.2 (m, 1H), 7.2-8.4 (m, 9H): MS(EI): 634 (M+H⁺, 100%)

[0598] Analysis of the diastereomeric mixture by analytical HPLC (40:60CH₃CN:20 mM KHPO₄ (pH 7 buffer) isocratic, 1 mL/min.; inertsil ODS-3column 4.6×250 mm; UV detection at 215 nM) showed two peaks (R_(t) 27.3mins. and 30.1 mins). The diastereomers were separated by preparativescale HPLC (40:60 to 50:50 CH₃CN: 20 mM KEPO₄ (pH 7 buffer) gradient, 12mL/min., 60 mins; inertsil ODS-3 column 250×20 mm; UV detection at 215nM). Lyophilisation and desalting of the eluents by NaHCO₃:ethyl acetateextraction provided diastereomer 1 (anal. R_(t)=27.3 mins.) anddiastereomer 2 (anal. R_(t)=30.1 mins).

Example 16

[0599] Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0600] a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0601] Following the procedure of Example 13c except substituting thecompound of Example 9b the title compound was prepared: MS(EI) 712(M+H⁺).

[0602] b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0603] Following the procedure of Example 1i except substituting thecompound of Example 16c the title compound was prepared: ¹H NMR(CDCl₃):): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 4H), 2.8(m, 2H), 2.9 (m, 1H), 3.5 (m, 1H), 3.7 (m, 4H), 3.9 (m, 3H), 4.3 (m,2H), 4.7 (m, 2H), 5.4 (m, 1H), 7.2-8.0 (m, 13H), 8.5 (m, 1H); MS(EI):710 (M+H⁺, 100%) MS(EI).

[0604] Analysis of the diastereomeric mixture by analytical HPLC (40:60CH₃CN:20 mM KHPO₄ (pH 7 buffer) isocratic, 1 mL/min.; inertsil ODS-3column 4.6×250 mm; UV detection at 215 nM) showed two peaks (Rt=33.9mins. and 37.9 mins). The diastereomers were separated by preparativescale HPLC (40:60 to 45:55 CH₃CN: 20 mM KHPO₄ (pH 7 buffer) gradient, 12mL/min., 60 mins; inertsil ODS-3 column 250×20 mm; UV detection at 215nM). Lyophilisation and desalting of the eluents by NaHCO₃:ethyl acetateextraction provided diastereomer 1: MS(EI) 710.3 (M+H⁺) (anal. Rt=33.9mins.) and diastereomer 2: MS(EI) 710.3 (M+H⁺) (anal. Rt=37.9 mins).

Example 17

[0605] Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid[(S)-1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0606] a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid[(S)-1-(benzoyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0607] Following the procedure of Example 13c except substituting thecompound of Example 11b the title compound was prepared: MS(EI) 621(M+H⁺).

[0608] b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0609] Following the procedure of Example 1i except substituting thecompound of Example 17a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H); 2.7 (m, 4H), 2.9 (m, 2H),3.0 (m, 1H), 3.7 (m, 5H), 4.0 (m, 1H), 4.1 (m, 2H), 4.7 (m, 2H), 5.4 (m,1H), 7.2-8.4 (m, 111H): MS(EI): 619 (M+H⁺, 100%)

[0610] Analysis of the diastereomeric mixture by analytical HPLC (40:60to 55:45 CH₃CN:20 mM KHPO₄ (pH 7 buffer) 30 min. gradient, 1 mL/min.;inertsil ODS-3 column 4.6×250 mm; UV detection at 215 nM) showed twopeaks (Rt=mins. 13.5 and 17.6 mins). The diastereomers were separated bypreparative scale HPLC (40:60 to 45:55 CH₃CN: mM KHPO₄ (pH 7 buffer) 60min. gradient, 15 mL/min., 60 mins; inertsil ODS-3 column 250×20 mm; UVdetection at 215 nM). Lyophilisation and desalting of the eluents byNaHCO₃:ethyl acetate extraction provided diastereomer I (anal. Rt=13.5mins.) and diastereomer 2 (anal. R_(t)=17.6 mins).

Example 18

[0611] Preparation of5-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0612] a.) 5-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0613] Following the procedure of Example 14c except substituting5-(2-pyrrolidin-1-yl-ethyloxy)-benzofuran-2-carboxylic acid for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 641 (M+H⁺).

[0614] b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0615] Following the procedure of Example 1i except substituting thecompound of Example 18a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 9H), 2.2 (m, 2H), 2.5 (m, 1H), 2.7 (m, 4H),3.0 (m, 2H), 3.4 (m, 1H), 4.0 (m, 1H), 4.1 (m, 2H), 4.5 (m, 1H), 4.6 (m,1H), 5.0 (m, 1H), 7.2-8.4 (m, 11H): MS(EI): 639 (M+H⁺, 100%).

Example 19

[0616] Preparation of5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic Acid [(S)-1(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0617] a.) 5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic Acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0618] Following the procedure of Example 14c except substituting5-(2-piperidin-1-yl-ethyloxy)-benzofuran-2-carboxylic acid for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 655 (M+H⁺).

[0619] b.) 5-(2-Piperidin-]-yl-ethoxy)-benzofuran-2-carboxylic Acid[(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0620] Following the procedure of Example 1i except substituting thecompound of Example 18a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 11H), 2.2 (m, 2H), 2.5 (m, 5H), 2.7 (m, 2H),3.5 (m, 1H), 4.0 (m, 1H), 4.1 (m, 2H), 4.5 (m, 1H), 4.6 (m, 1H), 5.0 (m,1H), 7.2-8.4 (m, 11H): MS(EI): 653 (M+H⁺, 100%).

Example 20

[0621] Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0622] a.) 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic AcidMethoxy Methyl Amide

[0623] To a solution of 3-(2-pyridyl)phenyl acetic acid (1g) indichloromethane was added N,O-dimethylhydroxylamine hydrochloride (0.92g), triethylamine (1.3 mL), HOBt (0.96 g) and EDC (1.1 g). The reactionwas stirred until complete. Workup and column chromatography (40% ethylacetate:hexanes provided 1.1 g of the title compound: MS(EI) 257 (M+H⁺).

[0624] b.) 5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde

[0625] To a solution of5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid methoxy methylamide (0.2 g) of Example 20a in THF was added LAH (2.0 mL of a 1 Msolution in THF). The reaction was stirred until complete consumption ofthe starting material. Workup gave 160 mg of the title compound.

[0626] c.)((S)-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-ethyl]-azepan-4-ylcarbamoyl}-3-methyl-butyl)-carbamicAcid Tert Butyl Ester

[0627] Following the general procedure of Example 2g except substituting5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde for benzaldehydethe title compound was prepared: MS(EI) 525 (M+H⁺).

[0628] d.) (S)-2-Amino-4-methyl-pentanoicacid-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-ethyl]-azepan-4-yl}-amide

[0629] Following the procedure of Example 2i except substituting thecompound of Example 20c the title compound was prepared.

[0630] e.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0631] Following the procedure of Example 13c except substituting thecompound of Example 20d the title compound was prepared.

[0632] f.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0633] Following the procedure of Example 1i except substituting thecompound of Example 20e the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 4H), 2.8 (m, 6H),3.1 (m, 1H), 3.3 (m, 1H), 3.5 (m, 1H), 3.7 (m, 4H), 4.2 (m, 3H), 4.6 (m,1H), 5.2 (m, 1H), 7.2-8.4 (m, 13H), 8.6 (m, 1H); MS(EI): 696 (M+H⁺,80%).

[0634] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 696 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 696 (M+H⁺, 100%).

Example 21

[0635] Preparation of Naphthlene-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0636] a.) Naphthlene-2-carboxylic Acid((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0637] Following the procedure of Example 20f except substituting2-naphthoic acid for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 579 (M+H⁺).

[0638] b.) Naphthlene-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0639] Following the procedure of Example 1i except substituting thecompound of Example 21b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 6H), 2.2 (m, 2H), 2.9 (m, 4H), 3.0 (m, 1H),3.4 (d, 1H). 3.5 (m, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 6.8-7.2 (m, 6H), 7.3(m, 1H), 7.5 (m, 2H), 7.9 (m, 6H), 8.2 (M, 1H), 8.7 (m, 1H): MS(EI):577(M+H⁺, 100%).

Example 22

[0640] Preparation of 1H-Indole-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0641] a.)((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0642] Following the procedure of Example 20f except substituting¹H-indole-2-carboxylic acid for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid the titlecompound was prepared:, MS(EI) 568 (M+H⁺).

[0643] b.)((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0644] Following the procedure of Example 1i except substituting thecompound of Example 22b the title compound was prepared: ¹H NMR(CDCl₃):): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.9 (m, 4H), 3.0(m, 1H), 3.4 (d, 11H). 3.5 (m, 11H), 4.7 (m, 1H), 5.0 (m, 1H), 6.8-7.2(m, 6H), 7.0-7.9 (m, 12H), 8.7 (m, 11H), 9.5 (m, 1H): MS(EI): 566 (M+H⁺,100%)

Example 23

[0645] Preparation of 1H-Indole-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0646] a.) 1H-Indole-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0647] Following the procedure of Example 2j except substituting thecompound of Example]4b and substituting 1H-indole-2-carboxylic acid fornaphthoic acid the title compound was prepared: MS(EI) 527 (M+H⁺).

[0648] b.) 1H-Indole-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0649] Following the procedure of Example 1i except substituting thecompound of Example 23b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (dd, 1H).3.9 (m, 1H), 4.5 (dd, 2H), 4.7 (m, 1H), 5.0 (m, 1H), 7.2-7.6 (m, 10H).9.5 (b, 1H); MS(EI): 525 (M+H⁺, 10%).

Example 24

[0650] Preparation of Benzofuran-2-carboxylic Acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0651] a.) Benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0652] Following the procedure of Example 23a except substitutingbenzofuran-2-carboxylic acid for 1H-indole 2-carboxylic acid the titlecompound was prepared: MS (EI) 528 (M+H⁺).

[0653] b.) Benzofuran-2-carboxylic Acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide

[0654] Following the procedure of Example 1i except substituting thecompound of Example 24b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (m, 1H), 3.5 (d, 1H).4.1 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.2 (m, 10H).

Example 25

[0655] Preparation of Benzofuran-2-carboxylic acid[(S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0656] a.) Benzofuran-2-carboxylic acid[(S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0657] Following the procedure of Example 20e except substitutingbenzofuran-2-carboxylic acid for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic the title compoundwas prepared: MS(EI) 569 (M+H⁺).

[0658] b.) Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0659] Following the procedure of Example 1i except substituting thecompound of Example 25b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 5H), 3.0 (m, 1H).3.3 (m, 1H), 3.5 (m, 1H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-7.7 (m, 14H),8.7 (m, 1H); MS(EI): 567 (M+H⁺, 100%)

[0660] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 656 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 656 (M+H⁺, 100%).

Example 26 Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbamoyl]-butyl}amide

[0661] Following the procedures of Examples 20c-f except substitutingphenylacetaldehyde for5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carbaldehyde of Example 20cthe title compound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1(m, 5H), 2.2 (m, 2H), 2.4 (m, 1H), 2.6 (m, 4H), 2.7 (m, 6H), 3.0 (m,1H), 3.3 (dd, 1H), 3.5 (q, 1H), 3.7 (m, 4H). 4.2 (m, 2H), 4.7 (m, 11H),5.0 (m, 1H), 7.2-7.2 (m, 11H); MS(EI): 619 (M+H⁺, 80%)

[0662] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 619 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 619 (M+H⁺, 100%).

Example 27

[0663] Preparation of Naphthylene-2-carboxylic Acid[(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbainoyl]-butyl}amide

[0664] Following the procedures of Examples 2h-k except substitutingphenylacetaldehyde for benzaldehyde of Example 2h the title compound wasprepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H),2.4 (m, 1H), 2.7 (m, 4H), 3.0 (m, 1H), 3.7 (d, 1H), 3.5 (q, 1H), 4.7 (m,1H), 5.1 (m, 1H), 6.9-7.2 (m, 7H), 7.5 (m, 2H), 7.9 (m, 4H) 8.4 (m, 1H);MS(EI): 500 (M+H⁺, 100%).

Example 28

[0665] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0666] a.) (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0667] Following the procedure of Examples 14a-b except substituting2-pyridinesulfonyl chloride for benzenesulfonyl chloride of Example 14athe title compound was prepared: MS(EI) 385 (M+H⁺).

[0668] b.) Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0669] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 28a(0.15 g) in dichloromethane was added TEA (0.11 mL), HOBt (49 mg), EDC(69 mg) and benzofuran-2-carboxylic acid (58 mg). The reaction wasstirred until complete. Workup and column chromatography (5%methanol:ethyl acetate) provided the title compound: MS(EI) 529 (M+H⁺).

[0670] c.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0671] Following the procedure of Example 1i except substituting thecompound of Example 28b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (dd, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6(m, 1H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 527 (M+H⁺, 40%).

[0672] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR: δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2(m, 2H), 2.7 (t, 1H), 3.7 (d, 1H); 4.0 (d, 1H), 4.7 (m, 2H), 5.0 (m,1H), 7.2-7.3 (m, 3H), 7.4 (m, 4H), 7.6 (m, 1H), 8.0 (m, 2H), 8.7 (m,1H); MS(EI): 527 (M+H⁺, 100%), and the slower eluting diastereomer;¹HNMR: δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.7 (d,1H); 4.0 (d, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 3H), 7.4 (m,4H), 7.6 (m, 1H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 527 (M+H⁺, 100%).

Example 29

[0673] Preparation of Naphthylene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0674] a.) Naphthylene-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0675] Following the procedure of Example 28b except substituting2-naphthoic acid for benzofuran-2-carboxylic acid the title compound wasprepared: MS(EI) 539 (M+H⁺).

[0676] b.) Naphthylene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)amide

[0677] Following the procedure of Example 1i except substituting thecompound of Example 29a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 51H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (dd,11H). 4.0 (m, 11H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 2H), 7.5 (m,3H), 7.9 (m, 6H), 8.3 (m, 1H), 8.4 (m, 1H); MS(EI): 537 (M+H⁺, 50%).

[0678] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 537 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 537 (M+H⁺, 100%).

Example 30

[0679] Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0680] a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0681] Following the procedure of Example 13c except substituting thecompound of Example 28a the title compound was prepared: MS(EI) 658(M+H⁺).

[0682] b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0683] Following the procedure of Example 1i except substituting thecompound of Example 29a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.5 (m, 4H).3.7 (m, 6H), 4.1 (m, 1H), 4.5 (m, 2H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3(m, 4H), 7.4 (m, 2H), 8.0 (m, 2H), 8.7 (m, 1H), 8.7 (m, 1H); MS(EI): 656(M+H⁺, 100%).

[0684] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 656 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 656 (M+H⁺, 100%).

Example 31

[0685] Preparation of4-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicAcid Tert-Butyl Ester

[0686] a.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Tert-Butyl Ester

[0687] To a solution of the compound of Example 1f (0.89 g) in ethylacetate:methanol (30 mL of a 2:1 mixture) was added 10% Pd/C and aballoon of hydrogen gas was attached. The reaction was stirred untilcomplete by TLC analysis whereupon it was filtered and concentrated toprovide the title compound (0.57 g).

[0688] b.)4-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-amino}-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Tert-Butyl Ester

[0689] Following the procedure of Example 13c except substituting thecompound of Example 31a the title compound was prepared.

[0690] c.)4-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicAcid Tert-Butyl Ester

[0691] Following the procedure of Example 1i except substituting thecompound of Example 31b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5 (m, 9H), 1.7 (m, 5H), 2.2 (m, 2H), 2.5 (m, 5H), 2.7(m, 2H), 3.5 (m, 1H). 3.8 (m, 4H), 4.1 (m, 3H), 4.2 (m, {H), 4.7 (m,2H), 5.0 (m, 1H), 7.2-7.3 (m, 5H); MS(EI): 615 (M+H⁺, 100%).

Example 32

[0692] Preparation of4-((S)-4-Methyl-2-[[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylicAcid [S-3-methyl-1-(3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0693] To a solution of the compound of Example 31c in THF (5 mL) wasadded 1 M HCl in ether (5 mL). Th reaction was stirred overnightwhereupon it was concentrated to provide the title compound: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (in, 4H), 3.2(dd, 3H). 3.7 (in, 6H), 4.0 (m, 3H), 4.5 (m, 2H), 5.0 (m, 1H), 7.2-7.3(m, 6H); MS(EI): 515 (M+H⁺, 100%).

Example 33

[0694] Preparation of 4-Methyl-pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-azepan-4-yl}-amide

[0695] a.) 3-Hydroxy-4-(4-methyl-pentanoylamino)-azepane-1-carboxylicAcid Tert-Butyl Ester

[0696] Following the procedure of Example 1f except substituting4-methylpentanoic Acid for Cbz-leucine the title compound was prepared:MS(EI) 329 (M+H⁺).

[0697] b.) 4-Methyl pentanoic acid (3-hydroxy-azepan-4-yl)-amide

[0698] To a solution of the compound of Example 33a (200 mg) in methanol(5 mL) was added 4M HCJ dioxane (5 mL). The reaction was stirred untilcomplete whereupon it was concentrated to provide the title compound (I32 mg): MS(EI) 229 (M+H⁺).

[0699] c.) 4-Methyl-pentanoic acid{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-azepan-4-yl}amide

[0700] Following the procedure of Example 9a except substituting thecompound of Example 33b the title compound was prepared: MS(EI) 424(M+H⁺).

[0701] d.) 4-Methyl-pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-azepan-4-yl}-amide

[0702] Following the procedure of Example 1i except substituting thecompound of Example 33c the title compound was prepared: ¹H NMR (CDCl₃)δ 1.0 (m, 6H), 1.5-2.1 (in, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 2.9 (m, 1H),3.5 (m, 1H), 3.7 (m, 2H), 4.1 (m, 3H), 4.6 (m, 1H), 5.3 (m, 1H), 7.2-8.0(m, 7H), 8.7 (m, 1H); MS(EI): 422 (M+H⁺, 100%).

Example 34

[0703] Preparation of((S)-3-Methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamicAcid Tert-Butyl Ester

[0704] a.) (S)-4-Methyl-2-[naphthalene-2-ylmethyl)-amino]-pentanoic AcidMethyl Ester

[0705] To a solution of leucine methyl ester hydrochloride (0.5 g) indichlormethane was added triethylamine (0.9 mL), 2-naphthaldehyde (0.43g) and sodium triacetoxyborohydride (0.87 g). The mixture was stirreduntil complete. Workup and column chromatography (5% ethylacetate:dichloromethane) provided 0.4 g of the title compound: MS(EI)286 (M+H⁺).

[0706] b.)(S)-2-(tert-Butoxycarbonyl-naphthlen-2-ylmethyl-amino)-4-metyhylPentanoic Acid Methyl Ester

[0707] To a solution of the compound of Example 34a (0.35 g) indichloromethane was added di-tert-butyldicarbonate (0.29 g). After 2hours at room temperature triethylamine was added and the reactionheated to reflux. Upon completion, the reaction was concentrated and theresidue was purified by column chromatography (50%hexane:dichloromethane) to provide 0.17 g of the title compound: MS(EI)386 (M+H⁺).

[0708] c.)(S)-2-(tert-Butoxycarbonyl-naphthlen-2-ylmethyl-amino)-4-methylPentanoic Acid

[0709] To a solution of the compound of Example 34b (0.17 g) inTHF:methanol (15 mL of a 2:1 solution) was added LiOH (0.019 g). Thereaction was stirred overnight whereupon it was concentrated to providethe title compound.

[0710] d.)4-[(S)-tert-butoxycarbonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0711] To a sloution of the compound of Example 2e (0.11 g) indichloromethane was added EDC (0.08 g), HOBt (0.06 g) and the acid ofExample 34c. Upon completion the reaction was worked up andchromatographed (5% methanol:dichloromethane) to provide the titlecompound (0.18 g): MS(EI) 618 (M+H⁺).

[0712] e.)[(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-naphthylen-2-ylmethylCarbamic Acid Tert-Butyl Ester

[0713] To a solution of the compound of Example 34d (0.17 g) in ethylacetate:methanol (20:10 mL) was added 10% Pd/C. A balloon of hydrogenwas attached and the reaction was stirred until complete consumption ofthe starting material. The reaction was filtered and concentrated toprovide the title compound (00.10 g): MS(EI) 484 (M+H⁺).

[0714] f.)((S)-3-Methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamicAcid Tert-Butyl Ester

[0715] Following the procedure of Example 9a except substituting thecompound of Example 34e the title compound was prepared: MS(EI) 679(M+H⁺).

[0716] g.)((S)-3-Methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamicAcid Tert-Butyl Ester

[0717] Following the procedure of Example 1i except substituting thecompound of Example 34f the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.2 (m, 16H), 2.7 (m, 1H), 3.2 (m, 1H). 3.7 (m, 3H),4.0 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.2-7.3 (m, 16H), 8.6 (m, 1H);MS(EI): 677 (M+H⁺, 100%).

Example 35

[0718] Preparation of(S)-4-Methyl-2-[(naphthylen-2-ylmethyl)-amino]-pentenoic Acid[3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide

[0719] To a solution of the compound of Example 34g (20 mg) in THF wasadded 1M HCl in ether. The reaction was stirred until completeconsumption of the starting material whereupon it was concentrated toprovide the title compound: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (m, 5H), 4.0 (m, 1H), 4.7 (m, 2H),4.4 (m, 1H), 7.2-8.0 (m, 16H), 8.7 (m, 1H); MS(EI): 577 (M+H⁺, 100%).

Example 36

[0720] Preparation of4-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicAcid Tert-Butyl Ester

[0721] a.)4-[2-(2-{(S)-3-Methyl-1-[3-hydroxy-1-(pyidine-2-sulfonyl)-azepan-4-ylcarbamoyl]butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicAcid Tert-Butyl Ester

[0722] To a solution of the compound of Example 28a (0.15 g) indichloromethane was added EDC (0.07 g), HOBt (0.05 g), triethylamine(0.11 mL) and4-[2-(2-carboxy-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acidtert-butyl ester. The reaction was stirred until complete. Work up andcolumn chromatography (10% methanol: ethyl acetate) provided the titlecompound (0.10 g): MS(EI) 757 (M+H⁺).

[0723] b.)4-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicAcid Tert-Butyl Ester

[0724] Following the procedure of Example 1i except substituting thecompound of Example 36a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 14H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0 (m, 2H),3.5 (m, 4H). 3.7 (m, 6H), 4.1 (m, 1H), 4.5 (m, 2H), 4.7 (m, 2H), 5.0 (m,1H), 7.0-7.6 (m, 6H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 755 (M+H⁺,100%).

Example 37

[0725] Preparation of5-(2-Piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic Acid (S)-3-methyl-1[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide

[0726] The compound of Example 36b (0.02 g) was dissolved in 4M HCl indioxane. The reaction was stirred until complete whereupon it wasconcentrated to provide the title compound: ¹H NMR (CDCl₃): δ 1.0 (m,6H), 1.5-1.7 (m, 7H), 2.7 (m, 2H), 3.3 (M, 2H), 3.5 (m, 1H). 3.8 (m,5H), 4.1 (m, 3H), 4.7 (m, 4H), 5.0 (m, 1H), 7.0-7.3 (m, 2H), 7.4 (m,6H), 8.0 (m, 2H), 8.7 (m, 1H): MS(EI): 655 (M+H⁺, 100%).

Example 38

[0727] Preparation of 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylicacid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0728] a.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0729] To a solution of the compound of Example 28a (0.15 g) indichloromethane was added EDC (0.07 g), HOBt (0.05 g), triethylamine(0.11 mL) and 5-(2-cyclohexyl-ethoxy)-benzofuran carboxylic acid (0.01g). The reaction was stirred until complete by TLC analysis. Workup andcolumn chromatography (100% ethyl acetate) provided the title compound(0.15 g): MS(EI) 655 (M+H⁺).

[0730] b.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0731] Following the procedure of Example 1i except substituting thecompound of Example 38a the title compound was prepared: MS(EI) 653(M+H⁺).

Example 39

[0732] Preparation of 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylicAcid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl1-butyl}amide

[0733] a.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0734] To a solution of the compound of Example 20d (0.15 g) indichloromethane was added EDC (0.06 g), HOBt (0.04 g), triethylamine(0.14 mL) and 5-(2-cyclohexyl-ethoxy)-benzofuran carboxylic acid (0.09g). The reaction was stirred until complete by TLC analysis. Workup andcolumn chromatography (100% ethyl acetate) provided the title compound(0.10 g): MS(EI) 695 (M+H⁺).

[0735] b.) 5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl)-butyl)amide

[0736] Following the procedure of Example 1i except substituting thecompound of Example 39a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 18H), 2.2 (m, 2H), 2.7 (m, 3H), 3.2 (m, 1H),3.5 (m, 1H). 3.9 (m, 4H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2-7.3 (m, 13H),8.7 (m, 1H): MS(EI): 693 (M+H⁺, 100%)

Example 40

[0737] Preparation of4-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl]azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicAcid Tert-Butyl Ester

[0738] a.)4-[2-(2-{(S)-3-Methyl-1-[3-hydroxy-1-(3-pyridin-2-yl-phenyl)-ethyl[azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicacid tert-butyl ester

[0739] To a solution of the compound of Example 20d (0.15 g) indichloromethane was added EDC (0.06 g), HOBt (0.04 g), triethylamine(0.14 mL) and4-[2-(2-carboxy-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylic acidtert-butyl ester (0.12 g). The reaction was stirred until complete byTLC analysis. Workup and column chromatography (10% methanol:ethylacetate) provided the title compound (0.09 g): MS(EI) 797 (M+H⁺).

[0740] b.)4-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl[azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicAcid Tert-Butyl Ester

[0741] Following the procedure of Example 1i except substituting thecompound of Example 40a the title compound was prepared: MS(EI) 795.9(M+H⁺).

Example 41

[0742] Preparation of5-(2-piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamovl}-butyl)amide

[0743] Following the procedure of Example 37 except substituting thecompound of Example 40b the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 3.4-3.6 (m, 19H), 4.5 (m,1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2 (m, 1H), 7.4 (m, 1H), 7.5 (m, 2H),7.7 (m, 2H), 7.8 (m, 1H), 8.1 (m, 2H), 8.4 (m, 1H), 8.7 (m, 1H); MS(EI):695 (M+H⁺, 70%).

Example 42

[0744] Preparation of(S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid[3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide

[0745] a.)4-[(S)-2-(tert-Butoxycarbonyl-methyl-amino)-4-methyl-pentanoylamino]-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0746] To a solution of the compound of Example 2e (0.35 g)indichloromethane was added N-methyl-N-Boc-leucine (0.36 g), HOBt (0.2 g)and EDC (0.28 g). The reaction was stirred until complete. Workup andcolumn chromatography (5% methanol:dichloromethane) provided 0.6 g ofthe title compound: MS(EI) 492 (M+H⁺).

[0747] b.)[(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-methyl-carbamicAcid Tert-Butyl Ester

[0748] To a solution of the compound of Example 42a (0.6 g) inmethanol:ethyl acetate (10:20 mL) was added 10% Pd/C and a balloon ofhydrogen was attached. The reaction was stirred overnight whereupon itwas filtered and concentrated to provide 0.50 g of the title: MS(EI) 358(M+H⁺).

[0749] c.){(S)—-[3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-methyl-carbamicAcid Tert-Butyl Ester

[0750] To a solution of the compound of Example 42b (0.2 g) indichloromethane was added triethylamine (0.16 mL) and 2-pyridinesulfonylchloride (0.15 g). The reaction was stirred until complete. Workup andcolumn chromatography (5% methanol:ethyl acetate) provided the titlecompound (0.23 g): MS(EI) 499 (M+H⁺).

[0751] d.) (S)-4-Methyl-2-methylamino-pentanoic acid[3-hydroxy-1-(2-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0752] To a solution of the compound of Example 42c (0.23 g) in methanol(3.0 mL) was added 4M HCl in dioxane (3.0 mL). The reaction was stirreduntil complete. Concentration provided the title compound: MS(EI) 399(M+H⁺).

[0753] e.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoicAcid [3-hydroxy-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide

[0754] To a solution of the compound of Example 42d (0.05 g) indichloromethane was added triethylamine (0.07 mL), 2-naphthaldehyde(0.05 g) and sodium triacetoxyborohydride (0.11 g). The reaction wasstirred until complete. Workup and column chromatography (5% methanolethyl acetate) provided the title compound (0.03 g): MS(EI) 539 (M+H⁺).

[0755] f.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoicAcid [3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide

[0756] Following the procedure of Example 1i except substituting thecompound of Example 42e the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 5H), 2.6 (m, 1H), 3.3 (m, 1H),3.7 (m, 2H), 4.1 (m, 1H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-8.0 (m, 10H),8.7 (m, 1H); MS(EI): 537 (M+H⁺, 100%).

Example 43

[0757] Preparation of(S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide

[0758] a.)((S)-]-{3-Hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl)-3-methyl-butyl)-methyl-carbamicAcid Tert-Butyl Ester

[0759] To a solution of the compound of Example 42b (0.25 g) was added3-(2-pyridyl)phenyl acetic acid (0.16 g), HOBt (0.12 g) and EDC (0.15g). The reaction was stirred until complete. Workup and columnchromatography (5% methanol:ethyl acetate) provided the title compound(0.24 g): MS(EI) 553 (M+H⁺).

[0760] b.) (S)-4-Methyl-2-methylamino-pentanoic Acid{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide

[0761] Following the procedure of Example 42d except substituting thecompound of Example 43a the title compound was produced: MS(EI) 453(M+H⁺).

[0762] c.) (S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoicAcid {3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide

[0763] Following the procedures of Examples 42e-f except substitutingthe compound of Example 43b the title compound was produced: ¹H NMR(CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 5H), 3.0 (m, 1H), 3.5(m, 1H), 3.7 (m, 4H), 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.2-8.0 (m,15H), 8.7 (m, 1H); MS(EI): 591 (M+H⁺, 100%).

Example 44

[0764] Preparation of5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid methyl((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0765] a.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acidmethyl((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0766] To a solution of the compound of Example 43b (0.1 g) indichloromethane was added5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid (0.06 g), HOBt(0.026 g), TEA (0.07 mL) and EDC (0.04 g). The reaction was stirreduntil complete. Workup and chromatography (20% methanol:ethyl acetate)provided the title compound (0.07 g): MS(EI) 726 (M+H⁺).

[0767] b.) 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acidmethyl((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide

[0768] Following the procedure of Example 1i except substituting thecompound of Example 44a the title compound was prepared: ¹H NMR(CDCl₃):): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 5H), 2.7 (m, 4H), 2.8(m, 2H), 2.9 (m, 1H), 3.5 (m, 1H), 3.7 (m, 4H), 3.9 (m, 3H), 4.3 (m,2H), 4.7 (m, 2H), 5.4 (m, 1H), 7.2-8.0 (m, 12H), 8.5 (m, 1H); MS(EI):724 (M+H⁺, 100%).

Example 45

[0769] Preparation of Benzofuran-2-carboxylic Acid Methyl{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0770] a.) Benzofuran-2-carboxylic Acid Methyl{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0771] To a solution of the compound of Example 42d (0.1 g) indichloromethane was added benzofuran-2-carboxylic acid (0.04 g), TEA(excess), HOBt (0.03 g), and EDC (0.04 g). The reaction was stirreduntil complete. Workup and column chromatography (5%methanol:dichloromethane) provided the title compound (0.04 g): MS(EI)542.9 (M+H⁺).

[0772] b.) Benzofuran-2-carboxylic acid methyl{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0773] Following the procedure of Example 1i except substituting thecompound of Example 45a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 8H), 2.2 (m, 2H), 2.7 (m, 1H), 3.0 (m, 1H),3.7 (1m, 2H), 4.1 (m, 1H), 4.7 (m, 1H), 5.2 (m, 1H), 7.2-8.0 (m, 8H),8.7 (m, 1H); MS(EI): 541 (M+H⁺, 10%).

Example 46

[0774] Preparation of2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-N-naphthylen-2-ylmethyl-acetamide

[0775] a.)(S)-4-Methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-acetyl)-amino]-pentanoicAcid Methyl Ester

[0776] To a solution of the compound of Example 34a (0.5 g) indichloromethane was added potassium carbonate (catalytic amount), andtrifluoroacetic acid (0.44 g). The reaction was stirred at roomtemperature for 1 hour whereupon it was concentrated and chromatographed(20% ethyl acetate:hexane) to provide the title compound.

[0777] b.)(S)-4-Methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-acetyl)-amino]-pentanoicAcid Lithium Salt

[0778] To a solution of the compound of Example 46a (0.49 g) inTHF:water (3 mL of a 2:1 solution) was added lithium hydroxidemonohydrate (0.06 g). The reaction was stirred overnight whereupon itwas concentrated to provide the title compound (0.46 g): MS(EI) 366(M+H⁺).

[0779] c.)3-Hydroxy-4-{(S)-4-methyl-2-[naphthylen-2-ylmethyl-(2,2,2-trifluoro-acetyl)-amino]-pentanoylamino1-azepane-1-carboxylic Acid Benzyl Ester

[0780] To a solution of the compound of Example 2e (0.29 g) indichloromethane was added EDC (0.24 g), HOBt (0.16 g) and the compoundof Example 46b (0.46 g). The reaction was stirred until complete. Workupand column chromatography (5% methanol:ethyl acetate) provided the titlecompound (0.25 g): MS(EI) 614 (M+H⁺).

[0781] d.)2,2,2-Trifluoro-N-[(S)-1-(3-hydroxy-azepan-ylcarbamoyl)-3-methyl-butyl]-N-naphthlen-2-ylmethyl-acetamide

[0782] Following the procedure of Example 42b except substituting thecompound of Example 46c the title compound was produced: MS(EI) 480(M+H⁺).

[0783] e.)2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-N-naphthylen-2-ylmethyl-acetamide

[0784] Following the procedure of Example 43a except substituting thecompound of Example 46d the title compound was produced: MS(EI) 675(M+H⁺).

[0785] f.)2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-N-naphthylen-2-ylmethyl-acetamide

[0786] Following the procedure of Example 1i except substituting thecompound of Example 46e the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.2 (m, 1H),3.7 (m, 3H), 4.1 (m, 1H), 4.5 (m, 2H), 4.7 (m, 2H), 5.2 (m, 1H), 7.2-8.0(m, 14H), 8.7 (m, 1H): MS(EI): 673 (M+H⁺, 100%).

Example 47

[0787] Preparation of4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-oxo-azepane-1-carboxylicAcid Benzyl Ester

[0788] a.)(S)-2-(Methanesulfonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoicAcid Methyl Ester

[0789] To a solution of the compound of Example 34a (0.5 g) indichloromethane was added triethylamine (0.36 mL) and methansulfonylchloride (0.16 mL). The reaction was stirred at room temperature untilcomplete. Workup and chromatography (20% ethyl acetate:hexanes) providedthe title compound (0.24 g).

[0790] b.)(S)-2-(Methanesulfonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoicAcid Lithium Salt

[0791] Following the procedure of Example 46b except substituting thecompound of Example 47a the title compound was prepared: MS(EI) 348(M+H⁺).

[0792] c.)4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0793] Following the procedure of Example 46c except substituting thecompound of Example 47b the title compound was prepared: MS(EI) 596(M+H⁺).

[0794] d.)4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-oxo-azepane-1-carboxylicAcid Benzyl Ester

[0795] Following the procedure of Example 1i except substituting thecompound of Example 47c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 5H), 3.0 (m, 1H), 3.5 (m, 1H),4.1 (m, 1H), 4.5 (m, 3H), 4.7 (m, 1H), 5.2 (m, 3H), 7.2-8.0 (m, 13H);MS(EI): 596 (M+3H⁺, 100%).

Example 48

[0796] Preparation of Quinoline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0797] a.) Quinoline-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0798] Following the procedure of Example 28b except substitutingquinoline-2-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 540 (M+H⁺).

[0799] b.) Quinoline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0800] Following the procedure of Example 1i except substituting thecompound of Example 48a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 11H).4.1 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0-7.2 (m, 1H), 7.3 (m, 1H), 7.5(m, 1H), 7.7 (m, 11H), 7.8 (m, 31H), 8.1 (m, 1H), 8.3 (m, 2H), 8.7 (m,2H); MS(EI): 538 (M+H⁺, 100%).

[0801] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 538 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 538 (M+H⁺, 100%).

Example 49

[0802] Preparation of Quinoline-8-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0803] a.) Quinoline-8-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0804] Following the procedure of Example 28b except substitutingquinoline-8-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 540 (M+H⁺).

[0805] b.) Quinoline-8-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0806] Following the procedure of Example 1i except substituting thecompound of Example 49a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.5 (m, 4H), 7.6 (m, 1H), 7.7 (m,3H), 8.2 (m, 1H), 8.6 (m, 1H), 8.7 (m, 1H), 8.9 (m, 1H); MS(EI): 538(M+H⁺,100%).

Example 50

[0807] Preparation of Quinoline-6-carboxylic Acid{(S)-3-methyl-1-[3-oxo-{-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0808] a.) Quinoline-6-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0809] Following the procedure of Example 28b except substitutingquinoline-6-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 540 (M+H⁺).

[0810] b.) Quinoline-6-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0811] Following the procedure of Example 1i except substituting thecompound of Example 50a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H),4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0 (m, 2H), 7.5 (m, 2H), 7.9 (m,2H), 8.0 (m, 3H), 8.2 (m, 1H), 8.7 (m, 1H), 8.9 (m, 1H); MS(EI): 538(M+H⁺, 100%).

[0812] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 538 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 538 (M+H⁺, 100%).

Example 51

[0813] Preparation of Quinoline-4-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0814] a.) Quinoline-4-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0815] Following the procedure of Example 28b except substitutingquinoline-4-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 540 (M+H⁺).

[0816] b.) Quinoline-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0817] Following the procedure of Example 1i except substituting thecompound of Example 51a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.5-7.2 (m, 2H), 7.4 (m, 2H), 7.5(m, 1H), 7.7 (m, 11H), 7.9 (m, 2H), 8.0 (m, 1H), 8.2 (m, 1H), 8.7 (m,1H), 8.9 (m, 1H); MS(EI): 538 (M+H⁺, 100%)

[0818] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 538 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 538 (M+H⁺, 100%).

Example 52

[0819] Preparation of Quinoline-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0820] a.) Quinoline-3-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0821] Following the procedure of Example 28b except substitutingquinoline-3-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 540 (M+H⁺).

[0822] b.) Quinoline-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0823] Following the procedure of Example 1i except substituting thecompound of Example 52a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2 (m, 2H), 7.5 (m, 1H), 7.6 (m,11H), 7.7-7.9 (m, 4H), 8.1 (m, 1H), 8.5 (m, 1H), 8.6 (m, 1H), 9.3 (m,1H); MS(EI): 538 (M+H⁺, 100%).

[0824] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 538 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 538 (M+H⁺, 100%).

Example 53

[0825] Preparation of Isoquinoline-3-carboxylic Acid{(S)-3-methyl-[1-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0826] a.) Isoquinoline-3-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0827] Following the procedure of Example 28b except substitutingisoquinoline-3-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 540 (M+H⁺).

[0828] b.) Isoquinoline-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0829] Following the procedure of Example 1i except substituting thecompound of Example 53a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0 (m, 1H). 7.5 (m, 1H), 7.7 (m,2H), 7.9 (m, 4H), 8.7 (m, 3H), 9.2 (m, 1H); MS(EI): 538 (M+H⁺, 100%).

Example 54

[0830] Preparation of Isoquinoline-1-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0831] a.) Isoquinoline-1-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0832] Following the procedure of Example 28b except substitutingisoquinoline-1-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 540 (M+H⁺).

[0833] b.) Isoquinoline-1-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0834] Following the procedure of Example 1i except substituting thecompound of Example 54a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, {H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.3 (m, 1H), 7.5 (m, 1H), 7.7-8.0(m, 6H), 8.7 (m, 3H), 9.5 (m, 1H); MS(EI): 538 (M+H⁺, 100%).

[0835] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 537 (M⁺, 100%), and the slowereluting diastereomer; MS(EI): 537 (M⁺, 100%).

Example 55

[0836] Preparation of Quinoxaline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0837] a.) Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0838] Following the procedure of Example 28b except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 541 (M+H⁺).

[0839] b.) Quinoxaline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0840] Following the procedure of Example 1i except substituting thecompound of Example 55a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0-7.2 (m, 2H), 7.5 (m, 1H), 7.7(m, 3H), 8.2 (m, 2H), 8.3 (m, 1H), 8.7 (m, 1H), 9.5 (m, 1H); MS(EI): 539(M+H⁺, 30%).

Example 56

[0841] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0842] a.) Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0843] Following the procedure of Example 28b except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 545 (M+H⁺).

[0844] b.) Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0845] Following the procedure of Example 1i except substituting thecompound of Example 56a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.8-7.2 (m, 1H), 7.5 (m, 3H), 8.0(m, 6H), 8.7 (m, 1H); MS(EI): 543 (M+H⁺, 60%).

[0846] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.2 (m,6H), 2.7 (m, 1H), 3.8 (m, 1H), 4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H),7.4-8.0 (m, 8H), 8.7 (m, 1H); MS(EI): 543 (M+H⁺, 100%), and the slowereluting diastereomer; 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.7 (m, 1H), 3.8 (m,1H), 4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H), 7.4-8.0 (m, 8H), 8.7 (m,1H); MS(EI): 543 (M+H⁺, 100%).

Example 57

[0847] Preparation of 1,8-Naphthyridine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0848] a.) 1,8-Naphthyridine-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0849] Following the procedure of Example 28b except substituting1,8-naphthyridine-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 541 (M+H⁺).

[0850] b.) 1,8-Naphthyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0851] Following the procedure of Example 1i except substituting thecompound of Example 57a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2 (m, 1H), 7.6 (m, 2H), 7.9 (m,2H), 8.3 (m, 1H), 8.4 (m, 2H), 8.5 (m, 2H), 9.2 (m, 1H); MS(EI): 539(M+H⁺, 100%)

Example 58

[0852] Preparation of 1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0853] a.) 1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0854] Following the procedure of Example 28b except substituting1H-indole-2-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 528 (M+H⁺).

[0855] b.) 1H-Indole-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0856] Following the procedure of Example 1i except substituting thecompound of Example 58a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.8 (m, 1H), 7.1 (m, 1H), 7.3 (m,3H), 7.4 (m, 1H), 7.5 (m, 1H), 7.6 (m, 1H), 8.0 (m, 2H), 8.7 (m, 1H),9.4 (b, 1H); MS(EI): 526 (M+H⁺, 80%).

Example 59

[0857] Preparation of 5-Methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0858] a.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0859] Following the procedure of Example 28b except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(EI) 559 (M+H⁺).

[0860] b.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0861] Following the procedure of Example 1i except substituting thecompound of Example 59a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 4H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.0 (m, 4H), 7.6 (m, 3H), 8.0 (m,2H), 8.7 (m, 11H); MS(EI): 557 (M+H⁺, 70%).

[0862] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.7 (m, 4H). 4.0 (d,1H), 4.7 (m, 2H), 5.0(d, 1H), 7.0 (m, 4H), 7.6 (m, 3H), 8.0 (m, 2H), 8.7 (d, 11H); MS(EI):557 (M+H⁺, 100%), and the slower eluting diastereomer; MS(EI): 557(M+H⁺, 100%).

Example 60

[0863] Preparation of 5-Bromo-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0864] a.) 5-Bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0865] Following the procedure of Example 28b except substituting5-bromo-2-furoic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 558 (M+H⁺).

[0866] b.) 5-Bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0867] Following the procedure of Example 1i except substituting thecompound of Example 60a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.5 (m, 1H), 6.7 (m, 1H), 7.1 (m,2H), 7.5 (m, 1H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 555 (M+H⁺, 60%).

[0868] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 555 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 555 (M+H⁺, 100%).

Example 61

[0869] Preparation of Furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0870] a.) Furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0871] Following the procedure of Example 28b except substituting2-furoic acid for benzofuran-2-carboxylic acid the title compound wasprepared: MS(EI) 479 (M+H⁺).

[0872] b.) Furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0873] Following the procedure of Example 1i except substituting thecompound of Example 61a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.5 (m, 1H), 7.2 (m, 3H), 7.5 (m,2H), 8.0 (m, 2H), 8.7 (m, 1H); MS(ET): 477 (M+H⁺, 50%).

Example 62

[0874] Preparation of 5-Nitro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-]-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0875] a.) 5-Nitro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0876] Following the procedure of Example 28b except substituting5-nitro-2-furoic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 524 (M+H⁺).

[0877] b.) 5-Nitro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0878] Following the procedure of Example 1i except substituting thecompound of Example 62a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.2 (m, 1H), 7.3 (m, 1H), 7.5(m,]H), 7.9 (m, 2H), 8.7 (m, 1H); MS(ET): 522 (M+H⁺, 80%).

Example 63

[0879] Preparation of 5-(4-Nitro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0880] a.) 5-(4-Nitro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0881] Following the procedure of Example 28b except substituting5-(4-nitrophenyl)-2-furoic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 600 (M+H⁺).

[0882] b.) 5-(4-Nitro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0883] Following the procedure of Example 1i except substituting thecompound of Example 63a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.9 (m, 1H), 7.2 (m, 1H), 7.5 (m,2H), 7.9-8.0 (m, 4H), 8.5 (m, 1H), 8.6 (m, 1H); MS(EI): 598 (M+H⁺, 80%).

Example 64

[0884] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0885] a.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylI amide

[0886] Following the procedure of Example 28b except substituting5-[3-(trifluoromethyl)phenyl]-2-furoic acid for benzofuran-2-carboxylicacid the title compound was prepared: MS(EI) 623 (M+H⁺).

[0887] b.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0888] Following the procedure of Example 1i except substituting thecompound of Example 64a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H).4.0 (m, 1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.1 (m, 1H), 7.5 (m, 3H), 8.0 (m,4H) 8.7 (m, 1H); MS(EI): 621 (M+H⁺, 80%).

[0889] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 621 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 621 (M+H⁺, 100%).

Example 65

[0890] Preparation of Tetrahydro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0891] a.) Tetrahydro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0892] Following the procedure of Example 28b except substitutingtetrahydrofuran-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 483 (M+H⁺).

[0893] b.) Tetrahydro-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0894] Following the procedure of Example 1i except substituting thecompound of Example 65a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.2 (m, 12H), 2.7 (m, 1H), 3.8 (m, 3H). 4.0 (m, 1H),4.5 (m, 2H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0 (m, 1H), 7.5 (m, 1H), 7.9 (m,2H), 8.7 (m, 1H). MS(EI): 481 (M+H⁺, 80%).

Example 66

[0895] Preparation of (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoicAcid [3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0896] a.) (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid[3-hydroxy-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0897] Following the procedure of Example 28b except substitutingphenoxyacetic acid for benzofuran-2-carboxylic acid the title compoundwas prepared: MS(EI) 519 (M+H⁺).

[0898] b.) (S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic Acid[3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0899] Following the procedure of Example 1i except substituting thecompound of Example 66a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (in, 6H), 1.5-2.1 (m, 5H), 2.2 (in, 2H), 2.7 (in, {H), 3.7 (d,1H). 4.0 (m, 1H), 4.5 (in, 3H), 4.7 (in, 1H), 5.1 (m, 1H), 7.0 (m, 3H),7.3 (m, 2H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H); MS(EI): 517 (M+H⁺,60%).

Example 67

[0900] Preparation of(S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic Acid[3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0901] a.) (S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoicacid [3-hydroxy-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0902] Following the procedure of Example 28b except substituting4-fluorophenoxyacetic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 537 (M+H⁺).

[0903] b.) (S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoicacid [3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[0904] Following the procedure of Example 1i except substituting thecompound of Example 67a the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.6 (d, 11H).4.0 (m, 1H), 4.5 (, 3H), 4.8 (m, 1H), 5.1 (m, 1H), 7.0 (m, 4H), 7.5 (m,1H), 7.9 (m, 2H), 8.6 (m, 1H); MS(EI): 535 (M+H⁺, 50%).

Example 68

[0905] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide

[0906] a.){(S)-1-[3-Hydroxy-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[0907] To a solution of the compound of Example 2g (0.25 g) indichloromethane was added picolinic acid (0.09 g), EDC (0.14 g) and HOBt(0.10 g). The reaction was stirred until complete. Workup and columnchromatography (5% methanol:ethyl acetate) provided the title compound(0.35 g).

[0908] b.) (S)-2-Amino-4-methylpentanoic Acid[3-hydroxy-1-(pyridine-2-carbonyl)-azepan-4-yl]-amide

[0909] To a solution of the compound of Example 68a (0.34 g) in methanol(6 mL) was added 4M HCl in dioxane (6 mL). The reaction was stirreduntil complete whereupon it was concentrated to provide the titlecompound (0.34 g): MS(EI) 349 (M+H⁺).

[0910] c.) Benzofuran-2-carboxylic acid{(S)-3-methyl--[3-hydroxy-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide

[0911] Following the procedure of Example 28b except substituting thecompound of Example 68b the title compound was prepared: MS(EI) 493(M+H⁺).

[0912] d.) Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide

[0913] Following the procedure of Example 1i except substituting thecompound of Example 68c the title compound was prepared: ¹H NMR (CDCl₃):δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.7 (m, 1H),4.7 (m, 4H), 5.0 (m, 1H), 7.0-7.5 (m, 8H), 8.2 (m, 1H); MS(EI): 491 (M⁺,100%).

Example 69

[0914] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0915] Following the procedures of Examples 68a-d except substitutingpicolinic acid N-oxide for picolinic acid of Example 68c the titlecompound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H),2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d, 1H). 4.0 (m, 1H), 4.7 (m, 3H), 5.5 (m,1H), 7.0 (m, 2H), 7.2-7.5 (m, 7H), 8.1 (m, 2H); MS(EI): 507 (M⁺, 20%).

Example 70

[0916] Preparation of4-((S)-2-tert-Butylcarbonylamino-4-methyl-pentanoylamino)-3-oxo-azepane-1-carboxylicAcid Benzyl Ester

[0917] Following the procedure of Example 92j, except substituting4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicacid benzyl ester for benzofuran-2-carboxylic acid{(S)-1-[3-hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 476.2; ¹H-NMR (400 MHz, CDCl₃):7.40-6.95 (m, 7H), 5.25-4.60 (m, 4H), 4.40-4.06 (m, 2H), 3.70-3.58 (t,1H), 2.70-2.50 (m, 1H), 2.25-1.30 (m, 1H); and the second elutingdiastereomer:, 1.00-0.85 (d, 6H); and the second eluting diastereomer:MS (M+H⁺) 476.2.

Example 71

[0918] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0919] a.){(S)-1-[3-Hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-ylcarbamoyl}-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[0920] To a solution of the amine of Example 2g in methylene chloride (5ml) was added pyridine (92 μL, 1.14 mmol) followed by1-methylimidazole-4-sulfonylchloride (0.112 g, 0.623 mmol). The reactionwas allowed to stir for 16 h at room temperature. The solution was thenwashed with saturated aqueous NaHCO₃, water and brine. The product waspurified by column chromatography (silica gel:methanol/methylenechloride) to yield the title compound as a white solid(0.172 g, 68%): ¹HNMR (400 MHz, CDCl₃) δ 7.6 (d, 1H), 7.5 (d, 1H), 6.6(d, 1H), 3.8 (s, 3H), 1.5 (s, 9H), 1 (d, 6H); MS(ESI): 488.2 (M+H)⁺

[0921] b.) (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-yl]-amide

[0922] To a solution of the compound of Example 71a (0.172 g, 0.353mmol) in minimal MeOH was added 4M HCl in dioxane (10 mL) and stirredfor 4 h at room temperature. The reaction mixture was concentrated andazeotroped with toulene (2×'s) to yield the title compound as an offwhite solid: MS(ESI): 388.2 (M+H)⁺

[0923] c.) 5,6-Dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0924] To a stirring solution of the compound of Example 71b (0.137 g,0.353 mmol), 5,6-dimethoxybenzofuran-2-carboxylic acid (0.86 g, 0.388mmol), triethylamine (246 mL, 1.77 mmol) and 1-hydroxybenzotriazole(0.01 g, 0.070 mmol) in DMF (5 mL) was added1-(3-dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.074 g,0.388 mmol). After stirring at room temperature for 16 h, the solutionwas diluted with EtOAc and washed successively with saturated aqueoussodium bicarbonate, water (2×'s), and saturated brine. The organic layerwas dried over Na₂SO₄, filtered and concentrated. The product waspurified by column chromatography (silica gel; methanol/dichloromethane)to yield the title compound as a white solid (0.088 g, 42%): MS(ESI):592.1 (M+H)₊

[0925] d.) 5,6-Dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0926] Oxalyl chloride (52RL, 0.596 mmol) chloride was cooled to −78°.To this was added dimethyl sulfoxide (1061L, 1.49 mmol) in methylenechloride dropwise. After stirring for 15 min at −78°, the alcohol inmethylene chloride was added slowly and allowed to stir for 1 h whenEt₃N (416 μL, 2.98 mmol) was added. The solution was then brought toroom temperature and quenched with water and extracted into methylenechloride. The organic layer was separated and washed with brine, driedover MgSO₄, filtered and concentrated. The product was purified bycolumn chromatography (silica gel: methanol/methylene chloride) to yieldthe title compound as white solid (0.068 g, 78%): ¹H NMR (400 MHz,CDCl₃) δ 6.8-7.6 (m, 14H), 4 (d, 12H), 1 (d, 12H); MS(ESI): 590.1 (M+H)⁺

Example 72

[0927] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(5-methyl-1H-[1,2,4]triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0928] a.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0929] To a stirring solution of the compound of Example 2f (3.5 g, 7.33mmol) in EtOAc (0.5 mL) was added 4M HCl in dioxane (12.8 mL). Themixture was stirred for 1 h at room temperature. The reaction mixturewas then concentrated and azeotroped with toluene (2×20 mL) to yield thetitle compound as a pale yellow oil (3.13 g, 100%): MS(ESI) 378.4 (M+H)⁺

[0930] b.)4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0931] To a stirring solution of the compound of Example 72a (3.13 g,7.57 mmol), benzofuran-2-carboxylic acid (1.35 g, 8.32 mmol),triethylamine (1.17 ml, 8.25 mmol) and 1-hydroxybenzotriazole (0.2 g,1.48 mmol) in DMF (30 mL) was added1-(3-dimethylaminopropyl)3-ethylcarbodimide hydrochloride (1.6 g, 8.33mmol). After stirring at room temperature for 16 h, the solution wasdiluted with EtOAc and washed successively with saturated aqueous sodiumbicarbonate, water (2×), and brine. The organic layer was dried overNa₂SO₄, filtered and concentrated. The product was purified by columnchromatography (silica gel; ethylacetate/dichloromethane) to yield thetitle compound (3.7 g, 93%). ¹HNMR (400 MHz, CDCl₃) δ 6.8-7.7 (m, 12H),5.35 (s, 2H), 1.0 (d, 6H): MS(ESI): 522 (M+H)⁺

[0932] c.) Benzofuran-2-carboxylic Acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0933] To a solution the compound of Example 72b (2.6 g, 4.9 mmol) inEtOAc (150 mL) was added 10% palladium on carbon (1.3 g) and stirred atroom temperature for 64 h under a hydrogen atmosphere. The mixture wasthen filtered through celite and the filtrate concentrated to yield thetitle compound as a white solid (1.92 g, 100%): ¹H NMR (400 MHz, CDCl₃)δ 6.8-7.7 (m, 7H), 1.02 (d, 6H); MS(ESI) 388 (M+H)⁺

[0934] d.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(5-methyl-1H-[1,2,4]triazole-3-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[0935] To a stirring solution of the compound of Example 72c (0.100 g,0.25 mmol) and triethylamine (35 μL, 0.25 mmol) in methylene chloride (2mL) was added 5-methyl-1H-1,2,4-triazolesulfonylchloride (0.043 g, 0.25mmol). The reaction was allowed to stir for 10 min and washed withsaturated aqueous NaHCO₃, water and saturated brine. The organic layerwas dried over Na₂SO₄, filtered and concentrated. The compound waspurified by column chromatography (silica gel; ethylacetate/hexane) toyield the title compound as a pale yellow oil (0.111, 84%): MS(ESI)532.73 (M+H)⁺

[0936] e.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(5-methyl-1H-[1,2,4]triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0937] To a stirring solution of the compound of Example 72d (0.108 g,0.206 mmol) in dimethylsulfoxide (2 mL) was added triethylamine (172RL,1.23 mmol) followed by sulfur trioxide pyridine (0.116 g, 0.718 mmol)and stirred for 16 h at room temperature. The reaction mixture wasdiluted with EtOAc and washed with water (×2). The organic layer wasdried over Na₂SO₄, filtered and conentrated. The crude product waspurified by column chromatography (silica gel;methanol/methylenechloride) to yield the title compound as a white solid(0.08 g, 81%): ¹HNMR (400 MHz, CDCl₃) δ 7.1-7.7 (m, 7H), 2.65 (s, 3H),1.0 (d, 6H); MS(ESI): 552.71 (M+Na)⁺

Example 73

[0938] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0939] a.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[0940] To a stirring solution of the compound of Example 72c (0.100 g,0.25 mmol) and triethylamine (35 μL, 0.25 mmol) was added1-methylimidazole sulfonyl chloride (0.046 g, 0.255 mmol). The reactionwas allowed to stir for 10 min and washed with saturated aqueous NaHCO₃,water and saturated brine. The organic layer was dried over Na₂SO₄,filtered and concentrated. The compound was purified by columnchromatography (silica gel; ethylacetate/hexane) to yield the titlecompound as a pale yellow oil (0.113 g, 82%): ¹HNMR (400 MHz, CDCl₃) δ6.9-7.7 (m, 9H), 3.9 (2s, 3H), 1.0 (d, 6H); MS(ESI): 531.8 (M+H)⁺

[0941] b.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0942] To a stirring solution of the compound of Example 73a (0.085 g,0.159 mmol) in dimethylsulfoxide was added triethylamine (133 μL, 0.95mmol) followed by sulfurtrioxide pyridine (0.08 g, 0.5 mmol) and stirredfor 16 h at room temperature. The reaction mixture was diluted withEtOAc and washed with water (×2). The organic layer was dried overNa₂SO₄, filtered and conentrated. The crude product was purified bycolumn chromatography (silica gel; methanol/methylenechloride) to yieldthe title compound as a white solid (0.072 g, 83%). MS(ESI): 529.76(M+H)⁺

Example 74

[0943] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0944] a.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0945] To a stirring solution of the compound of Example 72c (0.100 g,0.25 mmol) and triethylamine (35 μL, 0.25 mmol) was added2-imidazolesulfonyl chloride (0.046 g, 0.255 mmol). The reaction wasallowed to stir for 10 min and washed with saturated aqueous NaHCO₃,water and saturated brine. The organic layer was dried over Na₂SO₄,filtered and concentrated. The compound was purified by columnchromatography (silica gel; ethylacetate/hexane) to yield the titlecompound as a pale yellow oil (0.113 g, 82%): ¹HNMR (400 MHz, CDCl₃) δ7.1-7.7 (m, 9H), 4.8 (s, 1H), d, 6H); MS(ESI): 517.76 (M+H)⁺

[0946] b.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0947] To a stirring solution of the compound of Example 74a (0.107 g,0.206 mmol) in dimethylsulfoxide (2 mL) was added triethylamine (172FL,1.23 mmol) followed by sulfurtrioxide pyridine (0.115 g, 0.7]8 mmol) andstirred for 16 h at room temperature. The reaction mixture was dilutedwith EtOAc and washed with water (×2). The organic layer was dried overNa₂SO₄, filtered and conentrated. The crude product was purified bycolumn chromatography (silica gel; methanol/methylenechloride) to yieldthe title compound as a white solid (0.09 g, 85%); MS(ESI): 515.84(M+H)⁺

Example 75

[0948] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0949] a.){(S)-1-[3-Hydroxy-]-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl}-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[0950] To a solution of the compound of Example 2g (2.50 g, 7.29 mmol)in DCE (100 mL) was added P-NMM (4.0 g) and thioazole-2-sulphonylchloride (1.6 g, 8.75 mmol). After shaking at room temperatureovernight, the solution was filtered. The filtrate was concentrated toyield the title compound as white solid (2.50 g, 5.10 mmol, 70%); MS:490.91 (M+H)⁺.

[0951] b.) Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hyroxy-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[0952] To a solution of the compound of Example 75b (0.15 g, 0.45 mmol)in CH₂Cl₂ (20 mL) was added benzofuran-2-carboxylic acid (0.109 g, 0.172mmol), 1-hydroxybenzotriazole (0.106 g, 0.762 mmol), and P-EDC (0.85 g,1 mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperatureovernight, the solution was treated with tisamine (0.589 g, 3.75mmol/g). After shaking for another 2 hr, the solution was filtered andconcentrated to yield the title compound as a white solid (166.7 mg,70%); MS (ESI): 535.3 (M+H)⁺.

[0953] c.) Benzofuran-2-carboxylicAcid{S}-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[0954] To a stirring solution of the compound of Example 75c (166.7 mg,0.313 mmol) in dichloromethane (4 mL) was added Dess-Martin reagent(265.5 mg, 0.626 mmol). After stirring at room temperature for 2 h,solutions of sodium thiosulfate (2 mL of 10% in water) and saturatedaqueous sodium bicarbonate (2 mL) were added simultaneously to thesolution. The aqueous was extracted with dichloromethane (2×). Theorganic phases were combined, washed with saturated brine, dried(MgSO₄), filtered and concentrated. The residue was purified by HPLC(50:50 ethanol: hexane, 20 mL/min, 25 min, WhelkO-1 (R,R) 21×250 mmcolumn, UV detection at 280 nm and 305 nm) to yield the first elution asa white solid (84.8 mg, 50.8%). MS (ESI): 533.2 (M+H)⁺ and the secondelution as a white solid (50.1 mg, 30.0%) MS: 533.2 (M+H⁺).

Example 76

[0955] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0956] a.){(S)-1-[3-Hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-ylcarbamoyl}-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[0957] To a solution of the amine of Example 2g in methylenechloride (5ml) was added pyridine (921L, 1.14 mmol) followed by1-methylimidazole-4-sulfonylchloride (0.112 g, 0.623 mmol). The reactionwas allowed to stir for 16 h at room temperature. The solution was thenwashed with saturated aqueous NaHCO₃, water and brine. The product waspurified by column chromatography (silica gel:methanol/methylenechloride) to yield the title compound as a white solid(0.172 g, 68%): ¹HNMR (400 MHz, CDCl₃) δ 7.6 (d, 1H), 7.5 (d, 1H), 6.6(d, 1H), 3.8 (s, 3H), 1.5 (s, 9H), 1 (d, 6H); MS(ESI): 488.2 (M+H)⁺

[0958] b.) (S)-2-Amino-4-methyl-pentanoic Acid[3-hydroxy-1-(1-methyl-1H-imidazole-2-sulfonyl)-azepan-4-yl]-amide

[0959] To a solution of the compound of Example 76a (0.172 g, 0.353mmol) in minimal MeOH was added 4M HCl in dioxane (10 mL) and stirredfor 4 h at room temperature. The reaction mixture was concentrated andazeotroped with toulene (2×'s) to yield the title compound as an offwhite solid. MS(ESI): 388.2 (M+H)⁺

[0960] c.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[0961] To a stirring solution of the compound of Example 72c (0.2 g,0.471 mmol), benzofuran-2-carboxylic acid (0.084 g, 0.388 mmol),triethylamine (72 μL, 0.517 mmol) and 1-hydroxybenzotriazole (0.012 g,0.088 mmol) in DMF (5 mL) was added1-(3-dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.099 g,0.515 mmol). After stirring at room temperature for 16 h, the solutionwas diluted with EtOAc and washed successively with saturated aqueoussodium bicarbonate, water (2×'s), and saturated brine. The organic layerwas dried over Na₂SO₄, filtered and concentrated. The product waspurified by column chromatography (silica gel; methanol/dichloromethane)to yield the title compound as a white solid (0.226 g, 90%): ¹HNMR (400MHz, CDCl₃) δ 6.9-8.1 (m, 18H), 3.75 (2s, 6H), 1 (d, 12H); MS(ESI):531.80 (M+H)⁺

[0962] d.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0963] To a stirring solution of the compound of Example 76a (0.226 g,0.426 mmol) in dimethylsulfoxide (2 mL) was added triethylamine (355 μL,2.55 mmol) followed by sulfur trioxide pyridine (0.238 g, 1.48 mmol) andstirred for 16 h at room temperature. The reaction mixture was dilutedwith EtOAc and washed with water (×2). The organic layer was dried overNa₂SO₄, filtered and conentrated. The crude product was purified bycolumn chromatography (silica gel; methanol/methylenechloride) to yieldthe title compound as a white solid (0.168 g, 76%): ¹HNMR (400 MHz,CDCl₃) δ 7.1-7.79 m, 18H), 3.7 (2s, 6H), 0.9 (d, 12H); MS(ESI): 529.80(M+H)+

Example 77

[0964] Preparation of5-(4-Oxy-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic Acid}(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0965] To a solution of the compound of Example 30b (0.01 g) indichloromethane (2 mL) was added m-CPBA (0.008 g). The reaction wasstirred overnight. Workup and column chromatography (30%methanol:dichloromethane) provided the title compound: ¹H NMR (CDCl₃): δ1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 4H), 2.7 (m, 1H), 2.8(m 2H), 3.7 (m, 4H), 3.8 (q, 1H). 4.0 (m, 3H), 4.7 (m, 1H), 4.8 (m, 1H),5.0 (m, 1H), 7.0 (m, 3H), 7.4 (m, 2H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m,1H); MS(EI): 671 (M⁺,100%).

Example 78

[0966] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-13-oxo-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0967] a.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0968] To a solution of4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylicacid benzyl ester of Example 2f (4.0 g) in methanol (20 mL) was added 4MHCl in dioxane (20 mL). The reaction was stirred at room temperature for2 hours whereupon it was concentrated to provide the title compound (3.8g): MS(EI) 378 (M+H⁺).

[0969] b.)4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[0970] To a solution of4-((S)-2-amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicacid benzyl ester of Example 78a (3.2 g) in dichloromethane (200 mL) wasadded EDC (1.48 g), HOBt (1.05 g), TEA (1.29 mL) andbenzofuran-2-carboxylic acid. The reaction was stirred until complete.Workup and column chromatography (2% methanol:dichloromethane) providedthe title compound (3.78 g): MS(EI) 521 (M+H⁺).

[0971] c.) Benzofuran-2-carboxylic acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[0972] To a solution of4-{(S)-2-[(benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-carboxylicacid benzyl ester of Example 78b (1.6 g) in methanol:ethyl acetate (50mL: 100 mL) was added 10% Pd/C. The reaction was stirred under a balloonof hydrogen for 2 hours whereupon it was filtered and concentrated toprovide the title compound (1.16 g): MS(EI) 387 (M+H⁺).

[0973] d.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0974] To a solution of benzofuran-2-carboxylic acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide of Example78c (0.3 g) in dichloromethane was added triethylamine (0.17 mL)followed by 3-pyridinesulfonyl chloride (0.25 g). The reaction wasstirred at room temperature until complete as determined by TLCanalysis. Workup and column chromatography (5% methanol:ethyl acetate)provided 0.32 g of the title compound: MS(EI) 528 (M+H⁺).

[0975] e.) Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0976] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 78d the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d, 1H). 4.0 (m,1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0 (m, 2H), 7.2-7.5 (m,6H), 8.1 (m, 1H), 8.9-9.0 (m, 2H); MS(EI): 526 (M⁺, 100%).

Example 79

[0977] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(]-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0978] a.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0979] To a solution of benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 78d (0.05 g) in dichloromethane was added m-CPBA (0.05 g).The reacrton was stirred overnight. Workup and column chromatography(10% methanol:dichloromethane) provided the title compound (0.03 g):MS(EI) 544 (M+H⁺).

[0980] b.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[0981] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 79a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 1H), 3.5 (d, 1H). 4.0 (m,1H), 4.5 (m, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.2-7.5 (m, 7H), 8.1-8.2 (m,2H). MS(EI): 542 (M⁺, 50%).

Example 80

[0982] Preparation of Quinoline-3-carboxylic Acid{(S)-1-(3,4-dichloro-benzene-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl)1-3-methyl-butyl}-amide

[0983] Following the procedures of Example 75a-d except substituting3,4-dichlorosulfonyl chloride for thioazole-2-sulphonyl chloride ofExample 75a and quinoline-3-carboxylic acid for benzofura-2-carboxylicacid the title compound was prepared: ¹H NMR (CDCl₃, 400 MHz) δ 9.34 (s,1H), 8.61 (s, 1H), 8.14 (m, 1H), 7.81 (m, 3H), 7.60 (m, 3H), 7.19 m,2H), 5.09 (m, 1H), 4.88 (m, 1H), 4.50 (m, 1H), 3.92 (m, 1H), 3.51 (m,1H), 2.57 (m, 1H), 2.23 (m, 2H), 1.60 (m, 5H), 1.01 (m, 6H).

Example 81

[0984] Prepeparation of 5-Hydroxy-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(]-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0985] a.) 5-Hydroxy-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[0986] To a stirring solution of the compound of Example 76b (0.1 g,0.235 mmol), 5-hydroxybenzofuran-2-carboxylic acid(0.046 g, 0.256 mmol),triethylamine (36 μL, 0.258 mmol) and 1-hydroxybenzotriazole (0.006 g,0.044 mmol) in DMF (5 mL) was added1-(3-dimethylaminopropyl)3-ethylcarbodimide hydrochloride (0.05 g, 0.26mmol). After stirring at room temperature for 16 h, the solution wasdiluted with EtOAc and washed successively with saturated aqueous sodiumbicarbonate, water (2×), and saturated brine. The organic layer wasdried over Na₂SO₄, filtered and concentrated. The product was purifiedby column chromatography (silica gel; methanol/dichloromethane) to yieldthe title compound as a white solid (0.129 g, 100%). ¹HNMR (400 MHz,CDCl₃) δ 6.8-8 (m, 16H), 3.6 (2s, 6H), 0.85 (d, 12H).

[0987] MS(ES)I): 547.88 (M+H)⁺

[0988] b.) 5-Hydroxy-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[0989] Oxalyl chloride (13 μL, 0.149 mmol) chloride was taken to −780.To this was added dimethyl sulfoxide (28 GL, 0.394 mmol) in methylenechloride dropwise. After stirring for 15 min at −78°, the alcohol ofExample 81 a in methylene chloride was added slowly and allowed to stirfor 1 h when Et₃N (7 μL, 0.05 mmol) was added. The solution was thenbrought to room temperature and quenched with water and extracted intomethylene chloride. The organic layer was separated and washed withbrine, dried over MgSO₄, filtered and concentrated. The product waspurified by column chromatography (silica gel: methanol/methylenechloride) to yield the title compound as white solid (0.021 g, 78%):MS(ESI) 545.9 (M+H)⁺

Example 82 Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl}-amide

[0990] a.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl}-amide

[0991] To a solution of benzofuran-2-carboxylic acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide of Example78c (0.10 g) in dichloromethane was added triethylamine (0.07 mL)followed by 2-pyidinesulphonylchloride N-oxide. The reaction was stirredat room temperature overnight. Workup and chromatography (10%methanol:dichloromethane) provided the title compound (0.01 g): MS(EI)544 (M+H⁺).

[0992] b.){(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl}-amide

[0993] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl}-amideof Example 82a the title compound was prepared:

[0994]¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7(m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m,1H), 7.0-7.5 (m, 9H), 8.1-8.2 (m, 2H). MS(EI): 542 (M⁺, 20%).

[0995] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.8 (d, 1H). 4.0 (d, 1H), 4.7 (m, 1H),4.8 (d, 11H), 5.0 (m, 1H), 7.0-7.5 (m, 9H), 8.1-8.2 (m, 2H); MS(EI): 542(M⁺, 100%), and the slower eluting diastereomer; MS(EI): 542 (M+H⁺,100%).

Example 83

[0996] Preparation of2-(4-{(S)-2->(Benzofuran-2-carbonyl)-amino}-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoicAcid

[0997] a.)2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-sulfonyl)-benzoicAcid Methyl Ester

[0998] Following the procedure of Example 75a-c, except substituting2-carboxymethylsulphonyl chloride for 2-thiazolesulfonyl chloride, thetitle compound was prepared: MS (M+H⁺)=585.56, M+Na⁺=607.76,2M+H⁺=1170.48.

[0999] b.)2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-sulfonyl)-benzoicAcid

[1000]2-(4-{(S)-2-[(benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-sulfonyl)-benzoicacid methyl ester (compound 83a, 180 mg, 0.309 mmol) was dissolved in5:1 MeOH/water (6 ml) LiOH (14 mg, 0.34 mmol) was added and the reactionmixture was stirred and refluxed for 6 h. The reaction mixture was thenquenched with water and 6 N HCl (adjusted to pH=2), extracted with EtOAc(3×10 ml), dried with MgSO₄, filtered, concentrated, and chromatographed(silica gel, 1% acetic acid/4% MeOH/CH₂Cl₂) to yield the title compoundas a white solid (48 mg, 27%): M+H⁺=572.2

[1001] c.)2-(4-{(S)-2-[(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoicAcid

[1002] Following the procedure of Example 75d, except substituting2-(4-{(S)-2-[(benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-sulfonyl)-benzoicacid for benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyla}amide,the title compound was prepared: MS (M+H⁺): 570.2 (M+H⁺). ¹H NMR(400 Hz,CDCl₃-CD₃OD): δ 8.05-7.95 (m, 1H), 7.70-7.15 (m, 8H), 5.15-5.00 (m, 1H),4.95-4.75 (m, 2H), 4.15-4.00 (m, 1H), 3.65 (d, 1H), 2.85-2.70 (m, 1H),2.25-2.05 (m, 2H), 1.90-1.70 (m, 4H), 1.60-1.45 (m, 1H), 0.95 (d, 6H).

Example 84 Preparation of3-(4-{(S)-2-{(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoicAcid

[1003] Following the procedure of Example 83, except substituting3-carboxymethylbenzenesulphonyl chloride for2-carboxymethylbenzenesulfonyl chloride, the title compound wasprepared: MS 570.2 (M+H⁺); ¹H NMR (400 Hz, CDCl₃-CD₃OD): δ 8.46 (d, 1H),8.31-8.25 (m, 1H), 8.00-7.97 (m, 1H), 7.70-7.62 (m, 2H), 7.55-7.46 (m,1H), 7.45-7.35 (m, 1H), 7.30-7.25 (m, 1H), 5.10-5.05 (m, 1H), 4.95-4.78(m, 1H), 4.75-4.55 (q, 1H), 4.00 (d, 1H), 3.5 (d, 1H), 2.60-2.40 (m,2H), 2.25-2.15 (m, 1H), 1.95-1.70 (m, 4H), 1.55-1.40 (m, 1H), 0.98 (t,6H).

Example 85

[1004] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1005] a.){(S)-1-[3-Hydroxy-1-(1-oxy-pyridine-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl-carbamicAcid Tert-Butyl Ester

[1006] To a solution of[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acidtert butyl ester of Example 2g (2.5 g) in dichloromethane (100 mL) andsaturated sodium bicarbonate was added freshly prepared2-pyidinesulphonyl chloride N-oxide (prepared by bubbling chlorine gasthrough a solution of 2-mercaptopyridine-N-oxidein 9M HCl forapproximately 90 minutes. Removal of excess chlorine under vacuumprovided the 2-pyridinesulfonyl chloride-N-oxide). The reaction wasstirred at room temperature for 1 hour. Workup and column chromatography(10% methanol:dichloromethane) provided the title compound (2.0 g):MS(EI) 500 (M+H⁺).

[1007] b.) (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(1-oxy-pyyridine-sulfonyl)-azepan-4-yl]-amide

[1008] To a solution of{(S)-1-[3-hydroxy-1-(1-oxy-pyridine-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl-carbamicacid tert-butyl ester of Example 85a (2.0 g) in methanol (20 mL) wasadded 4M HCl in dioxane (20 mL). The reaction was stirred at roomtemperature for 1.5 hours whereupon it was concentrated to provide thetitle compound (1.8 g): MS(EI) 400 (M+H⁺).

[1009] c.) Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1010] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(1-oxy-pyyridine-sulfonyl)-azepan-4-yl]-amide of Example85b (0.25 g) in dichloromethane (12 mL) was added triethylamine (0.12mL), EDC (0.11 g), HOBt (0.077 g) and benzo[b]thiophene-2-carboxylicacid. The reaction was stirred until complete. Workup and columnchromatography (10% methanol: dichloromethane) provided the titlecompound (0.26 g): MS(EI) 560 (M+H⁺).

[1011] d.) Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1012] Following the procedure of Example 1i except substitutingbenzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 85c the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.5 (m, 4H), 7.8 (m, 3H),8.1-8.2 (m, 2H). MS(EI): 558 (M⁺, 100%).

[1013] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 558 (M⁺, 100%), and the slowereluting diastereomer; MS(EI): 558 (M⁺, 100%).

Example 86

[1014] Preparation of 5-Bromo-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1015] a. 5-Bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1016] Following the procedure of Example 85c except substituting5-bromo-2-furoic acid for benzo[b]thiophene-2-carboxylic acid the titlecompound was prepared: MS(EI) 574 (M+H⁺).

[1017] b.) 5-Bromo-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1018] Following the procedure of Example 1i except substituting5-bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 86a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0 (m, 2H), 7.4 (m, 2H),8.1-8.2 (m, 2H); MS(EI): 570 (M⁺, 100%).

[1019] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 572 (M+H+1, 100%), and the slowereluting diastereomer; MS(EI): 572 (M+H⁺, 100%).

Example 87

[1020] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1021] a.) 5,6-Dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1022] Following the procedure of Example 85c except substituting5,6-dimethoxybenzofuran-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 604 (M+H⁺).

[1023] b.) 5,6-Dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1024] Following the procedure of Example 1i except substituting5,6-dimethoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 87a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 7H). 4.0 (m,1H), 4.7 (m, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.0-7.5 (m, 5H), 8.1-8.2 (m,2H); MS(EI): 602 (M⁺, 100%).

[1025] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 602 (M⁺, 100%), and the slowereluting diastereomer; MS(EI): 602 (M⁺, 100%).

Example 88

[1026] Preparation of 1-Oxy-pyridine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo--(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1027] a.) 1-Oxy-pyridine-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1028] Following the procedure of Example 28b except substitutingpicolinic acid N-oxide for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 505 (M+H⁺).

[1029] b.) 1-Oxy-pyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1030] Following the procedure of Example 1i except substituting1-oxy-pyridine-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 88a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.1 (m,1H), 4.7 (m, 2H), 5.0 (m, 1H), 7.5 (m, 3H), 7.9 (m 2H), 8.3-8.4 (m, 2H),8.6 (m, 1H); MS(EI): 503 (M⁺, 100%).

Example 89

[1031] Preparation of(S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1032] a.) (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1033] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 28a(0.25 g) in dichloromethane was added triethylamine (0.27 mL) and2-pyridinesulfonyl chloride (0.15 g). The reaction was stirred untilcomplete. Workup and column chromatography (5% methanol:dichloromethane)provided the title compound (0.09 g): MS(EI) 525 (M+H⁺).

[1034] b.) (S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1035] Following the procedure of Example 1i except substituting(S)-4-methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 89a thetitle compound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4.7 (m, 1H),5.0 (m, 1H), 5.5 (m, 1H), 7.0 (m 1H), 7.5 (m, 2H), 7.9 (m 3H), 8.6 (m,2H). MS(EI): 523 (M⁺, 100%).

Example 90

[1036] Preparation of (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1037] a.) (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1038] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(pyyridine-sulfonyl)-azepan-4-yl]-amide of Example 28a(0.25 g) in dichloromethane was added triethylamine (0.17 mL) and benzylisocyanate (0.088 g). The reaction was stirred until complete. Workupand column chromatography (5% methanol:dichloromethane) provided thetitle compound (0.12 g).

[1039] b.) (S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1040] Following the procedure of Example 1i except substituting(S)-2-(3-benzyl-ureido)-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 89a thetitle compound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (m,]H), 3.8 (q, 1H). 4.0 (m, 3H), 4,5 (t, 1H), 4.7(m, 1H), 5.0 (m, 1H), 7.2 (, 5H), 7.5 (m, 1H), 7.9 (m, 2H), 8.6 (m, 1H);MS(EI): 515 (M⁺, 60%).

[1041] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 516 (M+H⁺, 100%), and the slowereluting diastereomer; MS(EI): 516 (M+H⁺, 100%).

Example 91

[1042] Preparation of (S)-2-(3-Phenyl-uriedo)-4-methyl pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1043] a.) (S)-2-(3-Phenyl-ureido)-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1044] Following the procedure of Example 90a except substituting phenylisocyante for benzyl isocyanate the title compound was prepared: MS(EI)503 (M+H⁺).

[1045] b.) (S)-2-(3-Phenyl-ureido)-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1046] Following the procedure of Example 1i except substituting(S)-2-(3-phenyl-ureido)-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 91a thetitle compound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m, 1H), 4, 5 (t, 1H),4.7 (m, 1H), 5.0 (m, 1H), 7.0-7.9 (m, 8H), 8.6 (m, 1H). MS(EI): 501 (M⁺,60%).

Example 92

[1047] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[6,6-dimethyl-3-oxo-1(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1048] a.) Allyl-(2,2-dimethyl-pent-4-enylidene)-amine

[1049] 2,2-Dimethyl-4-pentenal (2.8 g, 25 mmol) was dissolved in 15 mLbenzene. To this solution allylamine (2.85 g, 50 mmol) was added. A fewmolecular sieves were used to absorb water generated during thereaction. The mixture was stirred at room temperature overnight. Removalof the solvent and excess amount of allylamine on rotavapor provided3.76 g of the title compound as clear liquid (yield 100%). ¹H-NMR (400MHz, CDCl₃): •7.52 (s, 11H), 5.99-5.90 (m, 1H), 5.80-5.70 (m, 1H),5.15-4.99 (m, 4H), 4.01-3.99 (m, 2H), 2.17 (d, 2H), 1.06 (s, 6H).

[1050] b.) Allyl-(2,2-dimethyl-pent-4-enyl)-amine

[1051] Allyl-(2,2-dimethyl-pent-4-enylidene)-amine of Example 92a (3.76g, 25 mmol) was diluted in 5 ml MeOH. To the solution NaBH₄ (0.95 g, 25mmol) was added at 0° C. After addition the mixture was stirred at r.t.for 5 h. Methanol was removed on rotavapor and the residue waspartitioned between EtOAc/20% NaOH. The organic layer was dried overNa₂SO₄, fitered and evaperated to give 2.26 g of the title compound: MS(M+H⁺): 154.0; ¹H-NMR (400 MHz, CDCl₃): 5.93-5.76 (m, 2H), 5.29-4.99 (m,4H), 3.22 (d, 2H), 2.34 (s, 2H), 2.01 (d, 2H), 0.94 (s, 6H).

[1052] c.) Pyridine-2-sulfonic Acidallyl-(2,2-dimethyl-pent-4-enyl)-amide

[1053] Allyl-(2,2-dimethyl-pent-4-enyl)-amine (0.43 g, 2.8 mmol) and NMM(0.57 g, 5.6 mmol) were mixed in 30 mL CH₂Cl₂. 2-pryridinesulphonylchloride was added slowly to the solution while it was cooled in anice-water bath. After addition, the reaction mixture was stirred at r.t.overnight. Washed by 10% NaHCO₃ and the brine. Purified by columnchromatography gave 0.6 g colorless oil in 73% yield. MS (M+H⁺): 295.2;¹H-NMR (400 MHz, CDCl₃): 8.71-8.70 (d, 1H), 7.98-7.86 (m, 2H), 7.48-7.46(m, 1H), 5.88-5.77 (m, 1H), 5.55-5.45 (m, 1H), 5.13-5.00 (m, 4H),4.05-4.04 (d, 2H), 3.24 (s, 2H), 2.07-2.05 (d, 2H), 0.96 (s, 6H)

[1054] d.).3,3-Dimethyl-1-(pyridine-2-sulfonyl)-2,3,4,7-tetrahydro-1H-azepine

[1055] Pyridine-2-sulfonic Acid allyl-(2,2-dimethyl-pent-4-enyl)-amide(0.6 g, 2 mmol) was diluted in CH₂Cl₂ (50 ml) After carefully degass byAr, Grubbs catalyst (0.17 g, 0.2 mmol) was added under Ar protection.The mixture was then refluxed for 2 h before the solvent was removed onrotavapor. The crude product was purified by column chromatography(5%-20% E/H) to give 0.47 g of the title compound in 87% yield. MS(M+H⁺): 267.0; ¹H-NMR (400 MHz, CDCl₃): •8.70-8.69 (d, 11H), 7.96-7.88(m, 2H), 7.49-7.46 (m, 1H), 5.81-5.70 (m, 2H), 393-3.92 (d, 2H), 3.26(s, 2H), 2.13-2.12 (d, 2H), 1.00 (s, 6H)

[1056] e.)5,5-Dimethyl-3-(pyridine-2-sulfonyl)-8-oxa-3-aza-bicyclo[5.1.0]octane

[1057] To the solution of the compound of Example 92d (1.2 g, 4.5 mmol)in 50 mL CH₂Cl₂ was added NaHCO₃ (2.4 g, 13.5 mmol) and then MCPBA (1.2g, 13.5 mmol) in portions. The reaction was stirred at r.t. for 4 hbefore it was worked up by washing with 15% NaOH, saturated K₂CO₃, brineand dried (Na₂SO₄) to give 1.0 g crude product in 79 % yield (goodenough for next reaction without further purification.) MS (M+H⁺):283.0; ¹H-NMR (400 MHz, CDCl₃): •8.68-8.67 (d, 1H), 8.03-7.87 (m, 2H),7.49-7.40 (m, 1H), 4.44-3.89 (q, 1H), 3.62-3.59 (d, 1H), 3.50 (m, 1H),3.00 (m, 1H), 2.78-2.62 (m, 2H), 2.12-2.06 (m, 1H), 1.52-1.46 (q, 1H),1.20 (s, 3H), 0.89 (s, 3H).

[1058] f.) 4-Azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-ol

[1059]5,5-Dimethyl-3-(pyridine-2-sulfonyl)-8-oxa-3-aza-bicyclo[5.1.0]octanefrom Example 92e (1.2 g, 4.3 mmol) was dissolved in the mixture of 7 mlMeOH and 1 ml H₂O. NaN₃ (0.83 g, 13 mmol) and NH₄Cl (0.7 g, 13 mmol)were added to the solution. The resulting mixture was refluxedovernight. After the removal of MeOH, the residue was diluted in EtOAcand washed with 10% NaHCO₃ and brine. Purified on column chromatographygave 0.4 g 4-azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-ol(yield 29%); MS (M+H⁺): 326.2; ¹H-NMR (400 MHz, CDCl₃): 8.68-8.67 (m,1H), 8.05-7.90 (m, 2H), 7.53-7.50 (m, 1H), 3.75-3.60 (m, 3H), 3.49-3.30(m, 3H), 1.73-1.66 (m, 1H), 1.56-1.52 (d, 1H), 1.07 (s, 3H), 0.99 (s,3H)

[1060] g.) 4-Amino-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-ol

[1061] 4-Azido-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-ol fromExample 92f (0.4 g, 1.23 mmol) was dissolved in THF (50 ml) and H₂O (0.2ml). PPh₃ (0.48 g, 1.85 mmol) was added to this solution. The reactionmixture was stirred at 45° C. over night. TLC showed no startingmaterial left. THF was evaporated, azeotroped with toluene (2×'s). Theresulting thick oil was dissolved in MeOH, treated with HCl in ether toadjust pH to acidic. More ether was added and the solution turnedcloudy. 0.22 g white precipitate of the title compound was collected.(45% yield); ¹H-NMR (400 MHz, CD₃OD): 8.68 (m, 1H), 8.10-7.93 (m, 2H),7.62 (m, 1H), 3.90 (m, 1H), 3.68 (m, 1H), 3.40-2.90 (m, 4H), 1.82 (m,1H), 1.53 (d, 1H), 1.05 (s, 6H)

[1062] h.){(S)-1-[3-Hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1063] 4-Amino-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-3-ol HCl saltfrom Example 92g (0.22 g, 0.6 mmol) was dissolved in 5 ml DMF. To thissolution, was added Boc-Leu-OH (0.22 g, 0.9 mmol)and HBTU (0.34 g, 0.9mmol) and then NMM (0.24 g, 2.4 mmol). The mixture was stirred at r.t.overnight. DMF was removed under high vacuum. The residue was dilutedwith EtOAc and washed with H₂O, 10% NaHCO₃ and brine. Purification bycolumn chromatography gave 0.22 g of the title compound (72% yield); MS(M+H⁺): 512.9; ¹H-NMR (400 MHz, CDCl₃): •8.68-8.67 (d, 1H), 7.97-7.88(m, 2H), 7.69-7.64 (m, 1H), 6.62-6.53 (m, 1H), 5.06-5.00 (m, 1H),4.03-3.18 (m, 7H), 1.80-1.42 (m, 15H), 1.04-0.92 (m, 12H).

[1064] i.) Benzofuran-2-carboxylic Acid{(S)-1-[3-hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1065] To{(S)-1-[3-Hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicacid tert-butyl ester of Example 92h (0.22 g, 0.43 mmol) was addedHCl/dioxane (4M, 20 ml, 80 mmol). The mixture was stirred at r.t. for 2h before solvents and excess amount of HCl was removed on rotavapor. Theresulting white solid was dissolved in 5 ml DMF. To the solution wasadded 2-benzofurancarboxylic acid (84 mg, 0.52 mmol), HBTU (0.2 g, 0.52mmol) and NMM (0.2 g, 2 mmol). The mixture was stirred at r.t.overnight. DMF was then removed and the residue was re-dissolved inEtOAc (50 ml), washed with 10% NaHCO₃ (50 ml×2) and brine (50 ml).Evaporation of the solvent gave crude product 0.26 g. Purification bycolumn chromatograghy gave the title compound 0.15 g in 63% total yield;MS (M+H⁺): 556.8;

[1066]¹H-NMR (400 MHz, CDCl₃): 8.66-8.63 (m, 1H), 7.94-7.11 (m, 10H),4.72 (m, 1H), 4.01-2.98 (m, 7H), 1.78-1.39 (m, 5H), 1.02-0.85 (m, 12H).

[1067] j.) Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1068] To a solution of benzofuran-2-carboxylic acid{(S)-1-[3-hydroxy-6,6-dimethyl-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amidefrom Example 92i (100 mg, 0.18 mmol) in 2 ml CH₂Cl₂, was addedDess-Martin reagent (76 mg, 0.18 mmol) at r.t. The solution was stirredfor 2 h when 20 ml CH₂Cl₂ was added and then washed with NaHCO₃ andbrine. Purification by column chromatograghy (50% ethyl acetate inhexane) gave 70 mg of the title compound in 70% yield. MS (M+H⁺): 555.4;¹H-NMR (400 MHz, CDCl₃): •8.68-8.67 (d, 1H), 7.97-7.93 (m, 2H),7.69-7.28 (m, 6H), 7.32-6.92 (m, 2H), 5.24 (m, 1H), 4.79-4.69 (m, 2H),3.80-3.71 (m, 2H), 2.54-2.50 (d, 1H), 1.92-1.76 (m, 4H), 1.45-1.40 (m,4H), 1.01-0.91 (m, 9H).

[1069] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS (M+H⁺): 555.2, and the slower elutingdiastereomer; MS (M+H⁺): 555.2.

Example 93

[1070] Preparation of 5-Methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1071] a.) 5-Methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1072] Following the procedure of Example 85c except substituting5-methoxybenzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylicacid the title compound was prepared: MS(EI) 574 (M+H⁺).

[1073] b.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1074] Following the procedure of Example 1i except substituting5-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 93a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 4H). 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.6 (m, 8H) 8.0-8.2 (m,2H); MS(EI): 572 (M⁺, 30%).

[1075] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.7 (s, 3H), 3.8 (d, 1H). 4.0 (d, 1H),4,7 (m, 1H), 4.8 (d, 1H), 5.0 (m, 1H), 7.4-8.6 (m, 8H) 8.0-8.2 (m, 2H);MS(EI): 573 (M+H⁺, 100%) and the slower eluting diastereomer; MS(EI):573 (M+H⁺, 100%).

Example 94

[1076] Preparation of Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1077] a.) Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1078] Following the procedure of Example 85c except substitutingthieno[3,2-b]thiophene-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 566 (M+H⁺).

[1079] b.) Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1080] Following the procedure of Example 1i except substitutingthieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 94a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-7.5 (m, 6H), 7.7 (d,1H), 8.0-8.2 (m, 2H). MS(EI): 564 (M⁺, 100%).

[1081] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.7 (t, 1H), 3.8 (d, 1H). 4.0 (d, 1H), 4,5 (m, 1H),4.7 (d, 1H), 5.0 (m, 1H), 7.4-7.5 (m, 6H), 7.7 (d, 1H), 8.0-8.2 (m, 2H);MS(EI): 565 (M+H⁺, 100%) and the slower eluting diastereomer; MS(EI):565 (M+H⁺, 100%).

Example 95

[1082] Preparation of Quinoxaline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1083] a.) Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1084] Following the procedure of Example 85c except substitutingquinoxaline-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acidthe title compound was prepared: MS(EI) 556 (M+H⁺).

[1085] b.) Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyt]-butyl}amide

[1086] Following the procedure of Example 1i except substitutingquinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 95a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-7.5 (m, 2H), 7.9 (m,1H), 8.0-8.4 (m, 4H, 9.6 (d, 1H); MS(EI): 554 (M⁺, 100%).

[1087] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 555 (M+H⁺, 100%) and the slowereluting diastereomer; MS(EI): 555 (M+H⁺, 100%).

Example 96

[1088] Preparation of Quinoline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1089] a.) Quinoline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1090] Following the procedure of Example 85c except substitutingquinoline-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared: MS(EI) 555 (M+H⁺).

[1091] b.) Quinoline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1092] Following the procedure of Example 1i except substutingquinoline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 96a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.6 (m, 10H); MS(EI):553 (M⁺, 100%).

[1093] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 554 (M+H⁺, 100%) and the slowereluting diastereomer; MS(EI): 554 (M+H⁺, 100%).

Example 97

[1094] Preparation of Thiophene-3-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1095] a.) Thiophene-3-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1096] Following the procedure of Example 85c except substitutingthiophene-3-carboxylic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared: MS(EI) 510 (M+H⁺).

[1097] b.) Thiophene-3-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1098] Following the procedure of Example 1i except substutingthiophene-3-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 97a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H). 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 4H), 7.8 (m,1H), 8.1-8.2 (m, 2H); MS(EI): 508 (M⁺, 80%).

Example 98

[1099] Preparation of 1H-Indole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1100] a.) 1H-Indole-5-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1101] Following the procedure of Example 85c except substituting1H-indole-5-carboxylic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared: MS(EI) 543 (M⁺).

[1102] b.) 1H-Indole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1103] Following the procedure of Example 1i except substuting of1H-indole-5-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 98a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 7H), 8.1-8.2 (m,2H), 8.6 (b, 1H); MS(EI): 541 (M⁺, 100%).

[1104] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 542 (M+H⁺, 80%) and the slowereluting diastereomer; MS(EI): 542 (M+H⁺, 80%).

Example 99

[1105] Preparation of Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1106] a.) Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1107] Following the procedure of Example 85c except substitutingBenzo[1,3]dioxole-5-carboxylic acid for benzo[b]thiophene-2-carboxylicacid the title compound was prepared: MS(EI) 548 (M⁺).

[1108] b.) Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1109] Following the procedure of Example 1i except substutingbenzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 99a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4.5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 6.0 (s, 2H), 7.4-8.0 (m,5H), 8.1-8.2 (m, 2H); MS(EI): 546 (M⁺, 100%).

[1110] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer; MS(EI): 547 (M+H⁺, 100%) and the slowereluting diastereomer; MS(EI): 547 (M+H⁺, 100%).

Example 100

[1111] Preparation of Furan-2-carboxylic Acid{(S)-3-methyl-1-13-oxo-1-(]-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1112] a.) Furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1113] Following the procedure of Example 85c except substituting furoicacid for benzo[b]thiophene-2-carboxylic acid the title compound wasprepared: MS(EI) 494 (M⁺).

[1114] b.) Furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1115] Following the procedure of Example 1i except substutingfuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 100a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2 (m,2H); MS(EI): 492 (M⁺, 100%).

[1116] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer MS(EI): 493 (M+H⁺, 100%) and the slowereluting diastereomer; MS(EI): 493 (M+H⁺, 100%).

Example 101 Preparation of(S)-4-Methyl-2-(2-thiophen-2-1-acetylamino)-pentanoic Acid[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1117] a.) (S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic Acid[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1118] Following the procedure of Example 85c except substitutingthiophene-2-acetic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared.

[1119] b.) (S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1120] Following the procedure of Example 1i except substuting(S)-4-methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide of

[1121] Example 101a the title compound was prepared: ¹H NMR (CDCl₃): δ1.0 (m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 3H); 4.0(m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2(m, 2H); MS(EI): 522 (M+, 20%).

Example 102

[1122] Preparation of 1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1123] a.) 1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1124] Following the procedure of Example 85c except substituting1H-indole-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared: MS(EI) 543 (M⁺).

[1125] b.) 1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1126] Following the procedure of Example 1i except substuting1H-indole-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]butyl}amideof Example 102a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H),7.4-8.0 (m, 7H), 8.1-8.2 (m,2H), 9.4 (b, 1H); MS(EI): 541 (M⁺, 100%).

[1127] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereomer: MS(EI): 542 (M+H⁺, 100%) and the slowereluting diastereomer; MS(EI): 542 (M+H⁺, 100%).

Example 103

[1128] Preparation of4-Fluoro-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide

[1129] a.)4-Fluoro-{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide

[1130] Following the procedure of Example 85c except substituting4-fluorobenzoic acid for benzo[b]thiophene-2-carboxylic acid the titlecompound was prepared: MS(EI) 522 (M⁺).

[1131] b.)4-Fluoro-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide

[1132] Following the procedure of Example 1i except substuting4-fluoro-{(S)-3-methyl-1-[3-hydroxy-1-(-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl-benzamideof Example 103a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, 11H), 4.7 (m, 1H), 5.0 (m, 1H),7.4-8.0 (m, 6H), 8.1-8.2 (m,2H); MS(EI): 520 (M⁺, 100%).

[1133] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereomer: MS(EI): 521 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 521 (M+H⁺, 100%).

Example 104

[1134] Preparation of5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-buty}-amide

[1135] a.) 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-buty}-amide

[1136] Following the procedure of Example 85c except substituting5-(2-morpholin-4-yl-ethyloxy)benzofuran-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 673 (M⁺).

[1137] b.) 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-buty}-amide

[1138] Following the procedure of Example 1i except substuting5-(2-morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-buty}-amideof Example 104a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (m, 4H), 2.7 (m, 3H), 3.7 (m,4H); 3.9 (m, 1H), 4,5 (m, 3H), 4.7 (m, 11), 5.0 (m, 1H), 7.4-8.0 (m,6H), 8.1-8.2 (m, 2H); MS(EI): 671 (M⁺, 100%).

[1139] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereomer: MS(EI): 672 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 672 (M+H⁺, 100%).

Example 105

[1140] Preparation of Thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1141] a.) Thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1142] Following the procedure of Example 85c except substitutingthiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylic acid thetitle compound was prepared: MS(El) 510 (M⁺).

[1143] b.) Thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1144] Following the procedure of Example 1i except substutingthiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 105a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, In), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 5H), 8.1-8.2 (m,2H); MS(EI): 508 (M⁺, 100%).

[1145] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereomer: MS(EI): 509 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 509 (M+H⁺, 100%).

Example 106

[1146] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1147] a.) 3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1148] Following the procedure of Example 85c except substituting3-methylbenzofuran-2-carboxylic acid for benzo[b]thiophene-2-carboxylicacid the title compound was prepared: MS(EI) 558 (M⁺).

[1149] b.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1150] Following the procedure of Example 1i except substuting3-methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 106a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (d, 3H), 2.7 (m, 1H), 3.8 (q,1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,6H), 8.1-8.2 (m, 2H); MS(EI): 556 (M⁺, 100%).

[1151] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m,5H), 2.2 (m, 2H), 2.6 (s, 3H), 2.7 (t, 1H), 3.8 (d, 1H); 4.1 (d, 11H),4,7 (m, 1H), 4.7 (d, 1H), 5.0 (m, 1H), 7.0 (m, 2H), 7.3 (m, 2H), 7.4 (m,4H), 8.1 (d, 1H), 8.2 (d, 1H); MS(EI): 557 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 557 (M+H⁺, 100%).

Example 107

[1152] Preparation of6-Methyl-N-{(S)-3-methyl-1-[3-oxo-1-(-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamide

[1153] a.)6-Methyl-N-{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamide

[1154] Following the procedure of Example 85c except substituting6-methylnicotinic acid for benzo[b]thiophene-2-carboxylic acid the titlecompound was prepared: MS(EI) 519 (M⁺).

[1155] b.)6-Methyl-N-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamide

[1156] Following the procedure of Example 1i except substuting of6-methyl-N-[(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamideExample 107a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0 (m,6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (s, 3H), 2.7 (m, 1H), 3.8 (q,1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,3H), 8.1-8.2 (m, 3H), 9.0 (m, 1H); MS(EI): 517 (M⁺, 100%).

[1157] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 518 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 518 (M+H⁺, 100%).

Example 108

[1158] Preparation of(S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoicacid-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide

[1159] a.) (S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoicacid-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide

[1160] Following the procedure of Example 28b except substitutingthiophene-2-acetic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(ESI) 508.8 (M+H⁺).

[1161] b.) (S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoicacid-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide

[1162] Following the procedure of Example 1i except substuting(S)-4-methyl-2-(2-thiophen-yl-acetylamino)-pentanoicacid-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide ofExample 108a the title compound was prepared: MS(ESI) 506.8 (M+H⁺).

Example 109

[1163] Preparation of 1H-Indole-6-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1164] a.) 1H-Indole-6-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1165] Following the procedure of Example 28b except substituting1H-indole-6-carboxylic acid for benzofuran-2-carboxylic acid the titlecompound was prepared: MS(EI) 527 (M+H⁺).

[1166] b.) 1H-Indole-6-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1167] Following the procedure of Example 1i except substuting1H-indole-6-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 109a the title compound was prepared: MS(EI) 525 (M+H⁺).

Example 110

[1168] Preparation of Benzo[1,3]dioxole-5-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1169] a.) Benzo[1.3]dioxole-5-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1170] Following the procedure of Example 28b except substitutingpiperonylic acid for benzofuran-2-carboxylic acid the title compound wasprepared: MS(EI) 532.7 (M+H⁺).

[1171] b.) Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1172] Following the procedure of Example 1i except substutingbenzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 110a the title compound was prepared: MS(EI) 530.8 (M+H⁺).

Example 111

[1173] Preparation of 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylicAcid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1174] a.) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1175] Following the procedure of Example 85c except substituting3,4-dihydro-2H-1,5-benzodioxepine-7-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 576 (M⁺).

[1176] b.) 3,4-Dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1177] Following the procedure of Example 1i except substuting3,4-dihydro-2H-benzo[b][1,4]dioxepine-7-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 111a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 4H), 2.5 (d, 3H), 2.7 (m, 1H), 3.8 (q,1H); 4.0 (m, 1H), 4.2 (m, 4H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H),7.4-8.0 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 575 (M+H⁺, 100%).

[1178] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 575 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 575 (M+H⁺, 1400%).

Example 112

[1179] Preparation of 5-Methyl-thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1180] a.) 5-Methyl-thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1181] Following the procedure of Example 85c except substituting5-methyl thiophene-2-carboxylic acid for benzo[b]thiophene-2-carboxylicacid the title compound was prepared: MS(EI) 524 (M⁺).

[1182] b.) 5-Methyl-thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1183] Following the procedure of Example 1i except substuting5-methyl-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 112a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.5 (d, 3H), 2.7 (m, 1H), 3.8 (q,1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,4H), 8.1-8.2 (m, 2H); MS(EI): 523 (M+H⁺, 100%).

[1184] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 523 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 523 (M+H⁺, 100%).

Example 113

[1185] Preparation of 4,5-Dibromo-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1186] a.) 4,5-Dibromo-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1187] Following the procedure of Example 85c except substituting4,5-dibromo-thiophene-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 668 (M⁺).

[1188] b.) 4,5-Dibromo-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1189] **Following the procedure of Example 1i except substuting4,5-dibromo-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 113a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (q, 1H); 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 3H), 8.1-8.2 (m,2H); MS(EI): 665 (M+H⁺, 100%).

Example 114

[1190] Preparation of 3,5-Dimethyl-isoxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1191] a.) 3,5-Dimethyl-isoxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1192] Following the procedure of Example 85c except substituting3,5-dimethyl-isoxazole-4-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 524 (M+H⁺).

[1193] b.) 3,5-Dimethyl-isoxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1194] Following the procedure of Example 1i except substuting3,5-dimethyl-isoxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 114a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.4 (m, 3H), 2.6 (m, 3H), 2.7 (m,1H), 3.8 (q, 1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H),7.4-8.0 (m, 5H), 8.1-8.2 (m, 2H); MS(EI): 521 (M⁺, 100%).

Example 115

[1195] Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicAcid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1196] a.){(S)-1-[3-Hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid-Tert-Butyl Ester

[1197] [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamicacid-tert-butyl ester (compound 2g, 0.8 g, 2.33 mmol) was dissolved in1,2-dichloroethane (DCE, 20 ml). Then, morpholinemethyl polystyreneresin beads (1.26 g, 3.7 mmol/g, Nova) were added and the solution wasshaken for 5 minutes. Then, p-methoxybenzenesulfonyl chloride (0.48 g,2.33 mmol) was dissolved in DCE (10 ml), and this solution was added tothe reaction mixture. The reaction was shaken overnight, filtered,washed with DCE (2×10 ml), then CH₂Cl₂ (10 ml). The combined organicswere concentrated in vacuo, and used in the next reaction withoutfurther purification: M+H⁺=514.2.

[1198] b.) (S)-2-Amino-4-methyl-pentanoic Acid[3-hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-yl]-amide-HCl Salt

[1199]{(S)-1-[3-Hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicacid-tert-butyl ester (compound 207a, 0.59 g, 1.15 mmol) was dissolvedin CH₂Cl₂ (8 ml), then a solution of 4 M HCl in dioxane (8 ml) was addedand the reaction was stirred at RT for 4 h. The reaction mixture wasconcentrated in vacuo, azeotroped from toluene twice (IO ml) in vacuo,and was used in the next reaction without further purification:M+H⁺=413.8.

[1200] c.) (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[3-hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-yl]-amide

[1201] (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-yl]-amide-HCl salt(crude product from reaction mixture of 115b) was dissolved in MeOH (10ml) and was treated with carbonate-polystyrene resin beads (1.75 g, 2.63mmol/g, 4.6 mmol) and was shaken for 2 h, filtered, washed with MeOH (10ml) and the combined organics were concentrated in vacuo. The productwas then dissolved in DCE (2 ml) and morpholinemethyl polystyrene resinbeads (0.25 g, 3.77 mmol/g, 0.91 mmol, Nova) were added and the reactionwas shaken for 5 minutes. Then, benzylacetyl chloride (0.081 g, 0.44mmol) was added and the reaction mixture was shaken overnight. Then,trisamine polystyrene beads (0.1 g, 3.66 mmol/g, 0.366 mmol) was addedand the reaction mixture was shaken for 1.5 h. The reaction mixture wasthen filtered, washed with DCE (2×10 ml) and CH₂Cl₂ (10 ml), and thecombined organics were concentrated in vacuo. The crude product was usedin the next reaction without further purification: M+H⁺=562.2.

[1202] d.) (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1203] (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoic acid[3-hydroxy-1-(4-methoxy-benzenesulfonyl)-azepan-4-yl]-amide (compound207c, 0.24 g, 0.44 mmol) was dissolved in CH₂Cl₂ (5 ml), thenDess-Martin periodinane (0.3 g, 0.7 mmol) was added and the reaction wasstirred for 30 min. The reaction was diluted with CH₂Cl₂ (20 ml), thenwas extracted with aqueous 10% Na₂S₂O₅ (10 ml), then aqueous 10% NaHCO₃(10 ml), water (10 ml), brine (10 ml). The combined organics wereconcentrated in vacuo. The residue was purified by HPLC (50:50 Ethanol:hexanes, 20 mL/min, 25 min, WhelkO-1 (R,R) 21×250 mm column, UVdetection at 280 nm and 305 nm) to yield the first elution as a whitesolid (47 mg, 43%): MS 560.4 (M+H⁺). ¹H NMR (400 Hz, CDCl₃): δ 7.73 (d,2H), 7.40-7.30 (m, 5H), 7.05 (d, 2H), 3.99 (s, 2H), 3.88 (s, 3H),2.28-2.10 (m, 2H), 0.95 (t, 6H) and second eluting diastereomer: MS560.2 (M+H⁺).

Example 116

[1204] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid{(S)-3-methyl-]-(3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1205] a.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1206] Following the procedure of Example 85c except substituting5-(3-trifluoromethyl-phenyl)-furan-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 638 (M⁺).

[1207] b.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1208] Following the procedure of Example 1i except substuting5-(3-trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 116a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (d, 3H), 2.7 (m, 1H), 3.8 (q,11H); 4.1 (m, 1H), 4,7 (t, 1H), 4.8 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,9H), 8.1-8.2 (m, 2H); MS(EI): 637 (M+H⁺, 100%).

[1209] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(El): 637 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 637 (M+H⁺, 100%).

Example 117

[1210] Preparation of 5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1211] a.) 5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1212] Following the procedure of Example 85c except substituting5-methyl-2-phenyl-oxazole-4-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(EI) 585 (M⁺).

[1213] b.) 5-Methyl-2-phenyl-oxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1214] Following the procedure of Example 1i except substuting5-methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 117a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.6 (d, 3H), 2.7 (m, 1H), 3.8 (q,1H); 4.0 (m, 1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m,7H), 8.1-8.2 (m, 2H); MS(EI): 584 (M+H⁺, 100%).

[1215] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 584 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 584 (M+H⁺, 100%).

Example 118

[1216] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[1217] a.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}-amide

[1218] To a solution of benzofuran-2-carboxylic acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amideof Example 78c (0.175 g) in dichloromethane was added triethylamine (0.1mL) and 3,4-dimethoxybenzenesulfonyl chloride (0.12 g). The reaction wasstirred until complete. Workup and column chromatography (5%methanol:dicloromethane) provided the title compound (0.21 g): MS(EI)587 (M⁺).

[1219] b.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[1220] Following the procedure of Example 1i except substutingbenzofuran-2-carboxylic acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}-amideof Example 118a the title compound was prepared: ¹H NMR (CDCl₃): δ 10.0(m, 6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.5 (d, 1H); 3.7 (t, 6H), 4.0 (m,1H), 4,5 (t, 1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 8H); MS(EI): 586(M+H⁺, 100%).

Example 119

[1221] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(4-bromo-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1222] a.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(4-bromo-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1223] Following the procedure of Example 118a except substituting4-bromobenzenesulfonyl chloride for 3,4-dimethoxybenzenesulfonylchloride the title compound was prepared: MS(EI) 606 (M⁺).

[1224] b.) Benzofuran-2-carboxylic acid{(S)-1-[1-(4-bromo-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1225] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-1-[1-(4-bromo-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amideof Example 119a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.5 (d, 1H); 4.0 (m, 1H), 4,5 (t,1H), 4.7 (m, 1H), 5.0 (m, 1H), 7.4-8.0 (m, 9H); MS(EI): 604 (M⁺, 100%).

Example 120

[1226] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(benzol[1,2,5]oxadiazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1227] a.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1228] Following the procedure of Example 118a except substitutingbenzofurazan-4-sulfonyl chloride for 3,4-dimethoxybenzenesulfonylchloride the title compound was prepared: MS(EI) 569 (M⁺).

[1229] b.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1230] Following the procedure of Example 1i except substitutingBenzofuran-2-carboxylic acid{(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-hydroxy-azepan-4ylcarbamoyl]-3-methyl-butyl}-amideof Example 120a the title compound was prepared:

[1231]¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.1 (m, 6H), 2.6 (m, 1H), 3.7(m, 1H); 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); MS(EI):568 (M+H⁺, 100%).

Example 121

[1232] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1233] a.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1234] Following the procedure of Example 118a except substituting3,5-dimethyloxazole-4-sulphonyl chloride for3,4-dimethoxybenzenesulfonyl chloride the title compound was prepared:MS(EI) 546 (M⁺).

[1235] b.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1236] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amideof Example 121a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.4 (d, 3H), 2.7 (t, 3H), 3.6 (d,1H), 4.1 (m, 1H), 4.4 (t, 1H), 4.7 (m, 1H), 5.2 (m, 1H), 7.4-8.0 (m,5H); MS(ET): 544 (M⁺, 100%).

Example 122

[1237] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1238] a.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1239] Following the procedure of Example 28b except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(EI) 542 (M⁺).

[1240] b.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1241] Following the procedure of Example 1i except substituting3-methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 122a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.6 (d, 3H), 2.7 (m, 1H), 3.8 (m,11H), 4.1 (m, 1H), 4.7 (in, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 7H); 8.7 (m,1H); MS(EI): 540 (M⁺, 100%).

[1242] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.2 (m,6H), 2.2 (m, 2H), 2.6 (s, 3H), 2.7 (m, 1H), 3.8 (d, 1H); 4.1 (d, 1H),4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 7H); 8.7 (m, 1H); MS(EI): 541(M+H⁺, 100%) and the slower eluting diastereomer MS(ET): 541 (M+H⁺,100%).

Example 123

[1243] Preparation of Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1244] a.) Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1245] Following the procedure of Example 28b except substitutingthieno[3,2-b]thiophene-2-carboxylic acid for benzofuran-2-carboxylicacid the title compound was prepared: MS(EI) 550 (M⁺).

[1246] b.) Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1247] Following the procedure of Example 1i except substitutingthieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylamide of Example 123a the title compound was prepared: ¹H NMR (CDCl₃): δ1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 1H); 4.1(m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m, 1H); MS(EI):548 (M⁺, 100%).

[1248] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: ¹HNMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.2 (m,6H), 2.2 (m, 2H) 2.7 (t, 1H), 3.8 (d, 1H); 4.1 (d, 1H), 4.7 (m, 2H), 5.2(m, 1H), 7.4-8.0 (m, 8H); 8.7 (d, 1H); MS(EI): 549 (M+H⁺, 100%) and theslower eluting diastereomer MS(EI): 549 (M+H⁺, 100%).

Example 124

[1249] Preparation of5-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1250] a.) 5-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylicAcid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1251] Following the procedure of Example 28b except substituting5-tert-butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 620(M⁺).

[1252] b.) 5-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylicAcid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1253] Following the procedure of Example 1i except substituting5-tert-butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 124a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.45 (s, 9H), 1.5-2.2 (m, 6H), 2.2 (m, 2H) 2.4 (d, 3H), 2.7 (m,1H), 3.8 (m, 1H); 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m,4H); 8.7 (m, 1H); MS(EI): 618 (M⁺, 100%).

Example 125

[1254] Preparation of 5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1255] a.) 5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1256] Following the procedure of Example 28b except substituting5-methyl-2-phenyl-oxazole-4-carboxylic acid for benzofuran-2-carboxylicacid the title compound was prepared: MS(EI) 569 (M⁺).

[1257] b.) 5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1258] Following the procedure of Example 1i except substituting5-methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 125a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m, 1H), 2.6 (m, 3H), 3.8(m,1H); 4.1 (m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m,1H); MS(EI): 567 (M⁺, 100%).

[1259] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 568 (M+H⁺, 100%) and the slowereluting diastereomer MS(EI): 568 (M+H⁺, 100%)

Example 126

[1260] Preparation of 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylicAcid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1261] a.) 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-hydrox-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1262] Following the procedure of Example 28b except substituting2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid forbenzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 623(M⁺).

[1263] b.) 2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1264] Following the procedure of Example 1i except substituting2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-hydrox-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylamide of Example 126a the title compound was prepared: ¹H NMR (CDCl₃): δ1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.2 (m, 2H), 2.7 (m, 1H), 3.8 (m, 1H); 4.1(m, 1H), 4.7 (m, 2H), 5.2 (m, 1H), 7.4-8.0 (m, 8H); 8.7 (m, 1H); MS(EI):621 (M⁺, 100%).

[1265] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 622 (M+H⁺, 100%) and the slowereluting diastereomer: MS(EI): 622 (M+H⁺, 100%).

Example 127

[1266] Preparation of Quinoline-2-carboxylic Acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1267] Following the procedure of Example 75, except substitutingmethanesulfonyl chloride for thiazole-2-sulfonyl chloride and2-quinoline carboxylic acid for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 475.2; ¹H-NMR (400 MHz, CDCl₃): 8.65 (d, 1H),8.35-8.28 (q, 2H), 8.20-8.18 (d, 1H), 7.91-7.89 (d, 1H), 7.80-7.78 (t,1H), 7.67-7.65 (t, 1H), 7.10 (d, 1H), 5.08 (m, 1H), 4.73 (m, 1H),4.56-4.51 (d, 1H), 4.00 (m, 1H), 3.67-3.62 (d, 1H), 2.91 (s, 3H), 2.70(m, 1H), 2.32-2.10 (m, 2H), 1.95-1.40 (m, 5H), 1.02-1.00 (m, 6H); andthe second eluting diastereomer: MS (M+H⁺): 475.2

Example 128

[1268] Preparation of 1-Methyl-1H-indole-2-carboxylic Acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1269] Following the procedure of Example 75, except substitutingmethanesulfonyl chloride for thiazole-2-sulfonyl chloride andN-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 477.2; ¹H-NMR (400 MHz, CDCl₃):•7.65-7.63 (d, 1H), 7.39-7.33 (m, 2H), 7.17-7.14 (t, 1H), 6.98-6.95 (m,2H), 6.65 (d, 1H), 5.08 (m, 1H), 4.68 (m, 1H) 4.56-4.52 (d, 1H), 4.03(m, 4H), 3.67-3.613 (d, 1H), 2.92 (s, 3H), 2.71 (m, 1H), 2.32-2.10 (m,2H), 1.95-1.40 (m, 5H), 1.02-1.00 (d, 6H); and the second elutingdiastereomer: MS (M+H⁺): 477.2

Example 129

[1270] Preparation of Furan-2-carboxylic acid{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-amide

[1271] Following the procedure of Example 75, except substitutingmethanesulfonyl chloride for thiazole-2-sulfonyl chloride andN-(2-furan-carbonyl)-glycine for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 471.2; ¹H-NMR (400 MHz, CDCl₃): •7.50 (m, 1H),7.15 (m, 1H), 7.05 (m, 11H), 6.90 (d, 1H), 6.55 (m, 2H), 5.08 (m, 1H),4.55 (m, 2H), 4.12 (m, 2H), 4.05 (m, 1H), 3.70 (d, 1H), 2.92 (s, 3H),2.75 (m, 1H), 2.20-1.40 (m, 7H), 0.95 (m, 6H); and the second elutingdiastereomer: MS (M+H⁺): 471.4.

Example 130

[1272] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid[(S)-1-(]-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1273] Following the procedure of Example 75, except substitutingmethanesulfonyl chloride for thiazole-2-sulfonyl chloride and5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 494.2; ¹H-NMR (400 MHz, CDCl₃):•7.42-7.40 (d, 2H), 7.08-6.94 (m, 4H), 5.10 (m, 1H), 4.71 (m, 1H),4.56-4.52 (d, 1H), 4.02 (m, 1H), 3.86 (s, 3H), 3.68-3.63 (d, 1H), 2.92(s, 3H), 2.72 (m, 1H), 2.30-1.15 (m, 2H), 1.95-1.40 (m, 5H), 0.99 (d,6H); and the second eluting diastereomer: MS (M+H⁺): 494.2.

Example 131

[1274] Preparation of Quinoxaline-2-carboxylic Acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1275] Following the procedure of Example 75, except substitutingmethanesulfonyl chloride for thiazole-2-sulfonyl chloride andquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 476.2; ¹H-NMR (400 MHz, CDCl₃): 9.66(s, 1H), 8.38 (d, 1H), 8.20-8.18 (m, 2H), 7.88 (m, 2H), 7.0](d, 1H),5.10 (m, 1H), 4.77 (m, 1H), 4.57-4.52 (d, 1H), 4.08-4.00 (m, 1H),3.69-3.64 (d, 1H), 2.92 (s, 3H), 2.71 (m, 1H), 2.42-2.15 (m, 2H),1.95-1.42 (m, 5H), 1.02-1.01 (d, 6H); and the second elutingdiastereomer: MS (M+H⁺): 476.2.

Example 132

[1276] Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1277] a.) 5-(4-Chloro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1278] Following the procedure of Example 28b except substituting5-(4-chlorophenyl)-2-furoic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(EI) 590 (M+H⁺).

[1279] b.) 5-(4-Chloro-phenyl)-furan-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1280] Following the procedure of Example 1i except substituting5-(4-chloro-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 132a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.1 (m, 5H), 2.2 (m, 2H), 2.7 (m, 1H), 3.7 (d, 1H), 4.0 (m,1H), 4.7 (m, 2H), 5.0 (m, 1H), 6.7 (m, 1H), 7.2 (m, 1H), 7.3 (m, 2H),7.5 (m, 1H), 7.7 (m, 2H), 8.0 (m, 2H), 8.7 (m, 1H); MS(EI): 587 (M⁺,80%)

[1281] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 587 (M+H⁺, 100%) and the slowereluting diastereomer: MS(EI): 587 (M+H⁺, 100%).

Example 133

[1282] Preparation of(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid(1-methanesulfonyl-3-oxo-azepan-4-yl)-amide

[1283] Following the procedure of Example 75, except substituting4-methanesulfonyl chloride for thiazole-2-sulfonyl chloride and2-(4-methoxyphenyl)-acetic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 468.2; ¹H-NMR (400 MHz, CDCl₃):•7.19-7.17 (d, 2H), 6.90-6.88 (d, 3H), 5.83-5.81 (d, 1H), 5.00 (m, 1H),4.53-4.40 (in, 2H), 4.03-3.99 (m, 11H), 3.81 (s, 3H), 3.66-3.61 (d, 1H),3.53 (s, 2H), 2.91 (s, 3H), 2.73 (t, 1H), 2.22-2.10 (m, 2H), 1.99 (m,11H), 1.62-1.35 (m, 4H), 0.90-0.88 (d, 6H); and the second elutingdiastereomer: MS (M+H⁺): 468.2.

Example 134

[1284] Preparation of Quinoline-2-carboxylic Acid{[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1285] Following the procedure of Example 75, except substituting2-cyanobenzenesulfonyl chloride for thiazole-2-sulfonyl chloride andquinoline-2-carboxylic acid for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 562.2; ¹H-NMR (400 MHz, CDCl₃): 8.65 (d, 1H),8.48-8.40 (q, 2H), 8.25-8.10 (q, 2H), 7.91-7.65 (m, 6H); and the secondeluting diastereomer:, 7.12 (d, 1H), 5.10 (m, 1H), 4.73 (m, 1H)4,61-4.56 (d, 1H),4.20 (m, 1H),3.73-3.68 (d, 1H), 2.80 (m, 1H), 2.27 (m,2H), 1.91-1.40 (m, 5H), 1.03-1.01 (m, 6H); and the second elutingdiastereomer: MS (M+H⁺): 562.2.

Example 135

[1286] Preparation of 1-Methyl-1H-indole-2-carboxylic Acid{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1287] Following the procedure of Example 75, except substituting2-cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 564.2; ¹H-NMR (400 MHz, CDCl₃): •8.13(d, 1H), 7.89 (d, 1H), 7.77-7.67 (m, 3H), 7.38-7.16 (m, 4H), 6.97 (s,1H), 6.70 (d, 1H), 5.05 (m, 1H), 4.70-4.60 (m, 1H), 4.55-4.50 (d, 1H),4.07 (m, 1H), 4.05 (s, 3H), 3.76-3.71 (d, 1H), 2.75 (m, 1H), 2.30 (m,2H), 2.00-1.45 (m, 5H), 1.00 (d, 6H); and the second elutingdiastereomer: MS (M+H⁺) 564.2.

Example 136

[1288] Preparation of Furan-2-carboxylic acid{[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)-amide

[1289] Following the procedure of Example 75, except substituting2-cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-(2-furan-carbonyl)-glycine for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 558.2; ¹H-NMR (400 MHz, CDCl₃): •8.14-8.12 (d,1H), 7.91-7.90 (d, 1H), 7.80-7.72 (m, 2H), 7.48 (s, 1H), 7.14 (d, 2H),6.98 (d, 1H), 6.80 (d, 1H), 6.52-6.51 (t, 1H), 5.03 (m, 1H), 4.60-4.53(m, 2H), 4.17-4.14 (m, 3H), 3.74-3.69 (d, 1H), 2.80 (m, 1H), 2.25 (m,2H), 2.00-1.40 (m, 5H), 1.03-1.01 (m, 6H); and the second elutingdiastereomer: MS (M+H⁺) 558.2.

Example 137

[1290] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1291] Following the procedure of Example 75, except substituting2-cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 581.4; ¹H-NMR (400 MHz, CDCl₃):•8.15-8.13 (d, 1H), 7.92-7.90 (d, 1H), 7.81-7.74 (m, 2H), 7.42-7.40 (m,2H), 7.08-7.03 (m, 3H), 6.96 (d, 1H), 5.10 (m, 1H), 4.72-4.60 (m, 2H),4.17 (d, 1H), 3.85 (s, 3H), 3.75-3.70 (d, 1H), 2.83-2.76 (t, 1H), 2.27(m, 2H), 1.92-1.51 (m, 5H), 1.02-1.01 (m, 6H); and the second elutingdiastereomer: MS (M+H⁺) 581.2.

Example 138

[1292] Preparation of Quinoxaline-2-carboxylic Acid{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1293] Following the procedure of Example 75, except substituting2-cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 563.2; ¹H-NMR (400 MHz, CDCl₃): •9.65(s, 1H), 8.40 (m, 1H), 8.22-8.10 (m, 3H), 7.90-7.22 (m, 5H), 7.00 (d,1H), 5.10 (m, 1H), 4.75 (m, 1H), 4.65-4.60 (d, 1H), 4.20-4.10 (m, 1H),3.72-3.70 (d, 1H), 2.70 (m, 1H), 2.38 (m, 2H), 1.95-1.40 (m, 5H), 1.02(d, 6H); and the second eluting diastereomer: MS (M+H⁺) 563.2.

Example 139

[1294] Preparation of(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic Acid[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1295] Following the procedure of Example 75, except substituting2-cyanophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and2-(4-methoxyphenyl)-acetic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 555.2; ¹H-NMR (400 MHz, CDCl₃):•8.14-8.12 (d, 1H), 7.91-7.89 (d, 1H), 7.79-7.73 (m, 2H), 7.19-7.17 (d,2H), 6.90-6.88 (d, 3H), 5.80 (d, 1H), 5.02 (m, 1H), 4.59-4.55 (d, 1H),4.45-4.42 (m, 1H), 4.18-4.15 (m, 1H), 3.82 (s, 3H), 3.72-3.67 (d, 1H),3.53 (s, 2H), 2.82-2.79 (t, 1H), 2.22 (m, 2H), 1.92 (m, 1H), 1.60-1.30(m, 4H), 0.91-0.89 (d, 6H); and the second eluting diastereomer: MS(M+H⁺) 555.2.

Example 140

[1296] Preparation of Quinoline-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1297] Following the procedure of Example 75, except substituting4-methoxybenzenesulfonyl chloride for thiazole-2-sulfonyl chloride and2-quinoline carboxylic acid for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 567.2; ¹H-NMR (400 MHz, CDCl₃): 8.72-8.61 (d,1H), 8.35-8.28 (q, 2H) 8.21-8.18 (d, 1H), 7.91-7.60 (m, 5H), 7.10-6.99(m, 3H), 5.05 (m, 1H), 4.73 (m, 1H) 4,59-4.52 (d, 1H),4.00 (m, 1H), 3.88(s, 3H), 3.45-3.38 (d, 11H), 2.42 (m, 1H), 2.30-1.35 (m, 7H),1.03-1.0l(m, 6H); and the second eluting diastereomer: MS (M+H⁺) 567.2.

Example 141

[1298] Preparation of 1-Methyl-1H-indole-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1299] Following the procedure of Example 75, except substituting4-methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-methyl-indole-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 569.2; ¹H-NMR (400 MHz, CDCl₃):7.78-7.72 (d, 2H), 7.70-7.65 (d, 1H), 7.42-7.30 (m, 2H), 7.17-7.14 (t,1H), 7.05-6.95 (m, 4H), 6.65 (d, 1H), 5.05 (m, 1H), 4.70-4.50 (m, 2H),4.03 (s, 3H), 3.88 (s, 3H), 3.45-3.40 (d, 1H), 2.45 (m, 1H), 2.30-2.10(m, 2H), 1.90-1.35 (m, 6H); and the second eluting diastereomer:, 1.00(d, 6H); and the second eluting diastereomer: MS (M+H⁺) 569.2.

Example 142

[1300] Preparation of Furan-2-carboxylic Acid({(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)-amide

[1301] Following the procedure of Example 75, except substituting4-methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-(2-furan-carbonyl)-glycine for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 563.2; ¹¹H-NMR (400 MHz, CDCl₃): 7.74-7.72 (d,2H), 7.47 (s, 1H), 7.15-6.99 (m, 4H), 6.91 (d, 1H), 6.70 (d, 1H),6.52-6.51 (m, 1H), 5.01 (m, 1H), 4.53-4.49 (m, 2H), 4.17-4.14 (m, 2H),4.00-3.90 (m, 1H), 3.88 (s, 3H), 3.45-3.41 (d, 1H), 2.47 (m, 1H), 2.17(m, 2H), 1.85-1.40 (m, 5H), 0.95 (m, 6H); and the second elutingdiastereomer: MS (M+H⁺) 563.2.

Example 143

[1302] Preparation of 5-Methoxybenzofuran-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1303] Following the procedure of Example 75, except substituting4-methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 586.2; ¹H-NMR (400 MHz, CDCl₃):•7.75-7.73 (d, 2H), 7.42-7.40 (m, 2H), 7.08-6.99 (m, 5H), 6.91 (d, 1H),5.05 (m, 1H), 4.70-4.55 (m, 2H), 4.05-4.00 (m, 1H), 3.89 (s, 3H), 3.86(s, 3H), 3.45-3.40 (d, 1H), 2.50-2.40 (m, 1H), 2.30-2.10 (m, 2H),1.90-1.35 (m, 5H), 1.01 (m, 6H); and the second eluting diastereomer: MS(M+H⁺) 586.2.

Example 144

[1304] Preparation of Quinoxaline-2-carboxylic Acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1305] Following the procedure of Example 75, except substituting4-methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride andquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 568.2; ¹H-NMR (400 MHz, CDCl₃): •9.66(s, 1H), 8.40-8.35 (m, 1H), 8.19 (m, 2H), 7.88 (m, 2H), 7.75-7.73 (d,2H), 7.02-6.90 (m, 3H), 5.10-5.05 (m, 1H), 4.75 (m, 1H), 4.60-4.55 (d,1H), 4.05-3.95 (m, 1H), 3.89 (s, 3H), 3.45-3.41 (d, 1H), 2.45 (m, 1H),2.30-2.10 (m, 2H), 1.95-1.40 (m, 5H), 1.04-1.02 (d, 6H); and the secondeluting diastereomer: MS (M+H⁺) 568.2.

Example 145

[1306] Preparation of(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic Acid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1307] Following the procedure of Example 75, except substituting4-methoxyphenylsulfonyl chloride for thiazole-2-sulfonyl chloride and2-(4-methoxyphenyl)-acetic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 560.4; ¹H-NMR (400 MHz, CDCl₃):•7.74-7.71 (d, 2H), 7.19-7.17 (d, 2H), 7.01-6.99 (d, 2H), 6.90-6.88 (d,2H), 6.85 (d, 1H), 5.81 (d, 1H), 4.99 (m, 1H), 4.55-4.44 (m, 2H), 3.97(m, 1H), 3.88 (s, 3H), 3.81 (s, 3H), 3.53 (s, 2H), 3.43-3.38 (d, 1H),2.43 (t, 1H), 2.14 (m, 2H), 1.85-1.35 (m, 5H), 0.90-0.89 (d, 6H); andthe second eluting diastereomer: MS (M+H⁺) 560.2.

Example 146

[1308] Preparation of 1-Methyl-1H-indole-2-carboxylic acid {[(S)-1-l1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1309] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-methyl-indole-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 557.2; ¹H-NMR (400 MHz, CDCl₃):•7.84-7.80 (m, 2H), 7.66-7.65 (d, 1H), 7.40-7.14 (m, 5H), 6.95 (m, 2H),6.65-6.63 (d, 1H), 5.07 (m, 1H), 4.68-4.55 (m, 2H), 4.04 (s, 3H),3.48-3.43 (d, 1H), 2.49 (m, 1H), 2.25 (m, 2H), 1.89-1.38 (m, 6H); andthe second eluting diastereomer:, 1.0l(d, 6H); and the second elutingdiastereomer: MS (M+H⁺) 557.4.

Example 147

[1310] Preparation of Furan-2-carboxylic Acid({(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl]-methyl}-amide

[1311] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andN-(2-furan-carbonyl)-glycine for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 551.4; ¹H-NMR (400 MHz, CDCl₃): 7.81 (m, 2H),7.48 (s, 1H), 7.27-7.16 (m, 3H), 7.05 (m, 1H), 6.90 (d, 1H), 6.52 (m,2H), 5.00 (m, 1H), 4.60-4.48 (m, 2H), 4.14 (m, 2H), 4.00-3.90 (d, 1H),3.48-3.44 (d, 1H), 2.50 (m, 1H), 2.20 (m, 2H), 1.90-1.40 (m, 5H), 0.95(m, 6H); and the second eluting diastereomer: MS (M+H⁺) 551.2.

Example 148

[1312] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid{[(S)—-1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1313] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 574.2; ¹H-NMR (400 MHz, CDCl₃):•7.84-7.81 (m, 2H), 7.42-7.40 (m, 2H), 7.27-7.22 (m, 2H), 7.08-7.04 (m,3H), 6.93 (d, 1H), 5.10-5.02 (m, 1H), 4.69-4.55 (m, 2H), 4.05-4.00 (m,1H), 3.86 (s, 3H), 3.47-3.43 (d, 1H), 2.49 (m, 1H), 2.24 (m, 2H),1.90-1.40 (m, 5H), 1.01 (m, 6H); and the second eluting diastereomer: MS(M+H⁺): 574.2

Example 149

[1314] Preparation of Quinoxaline-2-carboxylic Acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1315] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride andquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 556.2; ¹H-NMR (400 MHz, CDCl₃): •9.66(s, 1H), 8.40-8.35 (d, 1H), 8.21-8.18 (m, 2H), 7.90-7.81 (m, 4H),7.27-7.22 (m, 2H), 6.97 (d, 1H), 5.10-5.02 (m, 1H), 4.75 (m, 1H),4.59-4.55 (d, 11H), 4.05-4.39 (m, 1H), 3.48-3.44 (d, 1H), 2.49 (m, 1H),2.32-2.10 (m, 2H), 1.90-1.40 (m, 5H), 1.03-1.02 (d, 6H); and the secondeluting diastereomer: MS (M+H⁺) 556.2.

Example 150

[1316] Preparation of(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic Acid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1317] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for thiazole-2-sulfonyl chloride and2-(4-methoxyphenyl)-acetic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 548.2; ¹H-NMR (400 MHz, CDCl₃):7.83-7.80 (m, 2H), 7.27-7.17 (m, 4H), 6.90-6.88 (d, 3H), 5.85 (d, 1H),4.98 (m, 1H), 4.55-4.43 (m, 2H), 4.00-3.97 (m, 1H), 3.81 (s, 3H), 3.53(s, 2H), 3.45-3.41 (d, 1H), 2.48 (t, 1H), 2.17-2.14 (m, 2H), 1.90-1.30(m, 5H), 0.90-0.88 (d, 6H); and the second eluting diastereomer: MS(M+H⁺): 548.4.

Example 151

[1318] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1319] a.){(S)-1-[1-(3-Chloro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1320] To a solution of the compound of Example 2g (2.50 g, 7.29 mmol)in DCE (100 ml) was added P-NMM (4.0 g) and 3-chlorobenzenesulphonylchloride (1.85 g, 8.75 mmol). After shaking at room temperatureovernight, the solution was filtered. The filtrate was concentrated toyield the title compound as white solid (3.13 g, 83.3%). MS: 539.78(M+Na)⁺.

[1321] b.) (S)-2-Amino-4-methyl-pentanoic acid[1-(3-chloro-benzenesulfonyl)-3-hydroxy-azepan-4-yl]-amide

[1322] To a stirring solution of the compound of Example 15la (1.0 g,1.93 mmol) in methnol (10 ml) was added HCl (4M in Dioxane) (10 ml).After stirring at room temperature for 3 hr the solution wasconcentrated to provide a white solid. To a solution of the white solid(0.68 g, 1.50 mmol, 78%) in methnol (37 ml) was added P-CO₃ (2.85 g,2.63 mmol/g). After shaking for 2 hr, the solution was filtered andconcentrated to yield the title compound as white solid (0.59 g, 1.42mmol, 95%). MS: 417.86 (M+H)⁺.

[1323] c.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1324] To a solution of the compound of Example 151b (0.14 g, 0.33 mmol)in CH₂Cl₂ (20 mL) was added benzofuran-2-carboxylic acid (0.81, 0.50mmol), 1-hydroxybenzotriazole (0.77 g, 0.57 mmol), and P-EDC (0.67 g, 1mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperature overnight,the solution was treated with tisamine (0.45 g, 3.75 mmol/g). Aftershaking for another 2 hr, the solution was filtered and concentrated toyield the title compound as a white solid (122 mg, 65%). MS (ESI): 562.2(M+H)⁺.

[1325] d.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1326] To a stirring solution of the compound of Example 151 c (122 mg,0.22 mmol) in dichloromethane (4 mL) was added Dess-Martin reagent (185mg, 0.44 mmol). After stirring at room temperature for 2 h, solutions ofsodium thiosulfate (2 mL of 10% in water) and saturated aqueous sodiumbicarbonate (2 mL) were added simultaneously to the solution. Theaqueous layer was extracted with dichloromethane (2×). The organicphases were combined, washed with saturated brine, dried (MgSO₄),filtered and concentrated. The residue was purified by HPLC to yield thefirst eluting diastereomer as a white solid (62.7 mg, 51.6%), MS (ESI):560.2 (M+H)⁺ and the second eluting diastereomer as a white solid (40.2mg, 33.1%). MS (ESI): 560.2 (M+H)⁺

Example 152

[1327] Preparation of 5-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1328] Following the procedure of Example 151c-d, except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidof Example 151c provided the title compound which was separated by HPLCto give the first eluting diastereomer as a white solid (64.4 mg,50.3%): MS (ESI): 590.2 (M+H)⁺ and the second eluting distereomer as awhite solid (44.4 mg, 34.7%): MS (ESI): 590.2 (M+H)⁺

Example 153

[1329] Preparation of 7-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1330] Following the procedure of Example 151c-d except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidof Example 151c provided the title compound which was separated by HPLCto give first eluting diastereomer as a white solid (51.1 mg, 39.9%), MS(ESI): 590.2 (M+H)⁺ and the second eluting diastereomer as a white solid(36.7 mg, 28.7%): MS (ESI): 590.2 (M+H)⁺

Example 154

[1331] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1332] Following the procedure of Example 151c-d except substituting5,6-dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylicacid of Example 151c provided the title compound which was separated byHPLC to give first eluting diastereomer as a white solid (51.1 mg,39.9%), MS (ESI): 622.2 (M+H)⁺ and the second eluting diastereomer as awhite solid (36.7 mg, 28.7%): MS (ESI): 622.2 (M+H)⁺

Example 155

[1333] Preparation of 3-Methylbenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1334] Following the procedure of Example 151c-d except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid instep 151c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (78.6 mg, 63.1%),MS (ESI): 574.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (40.7 mg, 32.6%). MS (ESI): 574.2 (M+H)⁺

Example 156

[1335] Preparation of Benzo[b]thiophene-2-carboxylicacid-1(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1336] Following the procedure of Example 151c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid instep 151c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (41.0 mg, 32.8%),MS (ESI): 576.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (31.0 mg, 24.8%). MS (ESI): 576.4 (M+H)⁺

Example 157

[1337] Preparation of 1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1338] Following the procedure of Example 151c-d except substituting1-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid instep 151c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (28.5 mg, 22.9%),MS (ESI): 573.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (28.5 mg, 22.9%). MS (ESI): 573.2 (M+H)⁺

Example 158

[1339] Preparation of Quinoxaline-2-carboxylicAcid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1340] Following the procedure of Example 151c-d except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid in step151c provided the title compound which was separated by HPLC to give thefirst eluting diastereomer as a white solid (63.1 mg, 50.8%), MS (ESI):572.2 (M+H)⁺ and the second eluting distereomer as a white solid (43.2mg, 34.8%), MS (ESI): 572.2 (M+H)⁺

Example 159

[1341] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1342] a.){(S)-1-[1-(2-Fluoro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1343] To a solution of the compound of Example 2g (1.03 g, 3.00 mmol)in DCE (20 ml) was added P-NMM (1.65 g, 3.64 mmol/g) and2-fluorobenzenesulphony lchloride (0.70 g, 3.60 mmol). After shaking atroom temperature overnight, the solution was filtered. The filtrate wasconcentrated to yield the title compound as white solid (1.13 g, 75.1%):MS: 523.88 (M+Na)⁺.

[1344] b.) (S)-2-Amino-4-methyl-pentanoic Acid[1-(2-fluoro-benzenesulfonyl)-3-hydroxy-azepan-4-yl]-amide

[1345] To a stirring solution of the compound of Example 159a (1.13 g,2.25 mmol) in methnol (15 ml) was added HCl (4M in dioxane) (15 ml).After stirring at room temperature for 3 hr, the solution wasconcentrated to get white solid. To a solution of the white solid (1.11g, 2.60 mmol, 75%) in methnol (50 ml) was added P-CO₃ (5.70 g, 2.63mmol/g). After shaking for 2 hr, the solution was filtered andconcentrated to yield the title compound as white solid (0.868 g, 2.16mmol, 96%): MS: 401.96 (M+H)⁺.

[1346] c.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1347] To a solution of the compound of Example 159b (0.11 g, 0.26 mmol)in CH₂Cl₂ (10 mL) was added benzofuran-2-carboxylic acid (64.7 mg, 0.39mmol), 1-hydroxybenzotriazole (61.1 g, 0.45 mmol), and P-EDC (0.53 g, 1mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperature overnight,the solution was treated with tisamine (0.35 g, 3.75 mmol/g). Aftershaking for another 2 hr, the solution was filtered and concentrated toyield the title compound as a white solid (103.5 mg, 70%): MS (ESI)546.2 (M+H)⁺.

[1348] d.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1349] To a stirring solution of the compound of Example 159c (103.5 mg,0.19 mmol) in dichloromethane (4 mL) was added Dess-Martin reagent(164.7 mg, 0.39 mmol). After stirring at room temperature for 2 h,solutions of sodium thiosulfate (2 mL of 10% in water) and saturatedaqueous sodium bicarbonate (2 mL) were added simultaneously to thesolution. The aqueous was extracted with dichloromethane (2×). Theorganic phases were combined, washed with saturated brine, dried(MgSO₄), filtered and concentrated. The residue was purified by HPLC toyield the first eluting diastereomer as a white solid (76.2 mg, 73.6%):MS (ESI) 544.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (20.7 mg, 20.0%) MS (ESI) 544.4 (M+H)⁺

Example 160

[1350] Preparation of 5-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1351] Following the procedure of Example 159c-d, except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 159c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (48.3 mg, 59.2%) MS(ESI): 574.2 (M+H)⁺ and the second eluting diastereomer as a white solid(24.2 mg, 29.6%) MS (ESI): 574.2 (M+H)⁺

Example 161

[1352] Preparation of 7-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1353] Following the procedure of Example 159c-d except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 159c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (47.7 mg, 58.5%):MS (ESI) 574.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (27.7 mg, 33.9%).

Example 162

[1354] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1355] Following the procedure of Example 159c-d except substituting5,6-dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylicacid in step 159c provided the title compound which was separated byHPLC to give the first eluting diastereomer: MS (ESI) 606.4 (M+H)⁺ andthe second eluting diastereomer as a white solid MS(ESI) 606.4 (M+H⁺).

Example 163

[1356] Preparation of 3-Methylbenzofuran-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1357] Following the procedure of Example 159c-d except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid instep 460c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (50.5 mg, 63.7%):MS (ESI) 558.2 and the second eluting diastereoemer as a white solid(20.6 mg); MS 558.2 (M+H)⁺.

Example 164

[1358] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1359] Following the procedure of Example 159c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid instep 159c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (52.5 mg, 65.9%):MS (ESI) 560.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (20.7 mg, 26.0%): MS(ESI) 560.2 (M+H)⁺.

Example 165

[1360] Preparation of 1-Methyl-]H-indole-2-carboxylicacid-[(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1361] Following the procedure of Example 159c-d except substituting1-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid instep 159c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (51.4 mg, 64.9%):MS (ESI) 557.2 (M+H)⁺ and the seond eluting diastereoemer as a whitesolid (21.0 mg, 26.5%): MS 557.2 (M+H)⁺.

Example 166

[1362] Preparation of(S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1363] a.) (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoicAcid [3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1364] To a solution of the compound of Example 28a (0.1 g) indichlorormethane (10 mL) and saturated NaHCO₃ was added2-pryridinesulfonyl chloride N-oxide (0.9 mL) in a dropwise fashion over3 minutes. The reaction was stirred at room temperature for 30 minutes.Workup and column chromatography provided 9.2 mg of the title compound:MS (ESI) 541 (M+H⁺).

[1365] b.) (S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1366] Following the procedure of Example 11 except substituting thecompound of Example 166a the title compound was prepared: MS (ESI) 539(M+H⁺).

Example 167

[1367] Preparation of Quinoxaline-2-carboxylicAcid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1368] Following the procedure of Example 159c-d except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid in step159c provided the title compound which was purified by HPLC to give thefirst eluting diastereomer as a white solid (49.7 mg, 62.9%): MS (ESI)556.2 (M+H)⁺ and the second eluting diastereomer as a white solid (19.9mg, 25.1%): MS 556.4 (M+H)⁺.

Example 168

[1369] Preparation of 5-Methoxybenzofuran-2-carboxylicAcid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1370] Following the procedure of Example 75a-d except substituting2-thiophensulfonyl chloride for 2-thiazolesupfonyl chloride of Example75a and 5-methoxybenzofuran-2carboxylic acid for benzofuran-2-carboxylicacid in step 75c provided the title compound which was purified by HPLCto give the first eluting diastereomer as a white solid (71 mg, 65%): MS(ESI) 562.2 (M+H)⁺ and the second eluting diastereomer as a white solid(21.6 mg, 20.0%) MS (ESI): 562.2 (M+H)⁺.

Example 169

[1371] Preparation of 7-Methoxybenzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1372] Following the procedure of Example 168 except substituting7-methoxybenzofuran-2-carboxylic acid for5-methoxybenzofuran-2-carboxylic acid provided the title compound whichws purified by HPLC to give the first eluting diastereomer as a whitesolid (88 mg, 80%): MS (ESI) 562.2 (M+H)⁺ and the second elutingdiastereomer as a white solid (18 mg, 16%) MS (ESI): 562.2 (M+H)⁺.

Example 170

[1373] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylicAcid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1374] Following the procedure of Example 168 except substituting5,6-dimethoxybenzofuran-2-carboxylic acid for5-methoxybenzofuran-2-carboxylic acid provided the title compound whichwas purified by HPLC to give the first eluting diastereomer MS (ESI)594.2 (M+H)⁺ and the second eluting diastereomer.

Example 171

[1375] Preparation of 3-Methylbenzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1376] Following the procedure of Example 168 except substituting3-methybenzofuran-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylicacid provided the title compound which was purified by HPLC to give thefirst eluting diastereomer as a white solid (88 mg, 83%): MS (ESI) 546.2(M+H)⁺ and the second eluting diastereomer as a white solid (16 mg,15%): MS (ESI) 546.2 (M+H)⁺.

Example 172

[1377] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1378] Following the procedure of Example 168 except substitutingbenzo[b]thiophene-2-carboxylic acid 5-methoxybenzofuran-2-carboxylicacid provided the title compound which was purified by HPLC to give thefirst eluting diastereomer as a white solid (43.4 mg, 41%): MS (ESI)548.4 (M+H)⁺ and the second eluting diastereomer as a white solid (33.4mg, 31.5%): MS (ESI) 548.2 (M+H)⁺.

Example 173

[1379] Preparation of 1-Methyl-1H-indole-2-carboxylicAcid-(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1380] Following the procedure of Example 168 except substituting1-methylindole-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylicacid provided the title compound which was separated by HPLC to give thefirst eluting diastereomer as a white solid (35.8 mg, 34.0%): MS (ESI)545.2 (M+H)⁺ and the second eluting diastereomer as a white solid (45.8mg, 43%): MS (ESI) 545.2 (M+H)⁺.

Example 174

[1381] Preparation of Quinoxaline-2-carboxylicAcid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1382] Following the procedure of Example 168 except substitutingquinoxaline-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylic acidprovided the title compound which was separated by HPLC to give thefirst eluting diastereomer as a white solid (60 mg, 56%): MS (ESI) 544.4(M+H)⁺ and the second eluting diastereomer as a white solid (38.7 mg,37%): MS (ESI) 544.4 (M+H)⁺.

Example 175

[1383] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1384] a.){(S)-1-[1-(3-Chloro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1385] To a solution of the compound of Example 2g (2.50 g, 7.29 mmol)in DCE (100 ml) was added P-NMM (4.0 g) and 4-chlorobenzenesulphonylchloride (1.85 g, 8.75 mmol). After shaking at room temperature for overnight, the solution was filtered. The filtrate was concentrated to yieldthe title compound as white solid (3.13 g, 83.3%). MS: 539.78 (M+Na)⁺.

[1386] b.) (S)-2-Amino-4-methyl-pentanoic Acid[1-(3-chloro-benzenesulfonyl)-3-hydroxy-azepan-4-yl]-amide

[1387] To a stirring solution of the compound of example 175a (1.0 g,1.93 mmol) in methnol (10 ml) was added HCl (4M in dioxane) (10 ml).After stirring at room temperature for 3 hr, the solution wasconcentrated to provide a white solid. To a solution of the white solid(0.68 g, 1.50 mmol, 78%) in methnol (37 ml) was added P-CO₃ (2.85 g,2.63 mmol/g). After shaking for 2 hr, the solution was filtered andconcentrated to yield the title compound as white solid (0.59 g, 1.42mmol, 95%): MS: 417.86 (M+H)⁺.

[1388] c.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1389] To a solution of the compound of Example 175b (0.14 g, 0.335mmol) in CH²Cl² (20 mL) was added benzofuran-2-carboxylic acid (0.81,0.50 mmol), 1-hydroxybenzotriazole (0.77 g, 0.569 mmol), and P-EDC (0.67g, 1 mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperatureovernight, the solution was treated with tisamine (0.446 g, 3.75mmol/g). After shaking for another 2 hr, the solution was filtered andconcentrated to yield the title compound as a white solid (122.2 mg,65%). MS (ESI): 562.2 (M+H)⁺.

[1390] d.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1391] To a stirring solution of the compound of Example 175c (122.2 mg,0.217 mmol) in dichloromethane (4 mL) was added Dess-Martin reagent(184.8 mg, 0.436 mmol). After stirring at room temperature for 2 h,solutions of sodium thiosulfate (2 mL of 10% in water) and saturatedaqueous sodium bicarbonate (2 mL) were added simultaneously to thesolution. The aqueous was extracted with dichloromethane (2×). Theorganic phases were combined, washed with saturated brine, dried(MgSO₄), filtered and concentrated. The residue was purified by HPLC toyield the first eluting diastereomer as a white solid (62.7 mg, 51.6%):MS (ESI) 560.2 (M+H)⁺ and the second elution as a white solid (32.7 mg,26.9%): MS (ESI) 560.2 (M+H)⁺.

Example 176

[1392] Preparation of 5-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1393] Following the procedure of Example 175c-d except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 175c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (64.4 mg, 50%): MS(ESI) 590.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(32.2 mg, 25.2%): MS (ESI) 590.0 (M+H)⁺.

Example 177

[1394] Preparation of 7-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1395] Following the procedure of Example 175c-d except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 175c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (51.1 mg, 40%): MS(ESI) 590.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(41 mg, 32%): MS (ESI) 590.2 (M+H)⁺.

Example 178

[1396] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1397] Following the procedure of Example 175c-d except substituting5,6-dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylicacid in step 175c provided the title compound which was separated byHPLC to give the first eluting diastereomer: MS (ESI) 622.2 (M+H)⁺ andthe second eluting diastereoemer: MS (ESI) 622.2 (M+H)⁺.

Example 179

[1398] Preparation of 3-Methylbenzofuran-2-carboxylicAcid-{(S)-1-1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1399] Following the procedure of Example 175c-d except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid instep 175c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (78.6 mg, 63%): MS(ESI) 574.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(27.6 mg, 22%): MS (ESI) 574.2 (M+H)⁺.

Example 180

[1400] Preparation of Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1401] Following the procedure of Example 175c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid instep 175c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (41 mg, 33%): MS(ESI) 576.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(32.6 mg, 26%): MS (ESI) 576.2 (M+H)⁺.

Example 181

[1402] Preparation of 1-Methyl-1H-indole-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1403] Following the procedure of Example 175c-d except substituting1-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid instep 175c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (28.5 mg, 23%): MS(ESI) 573.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(38.5 mg, 31%): MS (ESI) 573.2 (M+H)⁺.

Example 182

[1404] Preparation of Quinoxaline-2-carboxylicAcid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1405] Following the procedure of Example 175c-d except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid in step175c provided the title compound which was separated by HPLC to give thefirst eluting diastereomer as a white solid (63 mg, 51%): MS (ESI) 572.2(M+H)⁺ and the second eluting diastereoemer as a white solid (44.5 mg,36%): MS (ESI) 572.2 (M+H)⁺.

Example 183

[1406] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1407] a.){(S)-1-[1-(3-Methoxy-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1408] To a solution of the compound of Example 2g (1.60 g, 4.66 mmol)in DCE (50 ml) was added P-NMM (2.5⁶ g, 3.64 mmol/g) and3-methoxy-benzenesulphonyl chloride (1.15 g, 5.59 mmol). After shakingat room temperature for over night, the solution was filtered. Thefiltrate was concentrated to yield the title compound as white solid(1.70 g, 71.1%): MS 535.8 (M+Na)⁺.

[1409] b.) (S)-2-Amino-4-methyl-pentanoic acid[1-(3-methoxy-benzenesulfonyl)-3-hydroxy-azepan-4-yl]-amide

[1410] To a stirring solution of the compound of example 183a (1.70 g,3.31 mmol) in methnol (22 ml) was added HCl (4M in dioxane) (22 ml).After stirring at room temperature for 3 hr, the solution wasconcentrated to get white solid. To a solution of the white solid (1.19g, 2.64 mmol, 80%) in methnol (50 ml) was added P-CO₃ (5.02 g, 2.63mmol/g). After shaking for 2 hr the solution was filtered andconcentrated to yield the title compound as white solid (1.03 g, 2.49mmol, 96%): MS 413.90 (M+H)⁺.

[1411] c.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1412] To a solution of the compound of Example 183b (0.11 g, 0.26 mmol)in CH₂Cl₂ (10 mL) was added benzofuran-2-carboxylic acid (64.69 mg,0.399 mmol), 1-hydroxybenzotriazole (61.1 g, 0.452 mmol), and P-EDC(0.532 g, 1 mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperaturefor over night, the solution was treated with tisamine (0.355 g, 3.75mmol/g). After shaking for another 2 hr, the solution was filtered andconcentrated to yield the title compound as a white solid (103.5 mg,70%): MS (ESI) 558.2 (M+H)⁺.

[1413] d.) Benzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1414] To a stirring solution of the compound of Example 183c (103 mg,0.19 mmol) in dichloromethane (4 mL) was added Dess-Martin reagent (157mg, 0.37 mmol). After stirring at room temperature for 2 h, solutions ofsodium thiosulfate (2 mL of 10% in water) and saturated aqueous sodiumbicarbonate (2 mL) were added simultaneously to the solution. Theaqueous was extracted with dichloromethane (2×). The organic phases werecombined, washed with saturated brine, dried (MgSO₄), filtered andconcentrated. The residue was purified by HPLC to yield the firsteluting diastereomer as a white solid (76.2 mg, 73.6%): MS (ESI: 556.2(M+H)⁺ and the second eluting diastereomer as a white solid (24.1 mg,23.3%): MS (ESI) 556.2 (M+H)⁺.

Example 184

[1415] Preparation of 5-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1416] Following the procedure of Example 183c-d except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 183c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (33 mg, 31%): MS(ESI) 586.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(35.2 mg, 32%): MS (ESI) 586.2 (M+H)⁺.

Example 185

[1417] Preparation of 7-Methoxybenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1418] Following the procedure of Example 183c-d except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 183c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (41 mg, 38%): MS(ESI) 586.4 (M+H)⁺ and the second eluting diastereoemer as a white solid(39.5 mg, 36%): MS (ESI) 586.2 (M+H)⁺.

Example 186

[1419] Preparation of 4,5-Dimethoxybenzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1420] Following the procedure of Example 183c-d except substituting5,6-dimethoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylicacid in step 183c provided the title compound which was separated byHPLC to give the first eluting diastereomer: MS (ESI) 618.4 (M+H)⁺ andthe second eluting diastereoemer.

Example 187

[1421] Preparation of 3-Methylbenzofuran-2-carboxylicAcid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1422] Following the procedure of Example 183c-d except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid instep 183c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (76 mg, 72%): MS(ESI) 570.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(23.2 mg, 22%): MS (ESI) 570.2 (M+H)⁺.

Example 188

[1423] Preparation of Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1424] Following the procedure of Example 183c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid instep 183c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (37 mg, 35%): MS(ESI) 572.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(31 mg, 29%): MS (ESI) 572.2 (M+H)⁺.

Example 189

[1425] Preparation of 1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1426] Following the procedure of Example 183c-d except substituting1-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid instep 183c provided the title compound which was separated by HPLC togive the first eluting diastereomer as a white solid (34 mg, 32%): MS(ESI) 569.2 (M+H)⁺ and the second eluting diastereoemer as a white solid(38 mg, 38%): MS (ESI) 569.4 (M+H)⁺.

Example 190

[1427] Preparation ofQuinoxaline-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1428] Following the procedure of Example 183c-d except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid in step183c provided the title compound which was separated by HPLC to give thefirst eluting diastereomer as a white solid (71 mg, 67%): MS (ESI) 568.2(M+H)⁺ and the second eluting diastereoemer as a white solid (27 mg,24%): MS (ESI) 568.2 (M+H)⁺.

Example 191

[1429] Preparation of Benzofuran-2-carboxylicAcid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1430] Following the procedure of Example 168 except substitutingbenzofuran-2-carboxylic acid for 5-methoxybenzofuran-2-carboxylic acidprovided the title compound which ws purified by HPLC to give the firsteluting diastereomer as a white solid (76 mg, 73%): MS (ESI) 532.2(M+H)⁺ and the second eluting diastereomer as a white solid (25 mg, 23%)MS (ESI): 532.2 (M+H)⁺.

Example 192

[1431] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[(2,2′,4-trideuterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1432] To a solution of benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amideof Example 28c (0.03 g) in D₂O:CD₃OD (0.4:4 mL) was added triethylamine(0.04 mL). The reaction was heated to reflux for 2 hours whereupon itwas concentrated and dried under vacuum. The residue was the redissolvedin the same mixture and heated to reflux overnight. The reaction wasconcentrated and the residue purified by column chromatography (5%methanol:dichloromethane) to provide the title compound (0.02 g): ¹HNMR:δ 1.0 (m, 6H), 1.5-2.2 (m, 6H), 2.7 (m, 1H), 4.1 (m, 1H), 4.7 (m, 2H),7.4-8.0 (m, 8H), 8.7 (m, 1H); MS(EI): 529 (M⁺, 45%).

[1433] The diastereomeric mixture was separated by HPLC to provide thefaster eluting diastereoemer: MS(EI): 530 (M+H⁺, 100%) and the slowereluting diastereomer: MS(EI): 530 (M+H⁺, 100%).

Example 193

[1434] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1435] a.) 4-tert-Butoxycarbonylamino-3-hydroxy-azepane-1-carboxylicacidBenzyl Ester

[1436] To a stirring solution of compound of Example 2e (1.04 g, 3.92mmol) in THF was added di-tert-butyldicarbonate (0.864 g). Afterstirring at room temperature for 30 minutes, the reaction mixture wasdiluted with diethylether and extracted with saturated NaHCO₃ Theorganic layer was dried over anhydrous Na₂SO₄, filtered, concentrated,and purified by silica gel column to give the title compound as a yellowoil (0.963 g, 2.64 mmol, 67%). MS (ESI): 365.03 (M+H)⁺.

[1437] b.) (3-Hydroxy-azepan-4-yl)-carbamic Acid Tert-Butyl Ester

[1438] To a solution of compound of Example 193a (0.963 g, 2.64 mmol) inethyl acetate (16 ml) was added 10% palladium on carbon (500 mg). Afterstirring the solution at room temperature for 48 hours, the mixture wasfiltered through celite. The filterate was concentrated to yield thetitle compound (0.529 g, 2.29 mmol, 87%): MS(ESI): 231.92 (M+H)⁺.

[1439] c.) [3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-carbamic AcidTert-Butyl Ester

[1440] To a solution of the compound of Example 193b (0.53, 2.29 mmol)in dichloromethane (20 ml) was added triethylamine (232 mg) andpyridine-2-sulfonyl chloride (410 mg, 2.32 mmol). After stirring at roomtemperature for 30 minutes, the mixture was washed with saturated NaHCO₃The organic layer was dried, filtered, concentrated and purified on asilica gel column to give the title compound as a solid (0.58 g, 1.57mmol, 68%): MS(ESI): 372.95 (M+H)⁺.

[1441] d.) 4-Amino-1-(pryidine-2-sulfonyl)-azepan-3-ol

[1442] To a stirring solution of the compound of Example 193c (0.583 g,1.57 mmol) in ethyl acetate (0.5 ml) was added HCl (4M in dioxane, 3.9ml). After stirring the reaction mixture for 30 minutes at roomtemperature, the mixture was concentrated to yield a white solid. Thesolid was treated with NaOH and then extracted with ethylacetate. Theorganic layer was dried, filtered, and concentrated to yield a yellowsolid (0.35 g, 1.28 mmol, 81%): MS (ESI) 272.93 (M+H)⁺.

[1443] e.){(S)-1-[3-Hydroxy-1-(pryidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-meth-butyl}-CarbamicAcid Tert-Butyl Ester

[1444] To a solution of the compound of example 193d (19 mg, 0.070 mmol)in CH₂Cl₂ was added N-Boc-isoleucine (24.5 mg, 0.10 mmol),1-hydroxybenzotriazole (16.1 mg, 0.12 mmol), and P-EDC (140 mg, 0.14mmol) in CH₂Cl₂. After shaking at room temperature overnight, themixture was treated with PS-Trisamine. After shaking for another 2hours, the mixture was filtered and concentrated to yield the titlecompound as a solid. MS (ESI) 484.97 (M+H)⁺.

[1445] f.) (S)-2-Amino-3-methyl-penatanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1446] To a stirring solution of the compound of example 193e (34 mg,0.07 mmol) in CH₂Cl₂ (0.50 ml) was added HCl (4M in dioxane) (0.165 ml).After stirring at room temperature for 30 minutes, the mixture wasconcentrated, giving a white solid. The white solid was azeotroped withtoluene then treated with MP-carbonate (0.35 mmol) in methanol. Afterfour hours of shaking, the mixture was filtered and concentrated to givethe title compound as a solid.: MS(ESI) 384.9 (M+H)⁺.

[1447] g.) Benzofuran-2-carboxylic Acid{(S)-2-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1448] To a solution of the compound of example 193f (27 mg, 0.070 mmol)in CH₂Cl₂ was added 2-benzofurancarboxylic acid (17.0 mg, 0.106 mmol),1-hydroxybenzotriazole (16.1 mg, 0.12 mmol), and P-EDC (140 mg, 0.14mmol) in CH₂Cl₂. After shaking at room temperature overnight, themixture was treated with PS-Trisamine. After shaking for another 2hours, the mixture was filtered and concentrated to yield the titlecompound as a solid: MS (ESI) 528.9 (M+H)⁺.

[1449] h.) Benzofuran-2-carboxylic Acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1450] To a stirring solution of the compound of example 19³ g (37 mg,0.07 mmol) in CH₂Cl₂ (0.5 ml) was added Dess-Martin reagent (45 mg,0.105 mmol). After stirring for 30 minutes, solutions of sodiumthiosulfate (10% in water, 0.50 ml) and saturated aqueous sodiumbicarbonate (0.50 ml) were added simultaneously to the reaction. Themixture was then extracted with dichloromethane (2 times). The organiclayer was dried, filtered, and concentrated. The residue was purified byHPLC to yield the two diastereomers of the title compound as solids(first eluting: 7 mg, second cluting: 5.5 mg): MS (ESI) 526.91 (M+H)⁺.

Example 194

[1451] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide

[1452] Following the procedure of Example 193e-h, except substitutingN-Boc-alpha-aminobutyric acid in step 193e the title compound waspurified to yield two diastereomers as solids (first eluting: 5 mg,second eluting: 5 mg) MS(ESI) 543.8 (M+H)⁺.

Example 195

[1453] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-cylclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1454] Following the procedure of Example 193e-h, except substitutingN-Boc-cyclohexylalanine in step 193e, the title compound was purified toyield two diastereomers as solids (first eluting: 4.5 mg second eluting:4.5 mg): MS(ESI): 566.87 (M+H)⁺.

Example 196

[1455] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1456] Following the procedure of Example 193e-h, except substitutingN-Boc-alanine for step 193e, the title compound was purified to yieldtwo diastereomers as solids (first eluting: 5.5 mg, second eluting: 5mg).

Example 197

[1457] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methanesulfinyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide

[1458] Following the procedure of Example 193e-h, except substitutingN-Boc-L-methionine for step 1(f), the title compound was purified toyield two diastereomers as solids (first eluting: 3 mg, second eluting:3 mg). MS(ESI): 560.7 (M+H)⁺.

Example 198

[1459] Preparation of Benzofuran-2-carboxylic Acid 1[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-methyl}-amide

[1460] Following the procedure of Example 193e-h, except substitutingN-Boc-glycine for step 193e, the title compound was purified to yieldtwo diastereomers as solids (first eluting: 3 mg, second eluting: 3 mg).MS(ESI): 470.81 (M+H)⁺.

Example 199

[1461] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide

[1462] Following the procedure of Example 193e-h, except substitutingN-Boc-norleucine for step 193e, the title compound was purified to yieldtwo diastereomers as solids (first eluting: 4 mg, second eluting: 5 mg).MS(ESI): 526.85 (M+H)⁺.

Example 200

[1463] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1464] Following the procedure of Example 193e-h, except substitutingN-Boc-norvaline for step 193e, the title compound was purified to yieldtwo diastereomers as solids (first eluting: 7.5 mg, second eluting: 3.5mg). MS(ESI): 512.8 (M+H)⁺.

Example 201

[1465] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide

[1466] Following the procedure of Example 193e-h, except substitutingN-Boc-valine for step 193e, the title compound was purified to yield twodiastereomers as solids (first eluting: 6 mg, second eluting: 4.5 mg).MS(ESI): 512.8 (M+H)⁺.

Example 202

[1467] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide

[1468] Following the procedure of Example 193e-h, except substitutingN-Boc-L-threonine for step 193e, the title compound was purified toyield two diastereomers as solids (first eluting: 3 mg, second eluting:3 mg).

Example 203

[1469] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide

[1470] Following the procedure of Example 193e-h, except substitutingN-Boc-phenylalanine for step 193e, the title compound was purified toyield two diastereomers as solids (first eluting:5 mg, second eluting: 5mg). MS(ESI): 560.8 (M+H)⁺.

Example 204

[1471] Preparation of 1 (Benzofuran-2-carbonyl)-pyrrolidine-2-carboxylicAcid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1472] Following the procedure of Example] 93e-h, except substitutingN-Boc-L-proline for step 193e, the title compound was purified to yieldtwo diastereomers as solids (first eluting: 4 mg, second eluting: 5 mg).MS(ESI): (M+H)⁺.

Example 205

[1473] Preparation of3,4-Dimethoxy-N-{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-benzamide

[1474] Following the procedure of Example 115, except substituting3,4-dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 576.4 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.68 (d,2H),7.00 (d, 1H), 6.89 (s, 2H),3.84 (s, 3H),3.77 (s, 6H), 2.38 (t, 1H),0.94 (d, 6H): MS 576.4 (M+H⁺).

Example 206

[1475] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1476] Following the procedure of Example 115, except substituting2-thiophene-carbonyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 572.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.80-7.68 (m,5H), 7.38-7.34 (m, 2H), 7.01-6.93 (m, 4H), 3.83 (s, 3H), 2.38 (t, 1H),0.97 (d, 6H). Second eluting diastereomer: MS 572.2 (M+H⁺).

Example 207

[1477] Preparation of Benzo[1,3]dioxole-5-carboxylic Acid{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3methyl-butyl}-amide

[1478] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand 3,4-methylenedioxybenzoyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS 548.2 (M+H⁺); ¹H NMR (400 Hz, CDCl₃): δ7.85-7.78 (m, 2H), 7.38-7.20 (m, 4H), 7.05 (d, 1H), 2.52-2.40 (m, 1H),1.0 (d, 6H). Second eluting diastereomer: MS 548.2 (M+H⁺).

Example 208

[1479] Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicAcid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide

[1480] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chloride,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 548.2 (M+H⁺). ¹H NMR (400 Hz, CDCl₃-CD₃OD) δ7.88-7.80 (m, 2H), 7.45-7.30 (m, 5H), 7.30-7.20 (m, 2H), 4.00 (s, 2H),2.60-2.48 (m, 1H), 0.96 (t, 6H): MS 548.2 (M+H⁺).

Example 209

[1481] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-1-[-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1482] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand benzo[b]thiophenecarbonyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 560.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ7.80-7.72 (m, 5H).7.37-7.34 (m, 2H), 7.33-7.15 (m, 4H), 2.43 (t, 1H),0.96 (d, 6H). Second eluting diastereomer: MS 560.2 (M+H⁺).

Example 210

[1483] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-benzoyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1484] a.) Benzofuran-2-carboxylic Acid{(S)-1-[1-benzoyl-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1485] To a solution of benzofuran-2-carboxylic acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide of Example78c (0.2 g) in dichloromethane was added benzoic acid (0.12 g), HOBt(0.07 g) and EDC (0.99 g). The reaction was stirred until complete.Workup and column chromatography (5% methanol:dichloromethane) providedthe title compound (0.2 g): ¹H NMR (CDCl₃): δ 1.0 (m, 6H), 1.5-2.2 (m,6H), 2.7 (m, 1H), 3.8 (m, 1H), 4.1 (m, 1H), 4.7 (m, 2H), 5.1 (m, 1H),7.0-7.7 (m, 10H), 8.7 (m, 1H); MS(EI): 492 (M+H⁺, 100%).

[1486] b.) Benzofuran-2-carboxylicAcid{(S)-1-[1-benzoyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1487] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-1-[1-benzoyl-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amideof Example 210a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.7 (m, 1H), 3.7 (m, 1H), 4.0 (m, 1H), 4.7 (m,2H), 5.1 (m, 1H), 7.4-8.0 (m, 8H); MS(ET): 490 (M+H⁺, 100%).

Example 211

[1488] Preparation of(S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1489] a.) (S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1490] Following the procedure of Example 89a except substituting8-quinolinesulfonyl chloride for 2-pyridinesulfonyl chloride the titlecompound was prepared: MS(EI) 576 (M+H⁺).

[1491] b.) (S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic Acid[3-oxo-]-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1492] Following the procedure of Example 1i except substituting(S)-4-methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 211 athe title compound was prepared: ¹H NMR (CDCl₃): δ 0.5-0.8 (m, 6H),1.4-1.8 (m, 7H), 2.5 (m, 1H), 3.5-3.9 (m, 3H), 4.4 (m, 1H), 4.6 (m, 1H),5.5 (m, 1H), 6.7-7.0 (m, 2H), 7.5 (m, 3H), 8.0 (m, 2H), 8.3 (m, 2H), 8.6(m, 1H), 9.0 (m, 1H); MS(EI): 674 (M+H⁺, 100%).

Example 212

[1493] Preparation of(S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1494] a.) (S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic Acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1495] Following the procedure of Example 89a except substituting2-naphthylenesulfonyl chloride for 2-pyridinesulfonyl chloride the titlecompound was prepared: MS(EI) 575 (M+H⁺).

[1496] b.) (S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1497] Following the procedure of Example 1i except substituting(S)-4-methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 212athe title compound was prepared: ¹H NMR (CDCl₃): δ 0.5-0.8 (m, 6H),1.4-1.8 (m, 7H), 2.5 (m,]H), 3.5-3.9 (m, 3H), 4.5 (m, 1H), 4.6 (m, 1H),5.5 (m, 1H), 6.7 (m, 1H), 7.5-8.0 (m, 9H), 8.5-8.6 (m, 2H); MS(ET): 673(M+H⁺, 100%).

Example 213

[1498] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1499] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand 2-benzofurancarbonyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 544.2.(M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ7.79-7.77 (m, 2H), 7.61 (d, 1H), 7.46-7.38 (m, 3H), 7.25-7.06 (m, 5H),2.43 (t, 1H), 0.95 (d, 6H). Second eluting diastereomer: MS 544.4(M+H⁺).

Example 214

[1500] Preparation ofN-{(S)-1-[1-(4-Fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-3,4-dimethoxy-benzamide

[1501] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand 3,4-dimethoxybenzoyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 564.2.(M+H⁺). 1H NMR (500 MHz, CDCl₃): δ7.80-7.76 (m, 2H),7.19 (t, 2H),7.05 (d, 1H), 6.88 (s, 2H), 6.78 (d, 1H),6.53 (s, 1H), 3.77 (s, 6H), 2.43 (t, 1H), 0.94 (d, 6H). Second elutingdiastereomer: MS 546.2 (M+H⁺).

Example 215

[1502] Preparation of Cyclohexanecarboxylic Acid{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl1-3-methyl-butyl}-amide

[1503] Following the procedure of Example 115, except substituting4-fluorobenzenesulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand cyclohexylcarbonyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 510.4.(M+H⁺). ¹H NMR (400 Hz, CDCl₃): δ 7.83-7.80 (m,2H), 7.27-7.20 (m, 2H), 6.92 (d, 1H), 6.95 (d, 1H). 2.50 (t, 1H),1.90-1.20 (m, 15H), 0.94 (t, 6H). Second eluting diastereomer: MS 510.2(M+H⁺).

Example 216

[1504] Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicAcid [1-(methanesulfonyl)-3-oxo-azepan-4-yl]-amide

[1505] Following the procedure of Example 115, except substitutingmethanesulphonyl chloride for 4-methoxybenzenesulfonyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 468.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ7.37-7.24 (in, 4H), 6.93-6.91 (in, 2H), 5.02-5.00 (m, 1H), 2.88 (s, 3H),2.70 (t, 1H), 0.92 (t, 6H). Second eluting diastereomer: MS 468.2(M+H⁺).

Example 217

[1506] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-1-(-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1507] Following the procedure of Example 115, except substitutingmethanesulphonyl chloride for 4-methoxybenzenesulfonyl chloride andbenzo[b]thiophenecarbonyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 480.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ7.83-7.78 (m, 3H),7.42-7.37 (m, 2H),6.94 (d, 1H), 6.75 (d, 1H), 2.89 (s,3H), 2.68 (t, 1H), 0.97 (d, 6H). Second eluting diastereomer: MS 480.2(M+H⁺).

Example 218

[1508] Preparation of Benzo[1,31dioxole-5-carboxylicAcid-{(S)-1-(-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1509] Following the procedure of Example 115, except substitutingmethanesulphonyl chloride for 4-methoxybenzenesulfonyl chloride andpiperonylcarbonyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 468.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.31-7.24 (in,2H), 6.91 (d, 1H), 6.00 (s, 2H), 2.89 (s, 3H), 2.67 (t, 1H), 0.95 (d,6H). Second eluting diastereomer: MS 468.2 (M+H⁺).

Example 219

[1510] Preparation of Benzofuran-2-carboxylicAcid-{(S)-1-(]-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1511] Following the procedure of Example 115, except substitutingmethanesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and2-benzofurancarbonyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 464.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.64 (d, 1H),7.51-7.37 (m, 3H), 7.29-7.28 (m, 1H), 2.89 (s, 3H), 2.67 (t, 1H), 0.97(d, 6H). Second eluting diastereomer: MS 464.2 (M+H⁺).

Example 220

[1512] Preparation ofN-[(S)-1-(]-Methanesulfonyl)-3-oxo-azepan-4-ylcarbamoyl1-3-methyl-butyl}-3,4-dimethoxy-benzamide

[1513] Following the procedure of Example 115, except substitutingmethanesulphonyl chloride for 4-methoxybenzenesulfonyl chloride and3,4-dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 484.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 6.94-6.88 (m,3H), 6.58-6.55 (m, 2H), 3.80 (s, 6H), 2.89 (s, 3H), 0.95 (d, 6H). Secondeluting diastereomer: MS 484.2 (M+H⁺).

Example 221

[1514] Preparation of (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicAcid[1-(2-cyano-benzensulfonyl)-3-oxo-azepan-4-yl]-amide

[1515] Following the procedure of Example 115, except substituting2-cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chloride,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 555.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 8.10(d, 1H), 7.86 (d, 1H), 7.76-7.70 (m, 2H), 7.35-7.31 (m, 5H), 6.93 (d,2H), 4.61-4.47 (m, 4H), 2.77 (t, 1H), 0.92 (t, 6H). Second elutingdiastereomer: MS 555.2 (M+H⁺).

Example 222

[1516] Preparation ofN-{(S)-1-[1-(2-Cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-4-methanesulfonyl-1-benzamide

[1517] Following the procedure of Example 115, except substituting2-cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand 4-methanesulfonylbenzoyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 589.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 8.10(d, 1H), 7.96 (s, 4H), 7.88 (d, 1H), 7.78-7.71 (m, 2H), 3.05 (s, 3H),2.79 (t, 1H), 0.97 (t, 6H). Second eluting diastereomer: MS 589.2(M+H⁺).

Example 223

[1518] Preparation of Benzo[b]thiophene-2-carboxylicAcid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1519] Following the procedure of Example 115, except substituting2-cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand benzo[b]thiophene-2-carbonyl chloride for benzyloxyacetyl chloride,the title compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 567.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 8.10(d, 11H), 7.86-7.70 (m, 6H), 7.37-7.30 (m, 2H), 2.76 (t, 1H), 0.98 (d,6H). Second eluting diastereomer: MS 567.2 (M+H⁺).

Example 224

[1520] Preparation of Benzo[1,31dioxole-5-carboxylicAcid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1521] Following the procedure of Example 115, except substituting2-cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand piperonyloyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 555.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 8.11 (d, 1H),7.87 (d, 1H), 7.76-7.71 (m, 2H), 7.31-7.24 (m, 2H), 6.00 (s, 2H), 2.77(t, 1H), 0.97 (d, 6H). Second eluting diastereomer: MS 555.4 (M+H⁺).

Example 225

[1522] Preparation of(S)-4-Methyl-2-[4-oxo-4-((4-phenoxy-phenyl)-butvrylamino]-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1523] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for thiaxole-2-sulfonyl chloride and4-phenoxyphenyl-carboxylic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺) 635.4; ¹H-NMR (400 MHz, CDCl₃): •8.69(d, 1H), 7.99-7.94 (m, 4H), 7.53-7.39 (m, 3H), 7.23-6.95 (m, 7H), 6.20(d, 1H), 5.07 (m, 1H), 4.77-4.72 (d, 1H), 4.46 (m, 1H), 4.13-4.09 (m,1H), 3.85-3.80 (d, 1H), 3.33 (m, 2H), 2.70-2.64 (m, 3H), 2.20-1.40 (m,6H); and the second eluting diastereomer:, 0.96-0.92 (m, 6H); and thesecond eluting diastereomer: MS (M+H⁺) 635.4.

Example 226

[1524] Preparation ofN-{(S)-1-[(1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl-3-methyl-butyl1-3,4-dimethoxy-benzamide

[1525] Following the procedure of Example 115, except substituting2-cyanophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand 3,4dimethoxybenzoyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 571.4 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 8.10 (d, 1H),7.87 (d, 11H), 7.76-7.70 (m, 2H), 6.98 (s, 2H), 6.89 (s, 2H), 3.79 (s,6H), 2.76 (t, 1H), 0.96 (d, 6H). Second eluting diastereomer: MS 571.4(M+H⁺).

Example 227

[1526] Preparation of Cyclohexanecarboxylic Acid{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-amide

[1527] Following the procedure of Example 115, except substitutingcyclohexylcarbonyl chloride for benzyloxyacetyl chloride, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer: MS 522.4 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.70 (d, 2H),6.97 (d, 2H), 2.40 (t, 1H), 1.90-1.20 (m, 16H), 0.92 (d, 6H). Secondeluting diastereomer: MS 522.4 (M+H⁺).

Example 228

[1528] Preparation of4-Methansulfonyl-N-{(S)-1-[4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide

[1529] Following the procedure of Example 115, except substituting4-methanesulfonylbenzoyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 594.2 (M+H⁺). ¹H NMR (500 MHz, CDCl₃): δ 7.96(s, 4H), 7.69 (d, 2H), 7.25 (d, 1H), 6.98 (d, 3H), 3.85 (s, 3H), 3.04(d, 3H), 2.42 (t, 1H), 0.95 (d, 6H). Second eluting diastereomer: MS594.2 (M+H⁺).

Example 229

[1530] Preparation of4-Methansulfonyl-N-{(S)-1-[4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide

[1531] Following the procedure of Example 115, except substituting4-fluorophenylsulphonyl chloride for 4-methoxybenzenesulfonyl chlorideand substituting 4-methanesulfonylbenzoyl chloride for benzyloxyacetylchloride, the title compound was prepared. The residue was purified byHPLC. First eluting diastereomer: MS 582.2 (M+H⁺). ¹H NMR (500 MHz,CDCl₃): δ 7.94 (s, 4H), 7.80-7.77 (m, 2H), 7.25-7.19 (m, 3H), 7.00 (d,1H), 3.04 (s, 3H), 0.96 (d, 6H). Second eluting diastereomer: MS 582.2(M+H⁺).

Example 230

[1532] Preparation of({(S)-3-Methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-carbamicAcid Benzyl Ester

[1533] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for benzenesulfonyl chloride andN-carbobenzyloxycarbonyl-glycine for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 574.2; ¹H-NMR (400 MHz, CDCl₃): •8.60(d, 1H), 7.97-7.90 (m, 2H), 7.50 (m, 1H), 7.42-7.25 (m, 5H), 6.90 (m,1H), 6.42 (m, 1H), 5.38 (m, 1H), 5.18-5.10 (m, 4H), 4.78-4.72 (d, 11H),4.50 (m, 1H), 4.12-4.05 (m, 1H), 3.95-3.85 (m, 2H), 2.72 (m, 1H),2.25-2.10 (m, 2H), 1.90-1.40 (m, 5H), 0.92 (m, 6H); and the secondeluting diastereomer: MS (M+H⁺) 574.2.

Example 231

[1534] Preparation of(S)-2-[5-(4-Methoxy-phenyl)-pentanoylamniol-4-methyl-pentanoic Acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1535] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for benzenesulfonyl chloride and5-(4-methoxyphenyl)-pentanoic acid for benzofuran-2-carboxylic acid, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer; MS (M+H⁺): 573.4; ¹H-NMR (400 MHz, CDCl₃): •8.59(d, 1H), 7.97-7.94 (m, 2H), 7.53 (m, 1H), 7.09-7.07 (d, 2H), 6.89-6.81(m, 3H), 5.90 (m, 1H), 5.12 (m, 1H), 4.79-4.74 (d, 1H), 4.48 (m, 1H),4.12 (m, 1H), 3.86-3.81 (d, 1H), 3.79 (s, 3H), 2.69 (m, 1H), 2.59-2.57(m, 2H), 2.23-2.10 (m, 3H), 1.75-1.45 (m, 10H), 0.96-0.95 (m, 6H); andthe second eluting diastereomer: MS (M+H⁺) 573.4.

Example 232

[1536] Preparation of(S)-2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamniol-4-methylpentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1537] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for benzenesulfonyl chloride and(3-benzyloxy-4-methoxy-phenyl)-acetic acid for benzofuran-2-carboxylicacid, the title compound was prepared. The residue was purified by HPLC.First eluting diastereomer; MS (M+H⁺): 637.4; ¹H-NMR (400 MHz, CDCl₃):•8.69 (d, 1H), 7.98-7.91 (m, 2H), 7.53-7.30 (m, 6H); and the secondeluting diastereomer:, 6.89-6.82 (m, 4H), 5.82 (m, 1H), 5.14-5.07 (m,3H), 4.78-4.73 (d, 1H), 4.43 (m, 1H), 4.09 (m, 1H), 3.89 (s, 3H), 3.82(d, 1H), 3.49 (s, 2H), 2.69 (m, 1H), 2.14 (m, 2H), 1.82-1.40 (m, 5H),0.89 (d, 6H); and the second eluting diastereomer: MS (M+H⁺) 637.4.

Example 233

[1538] Preparation of 5,6-Difluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1539] a.) 5,6-Difluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1540] Following the procedure of Example 28b except substituting5,6-difluorobenzofuran-2-carboxylic acid for bernzofuran-2-carboxylicacid provided the title compound: MS (M+H⁺): 564

[1541] b.) 5,6-Difluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[i-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1542] Following the procedure of Example 1i except substituting thecompound of Example 233a provided the title compound. The residue waspurified by HPLC. First eluting diastereomer; MS (M+H⁺): 562; and thesecond eluting diastereomer: MS (M+H⁺) 562.

Example 234

[1543] Preparation of (S)-4-Methyl-2-(5-oxo-hexanoylamino)-pentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1544] Following the procedure of Example 115, except substituting2-pyridinesulphonyl chloride for 4-methoxybenzenesulfonyl chloride andsubstituting 5-oxo-hexanoyl chloride for benzyloxyacetyl chloride, thetitle compound was prepared. The residue was purified by HPLC. Firsteluting diastereomer: MS 495.4 (M+H⁺); Second eluting diastereomer: MS495.4 (M+H⁺).

Example 235

[1545] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1546] a.) 6-methyl-pyridine-2-sulphonyl Chloride

[1547] The title compound was prepared in a similar fashion as thatdescribed in Example 85a for the preparation of 2-pyridinesulfonylchloride-N-oxide.

[1548] b.){(S)-1-[3-Hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butylester

[1549] To a solution of[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acidtert-butyl ester of Example 2g (1.0 g) in dichloromethane (20 mL) wasadded saturated sodium bicarbonate (50 mL). To this solution was added6-methyl-pyridine-2-sulphonyl chloride (6.44 mL of a 0.13 g/mL solutionin 9M HCl). The reaction was stirred until complete. Workup and columnchromatography (5% methanol:dichloromethane) provided the title compound(1.2 g).

[1550] c.) (S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1551] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide ofExample 235a (1.2 g) in methanol (20 mL) was added 4M HCl in diopxane(20 mL). The reaction was stirred until complete whereupon it wasconcentrated to provide the title compound (1 g).

[1552] d.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1553] Following the procedure of Example 28b except substituting(S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide ofExample 235c the title compound was prepared: MS(EI) 542 (M⁺).

[1554] e.) Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1555] Following the procedure of Example 1i except substitutingbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 235d the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 4.1 (m, 1H), 4.7 (m,2H), 5.3 (m, 1H), 7.4-8.0 (m, 8H); MS(EI); 540 (M⁺, 100%).

Example 236

[1556] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1557] a.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1558] Following the procedure of Example 28b except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidand (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(6-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide ofExample 235c for (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide of Example 28b thetitle compound was prepared: MS(EI) 572 (M⁺).

[1559] b.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1560] Following the procedure of Example 1i except substituting5-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 236a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 3.8 (s, 3H); 4.1 (m,1H), 4.7 (m, 2H), 5.3 (m, 11H), 7.4-8.0, (m, 7H); MS(EI): 570 (M⁺,100%).

Example 237

[1561] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1562] a.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1563] Following the procedure of Example 236a except substituting3-methylbenzofuran-2-carboxylic acid for5-methoxybenzofuran-2-carboxylic acid the title compound was prepared:MS(EI) 556 (M⁺).

[1564] b.) 3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1565] Following the procedure of Example 1i except substituting3-methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 237a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H), 2.7 (m, 1H), 3.8 (s, 1H); 4.1 (m,{H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H); MS(EI): 564 (M⁺, 100%).

Example 238

[1566] Preparation of 7-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1567] a.) 7-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1568] Following the procedure of Example 28b except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(EI) 559 (M+H⁺).

[1569] b.) 7-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1570] Following the procedure of Example 1i except substituting7-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4ylcarbamoyl]-butyl}amideof Example 238a the title compound was prepared: MS(EI) 557 (M+H⁺).

Example 239

[1571] Preparation of 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1572] a.) 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1573] Following the procedure of Example 28b except substituting5,6-dimethoxy-benzo[b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid the title compound was prepared: MS(EI) 604(M⁺).

[1574] b.) 5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1575] Following the procedure of Example 1i except substituting5,6-dimethoxy-benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 239a the title compound was prepared: MS(EI) 602.9 (M+H⁺).

Example 240

[1576] Preparation of (R)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1577] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for thiazole-2-sulfonyl chloride and(R)-1-benzyl-5-oxo-pyrrolidine-2-carboxylic acid forbenzofuran-2-carboxylic acid, the title compound was prepared. Theresidue was purified by HPLC. First eluting diastereomer; MS (M+H⁺):584.4; ¹H-NMR (400 MHz, CDCl₃): 8.69 (d, 1H), 7.99-7.92 (m, 2H), 7.52(m, 1H), 7.32-7.22 (m, 5H), 6.92 (d, 1H), 6.38 (d, 1H), 5.15-5.08 (m,2H), 4.80-4.75 (d, 1H), 4.47-4.44 (m, 1H), 4.14-4.10 (m, 1H), 3.89-3.80(m, 3H), 2.75-2.63 (m, 2H), 2.46-1.44 (m, 10H), 0.95 (d, 6H); and thesecond eluting diastereomer: MS (M+H⁺) 584.4.

Example 241

[1578] Preparation of (S)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1579] Following the procedure of Example 75, except substituting2-pyridylsulfonyl chloride for benzenesulfonyl chloride and(S)-1-benzyl-5-oxo-pyrrolidine-2-carboxylic acid forbenzofuran-2-carboxylic acid, the title compound was prepared. Theresidue was purified by HPLC. First eluting diastereomer; MS (M+H⁺):584.4; ¹H-NMR (400 MHz, CDCl₃): •8.69 (d, 1H), 7.98-7.92 (m, 2H), 7.52(m, 1H), 7.32-7.22 (m, 5H), 6.92 (d, 1H), 6.38 (d, 1H), 5.22-5.18 (d,1H), 5.10 (m, 1H), 4.80-4.75 (d, 1H), 4.51 (m, 1H), 4.12-4.08 (m, 1H),3.91-3.79 (m, 3H), 2.71-1.38 (m, 12H), 0.97 (d, 6H); and the secondeluting diastereomer: MS (M+H⁺): 584.4.

Example 242

[1580] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-cyclopropyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1581] Following the procedure of Example 193e-h except substitutingN-Boc-cyclopropylalanine for step 193e, the title compound was purifiedto yield two diastereomers as solids (first eluting: 8 mg, secondeluting: 8 mg): MS(ESI): 525 (M+H)⁺.

Example 243

[1582] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methylsulfanyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-propyl]-amide

[1583] Following the procedures of Examples 193e-g except substitutedN-Boc-L-methionine in step 193e. The oxidation of Example 193g wasperformed by adding sulfur trioxide-pyridine complex (34 mg, 0.211 mmol)and triethylamine (0.077 ml) to the alcohol intermediate in DMSO solvent(0.200 ml). After stirring at room temperature for two hours, themixture was diluted with water and extracted with ethyl acetate. Theorganic layer was dried, filtered, concentrated, and purified by HPLC toyield two diastereomers of the title compound as solids (first eluting:8 mg, second eluting: 5 mg). MS(ESI): 545 (M+H)⁺.

Example 244

[1584] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1585] Following the procedure of Example 193e-h except substitutingexcept substituting N-(t-butoxycarbonyl)-3-(2-naphthyl)-L-alanine, thetitle compound was purified to yield two diastereomers as solids (firsteluting: 5.3 mg, second eluting: 3.3 mg): MS(ESI): 610.8 (M+H)⁺.

Example 245

[1586] Preparation of Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1587] a.) Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1588] Following the procedure of Example 236a except substitutingthieno[3,2-b]thiophene-2-carboxylic acid for5-methoxybenzofuran-2-carboxylic acid the title compound was prepared:MS(EI) 564 (M⁺).

[1589] b.) Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1590] Following the procedure of Example 1i except substitutingthieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 245a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H) 2.7 (m, 1H), 3.8 (s, 1H); 4.1 (m,1H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H); MS(ET): 562 (M⁺, 100%).

Example 246

[1591] Preparation of Thieno[3,2-b]thiophene-2-carboxylic {Acid(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1592] a.) (S)-2-Amino-4-methyl-pentanoic Acid[3-hydroxy-1-(3-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1593] Following the procedure of Examples 235b-c except substituting3-methyl-pyridine-2-sulfonyl chloride for 6-methyl-pyridine-2-sulfonylchloride the title compound was prepared: MS(EI) 399 (M⁺).

[1594] b.) Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1595] To a solution of (S)-2-amino-4-methyl-pentanoic acid[3-hydroxy-1-(3-methyl-pyridine-2-sulfonyl)-azepan-4-yl]-amide ofExample 246a (0.25 g) in dichloromethane was addedthieno[3,2-b]thiophene (0.10 g), triethylamine (0.12 mL), HOBt (0.085 g)and EDC (0.12 g). The reaction was stirred until complete. Workup andcolumn chromatography (5% methanol: dichloromethane) provided the titlecompound (0.18 g): MS(EI) 564 (M⁺).

[1596] c.) Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1597] Following the procedure of Example 1i except substitutingthieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 245a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (m, 3H) 3.0 (m, 1H), 3.8 (s, 3H); 4.1 (m,2H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 5H), 8.4 (m, 1H); MS(EI): 562(M⁺, 100%).

Example 247

[1598] Preparation of 3-Methylbenzofuran-2-carboxylic Acid(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1599] a.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1600] Following the procedure of Example 246c except substituting3-methylbenzofuran-2-carboxylic acid for thieno[3,2-b]thiophene thetitle compound was prepared: MS(EI) 556 (M⁺).

[1601] b.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1602] Following the procedure of Example 1i except substituting3-methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amideof Example 247a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (d, 3H), 2.6 (m, 3H), 3.0 (m, 1H), 4.1 (m,2H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H), 8.4 (m, 1H); MS(EI): 554(M⁺, 100%).

Example 248

[1603] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1604] a.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl}amide

[1605] Following the procedure of Example 246c except substituting5-methoxybenzofuran-2-carboxylic acid for thieno[3,2-b]thiophene thetitle compound was prepared: MS(EI) 572 (M⁺).

[1606] b.) 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide

[1607] Following the procedure of Example 1i except substituting5-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]-butyl)amideof Example 247a the title compound was prepared: ¹H NMR (CDCl₃): δ 1.0(m, 6H), 1.5-2.2 (m, 6H), 2.6 (d, 3H), 3.0 (m, 1H), 3.8 (s, 3H); 4.1 (m,2H), 4.7 (m, 2H), 5.3 (m, 1H), 7.4-8.0 (m, 6H), 8.4 (m, 1H); MS(EI): 570(M⁺, 100%).

Example 249

[1608] Preparation of 5,6-Difluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1609] a.) 5,6-Difluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1610] Following the procedure of Example 85c exept substituting5,6-difluorobenzofuran-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared:MS(ESI) 580.9 (M+H⁺).

[1611] b.) 5,6-Difluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-]-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1612] Following the procedure of Example 1i exept substituting thecompound of Example 249a the title compound was prepared: MS(ESI) 578.87(M+H⁺).

Example 250

[1613] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid{(S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyll-ethyl 1-amide

[1614] a.)4-((S)-2-tert-Butoxycarbonylamino-3-cyclohexyl-proprionylamino)-3-hydroxy-azepane-1-carboxylicacid benzyl ester

[1615] To a solution of the compound of Example 2e (3.2 g, 12.2 mmol) inDMF (35 mL) was added N-Boc-cyclohexylalanine (3.3 g), HOBt (1.8 g) andEDC (2.56 g). The reaction was stirred until complete. Workup and columnchromatography of the residue (65% hexanes:ethyl acetate) provided 5.5 gof the title compound.

[1616] b.)[(S)-Cyclohexyl-1-(3-hydroxy-azepan-4-ylcarbamoyl)-ethyl]-carbamic AcidTert-Butyl Ester

[1617] To a solution of the compound of Example 250a (5.5 g) in etyhlacetate:methanol (185 mL:40 mL) was added 10% Pd/C. This mixture wasstirred under an atmosphere of hydrogen until complete consumption ofthe starting material was observed. The reaction was filtered andconcentrated to provide 3.75 g of the title compound.

[1618] c.){(S)-2-Cyclohexyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-carbamicAcid Tert-Butyl Ester

[1619] To a solution of the compound of Example 250 b (1.0 g, 1.91 mmol)in dichloromethane (5 mL) was added water (10 mL) and sodium bicarbonate(1 g). To this mixture was added 2-pryidinesulfonyl chloride (0.55 g in5 mL dichloromethane) dropwise. The mixture was stirred for 20 minuteswhereupon the organic layer was separated and washed with water, brine,dried filtered and concentrated. Column chromatography (2%methanol:dichloromethane) of the residue provided 1.0 g of the titlecompound: MS (ESI) 525 (M+H⁺).

[1620] d.)(S)-2-Amino-3-cyclohexyl-N-[3-hydroxy-(pyridine-2-sulfonyl)-azepan-4-yl]-proprionamide

[1621] To a solution of the compound of Example 250c (1.0 g) in methanol(10 mL) was added HCl (10 mL of 4M HCl in dioxane). The reaction wasstirred until complete consumption of the starting material whereupon itwas concentrated. The residue was azeotroped with toluene then washedwith ether to provide 0.95 g of the title compound.

[1622] e.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-{3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amideTo a solution of the compound of Example 250d (0.20 g, 0.4 mmol) in DMF(0.5 mL) was added diisopropylethylamine (0.16 mL), HOBt (0.06 g), EDC(0.084 g) and 5-[3-(trifluoromethyl)phenyl]-2-furoic acid (0.11 g). Thereaction was stirred until complete consumption of the startingmaterial. Workup and column chromatography 4% methanol:dichloromethane)provided 0.23 g of the title compound.

[1623] f.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic Acid{(S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1624] Following the procedure of Example 75d except substituting thecompound of Example 250e the title compound was prepared. Separation ofthe diastereomers by HPLC provided the first eluting disatereomer (52mg): MS (ESI) 661.4 and the second eluting diastereomer (45.8 mg): MS(ESI) 661.6.

Example 251

[1625] Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylic Acid{(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1626] Following the procedures of Example 250e-f except substituting5-(4-chlorophenyl)-2-furoic acid for5-[3-(trifluoromethyl)phenyl]-2-furoic acid of Example 252e the titlecompound was prepared. Separation of the diastereomers by HPLC providedthe first eluting diastereomer (57 mg): MS (ESI) 627.4 and the secondeluting diastereomer (53 mg): MS (ESI) 627.4.

Example 252

[1627] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[6-methyl-3-oxo-1-(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1628] Following the procedure of Example 92, except substituting,2-methyl-4-pentenal for 2,2-dimethyl-4-pentenal the title compound wasprepared. The residue was purified by HPLC. First eluting diastereomer;MS (M+H⁺): 541.2; ¹H-NMR (400 MHz, CDCl₃): •8.71-8.66 (m, 1H), 7.98-7.93(m, 2H), 7.91 (d, 1H), 7.67-7.29 (m, 5H), 7.15-6.92 (m, 2H), 5.28-5.20(m, 1H), 4.82-4.47 (m, 2H), 3.97-3.78 (m, 1H), 3.65-2.98 (m, 1H),2.37-2.34 (m, 1H), 2.20-1.55 (m, 3H), 1.22-1.19 (m, 3H), 1.00-0.86 (m,9H).

Example 253

[1629] Preparation of 5-(4-Chloro-phenyl)-furan-2-carboxylicAcid{(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1630] Following the procedures of Example 250c-f except substituting2-pyridinesulfonyl chloride N-oxide for 2-pyridinesulfonyl chloride ofExample 250c and substituting 5-(4-chlorophenyl)-2-furoic acid for5-[3-(trifluoromethyl)phenyl]-2-furoic acid of Example 252e the titlecompound was prepared. Separation of the diastereomers by HPLC providedthe first eluting diastereomer: MS (ESI) 643.4 and the second elutingdiastereomer: MS (ESI) 643.2.

Example 254

[1631] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid{(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1632] Following the procedures of Example 250c-f except substituting2-pyridinesulfonyl chloride N-oxide for 2-pyridinesulfonyl chloride ofExample 250c the title compound was prepared. Separation of thediastereomers by HPLC provided the first eluting diastereomer: MS (ESI)677.2 and the second eluting diastereomer: MS (ESI) 677.4.

Example 255

[1633] Preparation of 5-Fluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1634] a.) 5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1635] Following the procedure of Example 28b except substituting5-fluorobenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS (ESI) 547 (M+H⁺).

[1636] b.) 5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1637] Following the procedure of Example 1i except substituting thecompound of Example 255a the title compound was prepared: MS(ESI) 544.9(M+H⁺).

Example 256

[1638] Preparation of 5,6-Dimethoxybenzofuran-2-carboxylic Acid{(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide

[1639] Following the procedures of Example 250c-f except substituting2-pyridinesulfonyl chloride N-oxide for 2-pyridinesulfonyl chloride ofExample 250c and substituting 5,6-dimethoxybenzofuran-2-carboxylic acidfor 5-[3-(trifluoromethyl)phenyl]-2-furoic acid of Example 252e thetitle compound was prepared. Separation of the diastereomers by HPLCprovided the first eluting diastereomer: MS (ESI) 643.4 and the secondeluting diastereomer: MS (ESI) 643.2.

Example 257

[1640] Preparation of 5,5-Bis-(4-methoxy-phenyl)-pent-4-enoic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]}-butyl}-amide

[1641] Following the procedure of Example 75 except substituting2-pyridylsulfonyl chloride for thiazole-2-sulfonyl chloride and5,5-bis-(4-methoxy-phenyl)-pent-4-enoic acid for benzofuran-2-carboxylicacid, the title compound was prepared. The residue was purified by HPLC.First eluting diastereomer; MS (M+H⁺) 677.4; ¹H-NMR (400 MHz, CDCl₃):8.69 (d, 1H), 7.98-7.92 (m, 2H), 7.53-7.50 (m, 1H), 7.27-6.77 (m, 10H),6.00-5.87 (m, 2H), 5.08 (m, 1H), 4.76-4.72 (d, 1H), 4.48 (m, 1H), 4.08(m, 1H), 3.83 (s, 3H), 3.78 (s, 3H), 2.70-1.35 (m, 12H), 0.91 (d, 6H);and the second eluting diastereomer: MS (M+H⁺) 677.4.

Example 258

[1642] Preparation of Quinoline-8-carboxylic Acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1643] a.) 4-Amino-1-(pyridine-2-sulfonyl)-azepan-3-ol

[1644] To a solution of the compound of Example 193c (1.5 g) in methanol(10 mL) was added HCl (10 μL of 4M HCl in dioxane). The reaction wasstirred until complete by TLC analysis whereupon it was concentrated toprovide 1.2 g of the title compound as a white solid.

[1645] b.){(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-napthylene-2-yl-ethyl}-carbamicAcid Tert-Butyl Ester

[1646] To a solution of the compound of Example 258a (225 mg) indichloromethane was added TEA (0.15 mL), HOBt (99 mg), EDC (140 mg) andN-Boc-L-2-naphthylalanine (230 mg). The reaction was stirred untilcomplete. Workup and column chromatography of the residue (3%methanol:dichloromethane) provided 0.35 g of the title compound: MS(ESI)569 (M+H⁺).

[1647] c.)(S)-2-Ainino-N-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-3-naphthylen-2-yl-proprionamide

[1648] To a solution of the compound of Example 258b (0.35 g) inmethanol (5 mL) was added HCl (5 mL of 4M HCl in dioxane). The reactionwas stirred until complete by TLC analysis whereupon it was concentratedto provide 0.31 g of the title compound as a white solid.

[1649] d.) Quinoline-8-carboxylic Acid{(S)-2-naphthylen-2-yl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1650] To a solution of the compound of Example 258c (131 mg) indichloromethane was added TEA, HOBt (39 mg), EDC (55 mg) andquinoline-8-carboxylic acid (51 mg). The reaction was stirred untilcomplete. Workup and column chromatography of the residue (5%methanol:dichloromethane) provided 0.35 g of the title compound: MS(ESI)574 (M+H⁺).

[1651] e.) Quinoline-8-carboxylic Acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1652] Following the procedure of Example 1i except substituting thecompound of Example 258d the title compound was prepared.

Example 259

[1653] Preparation of Naphthylene-1-carboxylic Acid{(S)-2-naphthylen-2-yl-1-[3-oxo-]-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide

[1654] Following the procedures of Examples 258d-e except substituting1-naphthoic acid for quinoline-8-carboxylic acid the title compound wasprepared.

Example 260

[1655] Preparation of Quinoline-8-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide

[1656] Following the procedures of Examples 258a-e except substitutingN-Boc-phenylalanine for N-Boc-L-2-naphthylalanine the title compound wasprepared,

Example 261

[1657] Preparation of Naphthyridine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1658] Following the procedure of Example 28b-c exept subsituting1,6-naphthyridine-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared.

Example 262

[1659] Preparation of Naphthylene-1-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide

[1660] Following the procedure of Example 260 except substitutingl-naphthoic acid for quinoline-8-carboxylic acid the title compound wasprepared.

Example 263

[1661] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1662] a.)4-{(S)-2-[(3-Methylbenzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[1663] To a solution of the compound of Example 72a (1.2 g, 2.67 mmol)was added EDC (0.56 g), HOBt (0.36 g), TEA (0.67 g) and3-methylbenzofuran-2-carboxylic acid (0.47 g). The reaction was stirreduntil complete consumption of the starting material was observed. Workupand colum chromatography (4:1 hexanes:ethyl acetate) provided 1.05 g ofthe title compound: MS (ESI) 536 (M+H⁺).

[1664] b.) 3-Methylbenzofuran-2-carboxylic Acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1665] Following the procedure of Example 2g except substituting thecompound of Example 263a the title compound was prepared: MS (ESI) 402(M+H⁺).

[1666] c.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1667] Following the procedure of Example 263a except substituting thecompound of Example 263b and 3-cyclohexylpropionic acid for3-methylbenzofuran-2-carboxylic acid the title compound was prepared: MS(ESI) 540 (M+H⁺).

[1668] d.) 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1669] Following the procedure of Example 1i except substituting thecompound of Example 263c the title compound was prepared: MS (ESI) 538(M+H⁺).

Example 264

[1670] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1671] Following the procedures of Example 263c-d except substituting4-methylpentanoic acid for 3-cyclohexylpropionic acid the title compoundwas prepared: MS (ESI) 498 (M+H⁺).

Example 265

[1672] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl--[3-oxo-1-(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1673] Following the procedures of Example 263c-d except substitutingpicolinic acid N-oxide for 3-cyclohexylpropionic acid the title compoundwas prepared: MS (ESI) 498 (M+H⁺).

Example 266

[1674] Preparation of (S)-Acetylamino-4-methyl-pentanoic Acid[3-oxo--(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1675] Following the procedure of Example 75c-d except substitutingacetic acid for benzofuran-2-carboxylic acid in step 75c provided thetitle compound which was separated by HPLC to give the first elutingdiastereoemer: MS (M+H⁺) 425.2; ¹H-NMR (400 Hz, CDCl₃): •8.69 (d, 1H),7.96-7.94 (m, 2H), 7.53-7.52 (m, 1H), 7.05 (m, 1H), 5.92 (m, 1H), 5.08(m, 1H), 4.69-4.53 (m, 2H), 4.05-3.90 (m, 2H), 2.80 (m, 1H), 2.25-2.12(m, 2H), 1.64 (s, 3H), 1.90-1.40 (m, 5H), 0.95 (m, 6H); and the secondeluting distereomer: MS (M+H⁺): 425.2

Example 267

[1676] Preparation of Quinoline-2-carboxylic Acid{(S)-]-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide

[1677] a.)4-((S)-2-tert-Butoxycarbonylamino-hexanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[1678] To a stirring solution of compound of the amino alcohol ofExample 2e (200 mg, 0.74 mmol) in DMF (4 ml) was added N-Boc-norleucine(175 mg, 0.76 mmol), EDC-HCl (145 mg, 0.76 mmol), and1-hydroxybenzotriazole (21 mg, 0.16 mmol). Reaction allowed to proceedovernight at room temperature. The following morning the mixture wasdiluted with ethyl acetate, washed with sat. NaHCO₃, H₂O, and brine.Dried on MgSO₄, filtered and purified by column chromatography to give300 mg of the title compound: MS(ESI) 478.11 (M+H)⁺.

[1679] b.) [(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-pentyl]-carbamic AcidTert-Butyl Ester

[1680] To a solution of compound of Example 267a (300 mg, 0.63 mmol) inethyl acetate (5 ml) was added 10% palladium on carbon (160 mg) and H₂from a filled balloon. After stirring the solution at room temperaturefor 48 hours, the mixture was filtered through celite. The filterate wasconcentrated to yield the title compound (crude, 161 mg, 0.47 mmol):MS(ESI): 344.19 (M+H)⁺.

[1681] c.){(S)-1-[3-Hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-carbamicAcid Tert-Butyl Ester

[1682] To a solution of the compound of Example 267b (161 mg, 0.47 mmol)in dichloromethane (6 ml) was added triethylamine (0.065 ml, 0.47 mmol)and pyridine-2-sulfonyl chloride (83 mg, 0.47 mmol). After stirring atroom temperature for 1 hr the mixture was washed with saturated NaHCO₃The organic layer was dried, filtered, concentrated and purified on asilica gel column to give the title compound (142 mg, 0.29 mmol):MS(ESI): 485.10 (M+H)⁺.

[1683] d.) (S)-2-Amino-hexanoic Acid{3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1684] To a stirring solution of the compound of Example 267c (142 mg,0.29 mmol) in ethyl acetate was added HCl (4M in dioxane) (0.760 ml, 3.0mmol). After stirring the reaction mixture for 1 hr at room temperature,the mixture was concentrated to yield a white solid. The solid wasazeotroped with toluene twice on rotavap and then treated with a resinbound carbonate (1.47 mmol) in methanol and placed on a shaker. After 4hr the suspension was filtered and concentrated to yield 104 mg crudeproduct: MS (ESI) 385.08 (M+H)⁺.

[1685] e.) Quinoline-2-carboxylic Acid{(S)-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide

[1686] To a solution of the compound of Example 267d (104 mg, 0.27 mmol)in CH₂Cl₂ was added quinaldic acid (47 mg, 0.27 mmol),1-hydroxybenzotriazole (7.4, 0.055 mmol), EDC-HCL (52 mg, 0.27 mmol) inDMF (2 ml). After stirring at room temperature overnight, the mixturewas diluted with ethylacetate, washed with sat. NaHCO₃, H₂O, dried onMgSO₄, and filtered to obtain 172 mg crude product: MS(ESI) 539.90(M+H)⁺.

[1687] f.) Quinoline-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide

[1688] To a stirring solution of the compound of Example 267e (172 mgcrude, 0.32 mmol) in 1 ml DMSO was added sulfur trioxide-pyridinecomplex (260 mg, 1.6 mmol)) and triethylamine (0.88 ml, 3.2 mmol). Afterstirring at room temperature for two hours, the mixture was diluted withwater and extracted with ethyl acetate. The organic layer was dried,filtered, concentrated, and purified by HPLC to yield two diastereomersof the title compound as solids (first: 40 mg: second: 43 mg): MS(EST)537.86 (M+H)⁺.

Example 268

[1689] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1690] Following the procedures of Example 263a-d except substitutingbenzofuran-2-carboxylic acid for 3-methylbenzofuran-2-carboxylic acid ofExample 263a the title compound was prepared: MS(ESI) 524 (M+H⁺).

Example 269

[1691] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl--[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1692] Following the procedures of Example 263a-d except substitutingbenzofuran-2-carboxylic acid for 3-methylbenzofuran-2-carboxylic acid ofExample 263a and 5-methyl pentanoic acid for cyclohexyl propionic acidthe title compound was prepared: MS(ESI) 484 (M+H⁺).

Example 270

[1693] Preparation of Quinoline-2-carboxylic Acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide

[1694] Following the procedure of Example 267a-f except substitutingN-Boc-phenylalanine for N-Boc-norleucine in step 267a the title compoundwas prepared. Separation of the mixture by HPLC provided twodiastereomers as solids (first eluting: 20.5 mg; second eluting: 27 mg):MS(ESI) 571.95 (M+H)⁺.

Example 271

[1695] Preparation of Benzofuran-2-carboxylicAcid{(S)-2-benzyloxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl1-amide

[1696] Following the procedure of Example 193e-h, except substitutingN-Boc-O-benzyl-L-serine in step 193e the title compound was prepared asa mixture of distereoemers. To a solution of benzofuran-2-carboxylicacid{(S)-2-benzyloxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide(90 mg) in ethyl acetate (2 mL) was added 10% Pd/C (50 mg). Uponhydrogenolysis of approximately 50% of the starting benzyl ether thereaction was filtered and concentrated. Purification of this 4 componentmixture by HPLC provided the first eluting diastereomer of the titlecompound (1 mg) and the second eluting diastereomer of the titlecompound (0.3 mg): MS(ESI): 590.94 (M+H)⁺. Additionally the twoindividual diastereoemers of benzofuran-2-carboxylic acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amidewere also isolated as described below in Example 272.

Example 272

[1697] Preparation of Benzofuran-2-carboxylic Acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide

[1698] The title compound was obtained as discussed above in Example271. Purification of the mixture by HPLC provided the two diastereomersin solid form (first eluting: 1.6 mg; second eluting 2.1 mg): MS(ESI):500.9 (M+H)⁺.

Example 273

[1699] Preparation of 5-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1700] Following the procedure of Example 75c-d except substituting5-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 75c provided the title compound which was separated by HPLC togive the first eluting diastereoemer as a white solid (144.3 mg, 85.1%):MS (ESI) 563.2 (M+H)⁺ and the second eluting diastereomer as a whitesolid (16.9 mg, 10.0%) MS (ESI): 563.0 (M+H)⁺

Example 274

[1701] Preparation of 7-Methoxybenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1702] Following the procedure of Example 75c-d except substituting7-methoxybenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidin step 75c provided the title compound which was separated by HPLC togive the first eluting diastereoemer as a white solid (75 mg, 47%): MS(ESI) 563.2 (M+H)⁺ and the second eluting diastereomer as a white solid(57 mg, 35%): MS (ESI) 563.0 (M+H)+

Example 275

[1703] Preparation of 3-Methylbenzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1704] Following the procedure of Example 75c-d except substituting3-methylbenzofuran-2-carboxylic acid for benzofuran-2-carboxylic acid instep 75c provided the title compound which was separated by HPLC to givethe first eluting diastereoemer as a white solid (69.5 mg, 42%): MS(ESI) 547.2 (M+H)⁺ and the second eluting diastereomer as a white solid(65 mg, 40%): MS (ESI) 547.2 (M+H)+

Example 276

[1705] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo--(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1706] Following the procedure of Example 75c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid instep 75c provided the title compound which was separated by HPLC to givethe first eluting diastereoemer as a white solid (79.5 mg, 48%): MS(ESI) 549.3 (M+H)⁺ and the second eluting diastereomer as a white solid(50.5 mg, 31%): MS (ESI) 549.2 (M+H)⁺

Example 277

[1707] Preparation of 1-Methyl-1H-indole-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide

[1708] Following the procedure of Example 75c-d except substituting1-methylindole-2-carboxylic acid for benzofuran-2-carboxylic acid instep 75c provided the title compound which was separated by HPLC to givethe first eluting diastereoemer as a white solid (75 mg, 47%): MS (ESI)563.2 (M+H)⁺ and the second eluting diastereomer as a white solid (57mg, 35%): MS (ESI) 563.0 (M+H)+

Example 278

[1709] Preparation of Quinoxaline-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyll-butyl}amide

[1710] Following the procedure of Example 75c-d except substitutingquinoxaline-2-carboxylic acid for benzofuran-2-carboxylic acid in step75c provided the title compound which was separated by HPLC to give thefirst eluting diastereoemer as a white solid (126 mg, 77%): MS (ESI)545.2 (M+H)⁺ and the second eluting diastereomer as a white solid (25mg, 15%): MS (ESI) 545.2 (M+H)⁺

Example 279

[1711] Preparation of Quinoline-2-carboxylic Acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1712] Following the procedure of Example 75, except substituting4-fluorophenylsulfonyl chloride for benzenesulfonyl chloride and2-quinoline carboxylic acid for benzofuran-2-carboxylic acid, the titlecompound was prepared. The residue was purified by HPLC. First elutingdiastereomer; MS (M+H⁺): 555.2; ¹H-NMR (400 Hz, CDCl₃): •8.62 (d, 1H),8.34-8.23 (q, 2H) 8.19-8.17 (d, 1H), 7.90-7.88 (d, 1H), 7.88-7.80 (m,3H), 7.66-7.64 (t, 1H), 7.25-7.07 (m, 3H), 5.08 (m, 1H), 4.72 (m, 1H),4.58-4.53 (d, 1H),4.00 (m, 1H), 3.46-3.42 (d, 1H), 2.47 (m, 1H),2.27-2.12 (m, 2H), 1.90-1.40 (m, 5H), 1.03-1.01 (m, 6H); and the secondeluting diastereomer: MS (M+H⁺): 555.4.

Example 280

[1713] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[-(3-fluoro-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl)-amide

[1714] a.) Allyl-pent-4-enyl-carbamic Acid Benzyl Ester

[1715] To a suspension of NaH (1.83 g, 76.33 mmol of 90% NaH) in DMF wasadded allyl-carbamic acid benzyl ester (7.3 g, 38.2 mmol) in a dropwisefashion. The mixture was stirred at room temperature for approximately10 minutes whereupon 5-bromo-1-pentene (6.78 mL, 57.24 mmol) was addedin a dropwise fashion. The reaction was heated to 40° C. forapproximately 4 hours whereupon the reaction was partitioned betweendichloromethane and water. The organic layer was washed with water(2×'s), brine, dried (MgSO₄), filtered and concentrated. Columnchromatography of the residue (10% ethyl acetate:hexanes) provided 10.3grams of the title compound as an oil: MS(ES) 260 (M+H⁺).

[1716] b.) 2,3,4,7-Tetrahydro-azepine-1-carboxylic Acid Benzyl Ester

[1717] To a solution of compound of Example 280a (50 g) indichloromethane was added bis(tricyclohexylphosphine)benzylidineruthenium (IV) dichloride (5.0 g). The reaction was heated to refluxuntil complete as determined by TLC analysis. The reaction wasconcentrated in vacuo. Column chromatography of the residue (50%dichloromethane:hexanes) gave 35 g of the title compound: MS(ES) 232(M+H⁺).

[1718] c.) 8-Oxa-3-aza-bicyclo[5.1.0]octane-3-carboxylic Acid BenzylEster

[1719] To a solution of the compound of Example 280b (35 g, 1.5 mol) inCH₂Cl₂ was added m-CPBA (78 g, 0.45 mol). The mixture was stirredovernight at room temperature whereupon it was filtered to remove thesolids. The filtrate was washed with saturated water and saturatedNaHCO₃ (several times). The organic layer was dried (MgSO₄), filteredand concentrated to give 35 g of the title compound which was ofsufficient purity to carry on to the next step: MS(ES) 248 (M+H⁺), 270(M+Na⁺).

[1720] d.) 4-Azido-3-hydroxy-azepane-1-carboxylic Acid Benzyl Ester

[1721] To a solution of the epoxide from Example 280c (2.0 g, 8.1 mmol)in methanol:water (8:1 solution) was added NH₄Cl (1.29 g, 24.3 mmol) andsodium azide (1.58 g, 24.30 mmol). The reaction was heated to 40° C.until complete consumption of the starting epoxide was observed by TLCanalysis. The majority of the solvent was removed in vacuo and theremaining solution was partitioned between ethyl acetate and pH 4buffer. The organic layer was washed with sat. NaHCO₃, water, brinedried (MgSO₄), filtered and concentrated. Column chromatography (20%ethyl acetate:hexanes) of the residue provided 1.3 g of the titlecompound: MS(ES) 291 (M+H⁺) plus 0.14 g oftrans-4-hydroxy-3-azido-hexahydro-1H-azepine e.)4-Amino-3-hydroxy-azepane-1-carboxylic acid benzyl ester To a solutionof the azido alcohol of Example 280d (1.1 g, 3.79 mmol) in methanol wasadded triethyamine (1.5 mL, 11.37 mmol) and 1,3-propanedithiol (1.1 mL,11.37 mmol.). The reaction was stirred until complete consumption of thestarting material was observed by TLC analysis whereupon the reactionwas concentrated in vacuo. Column chromatography of the residue (20%methanol:dichloromethane) provided 0.72 g of the title compound: MS(ES)265 (M+H⁺).

[1722] f.)4-((S)-2-tert-Butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylicAcid Benzyl Ester

[1723] To a solution of the amino alcohol of Example 280e (720 mg, 2.72mmol) in CH₂Cl₂ was added EDC (521 mg), HOBt (368 mg) and N-Boc-leucine(630 mg). The reaction was maintained at room temperature until completeconsumption of the starting material was observed by TLC analysis. Thereaction was diluted with ethyl acetate and washed with 1N HCl, sat.K₂CO₃, water, brine, dried (MgSO₄), filtered and concentrated. Columnchromatography of the residue (3% methanol:dichloromethane) gave 1.0 gof the title compound: MS(ES) 478 (M+H⁺).

[1724] g.)[(S)-1-(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic AcidTert Butyl Ester

[1725] To a solution of the compound of Example 280f (1.0 g) and 10%Pd/C (catalytic) in ethyl acetate:methanol (2:1 solution) was affixed aballoon of hydrogen. The reaction was stirred until complete consumptionof the starting material was observed by TLC analysis. The reaction wasfiltered to remove the catalyst and the filtrate was concentrated toprovide 0.82 g of the title compound: MS(ES) 344 (M+H⁺).

[1726] h.) (S)-2-Amino-4-methyl-pentanoic acid[1-(3-fluoro-benzenesulfonyl)-3-hydroxy-azepan-4-yl]-amide

[1727] To a solution of the compound of Example 280g (0.2 g) indichloroethane (20 mL) was added p-NMM (0.32 g) and3-fluorobenzenesulfonyl chloride (0.11 g). The reaction was stirreduntil complete as determined by MS analysis whereupon it was filtered,concentrated. The residue was dissolved in methanol (10 mL) and 4M HClin dioxane (10 mL) was added. The reaction was maintained at roomtemperature until complete consumption of the starting materialwhereupon it was concentrated. The residue was dissolved in methanolwhereupon p-carbonate resin was added. The mixture was shaken at roomtemperature for 4 hours then filtered and concentrated to provide 0.64 gof the title compound.

[1728] i.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-hydroxy-azepan-4-ylcarbamoyl]3-methyl-butyl}-amide

[1729] To a solution of the compound of Example 280h (0.15 g) in CH₂Cl₂was added benzofuran-2-carboxylic acid (0.56 mmol), HOBt (0.09 mg), andp-EDC (0.75 mg). The reaction was stirred overnight whereupon trisamine(0.50 g) was added and stirred an additional 1.5 hours. The reaction wasfiltered and concentrated to provide the title compound.

[1730] j.) Benzofuran-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]3-methyl-butyl}-amide

[1731] To a solution of the compound of Example 280i (0.3 mmol) inCH₂Cl₂ was added Dess-Martin periodinane (0.25 g). The reaction wasstirred until complete as determined by MS analysis. Workup and HPLCchromatography provided diastereomer 1: MS(ES) 543.2 (M+H)⁺ anddiastereomer 2: MS(ES) 543.2 (M+H)⁺.

Example 281

[1732] Preparation of(S)-4-Methyl-2-(3-piperidin-1-yl-propanoylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1733] Following the general procedures of Examples 280h-j exceptsubstituting 2-pyridinesulfonyl chloride for 3-fluorobenzenesulfonylchloride and 1-piperidinepropionoic acid for benzofuran-2-carboxylicacid the title compound was prepared: MS(ES) 521.9 (M+H)⁺.

Example 282

[1734] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[-(4-ethyl-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1735] Following the general procedures of Examples 280h-j exceptsubstituting 4-ethylnezenesulfonyl chloride for 3-fluorobenzenesulfonylchloride the title compound was prepared: Separation of thediastereomers provided diastereomer 1 MS(ES) 554.4 (M+H)⁺ anddistereomer 2 MS(ES) 554.4 (M+H)⁺.

Example 283

[1736] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid((S)-3-methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl]-butyl}-amide

[1737] a.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[1738] To a solution of the compound of Example 280f (7.32 g) inmethanol was added 4M HCl in dioxane (38 mL). The reaction was stirreduntil complete whereupon it was concentrated to give 6.9 g of the titlecompound as a white solid.

[1739] b.)3-Hydroxy-4-[(S)-4-methyl-2-({1-[5-(3-trifluoromethyl-phenyl)-furan-2-yl]-methanoyl}-amino)-pentanoylamino]azepane-1-carboxylicAcid Benzyl Ester

[1740] To a solution of the compound of Example 283a (1.2 g) indichloromethane was added TEA (0.93 mL), EDC (0.56 g), HOBt (0.36 g) and5-[3-(trifluoromethyl) phenyl]-2-furoic acid (0.68 g). The reaction wasstirred at room temperature until complete as determined by TLCanalysis. Workup and column chromatography provided 1.35 g of the titlecompound: MS (ES) 616 (M+H)⁺.

[1741] c.) 5-[3-(Trifluoromethyl)phenyl]-furan-2-carboxylic Acid[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1742] To a solution of the compound of Example 283b (1.3 g) in ethylacetate:methanol (20 mL of an 8:1 mixture) was added 10% Pd\C. Themixture was stirred under a balloon of hydrogen gas until completeconsumption of the starting material was observed by TLC analysis. Thereaction was filtered and concentrated to provide 0.96 g of the titlecompound which was used directly in the following reaction with nofurther purification.

[1743] d.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid((S)-3-methyl-1-{3-hydroxy-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1744] To a solution of the compound of Example 283c (0.3 g) indichloromethane was added TEA (0.22 mL), EDC (0.13 g), HOBt (0.8 g) andpicolinic acid N-oxide (0.09 g). The reaction was stirred at roomtemperature until complete as determined by TLC analysis. Workup andcolumn chromatography provided 0.16 g of the title compound: MS (ES) 603(M+H)⁺.

[1745] e.) 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1746] To a solution of the compound of Example 283d (0.15 g) in DMSO(1.5 mL) was added TEA (0.37 mL) and pyridine sulfur trioxide complex(0.21 g). The reaction was stirred until complete as determined by LCMS.Workup and column chromatography (10% methanol:dichloromethane) provided0.12 g of the title compound: MS (ES) 601 (M+H)⁺. The diastereomers wereseparated by HPLC to provide diastereomer 1 and diastereomer 2.

Example 284

[1747] Preparation of Benzo[1,3]-dioxole-5-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1748] Following the general procedures of Examples 283b-e exceptsubstituting piperonylic acid for 5-[3-(trifluoromethyl)phenyl]-2-furoic acid the title compound was prepared: MS(ES) 511(M+H)⁺.

[1749] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 285

[1750] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicAcid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1751] Following the general procedures of Examples 283b-e exceptsubstituting 3-cyclohexylpropionic acid for picolinic acid N-oxide thetitle compound was prepared: MS(ES) 618 (M+H)⁺.

[1752] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 286

[1753] Preparation of Benzo[1,31-dioxole-5-carboxylic acid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1754] Following the general procedures of Examples 283b-e exceptsubstituting 3-cyclohexylpropionic acid for picolinic acid N-oxide andpiperonylic acid for 5-[3-(trifluoromethyl) phenyl]-2-furoic acid thetitle compound was prepared: MS(ES) 528 (M+H)⁺.

[1755] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 287

[1756] Preparation of 5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylicacid{(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1757] Following the general procedures of Examples 283b-e exceptsubstituting 4-methyl-pentanoic acid for picolinic acid N-oxide thetitle compound was prepared: MS(ES) 578 (M+H)⁺.

[1758] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 288

[1759] Preparation of Benzo[1,31-dioxole-5-carboxylic Acid{(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1760] Following the general procedures of Examples 283b-e exceptsubstituting 4-methyl-pentanoic acid for picolinic acid N-oxide andpiperonylic acid for 5-[3-(trifluoromethyl) phenyl]-2-furoic acid thetitle compound was prepared: MS(ES) 488 (M+H)⁺.

[1761] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 289

[1762] Preparation of Benzofuran-2-carboxylic Acid{(S)1-3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1763] Following the general procedures of Examples 280h-j exceptsubstituting propanesulfonyl chloride for 3-fluorosulfonyl chloride thetitle compound was prepared.

[1764] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 491.2 (M+H)⁺ and diastereomer 2: MS(ES) 491.2 (M+H)⁺.

Example 290

[1765] Preparation of Benzofuran-2-carboxylic Acid[(S)-1-[3-oxo-1-(ethanesulfonyl-azepan-4-ylcarbamoyl)-3-methyl-1-butyl]-amide

[1766] Following the general procedures of Examples 280h-j exceptsubstituting ethanesulfonyl chloride for 3-fluorobenzenesulfonylchloride the title compound was prepared.

[1767] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 477.4 (M+H)⁺ and diastereomer 2: MS(ES) 477.4 (M+H)⁺.

Example 291

[1768] Preparation of 5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1769] a.){(S)-1-[3-Hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1770] Generation of 2-pyridinesulfonylchloride-N-oxide: To a 0° C.solution of 2-mercaptopyridine-N-oxide (2.23 g, 17.55 mmol) in 9M HCl(33 mL) was bubbled chlorine gas for approximately 90 minutes. Thedissolved chlorine was removed under vacuum at 0° C.

[1771] To a solution of[(S)-1-(3-hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acidtert butyl ester of Example 280g (2.5 g, 7.28 mmol) in CH₂Cl₂ (100 mL)and sat. NaHCO₃ (400 mL) was added the solution of2-pyridinesulfonylchloride-N-oxide (27 mL, 102 mg/mL) dropwise inportions. As the addition proceeds additional sat. NaHCO₃ is added inorder to maintain the pH at approximately 8-9. Upon complete addition ofthe sulfonylchloride the reaction is stirred for an additional hourwhereupon the organic layer was removed and washed with brine. Theorganic layer was evaporated and the residue chromatographed (5%methanol:dichloromethane) to provide 2.5 g of the title compound: MS(ES) 500 (M+H⁺).

[1772] b.) (S)-2-Amino-4-methyl-pentanoicAcid-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1773] To a solution of{(S)-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicacid tert-butyl ester of Example 291a (2.0 g) in methanol (20 mL) wasadded 4 M HCl in dioxane (20 mL). The reaction was stirred at roomtemperature for 1.5 hours whereupon it was concentrated to provide 1.8 gof the title compound: MS (ES) 400 (M+H⁺).

[1774] c.) 5-Fluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1775] To a solution of the compound of Example 291 b (0.30 g) in CH₂Cl₂was added 5-fluoro-benzofuran-2-carboxylic acid (0.11 g), EDC (0.13 g),HOBt (0.086 g), and TEA (0.22 mL). The reaction was stirred untilcomplete as determined by LCMS whereupon it was diluted with ethylacetate and washed with water, sat. K₂CO₃, 1N HCl, brine, dried (MgSO₄),filtered and concentrated. Column chromatography (10% methanol:dichloromethane) of the residue provided 0.27 g of the title compound:MS(ES) 563 (M+H)⁺.

[1776] d.) 5-Fluoro-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1777] To a solution of the compound of Example 291c (0.19 g) in DMSO(1.5 mL) was added sulfur trioxide pyridine complex (0.26 g). Thereaction was stirred until complete as determined by LCMS whereupon itwas diluted with ethyl acetate and washed with sat. NaHCO₃, brine dried,filtered and concentrated. Column chromatography of the residue provided0.15 g of the title compound as a mixture of diastereomers: MS(ES) 561(M+H)⁺.

[1778] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 292

[1779] Preparation of 5-Fluoro-3-methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1780] Following the general procedure of Examples 29 Ic-d exceptsubstituting 5-fluoro-3-methyl benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 575 (M+H)⁺.

[1781] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 293

[1782] Preparation of 6-Fluoro-3-methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1783] Following the general procedure of Examples 291c-d exceptsubstituting 6-fluoro-3-methyl benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 575 (M+H)⁺.

[1784] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 294

[1785] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(R)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1786] Following the general procedures of Examples 280f-i exceptsubstituting N-Boc-D-leucine for N-Boc-L-leucine,2-pyridinesulfonylchloride N-oxide for 3-fluorobenzenesulfonyl chlorideand 3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylicacid the title compound was prepared: MS(ES) 556 (M+H)⁺.

[1787] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 295

[1788] Preparation of 3-Methyl-furo[3,2-b]-pyridine-2-carboxylic Acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1789] Following the general procedure of Examples 29tc-d exceptsubstituting 3-methyl-furo[3,2-b]-pyridine-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 558 (M+H)⁺.

[1790] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 296

[1791] Preparation of 5-Methoxy-benzofuran-2-carboxylic Acid{(S)-1-[-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1792] Following the general procedure of Examples 280h-j exceptsubstituting 5-methoxy-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1793] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 574.5 (M+H)⁺ and diastereomer 2 574.5 (M+H)⁺.

Example 297

[1794] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1795] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1796] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 557.4 (M+H)⁺ and diastereomer 2 557.4 (M+H)⁺.

Example 298

[1797] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1798] Following the general procedure of Examples 280h-j exceptsubstituting benzo[b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1799] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 559.4 (M+H)⁺ and diastereomer 2 559.4 (M+H)⁺.

Example 299

[1800] Preparation of 3-Methyl-furan-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1801] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-furan-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1802] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 507.2 (M+H)⁺ and diastereomer 2 507.4 (M+H)⁺.

Example 300

[1803] Preparation of Quinoline-2-carboxylic Acid{(S)-1-[1]-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1804] Following the general procedure of Examples 280h-j exceptsubstituting quinolide-2-carboxylic acid for benzofuran-2-carboxylicacid provided the title compound as a mixture of diastereomers.

[1805] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 554.2 (M+H)⁺ and diastereomer 2 MS(ES) 545.2 (M+H)⁺.

Example 301

[1806] Preparation of Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1807] Following the general procedure of Examples 280h-j exceptsubstituting thieno[3,2-b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1808] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 565.2 (M+H)⁺ and diastereomer 2 MS(ES) 565.2 (M+H)⁺.

Example 302

[1809] Preparation of Quinoxaline-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1810] Following the general procedure of Examples 280h-j exceptsubstituting quinoxaline-2-carboxylic acid for benzofuran-2-carboxylicacid provided the title compound as a mixture of diastereomers.

[1811] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 555.4 (M+H)⁺ and diastereomer 2 MS(ES) 555.4 (M+H)⁺.

Example 303

[1812] Preparation of Thiophene-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1813] Following the general procedure of Examples 280h-j exceptsubstituting thiophene-2-carboxylic acid for benzofuran-2-carboxylicacid provided the title compound as a mixture of diastereomers.

[1814] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 509.4 (M+H)⁺ and diastereomer 2 MS(ES) 509.2 (M+H)⁺.

Example 304

[1815] Preparation of 5-Methyl-thiophene-2-carboxylic Acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1816] Following the general procedure of Examples 280h-j exceptsubstituting 5-methyl-thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid provided the title compound as a mixture ofdiastereomers.

[1817] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 523.2 (M+H)⁺ and diastereomer 2 MS(ES) 523.4 (M+H)⁺.

Example 305

[1818] Preparation of 5-Methoxy-benzofuran-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1819] Following the general procedure of Examples 280h-j exceptsubstituting 5-methoxy-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1820] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 507.4 (M+H)⁺ and diastereomer 2 MS(ES) 507.4 (M+H)⁺.

Example 306

[1821] Preparation of 3-Methyl-benzofuran-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1822] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1823] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 491.2 (M+H)⁺ and diastereomer 2 MS(ES) 491.2 (M+H)⁺.

Example 307

[1824] Preparation of Benzo[b]thiophene-2-carboxylic Acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1825] Following the general procedure of Examples 280h-j exceptsubstituting benzo[b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1826] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 493.4 (M+H)⁺ and diastereomer 2 MS(ES) 493.4 (M+H)⁺.

Example 308

[1827] Preparation of 3-Methyl-furan-2-carboxylic Acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1828] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-furan-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1829] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 441.2 (M+H)⁺ and diastereomer 2 MS(ES) 441.2 (M+H)⁺.

Example 309

[1830] Preparation of Quinoline-2-carboxylic Acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1831] Following the general procedure of Examples 280hj exceptsubstituting quinoline-2-carboxylic acid for benzofuran-2-carboxylicacid and ethanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1832] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 488.2 (M+H)⁺ and diastereomer 2 MS(ES) 488.2 (M+H)⁺.

Example 310

[1833] Preparation of Thieno[3,2-b]thiophene-2-carboxylic acid[(S)-1-(]-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1834] Following the general procedure of Examples 280h-j exceptsubstituting thieno[3,2-b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1835] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 499.4 (M+H)⁺ and diastereomer 2 MS(ES) 499.4 (M+H)⁺.

Example 311

[1836] Preparation of Quinoxaline-2-carboxylic Acid[(S)-1-(]-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1837] Following the general procedure of Examples 280h-j exceptsubstituting quinoxaline-2-carboxylic acid for benzofuran-2-carboxylicacid and ethanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1838] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 489.2 (M+H)⁺ and diastereomer 2 MS(ES) 489.2 (M+H)⁺.

Example 312

[1839] Preparation of Thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1840] Following the general procedure of Examples 280h-j exceptsubstituting thiophene-2-carboxylic acid for benzofuran-2-carboxylicacid and ethanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1841] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 443.4 (M+H)⁺ and diastereomer 2 MS(ES) 443.2 (M+H)⁺.

Example 313

[1842] Preparation of 5-Methyl-thiophene-2-carboxylic Acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1843] Following the general procedure of Examples 280h-j exceptsubstituting 5-methyl-thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and ethanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1844] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 457.2 (M+H)⁺ and diastereomer 2 MS(ES) 457.4 (M+H)⁺.

Example 314

[1845] Preparation of 5-Methoxy-benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1846] Following the general procedure of Examples 280h-j exceptsubstituting 5-methoxy-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1847] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 521.4 (M+H)⁺ and diastereomer 2 MS(ES) 521.2 (M+H)⁺.

Example 315

[1848] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1849] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1850] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 505.4 (M+H)⁺ and diastereomer 2 MS(ES) 505.2 (M+H)⁺.

Example 316

[1851] Preparation of Benzo[b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1852] Following the general procedure of Examples 280h-j exceptsubstituting benzo[b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1853] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 507.4 (M+H)⁺ and diastereomer 2 MS(ES) 507.4 (M+H)⁺.

Example 317

[1854] Preparation of 3-Methyl-furan-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1855] Following the general procedure of Examples 280h-j exceptsubstituting 3-methyl-furan-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1856] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 455.2 (M+H)⁺ and diastereomer 2 MS(ES) 455.4 (M+H)⁺.

Example 318

[1857] Preparation of 2,5-Dimethyl-benzofuran-2-carboxylic acid(S)-1-[3-oxo-{-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1858] Following the general procedure of Examples 280h-j exceptsubstituting 2,5-dimethyl-benzofuran-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1859] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 469.4 (M+H)⁺ and diastereomer 2 MS(ES) 469.2 (M+H)⁺.

Example 319

[1860] Preparation of Quinoline-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1861] Following the general procedure of Examples 280h-j exceptsubstituting quinoline-2-carboxylic acid for benzofuran-2-carboxylicacid and 1-propanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1862] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 565.2 (M+H)⁺ and diastereomer 2 MS(ES) 565.2 (M+H)⁺.

Example 320

[1863] Preparation of Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1864] Following the general procedure of Examples 280h-j exceptsubstituting thieno[3,2-b]thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1865] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 513.2 (M+H)⁺ and diastereomer 2 MS(ES) 513.2 (M+H)⁺.

Example 321

[1866] Preparation of Quinoxaline-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1867] Following the general procedure of Examples 280h-j exceptsubstituting quinoxaline-2-carboxylic acid for benzofuran-2-carboxylicacid and 1-propanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1868] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 503.4 (M+H)⁺ and diastereomer 2 MS(ES) 503.4 (M+H)⁺.

Example 322

[1869] Preparation of Thiophene-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1870] Following the general procedure of Examples 280h-j exceptsubstituting thiophene-2-carboxylic acid for benzofuran-2-carboxylicacid and 1-propanesulfonyl chloride for 3-flurobenzenesulfonyl chlorideprovided the title compound as a mixture of diastereomers.

[1871] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 457.4 (M+H)⁺ and diastereomer 2 MS(ES) 457.4 (M+H)⁺.

Example 323

[1872] Preparation of 5-Methyl-thiophene-2-carboxylic Acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide

[1873] Following the general procedure of Examples 280h-j exceptsubstituting 5-methyl-thiophene-2-carboxylic acid forbenzofuran-2-carboxylic acid and 1-propanesulfonyl chloride for3-flurobenzenesulfonyl chloride provided the title compound as a mixtureof diastereomers.

[1874] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 471.4 (M+H)⁺ and diastereomer 2 MS(ES) 471.4 (M+H)⁺.

Example 324

[1875] Preparation of 5-Methoxy-3-methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1876] Following the general procedure of Examples 291c-d exceptsubstituting 5-methoxy-3-methyl-benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 587 (M+H)⁺.

[1877] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 565.2 (M+H)⁺ and diastereomer 2 MS(ES) 565.2 (M+H)⁺.

Example 325

[1878] Preparation of 3,5-Dimethyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(]-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1879] Following the general procedure of Examples 291 c-d exceptsubstituting 3,5-dimethyl-benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 571 (M+H)⁺.

[1880] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 326

[1881] Preparation of 3-Ethyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1882] Following the general procedure of Examples 291c-d exceptsubstituting 3-ethyl-benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 571 (M+H)⁺.

[1883] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 327

[1884] Preparation of 4-Methoxy-3-methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1885] Following the general procedure of Examples 291 c-d exceptsubstituting 4-methoxy-3-methyl-benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 587 (M+H)⁺.

[1886] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 328

[1887] Preparation of 1-Methyl-naphtho[2,1-b]-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1888] Following the general procedure of Examples 291c-d exceptsubstituting 1-methyl-naphtho[2,1-b]-furan-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 607 (M+H)⁺.

[1889] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 329

[1890] Preparation of 6-Methoxy-3-methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1891] Following the general procedure of Examples 291c-d exceptsubstituting 6-methoxy-3-methyl-benzofuran-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 587 (M+H)⁺.

[1892] Separation of the diastereomers by HPLC provided diastereomer 1and diastereomer 2.

Example 330

[1893] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{1,3-dimethyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1894] a.)4-(2-tert-Butoxycarbonylamino-2,4-dimethyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid Benzyl Ester

[1895] To a solution ofN-[(1,1-dimethylethoxy)carbonyl]-2-methyl-(d,1)-leucine (3.0 g) inmethlene chloride was added EDC (2.34 g), HOBt (1.65 g), Et₃N (1.7 ml)and the compound of Example 280e (3.23 g). After stirring at roomtemperature over night the mixture was washed with 0.1N HCl, Sat.NaHCO₃, H₂O, Brine. The organic layer was concentrated and residue waspurified by flash column chromatography eluting with CH₂Cl₂: CH₃OH(95:5) to give the title compound as a white solid (4.0 g, 66.6%). MS:492.4 (M+H)⁺

[1896] b.)[1-(3-Hydroxy-azepan-4-ylcarbamoyl)-1,3-dimethyl-butyl]-carbamic AcidTert-Butyl Ester

[1897] To a solution of the compound of Example 330 (a) (3.04 g, 8.00mmol) in ethyl acetate (50 mL) was added 10% palladium on carbon (1.5g). After stirring at room temperature under a hydrogen atmosphere for16 h, the mixture was filtered through celite. The filtrate wasconcentrated to yield the title compound as a yellow oil (1.97 g, 100%).MS (ESI): 358.4 (M+H)⁺.

[1898] c.){1-[3-Hydroxy-1-(]-hydroxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-1,3-dimethyl-butyl}-carbamicAcid Tert-Butyl Ester

[1899] 2-Mercaptane N-oxide (1.25 g) was disolved in concentrated HCl(5.5 ml). After cooled to 0° C. water (3 ml) was added. Cl₂ gas wasbubbled through this solution for 1.5 h. Water solution was extactedwith cold CH₂Cl₂ then the combined organic layer was washed withSat.NaHCO₃, brine. To a solution of the compound of Example 330b (1.20g) and Et₃N (1.3 ml) in DCE (10 ml) was added the sulfonyl chloridewhich was freshly prepared above at 0° C. Stirring was kept for 1 h thenthe reaction mixture was washed with brine, dried over Na₂SO₄,concentrated and purified through flash column chromatograpghy elutingwith CH₂Cl₂: CH₃OH (95:5). The filtrate was concentrated to yield thetitle compound as white solid (1.2 g, 70%). MS: 515.4 (M+H)⁺.

[1900] d.) 2-Amino-2,4-dimethyl-pentanoic acid[3-hydroxy-{-(hydroxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide

[1901] To a stirring solution of the compound of Example 330c (1.0 g,2.04 mmol) in methanol (10 ml) was added HCl (4M in Dioxane) (10 ml).After stirring at room temperature for 3 hr, the solution wasconcentrated to get white solide. To a solution of the white solid (0.81g, 1.53 mmol, 75%) in methnol (30 ml) was added P-CO₃ (2.9 g, 2.63mmol/g). After shaking for 2 hr, the solution was filtered andconcentrated to yield the title compound as white solid (0.57 g, 1.45mmol, 95%). MS: 415.4 (M+H)⁺.

[1902] e.) 3-Methyl-benzofuran-2-carboxylic acid{1,3-dimethyl-1-[3-hydroxy-1-(]-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1903] To a solution of the compound of Example 330d (0.150 g, 0.448mmol) in CH₂Cl₂ (20 mL) was added 3-methyl benzofuran-2-carboxylic acid(0.109 g), 1-hydroxybenzotriazole (0.106 g, 0.762 mmol), and P-EDC (0.85g, 1 mmol/g) in CH₂Cl₂ (10 mL). After shaking at room temperature forover night, the solution was treated with tisamine (0.589 g, 3.75mmol/g). After shaking for another 2 hr, the solution was filtered andconcentrated to yield the title compound as a white solid (166.7 mg,70%). MS (ESI): 573.2 (M+H)⁺.

[1904] f.) 3-Methyl-benzofuran-2-carboxylic Acid{1,3-dimethyl-1-[3-oxo-1-(oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[1905] To a stirring solution of the compound of Example 330e (140.7 mg,0.245 mmol) in DMSO (2 mL) was added Py-SO₃ (155.7 mg, 0.98 mmol) andEt₃N (0.27 ml, 1.96 mmol). After stirring at room temperature for 2 h.Sat. NaHCO₃ and ethyl acetate was added to quench the reaction. Organiclayer was washed with brine, dried over Na₂SO₄ and concentrated. Theresidue was purified through flash column chromatograghy eluting withCH₂Cl₂:CH₃OH (95:5) to yield the title compound as a white solid (69.9mg, 50.8%). MS (ESI): 571.2 (M+H)⁺.

Example 331

[1906] Preparation of Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide

[1907] a.)[(S)-1-(3-Hydroxy-1-quinoline-2-ylmethyl-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamicAcid Tert-Butyl Ester

[1908] To a solution of the compound of Example 280g (1.0 g) in CH₂Cl₂was added α-quinoline carbaldehyde (0.68 g) and NaBH(OAc)₃ (1.2 g).Workup and column chromatography (6% methanol: dichloromethane) provided1.4 g of the title compound: MS(ES) 485 (M+H)⁺.

[1909] b.) (S)-2-Amino-4-methyl-pentanoic Acid(3-hydroxy-1-quinolin-2-methyl-azepan-4-yl)-amide

[1910] To a solution of the compound of Example 33 la (1.4 g) inmethanol (20 mL) was added 4M HCl in dioxane (20 mL). The reaction wasstirred until complete whereupon the reaction was concentrated toprovide 1.3 g of the title compound: MS(ES) 385 (M+H)⁺.

[1911] c.) Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-[3-hydroxy-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide

[1912] Following the general procedure of Example 291c exceptsubstituting the compound of Example 331 b and benzofuran-2-carboxylicacid for 5-fluoro-benzofuran-2-carboxylic acid the title compound wasprepared: MS(ES) 545 (M+H)⁺.

[1913] d.) Benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide

[1914] Following the general procedure of Example 291 d exceptsubstituting the compound of Example 331 c the title compound wasprepared: MS(ES) 543 (M+H)⁺.

Example 332

[1915] Preparation of 3-Methyl-benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide

[1916] Following the procedure of Example 331c-d except substituting3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(ES) 541 (M+H)⁺.

Example 333

[1917] Preparation of Benzo[b]thiophene-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide

[1918] Following the procedure of Example 331c-d except substitutingbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(ES) 541 (M+H)⁺.

Example 334

[1919] Preparation of Benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1920] a.)((S)-1-{3-Hydroxy-1-[-(toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-3-methyl-butyl)-carbamicAcid tert-butyl ester

[1921] To a solution of the compound of Example 280g (1.0 g) in CH₂Cl₂was added o-toluenesulfonyl isocyanate (0.68 g). The reaction wasstirred until complete consumption of the starting material wasobserved. Workup and column chromatography (6% methanol:dichloromethane)provided 1.28 g of the title compound: MS(ES) 541 (M+H)⁺.

[1922] b.) (S)-2-Amino-4-methyl-pentanoic Acid{3-hydroxy-1-[1-(toluene-2-sulfonylamino)-methanoyl]-azepan-4-yl}-amide

[1923] Following the procedure of Example 283a except substituting thecompound of Example 334a the title compound was prepared: MS(ES) 441(M+H)⁺.

[1924] c.) Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-hydroxy-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1925] Following the procedure of Example 280i except substituting thecompound of Example 334b the title compound was prepared: MS(ES) 585(M+H)⁺.

[1926] d.) Benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1927] Following the procedure of Example 291 d except substituting thecompound of Example 334c the title compound was prepared: MS(ES) 583(M+H)⁺.

Example 335

[1928] Preparation of 3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1929] Following the procedures of Example 334c-d except substituting3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(ES) 597 (M+H)⁺.

Example 336

[1930] Preparation of Benzo[b]thiophene-2-carboxylic Acid((S)-3-methyl-1-3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1931] Following the procedures of Example 334c-d except substitutingBenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(ES) 599 (M+H)⁺.

Example 337

[1932] Preparation of Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamovl}-butyl)-amide

[1933] Following the procedures of Example 334a-d except substituting2-chlorobenzenesulfonyl isocyanate for o-toluenesulfonyl isocyanate thetitle compound was prepared: MS(ES) 603 (M+H)⁺.

Example 338

[1934] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1935] Following the procedures of Example 334a-d except substituting2-chlorobenzenesulfonyl isocyanate for o-toluenesulfonyl isocyanate and3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(ES) 617 (M+H)⁺.

Example 339

[1936] Preparation of Benzo[b]thiophene-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1937] Following the procedures of Example 334a-d except substituting2-chlorobenzene sulfonyl isocyanate for o-toluenesulfonyl isocyanate andbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(ES) 619 (M+H)⁺.

Example 340

[1938] Preparation of Benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1939] Following the procedures of Example 334a-d except substituting4-fluorobenzene sulfonyl isocyanate for o-toluenesulfonyl isocyanate thetitle compound was prepared: MS(ES) 587 (M+H)⁺.

Example 341

[1940] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1941] Following the procedures of Example 334-d except substituting4-fluorobenzene sulfonyl isocyanate for o-toluenesulfonyl isocyanate and3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(ES) 601 (M+H)⁺.

Example 342

[1942] Preparation of Benzo[b]thiophene-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl1-butyl)-amide

[1943] Following the procedures of Example 334a-d except substituting4-fluorobenzene sulfonyl isocyanate for o-toluenesulfonyl isocyanate andbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(ES) 603 (M+H)⁺.

Example 343

[1944] Preparation of Benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1945] Following the procedures of Example 334a-d except substitutingp-toluenesulfonyl isocyanate for o-toluenesulfonyl isocyanate the titlecompound was prepared: MS(ES) 583 (M+H)⁺.

Example 344

[1946] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1947] Following the procedures of Example 334a-d except substitutingp-toluenesulfonyl isocyanate for o-toluenesulfonyl isocyanate and3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared: MS(ES) 597 (M+H)⁺.

Example 345

[1948] Preparation of Benzo[b]thiophene-2-carboxylic Acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide

[1949] Following the procedures of Example 334a-d except substitutingp-toluenesulfonyl isocyanate for o-toluenesulfonyl isocyanate andbenzo[b]thiophene-2-carboxylic acid for benzofuran-2-carboxylic acid thetitle compound was prepared: MS(ES) 597 (M+H)⁺.

Example 346

[1950] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[1951] Following the general procedures of Example 331a-d exceptsubstituting 6-methylpyridine-2-aldehyde for α-quinoline carbaldehydethe title compound was prepared: MS(ES) 491 (M+H)⁺.

[1952] The diastereomers were separated by HPLC to provide diastereoemr1 and diastereomer 2.

Example 347

[1953] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[1954] Following the general procedures of Example 331 a-d exceptsubstituting 6-methylpyridine-2-aldehyde for a-quinoline carbaldehydeand 3-methyl-benzofuran-2-carboxylic acid for benzofuran carboxylic acidthe title compound was prepared: MS(ES) 505 (M+H)⁺.

[1955] The diastereomers were separated by HPLC to provide diastereoemr1 and diastereomer 2.

Example 348

[1956] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[1957] Following the general procedures of Example 331 a-d exceptsubstituting 6-methylpyridine-2-aldehyde for α-quinoline carbaldehydeand benzo[b]thiophene-2-carboxylic acid for benzofuran carboxylic acidthe title compound was prepared: MS(ES) 507 (M+H)⁺.

[1958] The diastereomers were separated by HPLC to provide diastereomer1 and diastereomer 2.

Example 349

[1959] Preparation of Benzo[b]thiophene-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1960] a.){(S)-1-[1-(2-fluorophenylcarbamoyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-carbamicAcid Tert-Butyl Ester

[1961] To a solution of the compound of Example 280g (0.1 gm, 0.29 mmol)dissolved in THF was added 2-flurophenyl isocyanate (32 ml, 0.29 mmol)and stirred for 1 hr. THF was removed in vaccuo and the compound wasdirectly used in the next step: MS(ES): 481.02 (M+H)+.

[1962] b.)4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepane-1-carboxylicAcid (2-fluoro-phenyl)-amide

[1963] To a solution of the compound of Example 349a (1.96 g, 4.1 mmol)dissolved in MeOH was added 4M HCl/dioxane (5 ml, 20.3 mmol) and allowedto stir at RT for 2 hr. Excess reagent was removed in vaccuo andazeotroped with toluene to yield 1.84 gm of the product.

[1964] c.) Benzo[b]thiophene-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-hydroxy-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1965] To a solution of the compound of Example 349b (0.11 g, 0.28 mmol)dissolved in dichloromethane were added P-EDC (0.35 g, 1.8 mmol/g), HOBT(0.06 g, 0.49 mmol) and 2-benzothiophene carboxylic acid (0.077 gm,0.432 mmol). The reaction mixture was shaken for 16 hr. The reaction wascontinued for one more hour by the addition of trisamine(0.38 gm, 3.7mmol/g), followed by the filtration of the product. The product waspurified on a silica gel column to yield 112.5 mg of the product:MS(ES): 541.2 (M+H)⁺.

[1966] d.) Benzo[b]thiophene-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1967] To a solution of the compound of example 349c (0.112 g, 0.2 mmol)was dissolved in dichloromethane followed by the addition of Dess-Martinperiodinane (0.175 g, 0.41 mmol). The reaction was stirred for 1 hrfollowed whereupon it was washed with Na₂S₂O₃, NaHCO₃ and brine. Thecompound was purified on a silica gel column to yield 78 mg of theproduct as a mixture of diastereomers. Separation of the diastereomersby HPLC provided diastereomer 1: MS (ES) 539 (M+H)⁺ and diastereomer2:539 MS(ES) (M+H)⁺.

Example 350

[1968] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1969] Following the general procedures of example 349c-d exceptsubstituting 3-methyl-benzofuran-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1970] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 537 (M+H)⁺ and diastereomer 2: MS(ES) 537 (M+H)⁺.

Example 351

[1971] Preparation of 2,4-Dimethylfuran-3-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1972] Following the general procedures of example 349c-d exceptsubstituting 2,4-dimethylfuran-3-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1973] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 501 (M+H)⁺ and diastereomer 2: MS(ES) 501 (M+H)⁺.

Example 352

[1974] Preparation of Quinoxaline-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1975] Following the general procedures of example 349c-d exceptsubstituting quinoxaline-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1976] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 535 (M+H)⁺ and diastereomer 2: MS(ES) 535 (M+H)⁺.

Example 353

[1977] Preparation of Thieno[3,2-b]thiophene-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1978] Following the general procedures of example 349c-d exceptsubstituting thieno[3,2-b]thiophene-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1979] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 545 (M+H)⁺ and diastereomer 2: MS(ES) 545 (M+H)⁺.

Example 354

[1980] Preparation of Quinoline-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1981] Following the general procedures of example 349c-d exceptsubstituting quinoline-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1982] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 534 (M+H)³⁰ and diastereomer 2: MS(ES) 534 (M+H)⁺.

Example 355

[1983] Preparation of 4-Methyl-thiophene-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1984] Following the general procedures of example 349c-d exceptsubstituting 4-methyl-thiophene-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1985] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 503 (M+H)⁺ and diastereomer 2: MS(ES) 503 (M+H)⁺.

Example 356

[1986] Preparation of 5-Methoxy-benzofuran-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1987] Following the general procedures of example 349c-d exceptsubstituting 5-methoxy-benzofuran-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1988] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 553 (M+H)⁺ and diastereomer 2: MS(ES) 553 (M+H)⁺.

Example 357

[1989] Preparation of 4-Methyl-furan-2-carboxylic Acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1990] Following the general procedures of example 349c-d exceptsubstituting 4-methyl-furan-2-carboxylic acid forbenzo[b]thiophene-2-carboxylic acid the title compound was prepared.

[1991] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 487 (M+H)⁺ and diastereomer 2: MS(ES) 487 (M+H)⁺.

Example 358

[1992] Preparation of Benzofuran-2-carboxylic Acid[(S)-1-(]-butyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1993] Following the general procedure of Examples 331 a-d exceptsubstituting butyraldehyde for (c-quinoline carbaldehyde the titlecompound was prepared. Separation of the diastereomers by HPLC provideddiastereomer 1: MS(ES) 441.9 (M+H)⁺ and diastereomer 2: MS(ES) 441.9(M+H)⁺.

Example 359

[1994] Preparation of Benzofuran-2-carboxylic Acid[(S)-1-(1-propyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide

[1995] Following the general procedure of Examples 331a-d exceptsubstituting propionaldehyde for α-quinoline carbaldehyde the titlecompound was prepared.

[1996] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 428 (M+H)⁺ and diastereomer 2: MS(ES) 428 (M+H)⁺.

Example 360

[1997] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(494.2)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[1998] Following the general procedure of Examples 331 a-d exceptsubstituting 2-fluorobenzaldeyde for α-quinoline carbaldehyde the titlecompound was prepared.

[1999] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) (M+H)⁺ and diastereomer 2: MS(ES) 494.2 (M+H)⁺.

Example 361

[2000] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[1-(2-morpholin-4-yl-thiazol-4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[2001] Following the general procedure of Examples 331 a-d exceptsubstituting 2-morpholin-4-yl-thiazole-4-carbaldehyde for α-quinolinecarbaldehyde the title compound was prepared. Separation of thediastereomers by HPLC provided diastereomer 1: MS(ES) 568.2 (M+H)⁺ anddiastereomer 2: MS(ES) 568.4 (M+H)⁺.

Example 362

[2002] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1]-(5-ethyl-furan-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2003] Following the general procedure of Examples 331 a-d exceptsubstituting 5-ethyl-2-furaldehyde for α-quinoline carbaldehyde thetitle compound was prepared. Separation of the diastereomers by HPLCprovided diastereomer 1: MS(ES) 549.4 (M+H)⁺ and diastereomer 2: MS(ES)549.4 (M+H)⁺.

Example 363

[2004] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,4-dimethyl-thieno[3,2-b]thiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2005] Following the general procedure of Examples 331 a-d exceptsubstituting 3,4-diemethylthieno[b]thiophene-2-carboxaldehyde forα-quinoline carbaldehyde the title compound was prepared. Separation ofthe diastereomers by HPLC provided diastereomer 1: MS(ES) 566.2 (M+H)⁺and diastereomer 2: MS(ES) 566.2 (M+H)⁺.

Example 364

[2006] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(3-phenyl-3H-[1,2,3]triazol-4-ylmethyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2007] Following the general procedure of Examples 331a-d exceptsubstituting 2-phenyl-2H-pyrazole-3-carbaldehyde for α-quinolinecarbaldehyde the title compound was prepared. Separation of thediastereomers by HPLC provided diastereomer 1: MS(ES) 543.2 (M+H)⁺ anddiastereomer 2: MS(ES) 543.4 (M+H)⁺.

Example 365

[2008] Preparation of Benzofuran-2-carboxylic acid[(S)-1-[1-(isothiazol-3-ylmethyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl}-amide

[2009] Following the general procedure of Examples 331a-d exceptsubstituting isothiazole-3-carbaldehyde for α-quinoline carbaldehyde thetitle compound was prepared.

[2010] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 483.1 (M+H)⁺ and diastereomer 2: MS(ES) 483.1 (M+H)⁺.

Example 366

[2011] Preparation of Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-(3-oxo-1-thiophen-2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide

[2012] Following the general procedure of Examples 331 a-d exceptsubstituting thiophene-2-carbaldehyde for α-quinoline carbaldehyde thetitle compound was prepared.

[2013] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 582 (M+H)⁺ and diastereomer 2: MS(ES) 582,(M+H)⁺.

Example 367

[2014] Preparation of Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-(3-oxo-1-thiophen-2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide

[2015] Following the general procedure of Examples 331a-d exceptsubstituting benzo[b]thiophene-2-carbaldehyde for α-quinolinecarbaldehyde the title compound was prepared. Separation of thediastereomers by HPLC provided diastereomer 1: MS(ES) 546 (M+H)⁺ anddiastereomer 2: MS(ES) 546 (M+H)⁺.

Example 368

[2016] Preparation of Benzofuran-2-carboxylic Acid[(S)-3-methyl-1-(3-oxo-1-pentyl-azepan-4-ylcarbamoyl)-butyl]-amide

[2017] Following the general procedure of Examples 331a-d exceptsubstituting pentanal for a-quinoline carbaldehyde the title compoundwas prepared. Separation of the diastereomers by HPLC provideddiastereomer 1: MS(ES) 556 (M+H)⁺ and diastereomer 2: MS(ES) 556 (M+H)⁺.

Example 369

[2018] Preparation of Benzofuran-2-carboxylic Acid{(S)-3-methyl-1-[-(1-methyl-1H-imidazol-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide

[2019] Following the general procedure of Examples 331 a-d exceptsubstituting 3-methyl-3H-imidazole-4-carbaldehyde for α-quinolinecarbaldehyde the title compound was prepared: MS(ES) 480.4 (M+H)⁺.

Example 370

[2020] Preparation of 1-Oxy-pyridine-2-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2021] Following the procedure of Example 280h-j except substituting1-oxy-pyridine-2-carboxylic acid for 2-benzofuran-2-carboxylic acid and2-pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chlorideprovided the title compound. Separation of the diastereomers by HPLCgave diastereomer 1 (ESMS: M+H⁺=504.2) and diastereomer 2 (ESMS:M+H⁺=504.2).

Example 371

[2022] Preparation of 2-Oxy-pyridine-3-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2023] Following the procedure of Example 280h-j except substituting2-oxy-pyridine-3-carboxylic acid for 2-benzofuran-2-carboxylic acid and2-pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chlorideprovided the title compound. Separation of the diastereomers by HPLCgave diastereomer 1 (ESMS: M+H⁺=504.2) and diastereomer 2 (ESMS:M+H⁺=504.2).

Example 372

[2024] Preparation of 1H-Benzoimidazole-5-carboxylic Acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2025] Following the procedure of Example 280h-j except substituting1H-benzoimidazole-5-carboxylic acid for 2-benzofuran-2-carboxylic acidand 2-pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chlorideprovided the title compound. Separation of the diastereomers by HPLCgave diastereomer 1 (ESMS: M+H⁺=504.2) and diastereomer 2 (ESMS:M+H⁺=504.2).

Example 373

[2026] Preparation of4-{(S)-2-[(1-Benzofran-2-yl-methanoyl)-amino]-4-methyl-pentanoylamino}-1-methyl-3-oxo-1-pentyl-azepanium

[2027] A solution of the compound of Example 368 in neat methyl iodidewas heated at reflux for 48 hours whereupon the mixture was concentratedto provide the title compound: MS(ES) 471.6 (M+H)⁺.

Example 374

[2028] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-1,2-dimethyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2029] Following the procedure of Example 280h-j except substituting1,2-dimethyl-1H-imidazole-4-sulfonyl chloride for3-fluorobenzenesulfonyl chloride provided the title compound: MS(ES)544.4 (M+H)⁺.

Example 375

[2030] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2031] Following the procedure of Example 280h-j except substituting1-methyl-1H-imidazole-4-sulfonyl chloride for 3-fluorobenzenesulfonylchloride provided the title compound: MS(ES) 530.2 (M+H)⁺.

Example 376

[2032] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2033] Following the procedure of Example 280h-j except substituting4-methanesulfonyl-benzenesulfonyl chloride for 3-fluorobenzenesulfonylchloride provided the title compound. Separation of the diastereomers byHPLC gave diastereomer 1: MS(ES) 604.2 (M+H)⁺ and diastereomer 2: MS(ES)604.2 (M+H)⁺.

Example 377

[2034] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(2-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2035] Following the procedure of Example 280h-j except substituting2-methanesulfonyl-benzenesulfonyl chloride for 3-fluorobenzenesulfonylchloride provided the title compound. Separation of the diastereomers byHPLC gave diastereomer 1: MS(ES) 604.2 (M+H)⁺ and diastereomer 2: MS(ES)604.2 (M+H)⁺.

Example 378

[2036] Preparation of Benzofuran-2-carboxylic Acid{(S)-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide

[2037] Following the procedure of Example 280h-j except substituting3,5-dimethyl-isoxazole-4-sulfonyl chloride for 3-fluorobenzenesulfonylchloride provided the title compound. Separation of the diastereomers byHPLC gave diastereomer 1: MS(ES) 545.2 (M+H)⁺ and diastereomer 2: MS(ES)545.2 (M+H)⁺.

Example 379

[2038] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid{(1S,2R)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2039] a.) 3-Methyl-benzofuran-2-carboxylic acid{(1S,2R)-2-methyl-1-[3-hydroxy-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2040] Following the general proceures of Example 280f-i exceptsubstituting N-Boc-allo-isoleucine for N-Boc-leucine and2-pyridinesulfonyl chloride for 3-fluorobenzenesulfonyl chloride and3-methyl-benzofuran-2-carboxylic acid for benzofuran-2-carboxylic acidthe title compound was prepared.

[2041] b.) 3-Methyl-benzofuran-2-carboxylic Acid{(1S,2R)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2042] Following the general procedure of Example 291d exceptsubstituting the compound of Example 105b the title compound wasprepared. Separation of the diastereomers by HPLC provided diastereomer1: MS(ES) 541 (M+H)⁺ and diastereomer 2: MS(ES) 541 (M+H)⁺.

Example 380

[2043] Preparation of 3-Methyl-benzofuran-2-carboxylic Acid1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-cyclopentyl}-amide

[2044] Following the general procedures of Examples 379a-b exceptsubstituting N-Boc-cycloleucine for N-Boc-allo-leucine the titlecompound was prepared: MS(ES) 539 (M+H)⁺.

Example 381

[2045] Preparation of Furo[3,2-b]-pyridine-2-carboxylic acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide

[2046] Following the general procedure of Examples 291 c-d exceptsubstituting furo[3,2-b]-pyridine-2-carboxylic acid for5-fluoro-benzofuran-2-carboxylic acid provided the title compound as amixture of diastereomers: MS(ES) 587 (M+H)⁺.

[2047] Separation of the diastereomers by HPLC provided diastereomer 1:MS(ES) 544.2 (M+H)⁺ and diastereomer 2: MS(ES) 544.2 (M+H)⁺.

[2048] The above specification and Examples fully disclose how to makeand use the compounds of the present invention. However, the presentinvention is not limited to the particular embodiments describedhereinabove, but includes all modifications thereof within the scope ofthe following claims. The various references to journals, patents andother publications which are cited herein comprise the state of the artand are incorporated herein by reference as though fully set forth.

We claim:
 1. A compound of Formula I:

wherein: R¹ is selected from the group consisting of:

R² is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹C(S)—,R⁹SO₂—, R⁹OC(O)—, R⁹R¹¹NC(O)—, R⁹R¹¹NC(S)—, R⁹(R¹¹)NSO₂—

and R⁹SO₂R¹¹NC(O)—; R³ is selected from the group consisting of: H,C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,HetC₀₋₆alkyl and ArC₀₋₆alkyl; R³ and R′ may be connected to form apyrrolidine, piperidine or morpholine ring; R⁴ is selected from thegroup consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)—, R⁵C(S)—, R⁵SO₂—, R⁵OC(O)—,R⁵R¹²NC(O)—, and R⁵R¹²NC(S)—; R⁵ is selected from the group consistingof: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R⁶ is selected from the group consistingof: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R⁷ is selected fromthe group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R¹⁰C(O)—, R¹⁰C(S)—, R¹⁰SO₂—, R¹⁰OC(O)—,R¹⁰R¹³NC(O)—, and R¹⁰R¹³NC(S)—; R⁸ is selected from the group consistingof: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl andArC₀₋₆alkyl; R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R¹⁰ isselected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R¹¹ isselected from the group consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, andHet-C₀₋₆alkyl; R¹² is selected from the group consisting of: H,C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R¹³ is selected from thegroup consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R′is selected from the group consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl,and Het-C₀₋₆alkyl; R″ is selected from the group consisting of: H,C₁₋₆alkyl, Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl; R′″ is selected from thegroup consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R″″ is selected from the groupconsisting of: C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl C₂₋₆alkenyl,C₂₋₆alkynyl, HetC₀₋₆alkyl and ArC₀₋₆alkyl; X is selected from the groupconsisting of: CH₂, S, and O; Z is selected from the group consistingof: C(O) and CH₂; n is an integer from 1 to 5; and pharmaceuticallyacceptable salts, hydrates and solvates thereof.
 2. A compound accordingto claim 1 wherein R¹ is


3. A compound according to claim 1 wherein R³ is selected from the groupconsisting of: H, methyl, ethyl, n-propyl, prop-2-yl, n-butyl, isobutyl,but-2-yl, cyclopropylmethyl, cyclohexylmethyl, 2-methanesulfinyl-ethyl,1-hydroxyethyl, toluyl, naphthalen-2-ylmethyl, benzyloxymethyl, andhydroxymethyl.
 4. A compound according to claim 3 wherein R³ is selectedfrom the group consisting of: toluyl, isobutyl and cyclohexylmethyl. 5.A compound according to claim 4 wherein R³ is isobutyl.
 6. A compoundaccording to claim 1 wherein R⁴ is selected from the group consistingof: R⁵OC(O)—,R⁵C(O)— or R⁵SO₂—.
 7. A compound according to claim 6wherein R⁴ is R⁵C(O)—.
 8. A compound according to claim 7 wherein R⁵ isselected from the group consisting of: C₁₋₆alkyl, Ar—C₀₋₆alkyl andHet-C₀₋₆alkyl.
 9. A compound according to claim 8 wherein R⁵ is selectedfrom the group consisting of: methyl, halogenated methyl, C₁₋₆alkoxysubstituted methyl, heterocycle substituted methyl; ethyl; butyl, arylsubstituted butyl; isopentyl; cyclohexyl; butenyl, aryl substitutedbutenyl; acetyl; phenyl, phenyl substituted with one or more halogens,phenyl substituted with one or more aryloxy or C₁₋₆alkoxy groups, phenylsubstituted with one or more C₁₋₆alkyl sulfonyl groups; benzyl;naphthylenyl; benzo[1,3]dioxolyl; furanyl, halogen substituted furanyl,aryl substituted furanyl, C₁₋₆alkyl substituted furanyl;tetrahydrofuranyl; benzofuranyl, C₁₋₆alkoxy substituted benzofuranyl,halogen substituted benzofuranyl, C₁₋₆alkyl substituted benzofuranyl;napththo[2,1-b]-furanyl, C₁₋₆alkyl substituted napththo[2,1-b]-furanyl;benzo[b]thiophenyl, C₁₋₆alkoxy substituted benzo[b]thiophenyl;quinolinyl; quinoxalinyl; 1,8 naphthyridinyl; indolyl, C₁₋₆alkylsubstituted indolyl; pyridinyl, C₁₋₆alkyl substituted pyridinyl,1-oxy-pyridinyl; furo[3,2-b]-pyridinyl, C₁₋₆alkyl substitutedfuro[3,2-b]-pyridinyl; thiophenyl, C₁₋₆alkyl substituted thiophenyl,halogen substituted thiophenyl; thieno[3,2-b]thiophenyl; isoxazolyl,C₁₋₆alkyl substituted isoxazolyl; oxazolyl; and 1H-benzoimidazolyl. 10.A compound according to claim 8 wherein R⁵ is selected from the groupconsisting of: pentanonyl; naphthylen-2-yl; benzo[1,3]dioxol-5-yl,furan-2-yl; tetrahydrofuran-2-yl; benzofuran-2-yl;napththo[2,1-b]-furan-2-yl benzo[b]thiophen-2-yl; quinolin-2-yl,quinolin-3-yl, quinolin-4-yl, quinolin-6-yl, and quinolin-8-yl;quinoxalin-2-yl; 1,8 naphthyridin-2-yl; indol-3-yl, indol-5-yl;pyridin-2-yl, pyridin-3-yl, pyridin-5-yl; furo[3,2-b]-pyridin-2-yl;thiophen-3-yl; thieno[3,2-b]thiophene-2-yl; isoxazol-4-yl; oxazol-4-yl;and 1H-benzoimidazol-5-yl.
 11. A compound according to claim 8 whereinR⁵ is selected from the group consisting of: trifluoromethyl,phenoxy-methyl, 4-fluoro-phenoxy-methyl, 2-thiophenyl-methyl;piperidin-1-yl-ethyl; 4-(4-methoxy)phenyl-butyl; 4-pentanonyl;4,4-bis(4-methoxyphenyl)-but-3-enyl; 3,4-dichlorophenyl, 4-fluorophenyl,3,4-dimethoxy-phenyl, 3-benzyloxy-4-methoxy-phenyl,4-methanesulfonyl-phenyl; 5-nitro-furan-2-yl,5-(4-nitrophenyl)-furan-2-yl, 5-(3-triflouromethyl-phenyl)-furan-2-yl,5-bromo-furan-2-yl, 5-(4-chloro-phenyl)-furan-2-yl),3-methyl-furan-2-yl, 4-methyl-furan-2-yl, 2,5-dimethyl-furan-2-yl,2,4-dimethyl-furan-2-yl; 5-(2-piperazin-4-carboxylic acid tert-butylester-ethoxy) benzofuran-2-yl,5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-yl,5-(2-piperazin-1-yl-ethoxy)benzofuran-2-yl,5(2-cyclohexyl-ethoxy)-benzofuran-2-yl, 7-methoxy-benzofuran-2-yl,5-methoxy-benzofura-2-yl, 5,6-dimethoxy-benzofuran-2-yl,5-fluoro-benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl,3-methyl-benzofuran-2-yl, 3,5-dimethyl-benzofuran-2-yl, and3-ethyl-benzofuran-2-yl; also 5-fluoro-3-methyl-benzofuran-2-yl,6-fluoro-3-methyl-benzofuran-2-yl, 5-methoxy-3-methyl-benzofuran-2-yl,4-methoxy-3-methyl-benzofuran-2-yl, and6-methoxy-3-methyl-benzofuran-2-yl; 1-methyl-naphtho[2,1-b]-furan-2-yl;5,6-dimethoxy-benzo[b]thiophen-2-yl; N-methyl-indol-2-yl;1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl, 2-methyl-pyridin-5-yl;5-methyl-thiophen-2-yl, 4,5-dibromo-thiophen-2-yl; 5-tert-butyl-3-methylthieno[3,2-b]thiophen-2-yl; 3,5-dimethyl-isoxazol-4-yl; and5-methyl-2-phenyl oxazol-4-yl, and2-phenyl-5-trifluoromethyl-oxazol-4-yl.
 12. A compound according toclaim 8 wherein R⁵ is selected from the group consisting of:3-methyl-benzofuran-2-yl, thieno[3,2-b]thiophen-2-yl,5-methoxybenzofuran-2-yl, quinoxalin-2-yl, and quinolin-2-yl.
 13. Acompound according to claim 1 wherein R is selected from the groupconsisting of H and naphthalen-2-yl-methyl.
 14. A compound according toclaim 13 wherein R′ is H.
 15. A compound according to claim 1 wherein R″is H.
 16. A compound according to claim 1 wherein R′″ is selected fromthe group consisting of H and 6,6-dimethyl.
 17. A compound according toclaim 16 wherein R′″ is H.
 18. A compound according to claim 1 whereinR” and R′″ are both H.
 19. A compound according to claim 1 wherein R¹ is


20. A compound according to claim 1 wherein R¹ is


21. A compound according to claim 19 wherein R² is selected from thegroup consisting of: Ar—C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂, R⁹R¹¹NC(O)—, and


22. A compound according to claim 21 wherein R² is selected from thegroup consisting of: Ar—C₀₋₆alkyl, R⁹C(O)—, and R⁹SO₂.
 23. A compoundaccording to claim 22 wherein R² is R⁹SO₂.
 24. A compound according toclaim 20 wherein R⁶ is H.
 25. A compound according to claim 20 whereinR⁷ is R¹⁰C(O).
 26. A compound according to claim 20 wherein R⁸ isC₁₋₆yl.
 27. A compound according to claim 26 wherein R⁸ is isobutyl. 28.A compound according to claim 20 wherein R⁹ is selected from the groupconsisting of: C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl.
 29. A compoundaccording to claim 28 wherein R⁹ is selected from the group consistingof: methyl; ethyl, and C₁₋₆alkyl-substituted ethyl; propyl; butyl,C₁₋₆alkyl-substituted butyl; tert-butyl; isopentyl; phenyl, halogensubstituted phenyl, C₁₋₆alkoxy phenyl, C₁₋₆alkyl substituted phenyl,cyanophenyl, C₁₋₆alkyl sulfonyl substituted phenyl; toluyl,Het-substituted toluyl; benzoic acid; naphthylenyl; benzo[1,3]dioxolyl;benzo[1,2,5]oxadiazolyl; pyridinyl, 1-oxy-pyridinyl, C₁₋₆alkylpyridinyl; thiophene; thiazolyl; 1H-imidazolyl, C₁₋₆alkyl substitutedimidazolyl; 1H-[1,2,4]triazolyl, C₁₋₆alkyl substituted1H-[1,2,4]triazolyl; and isoxazolyl, C₁₋₆alkyl substituted isoxazolyl.30. A compound according to claim 28 wherein R⁹ is selected from thegroup consisting of: 2-cyclohexyl-ethyl; 3-methylbutyl;3,4-dichlorophenyl, 4-bromophenyl, 2-fluorophenyl, 3-fluorophenyl4-fluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2-cyanophenyl;4-ethyl-phenyl, 2-methyl phenyl, 4-methyl phenyl, 4-methanesulfonylphenyl, 2-methanesulfonyl phenyl; 2-benzoic acid; naphthylen-2-yl;benzo[1,3]dioxol-5-yl; benzo[1,2,5]oxadiazol-4-yl; pyridin-2-yl,pyridin-3-yl, 1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl,3-methyl-pyridin-2-yl, 6-methyl-pyridin-2-yl; thiophene-2-yl;thiazol-2-yl; 1H-imidazol-2-yl, 1H-imidazol-4-yl,1-methyl-1H-imidazol-2-yl, 1-methyl-1H-imidazol-4-yl,1,2-dimethyl-1H-imidazol-4-yl; 1H-[1,2,4]triazol-3-yl,5-methyl-1H-[1,2,4]triazol-3-yl; and 3,5-dimethyl-isoxazol-4-yl.
 31. Acompound according to claim 1 wherein: R¹ is

R² is selected from the group consisting of: Ar—C₀₋₆alkyl, R⁹C(O)—,R⁹SO₂, R⁹R¹ INC(O)—, and

R³ is selected from the group H, C_(1*6)alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,and Ar C₀₋₆alkyl; R⁴ is selected from the group consisting of: R⁵OC(O)—,R⁵C(O)— or R⁵SO₂—; R⁵ is selected from the group consisting of:C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R⁶ is H; R⁷ is R¹⁰OC(O); R⁸is C₁₋₆alkyl; R⁹ is selected from the group consisting of: C₁₋₆alkyl,Ar—C₀₋₆alkyl and Het-Co ₆alkyl; R¹⁰ is selected from the groupconsisting of: C₁₋₆alkyl, Ar—C₀₋₆alkyl and Het-Co ₆alkyl; R ′ is H; R″is H; and R′″ is H.
 32. A compound according to claim 31 wherein: R² isselected from the group consisting of: Ar—Co-6alkyl, R⁹C(O)— and R⁹SO₂;R³ is selected from the group consisting of: H, methyl, ethyl, n-propyl,prop-2-yl, n-butyl, isobutyl, but-2-yl, cyclopropylmethyl,cyclohexylmethyl, 2-methanesulfinyl-ethyl, 1-hydroxyethyl, toluyl,naphthalen-2-ylmethyl, benzyloxymethyl, and hydroxymethyl; R⁴ isR⁵C(O)—; R⁵ is selected from the group consisting of: methyl,halogenated methyl, alkoxy substituted methyl, heterocycle substitutedmethyl; butyl, aryl substituted butyl; isopentyl; cyclohexyl; butenyl,aryl substituted butenyl; acetyl; phenyl, phenyl substituted with one ormore halogens, phenyl substituted with one or more alkoxy groups, phenylsubstituted with one or more sulfonyl groups; benzyl; naphthylenyl;benzo[1,3]dioxolyl; furanyl, halogen substituted furanyl, arylsubstituted furanyl; tetrahydrofuran-2-yl; benzofuranyl, alkoxysubstituted benzofuranyl, halogen substituted benzofuranyl, alkylsubstituted benzofuranyl; benzo[b]thiophenyl, alkoxy substitutedbenzo[b]thiophenyl; quinolinyl; quinoxalinyl; 1,8 naphthyridinyl;indolyl (22), alkyl substituted indolyl; pyridinyl, alkyl substitutedpyridinyl, 1-oxy-pyridinyl; thiophenyl, alkyl substituted thiophenyl,halogen substituted thiophenyl; thieno[3,2-b]thiophenyl; isoxazolyl,alkyl substituted isoxazolyl; and oxazolyl; R⁹ is selected from thegroup consisting of: methyl; ethyl, C₁₋₆alkyl-substituted ethyl; butyl,C₁₋₆alkyl-substituted butyl; tert-butyl; isopentyl; phenyl, halogensubstituted phenyl, C₁₋₆alkoxy phenyl, cyanophenyl; toluyl,Het-substituted toluyl; benzoic acid; naphthylenyl; benzo[1,3]dioxolyl;benzo[1,2,5]oxadiazolyl; pyridinyl, 1-oxy-pyridinyl, C₁₋₆alkylpyridinyl; thiophene; thiazolyl; 1H-imidazolyl, C₁₋₆alkyl substitutedimidazolyl; 1H-[1,2,4]triazolyl, C₁₋₆alkyl substituted1H-[1,2,4]triazolyl; and quinolinyl.
 33. A compound according to claim31 wherein: R⁵ is selected from the group consisting of: pentanonyl;naphthylen-2-yl; benzo[1,3]dioxol-5-yl, furan-2-yl; benzofuran-2-yl;benzo[b]thiophen-2-yl; quinolin-2-yl, quinolin-3-yl, quinolin-4-yl,quinolin-6-yl, and quinolin-8-yl; quinoxalin-2-yl; 1,8naphthyridin-2-yl; indol-3-yl, indol-5-yl; pyridin-2-yl, pyridin-5-yl,thiophen-3-yl; thieno[3,2-b]thiophene-2-yl; isoxazol-4-yl; andoxazol-4-yl.
 34. A compound according to claim 31 wherein R⁵ is selectedfrom the group consisting of: trifluoromethyl, phenoxy-methyl,4-fluoro-phenoxy-methyl, 2-thiophenyl-methyl; 4-(4-methoxy)phenyl-butyl;4-pentanonyl; 4,4-bis(4-methoxyphenyl)-but-3-enyl; 3,4-dichlorophenyl,4-fluorophenyl, 3,4-dimethoxy-phenyl, 3-benzyloxy-4-methoxy-phenyl,4-methanesulfonyl-phenyl; 5-nitro-furan-2-yl,5-(4-nitrophenyl)-furan-2-yl, 5-(3-triflouromethyl-phenyl)-furan-2-yl,5-bromo-furan-2-yl, 5-(4-chloro-phenyl)-furan-2-yl;5-(2-piperazin-4-carboxylic acid tert-butyl ester-ethoxy)benzofuran-2-yl, 5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-yl(44),5-(2-piperazin-1-yl-ethoxy)benzofuran-2-yl,5-(2-cyclohexyl-ethoxy)-benzofuran-2-yl, 7-methoxy-benzofuran-2-yl,5-methoxy-benzofura-2-yl, 5,6-dimethoxy-benzofuran-2-yl,5-fluoro-benzofuran-2-yl, 5,6-difluoro-benzofuran-2-yl,3-methyl-benzofuran-2-yl; 5,6-dimethoxy-benzo[b]thiophen-2-yl;N-methyl-indol-2-yl; 1-oxy-pyridin-2-yl, 2-methyl-pyridin-5-yl;5-methyl-thiophen-2-yl, 4,5-dibromo-thiophen-2-yl; 5-tert-butyl-3-methylthieno[3,2-b]thiophen-2-yl; 3,5-dimethyl-isoxazol-4-yl;5-methyl-2-phenyl oxazol-4-yl, and2-phenyl-5-trifluoromethyl-oxazol-4-yl.
 35. A compound according toclaim 31 wherein R⁹ is selected from the group consisting of:2-cyclohexyl-ethyl; 3-methylbutyl; 3,4-dichlorophenyl, 4-bromophenyl,2-fluorophenyl, 4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl,3-methoxyphenyl, 4-methoxyphenyl, 3,4-dimethoxyphenyl, 2-cyanophenyl;2-benzoic acid; naphthylen-2-yl; benzo[1,3]dioxol-5-yl;benzo[1,2,5]oxadiazol-4-yl; pyridin-2-yl, pyridin-3-yl,1-oxy-pyridin-2-yl, 1-oxy-pyridin-3-yl, 3-methyl-pyridin-2-yl,6-methyl-pyridin-2-yl; thiophene-2-yl; thiazol-2-yl; 1H-imidazol-2-yl,1H-imidazol-4-yl, 1-methyl-1 H-imidazol-2-yl, 1-methyl-1H-imidazol-4-yl;1H-[1,2,4]triazol-3-yl, 5-methyl-1H-[1,2,4]triazol-3-yl; andquinolin-2-yl.
 36. A compound according to claim 31 wherein: R² isR⁹SO₂; R³ is isobutyl; R⁴ is R⁵C(O); R⁵ is selected from the groupconsisting of: 3-methyl-benzofuran-2-yl, thieno[3,2-b]thiophen-2-yl,5-methoxybenzofuran-2-yl, quinoxalin-2-yl, or quinolin-2-yl; and R⁹ isselected from the group consisting of: pyridin-2-yl and1-oxy-pyridin-2-yl.
 37. A compound according to claim 36 wherein R⁵ is3-methyl-benzofuran-2-yl.
 38. A compound according to claim 36 whereinR⁹ is 1-oxy-pyridin-2-yl.
 39. A compound according to claim 1 selectedfrom the group consisting of:{(S)-1-[1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl}carbamicacid benzyl ester; Naphthylene-2-carboxylicacid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Benzo[1,3]dioxole-5-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Benzofuran-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Benzo[b]thiophene-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Naphthylene-2-sulphonyl[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoline-2-carboxylic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;3,4-dichlorobenzoic acid[(S)-1-(1-benzyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;4-{(S)-Methyl-2-[(quinoline-2-carbonyl)-amino]pentanoylamino}-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]azepanium;1-((S)-2-Benzyloxycarbonylamino-4-methyl-pentyl)-4-{(S)-4-methyl-2-[(2-quinoiline-2-carbonyl)-amino]-pentanoylamino)-3-oxo-azepanium;1-Benzoyl-4-((S)-2-(benzo[1,3]dioxole-carbonylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium;1-Benzoyl-4-((S)-2-(4-fluoro-benzoylamino)-4-methyl-pentanoylamino)-3-oxo-azepanium;3-Oxo-4-((S)-4-methyl-2-{[5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-1-(4-methyl-pentanoyl)-azepanium;5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;4-((S)-4-Methyl-2-{([5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicacid phenylamide; 5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylicacid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide;5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(benzoyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;5-(2-Pyrrolidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;5-(2-Piperidin-1-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;Naphthlene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;1H_Indole-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-buty])amide;1H-Indole-2-carboxylic acid[(S)-1-(1-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Benzofuran-2-carboxylic acid[(S)-1-({-benzenesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbamoyl]-butyl}amide;Naphthylene-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-phenethyl-azepan-4-ylcarbamoyl]-butyl) amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Naphthylene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;4-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carbonyl]-amino}-pentanoylamino)-3-oxo-azepane-1-carboxylicacid tert-butyl ester;4-((S)-4-Methyl-2-{[(5-(2-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylicacid [(S)-3-methyl-1-(3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;4-Methyl-pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl-acetyl]-azepan-4-yl}-amide;((S)-3-Methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-naphthylene-2-methyl-carbamicacid tert-butyl ester;(S)-4-Methyl-2-[(naphthylen-2-ylmethyl)-amino]-pentenoic acid[3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide;4-[2-(2-{(S)-3-Methyl-1-[3-oxo-1-(pyidine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicacid tert-butyl ester;5-(2-Piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-3-butyl}-amide;5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-(2-Cyclohexyl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl)-butyl)amide;4-[2-(2-1 (S)-3-Methyl-1-[3-oxo-1-(3-pyridin-2-yl-phenyl)-ethyl[azepan-4-ylcarbamoyl]-butylcarbamoyl}-benzofuran-5-yloxy)-ethyl]-piperazine-1-carboxylicacid tert-butyl ester;5-(2-piperizin-1-yl-ethoxy)-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)ethyl]-azepan-4-ylcarbamoyl}-butyl)amide;(S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid[3-oxo-1-(pyridine-2-sulphonyl)-azepan-4-yl]-amide;(S)-4-Methyl-2-(methyl-naphthalen-2-ylmethyl-amino)pentanoic acid{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide;5-(2-Morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid methyl((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)acetyl]-azepan-4-ylcarbamoyl}-butyl)amide;Benzofuran-2-carboxylic acid methyl{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;2,2,2-Trifluoro-N-((S)-3-methyl-1-{3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-N-naphthylen-2-ylmethyl-acetamide;4-[(S)-(Methanesulphonyl-naphthylen-2-ylmethyl-amino)-4-methyl-pentanoylamino]-3-oxo-azepane-1-carboxylicacid benzyl ester; Quinoline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-8-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-6-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Isoquinoline-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Isoquinoline-1-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;1,8-Naphthyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-Bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylamide; 5-Nitro-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-(4-Nitro-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Tetrahydro-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-4-Methyl-2-(2-phenoxy-acetylamino)-pentanoic acid[3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;(S)-2-[2-(4-Fluoro-phenoxy)-acetylamino]-4-methyl-pentanoic acid[3-oxo-(pyridine-2-sulfonyl)-azepan-4-yl]-amide; Benzofuran-2-carboxylicacid{(S)-3-methyl-1-[3-oxo--(pyridine-2-carbonyl)-azepan-4-ylcarbamoyl)-3-butyl]-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}amide;4-((S)-2-tert-Butylcarbonylamino-4-methyl-pentanoylamino)-3-oxo-azepane-1-carboxylicacid benzyl ester; ,6-Dimethoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-methyl-1H-imidazole-4-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(5-methyl-1H-[1,2,4]triazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-3-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1H-imidazole-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoy]]-butylamide; Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;5-(4-Oxy-morpholino-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-3-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-3-carboxylic acid{(S)-1-(3,4-dichloro-benzene-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl)]-3-methyl-butyl)-amide;5-Hydroxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)]-3-methyl-butyl)-amide;2-(4-{(S)-2-{(Benzofuran-2-carbonyl)-amino}-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoicacid;3-(4-{(S)-2-{(Benzofuran-2-carbonyl)-amino]-4-methyl-pentanoylamino}-3-oxo-azepane-1-sulfonyl)-benzoicacid; Benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-Bromo-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5,6-Dimethoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;1-Oxy-pyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-4-Methyl-2-(pyridine-2-sulfonylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;(S)-2-(3-Benzyl-ureido)-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;(S)-4-Methyl-2-(3-phenyl-uriedo)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Benzofuran-2-carboxylic acid{(S)-1-[6,6-dimethyl-3-oxo-1(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Thiophene-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;1H-Indole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(]-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-4-Methyl-2-(2-thiophen-2-yl-acetylamino)-pentanoic acid[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-yl]-amide;1H-Indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;4-Fluoro-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulphonyl)-azepan-4-carbamoyl]-butyl}-benzamide;5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-(1-oxy-pyridine2-sulphonyl)-azepan-4-ylcarbamoyl]-buty}-amide;Thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylamide; 3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;6-Methyl-N-{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-nicotinamide;(S)-4-Methyl-2-(2-thiophen-yl-acetylamino)-pentanoicacid-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-butyl}amide;1H-Indole-6-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzo[1,3]dioxole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;3,4-Dihydro-2H-benzo[b] [1,4]dioxepine-7-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]butyl}amide;5-Methyl-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;4,5-Dibromo-thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;3,5-Dimethyl-isoxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicacid[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,4-dimethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(4-bromo-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(benzo[1,2,5]oxadiazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,5-dimethyl-oxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylamide; Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-tert-Butyl-3-methyl-thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-Methyl-2-phenyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;2-Phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-2-carboxylic acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;1-Methyl-1H-indole-2-carboxylic acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Furan-2-carboxylic acid{[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butylcarbamoyl]-methyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoxaline-2-carboxylic acid[(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;5-(4-Chloro-phenyl)-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid(1-methanesulfonyl-3-oxo-azepan-4-yl)-amide; Quinoline-2-carboxylic acid{[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;1-Methyl-1H-indole-2-carboxylic acid{[(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Furan-2-carboxylic acid({(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;Quinoline-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;1-Methyl-1H-indole-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Furan-2-carboxylic acid({(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)-amide;5-Methoxy-benzofuran-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{[(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; (S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoicacid [1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;1-Methyl-1H-indole-2-carboxylic acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Furan-2-carboxylic acid({(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butylcarbamoyl}-methyl)-amide;5-Methoxy-benzofuran-2-carboxylic acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;(S)-2-[2-(4-Methoxy-phenyl)-acetylamino)-4-methyl-pentanoic acid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;Benzofuran-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;7-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5,6-Dimethoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylicacid-{(S)-1-[1-(3-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylicacid-((S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;7-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5,6-Dimethoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methyl-benzofuran-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;(S)-4-Methyl-2-(1-oxy-pyridine-2-sulfonylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Quinoxaline-2-carboxylicacid-{(S)-1-[1-(2-fluoro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;7-Methoxy-benzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5,6-Dimethoxy-benzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-buty}-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;1-Methyl-1-H-indole-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Quinoxaline-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;7-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; 5,6-Dimethoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; 1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[i-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylicacid-{(S)-1-[1-(4-chloro-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;7-Methoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; 5,6-Dimethoxy-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;1-Methyl-1H-indole-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylicacid-{(S)-1-[1-(3-methoxy-benzenesulphonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylicacid-{(S)-3-methyl-1-[3-oxo-1-(thiophene-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[(2,2′,4-tridueterio)-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide;Benzofuran-2-carboxylic acid{(S)-2-cyclohexyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl1-amide; Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methanesulfinyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide;Benzofuran-2-carboxylic acid{[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-methyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide;Benzofuran-2-carboxylic acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-propyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide;1-(Benzofuran-2-carbonyl)-pyrrolidine-2-carboxylic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;3,4-Dimethoxy-N-{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-benzamide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(4-imethoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[1,3]dioxole-5-carboxylic acid{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3methyl-butyl1-amide; (S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicacid[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-yl]-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl)-amide; Benzofuran-2-carboxylic acid{(S)-1-[1-benzoyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;(S)-4-Methyl-2-(quinoline-8-sulfonylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;(S)-4-Methyl-2-(naphthylene-2-sulfonylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Benzofuran-2-carboxylicacid-{(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;N-{(S)-1-[1-(4-Fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl-3,4-dimethoxy-benzamide;Cyclohexanecarboxylic acid((S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-amide;(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicacid[1-(methanesulfonyl)-3-oxo-azepan-4-yl]-amide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; Benzo[1,3]dioxole-5-carboxylicacid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; Benzofuran-2-carboxylicacid-{(S)-1-(1-methanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;N-[(S)-1-(1-Methanesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-3,4-dimethoxy-benzamide;(S)-2-(2-Benzyloxy-acetylamino)-4-methyl-pentanoicacid[1-(2-cyano-benzensulfonyl)-3-oxo-azepan-4-yl]-amide;N-{(S)-1-[1-(2-Cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-4-methanesulfonyl-1-benzamide;Benzo[b]thiophene-2-carboxylicacid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide; Benzo[1,3]dioxole-5-carboxylicacid-{(S)-1-[1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;(S)-4-Methyl-2-[4-oxo-4-((4-phenoxy-phenyl)-butyrylamino}-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;N-{(S)-1-[(1-(2-cyano-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-3,4-dimethoxy-benzamide;Cyclohexanecarboxylic acid{(S)-1-[1-(4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl}-3-methyl-butyl}-amide;4-Methansulfonyl-N-{(S)-1-[4-methoxy-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide;4-Methansulfonyl-N-{(S)-1-[4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-carbamoyl]-3-methyl-butyl-benzamide;({(S)-3-Methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butylcarbamoyl}-carbamicacid benzyl ester;(S)-2-[5-(4-Methoxy-phenyl)-pentanoylamnio]-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;(S)-2-[2-(3-Benzyloxy-4-methoxy-phenyl)-acetylamnio]-4-methylpentanoicacid [3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;5,6-Difluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;(S)-4-Methyl-2-(5-oxo-hexanoylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;7-Methoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;5,6-Dimethoxy-benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;(R)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic acid{(S)-3-methyl-1-{3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;(S)-1-Benzyl-5-oxo-pyrrolidine-2-carboxylic acid{(S)-3-methyl-1-{3-oxo-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzofuran-2-carboxylic acid{(S)-2-cyclopropyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;Benzofuran-2-carboxylic acid{(S)-3-methylsulfanyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-propyl]-amide;Benzofuran-2-carboxylic acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(3-methyl-pyridine-2-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}amide;5,6-Difluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;5-(4-Chloro-phenyl)-furan-2-carboxylicacid((S)-2-cyclohexyl-1-{3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[6-methyl-3-oxo-1-(pyridine-sulphonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-(4-Chloro-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-2-cyclohexyl-]-[3-oxo-1-(-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methy]-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5,6-Dimethoxy-benzofuran-2-carboxylic acid{(S)-2-cyclohexyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-ethyl}-amide;5,5-Bis-(4-methoxy-phenyl)-pent-4-enoic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]}-butyl}-amide;Quinoline-8-carboxylic acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;Naphthylene-1-carboxylic acid{(S)-2-naphthylen-2-yl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl)-ethyl]-amide;Quinoline-8-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide;Naphthyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Naphthylene-1-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl-amide;3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl1-amide; 3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-carbonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;(S)-Acetylamino-4-methyl-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Quinoline-2-carboxylic acid{1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-pentyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(cyclohexyl-proprionyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(4-methyl-pentanoyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-2-phenyl-ethyl}-amide;Benzofuran-2-carboxylic acid{(S)-2-benzyloxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide;Benzofuran-2-carboxylic acid{(S)-2-hydroxy-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepane-4-ylcarbamoyl]-ethyl}-amide;5-Methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;7-Methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;3-Methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-]-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;1-Methyl-1H-indole-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(thiazole-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;Quinoline-2-carboxylic acid{[(S)-1-[1-(4-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;The following compounds are also particularly preferred embodiments ofthe present invention: Benzofuran-2-carboxylic acid{(S)-1-[-(3-fluoro-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;(S)-4-methyl-2-(3-piperidin-1-yl-propanoylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Benzofuran-2-carboxylic acid{(S)-1-[-(4-ethyl-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[1,3]-dioxole-5-carboxylic acid((S)-3-methyl-1-13-oxo-1-[1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[1,3]-dioxole-5-carboxylic acid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)—-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[1,3]-dioxole-5-carboxylic acid{(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-[3-oxo-1-(ethanesulfonyl-azepan-4-ylcarbamoyl)-3-methyl-1-butyl]-amide;5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-Fluoro-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)-amide;6-Fluoro-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(R)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-furo[3,2-b]-pyridine-2-carboxylic acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-methyl-furan-2-carboxylic acid{(S)-1-[3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methyl-thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid[(S)-1-(]-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;3-Methyl-benzofuran-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzo[b]thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;3-Methyl-furan-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoline-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Thieno[3,2-b]thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoxaline-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;5-Methyl-thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;3-Methyl-furan-2-carboxylic acid{(S)-1-[3-oxo-]-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;2,5-Dimethyl-furan-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-Methyl-thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3,5-Dimethyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl1-amide; 3-Ethyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;4-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;1-methyl-naphtho[2, 1-b]-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;6-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{1,3-dimethyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl1-butyl)-amide; Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;2,4-Dimethylfuran-3-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;4-Methyl-thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;4-Methyl-furan-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-(]-butyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-1-(1-propyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-benzyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(2-morpholin-4-yl-thiazol-4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(5-ethyl-furan-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,4-dimethyl-thieno[3,2-b]thiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(3-phenyl-3H-[1,2,3]triazol-4-ylmethyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-[1-(isothiazol-3-ylmethyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-thiophen-2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-1-(1-benzo[b]thiophen-2-ylmethyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-pentyl-azepan-4-ylcarbamoyl)-butyl]-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(1-methyl-1H-imidazol-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-buty}-amide;1-Oxy-pyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;2-Oxy-pyridine-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;1H-Benzoimidazole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;4-{(S)-2-[(1-Benzofuran-2-yl-methanoyl)-amino]-4-methyl-pentanoylamino}-1-methyl-3-oxo-1-pentyl-azepanium;Benzofuran-2-carboxylic acid{(S)-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid {(S)-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(4-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(2-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(1S,2R)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-cyclopentyl}-amide;and Furo[3,2-b]-pyridine-2-carboxylic acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide.40. A compound of Formula I

wherein: R¹ is selected from the group consisting of:

R² is selected from the group consisting of: C₁₋₆alkyl, Ar—C₀₋₆alkyl,Het-C₀₋₆alkyl, R⁹C(O)—, R⁹SO₂—, R⁹R¹¹NC(O)—, and R⁹SO₂R¹¹NC(O)—; R³ isselected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, Het-C₀₋₆alkyl andAr—C₀₋₆alkyl; R³ and R′ may be connected to form a pyrrolidine,piperidine or morpholine ring; R⁴ is R⁵C(O)—; R⁵ is slected from thegroup consisting of: C₁₋₆alkyl and Het-C₀₋₆alkyl; R⁹ is selected fromthe group consisting of: C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R¹¹ is H; R′ is H; R″ is H; R′″ isselected from the group consisting of: H and C₁₋₆alkyl; R″″ is selectedfrom the group consisting of: C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkylC₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl and ArC₀₋₆alkyl; and n is aninteger from 1 to 5; and pharmaceutically acceptable salts, hydrates andsolvates thereof.
 41. A compound according to claim 40 selected from thegroup consisting of: Benzofuran-2-carboxylic acid{(S)-1-[-(3-fluoro-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;(S)-4-methyl-2-(3-piperidin-1-yl-propanoylamino)-pentanoic acid[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-yl]-amide;Benzofuran-2-carboxylic acid{(S)-1-[-(4-ethyl-benzensulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-(1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[1,3]-dioxole-5-carboxylic acid((S)-3-methyl-1-3-oxo-1-[1-oxy-pyridin-2-yl)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-1-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl1-amide; Benzo[1,3]-dioxole-5-carboxylic acid{(S)-]-[1-(3-cyclohexyl-propanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-(3-Trifluoromethyl-phenyl)-furan-2-carboxylic acid{(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[1,3]-dioxole-5-carboxylic acid{(S)-1-[1-(4-methyl-pentanoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid {(S)1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-[3-oxo-1-(ethanesulfonyl-azepan-4-ylcarbamoyl)-3-methyl-1-butyl]-amide;5-Fluoro-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-Fluoro-3-methyl-benzofuran-2-carboxylic acid((S)-3-methyl-]-[3-oxo-1-(-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;6-Fluoro-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl)}-amide;3-Methyl-benzofuran-2-carboxylic acid{(R)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-furo[3,2-b]-pyridine-2-carboxylic acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-methyl-furan-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thiophene-2-carboxylic acid{(S)-1-[1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methyl-thiophene-2-carboxylic acid{(S)-1-{1-(3-fluoro-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;3-Methyl-benzofuran-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzo[b]thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;3-Methyl-furan-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoline-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Thieno[3,2-b]thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Quinoxaline-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;5-Methyl-thiophene-2-carboxylic acid[(S)-1-(1-ethanesulfonyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;3-Methyl-furan-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;2,5-Dimethyl-furan-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;Thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-Methyl-thiophene-2-carboxylic acid{(S)-1-[3-oxo-1-(propane-1-sulfonyl)-azepan-4-ylcarbamoyl]-3-methyl-1-butyl}-amide;5-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3,5-Dimethyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Ethyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;4-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;1-methyl-naphtho[2, 1-b]-furan-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;6-Methoxy-3-methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid {1,3-dimethyl-1-[3-oxo-1(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid[(S)-3-methyl-1-[3-oxo-1-quinolin-2-ylmethyl-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-2-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[2-chloro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-13-oxo-1-[4-fluoro-benzenesulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl1-butyl)-amide; 3-Methyl-benzofuran-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl}-butyl)-amide;Benzo[b]thiophene-2-carboxylic acid((S)-3-methyl-1-{3-oxo-1-[1-toluene-4-sulfonylamino)-methanoyl]-azepan-4-ylcarbamoyl1-butyl)-amide; Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[1-(6-methyl-pyridin-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzo[b]thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;2,4-Dimethylfuran-3-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoxaline-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Thieno[3,2-b]thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Quinoline-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;4-Methyl-thiophene-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;5-Methoxy-benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyt}-amide;4-Methyl-furan-2-carboxylic acid{(S)-1-[1-(2-fluoro-phenylcarbamoyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-(1-butyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-1-(1-propyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(2-fluoro-benzyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[1-(2-morpholin-4-yl-thiazol-4-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(5-ethyl-furan-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,4-dimethyl-thieno[3,2-b]thiophene-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(3-phenyl-3H-[1,2,3]triazol-4-ylmethyl)-azepan-4-ylcarbamoyl]-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-1-[1-(isothiazol-3-ylmethyl-3-oxo-azepan-4-ylcarbamoyl)-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-thiophen-2-ylmethyl-azepan-4-ylcarbamoyl)-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-1-(1-benzo[b]thiophen-2-ylmethyl-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl]-amide;Benzofuran-2-carboxylic acid[(S)-3-methyl-1-(3-oxo-1-pentyl-azepan-4-ylcarbamoyl)-butyl]-amide;Benzofuran-2-carboxylic acid{(S)-3-methyl--[1-(1-methyl-1H-imidazol-2-ylmethyl)-3-oxo-azepan-4-ylcarbamoyl]-buty}-amide;1-Oxy-pyridine-2-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;2-Oxy-pyridine-3-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;1H-Benzoimidazole-5-carboxylic acid{(S)-3-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;4-{(S)-2-[(1-Benzofuran-2-yl-methanoyl)-amino]-4-methyl-pentanoylamino}-1-methyl-3-oxo-1-pentyl-azepanium;Benzofuran-2-carboxylic acid{(S)-1-[1-(1,2-dimethyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(1-methyl-1H-imidazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(4-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(2-methanesulfonyl-benzenesulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl}-amide;Benzofuran-2-carboxylic acid{(S)-1-[1-(3,5-dimethyl-isoxazole-4-sulfonyl)-3-oxo-azepan-4-ylcarbamoyl]-3-methyl-butyl]-amide;3-Methyl-benzofuran-2-carboxylic acid{(1S,2R)-2-methyl-1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide;3-Methyl-benzofuran-2-carboxylic acid{1-[3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-cyclopentyl}-amide;and Furo[3,2-b]-pyridine-2-carboxylic acid{(S)-3-methyl-1-[-3-oxo-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide42. A pharmaceutical composition comprising a compound according toclaims 1 to 41 and a pharmaceutically acceptable carrier, diluent orexcipient.
 43. A method of inhibiting a protease, comprisingadministering to a patient in need thereof an effective amount of acompound according to claims 1 to
 41. 44. A method according to claim 43wherein said protease is selected from the group consisting of acysteine protease and a serine protease.
 45. A method according to claim44 wherein said protease is a cysteine protease.
 46. A method accordingto claim 45 wherein said cysteine protease is cathepsin K.
 47. A methodof treating a disease characterized by bone loss comprising inhibitingsaid bone loss by administering to a patient in need thereof aneffective amount of a compound according to claims 1 to
 41. 48. A methodaccording to claim 47 wherein said disease is osteoporosis.
 49. A methodaccording to claim 47 wherein said disease is periodontitis.
 50. Amethod according to claim 47 wherein said disease is gingivitis.
 51. Amethod of treating a disease characterized by excessive cartilage ormatrix degradation comprising inhibiting said excessive cartilage ormatrix degradation by administering to a patient in need thereof aneffective amount of a compound according to claims 1 to
 41. 52. A methodaccording to claim 51 wherein said disease is osteoarthritis.
 53. Amethod according to claim 51 wherein said disease is rheumatoidarthritis.
 54. A compound of Formula IT:

wherein: R¹ is selected from the group consisting of:

R² is selected from the group consisting of: H, C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁹C(O)—, R⁹C(S)—,R⁹SO₂—, R⁹OC(O)—, R⁹R¹¹NC(O)—, R⁹R¹¹NC(S)—, R⁹ (R¹¹)NSO₂—

and R⁹SO₂R¹¹NC(O)— R³ is selected from the group consisting of: H, C16alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl,HetC₀₋₆alkyl and ArC₀₋₆alkyl; R³ and R′ may be connected to form apyrrolidine, piperidine or morpholine ring; R⁴ is selected from thegroup consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R⁵C(O)—, R⁵C(S)—, R⁵SO₂—, R⁵OC(O)—,R⁵R¹²NC(O)—, and R⁵R¹²NC(S)—; R⁵ is selected from the group consistingof: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R⁶ is selected from the group consistingof: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl; R⁷ is selected fromthe group consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, Het-C₀₋₆alkyl, R¹⁰C(O)—, R¹⁰C(S)—, R¹⁰SO₂—, R¹⁰C(O)—,R⁰R¹³NC(O)—, and R¹⁰R¹³NC(S)—; R⁸ is selected from the group consistingof: H, C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, HetC₀₋₆alkyl andArC₀₋₆alkyl; R⁹ is selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R¹⁰ isindependently selected from the group consisting of: C₁₋₆alkyl,C₃₋₆cycloalkyl-C₀₋₆alkyl, Ar—C₀₋₆alkyl and Het-C₀₋₆alkyl; R¹¹ isselected from the group consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, andHet-C₀₋₆alkyl; R¹² is selected from the group consisting of: H,C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R¹³ is selected from thegroup consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R′is selected from the group consisting of: H, C₁₋₆alkyl, Ar—C₀₋₆alkyl,and Het-C₀₋₆alkyl; R″ is selected from the group consisting of: H,C₁₋₆alkyl, Ar—C₀₋₆alkyl, or Het-C₀₋₆alkyl; R′″ is selected from thegroup consisting of: H, C₁₋₆alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl,Ar—C₀₋₆alkyl, and Het-C₀₋₆alkyl; R″″ is selected from the groupconsisting of: C 16alkyl, C₃₋₆cycloalkyl-C₀₋₆alkyl C₂₋₆alkenyl,C₂₋₆alkynyl, HetC₀₋₆alkyl and ArC₀₋₆alkyl; X is selected from the groupconsisting of: CH₂, S, and O; Z is selected from the group consistingof: C(O) and CH₂; n is an integer of from 1 to 5; and pharmaceuticallyacceptable salts, hydrates and solvates thereof.
 55. A compoundaccording to claim 51 selected from the group consisting of: [(S)-1(3-Hydroxy-azepan-4-ylcarbamoyl)-3-methyl-butyl]-carbamic acid benzylester; (S)-2-Amino-4-methyl-pentanoic acid(1-benzyl-3-hydroxy-azepan-4-yl)-amide; (S)-2-Amino-4-methyl-pentanoicacid{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-yl}-amide;{(S)-1-[4-((S)-2-Amino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-ylmethyl]-3-methyl-butyl)-carbamicacid benzyl ester; (S)-2-Amino-4-methyl-pentanoicacid-(1-benzoyl-3-hydroxy-azepan-4-yl)-amide;(S)-2-Amino-4-methyl-pentanoic acid[3-hydroxy-1-(4-methyl-pentanoyl)-azepan-4-yl]-amide;(S)-2-Amino-4-methyl-pentanoic acid(1-benzenesulfonyl-3-hydroxy-azepan-4-yl)-amide;thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;5-methoxybenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;thieno[3,2-b]thiophene-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy--(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;3-methylbenzofuran-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;quinoline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide;and quinoxaline-2-carboxylic acid{(S)-3-methyl-1-[3-hydroxy-1-(1-oxy-pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}amide.56. A process for the synthesis of a compound according to claim 1comprising the step of oxidizing a corresponding compound of claim 54with an oxidant to provide the compound of Formula (I) as a mixture ofdiastereomers.
 57. The process of claim 56 wherein the oxidant is sulfurtrioxide pyridine complex in DMSO and triethylamine.
 58. The process ofclaim 56 further comprising the step of separating the diasteromers byseparating means.
 59. The process of claim 58 wherein said separatingmeans is high presssure liquid chromatography (HPLC).
 60. The process ofclaim 56 further comprising the step of deuterating said diastereomerswith a deuterating agent.
 61. The process of claim 60 wherein saiddeuterating agent is CD₃OD: D₂O (10:1) in triethylamine.